dalteparin has been researched along with Thromboembolism, Venous in 939 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 9.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "The results of this randomized controlled trial demonstrate that patients with surgical orthopaedic trauma prefer an oral anticoagulant for postoperative venous thromboembolism chemoprophylaxis and suggest that rivaroxaban may be a viable option." | 9.51 | A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma. ( Chase, CB; Downes, K; John, MP; Mir, HR; Streufert, BD, 2022) |
| " We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study." | 9.51 | Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022) |
| " We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old." | 9.51 | A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022) |
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 9.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study." | 9.41 | Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 9.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 9.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "In the 'Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism' (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients with cancer." | 9.34 | Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. ( de Jong, LA; Hulst, MV; Postma, MJ; van der Velden, AWG, 2020) |
| "Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin." | 9.30 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. ( Ageno, W; Cohen, AT; Gibson, CM; Goldhaber, SZ; Hernandez, A; Hull, RD; Lopes, RD; Yee, MK, 2019) |
| "To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients." | 9.30 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jafarizade, M; Kahe, F; Kalayci, A; Liu, Y; Sharfaei, S, 2019) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 9.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 9.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding." | 9.27 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 9.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism." | 9.22 | Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016) |
| "Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE)." | 9.22 | Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism: Initial Experience in a Single Center. ( Fukuda, JM; Guerra, JC; Krutman, M; Kuzniec, S; Ramacciotti, E; Teivelis, M; Varella, AY; Wolosker, N, 2016) |
| "Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial." | 9.22 | Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. ( Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI, 2016) |
| "In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0." | 9.22 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. ( Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S, 2016) |
| "The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for preventing venous thromboembolism (VTE) after lumbar spine surgery." | 9.20 | Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. ( Du, W; Liu, J; Shen, B; Wang, J; Zhao, C; Zheng, Y, 2015) |
| "To evaluate the effect of prestudy heparin on the efficacy and safety of rivaroxaban relative to enoxaparin/VKA, the 3-month incidence of recurrent VTE, and the 14-day incidence of major and nonmajor clinically relevant bleeding were compared in patients who did and did not receive prestudy heparin." | 9.20 | Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. ( Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC, 2015) |
| "The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)." | 9.20 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015) |
| "In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism-related death, with significantly less bleeding." | 9.20 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. ( Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J, 2015) |
| "Major bleeding was less frequent during dalteparin therapy beyond 6 months." | 9.20 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 9.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 9.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 9.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials." | 9.17 | Oral apixaban for the treatment of acute venous thromboembolism. ( Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI, 2013) |
| "Venous thromboembolism (VTE) has a significant impact on healthcare costs but is largely preventable with anticoagulant prophylaxis using low-molecular-weight heparins (LMWHs), such as enoxaparin or dalteparin." | 9.17 | Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. ( Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M, 2013) |
| "Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear." | 9.17 | Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 9.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding." | 9.16 | A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012) |
| "A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme)." | 9.14 | Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. ( Bandel, TJ; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG, 2009) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 9.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| "Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty." | 9.13 | Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. ( Brenner, B; Dahl, OE; Eriksson, BI; Haas, S; Kakkar, AK; Misselwitz, F; Mouret, P; Muntz, J; Pap, AF; Soglian, AG, 2008) |
| "Aspirin is perceived to be non-inferior to enoxaparin, a low-molecular-weight heparin, for the prevention of venous thromboembolism (VTE) following elective arthroplasty of the hip or knee and is recommended in clinical guidelines internationally." | 9.12 | Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis. ( An, VVG; Farey, JE; Harris, IA; Karunaratne, S; Sidhu, V, 2021) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 9.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| "The meta-analysis indicated that rivaroxaban prophylaxis was associated with lower rates of symptomatic venous thromboembolism (VTE) (relative risk[RR]:0." | 8.98 | Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis. ( Huang, HF; Li, SS; Tian, XB; Xie, Q; Yang, XT, 2018) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 8.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "To systematically review the efficacy and safety of fondaparinux and enoxaparin in the prevention of venous thromboembolism (VTE) after major orthopedic surgery." | 8.89 | [Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis]. ( Li, H; Shi, Z; Wang, J; Xiao, J, 2013) |
| "In order to compare the effect of oral apixaban (a factor Xa inhibitor) with subcutaneous enoxaparin on major venous thromboembolism and major and non-major clinically relevant bleeding after total knee and hip replacement, we conducted a pooled analysis of two previously reported double-blind randomised studies involving 8464 patients." | 8.88 | Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. ( Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramirez, LM; Raskob, GE; Wright, RT, 2012) |
| "We searched for reports of randomized controlled trials on rivaroxaban versus enoxaparin in venous thromboembolism prophylaxis after knee- or hip-joint replacement in the Cochrane library, Embase, Pubmed, the Ovid database, and Chinese databases including VIP, CNKI, and CBM." | 8.87 | A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. ( Banghua, L; Jin, C; Turun, S; Ying, N; Yuan, Y; Zhenhui, L, 2011) |
| "Oral dabigatran was as effective as subcutaneous enoxaparin in reducing the risk of major VTE and VTE-related mortality after hip or knee arthroplasty and has a similar bleeding profile." | 8.86 | Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. ( Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM, 2010) |
| "Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE)." | 8.85 | Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. ( Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of dabigatran etexilate (DBG) for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip and knee surgery based upon a review of the manufacturer's submission to the NICE as part of the single technology appraisal (STA) process." | 8.85 | Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. ( Carroll, C; Holmes, M; Papaioannou, D, 2009) |
| "Aspirin and enoxaparin are commonly used for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA)." | 8.31 | Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty. ( Ackerman, I; Adie, S; Bastiras, D; Buchbinder, R; Harris, IA; Naylor, JM; Sidhu, V, 2023) |
| "In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA)." | 8.12 | Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. ( Bavalia, R; Bistervels, IM; Coppens, M; Gebel, M; Lensing, AWA; Middeldorp, S; Prins, MH, 2022) |
| " This study aims to evaluate whether in clinical practice there is an increase in the occurrence of bleeding in patients with renal insufficiency (RI) during treatment or prophylaxis with dalteparin, and to analyse the risk factors potentially influencing the appearance of such bleeding events." | 8.12 | Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin. ( Corregidor Luna, L; Díaz Gómez, E; García Díaz, B; Iglesias-Peinado, I; Suárez Del Olmo, D, 2022) |
| "This article describes the population pharmacokinetics (PK) of dalteparin in pediatric patients with venous thromboembolism (VTE)." | 8.02 | Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. ( Damle, B; Jani, D; Jen, F; Sherman, N; Sweeney, K, 2021) |
| "To determine the effect and safety of sequential treatment with the low-molecular-weight heparin dalteparin and the direct oral anticoagulants rivaroxaban in patients with cancer- associated venous thromboembolism (VTE)." | 8.02 | Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism. ( Chen, L; Chen, Q; Zhu, M; Zhuang, Z, 2021) |
| " The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared with current SoC (enoxaparin overlapped with warfarin) for the treatment of acute deep vein thrombosis (DVT) in China." | 7.96 | Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. ( Wu, J; Yang, L, 2020) |
| "In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin." | 7.96 | Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. ( Huh, JW; Jo, KW; Lee, JH; Lee, JS; Oh, YM, 2020) |
| " Food and Drug Administration (FDA) approved dalteparin sodium for the treatment of symptomatic venous thromboembolism (VTE) to reduce the risk of recurrence in pediatric patients 1 month of age and older." | 7.96 | FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients. ( Ande, A; De Claro, RA; Farrell, A; Hariharan, S; Liu, C; Merino, M; Pazdur, R; Reaman, G; Richardson, N; Zvada, S, 2020) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 7.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy." | 7.88 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018) |
| "A real-world US database analysis was conducted to evaluate the hospital resource utilization and costs of patients hospitalized for venous thromboembolism (VTE) treated with warfarin versus apixaban." | 7.88 | Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. ( Deitelzweig, S; Guo, JD; Gupta, A; Hlavacek, P; Lin, J; Lingohr-Smith, M; Mardekian, J; Marshall, A; Menges, B; Nadkarni, A; Pan, X; Rosenblatt, L; Wygant, G, 2018) |
| "Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up CLINICAL TRIAL REGISTRATION: URL: http://www." | 7.85 | Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). ( Arbetter, D; Bandman, O; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S, 2017) |
| " The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban." | 7.85 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017) |
| "Rivaroxaban is a cost-effective alternative to enoxaparin for VTE prophylaxis in patients undergoing THR and TKR." | 7.85 | Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. ( Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS, 2010) |
| "Apixaban and enoxaparin are indicated for preventing venous thromboembolism (VTE)." | 7.83 | Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. ( Gu, X; Lin, H; Wu, B; Yan, X; Zhou, L, 2016) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 7.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012." | 7.81 | Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. ( Charters, MA; Dobson, C; Frisch, NB; Les, CM; Silverton, CD; Wessell, NM, 2015) |
| "This study focused on the clinical outcomes in multiple myeloma (MM) patients with venous thromboembolism (VTE) who received low-molecular-weight heparin (dalteparin) therapy." | 7.81 | Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, M; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH, 2015) |
| " The primary analysis compared the temporal course of event rates and rate differences between rivaroxaban and enoxaparin prophylaxis for symptomatic venous thromboembolism plus all-cause mortality (efficacy events) versus nonfatal major bleeding (safety events)." | 7.80 | Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. ( Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z, 2014) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 7.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 7.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 7.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "Four phase III studies compared oral rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA or TKA)." | 7.77 | Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. ( Bandel, TJ; Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG; Westermeier, T, 2011) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 7.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "The objective of this analysis was the evaluation of the outcomes and costs associated with rivaroxaban and enoxaparin for the prevention of postsurgical venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) and total knee replacement (TKR) from the US payer perspective." | 7.77 | Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. ( Diamantopoulos, A; Duran, A; Forster, F; Kwong, L; Lees, M; Sengupta, N, 2011) |
| "Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement." | 7.76 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010) |
| "Rates of VTE and bleeding events did not differ significantly between dabigatran etexilate and enoxaparin." | 7.75 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. ( Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2009) |
| "This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE)." | 7.74 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. ( Hyers, TM; Spyropoulos, AC, 2007) |
| "Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery." | 7.30 | Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. ( Wang, CC; Wu, T; Zhang, GQ; Zhang, LT; Zhou, LB, 2023) |
| "Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2." | 7.11 | Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022) |
| " Secondary outcomes included incidence of venous thromboembolic events, adverse events, medication adherence, participant quality of life, and medication satisfaction." | 6.94 | Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. ( Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ, 2020) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 6.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 6.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7." | 6.84 | Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | 6.82 | Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| " This analysis supports dosing patients with renal impairment in accordance with patients with normal renal function; however, anti-Xa monitoring could be considered to further support safety in selected patients, particularly those with very severe renal impairment." | 6.82 | A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. ( Abreu, P; Feugère, G; Heissler, J; Jen, F; Ruiz, MT; Woodruff, S, 2016) |
| "This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty." | 6.79 | Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). ( Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014) |
| " There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs." | 6.79 | Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014) |
| "Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery." | 6.77 | Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. ( Gallerani, M; Imberti, D; Manfredini, R, 2012) |
| "Symptomatic acute pulmonary embolism treatment with full therapeutic doses of tinzaparin for 6 months is a feasible alternative to conventional treatment with vitamin K antagonists." | 6.75 | Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. ( Colomé-Nafria, E; Golpe, R; Leiro-Fernández, V; Méndez-Marote, L; Núñez-Delgado, JM; Palacios-Bartolomé, A; Pérez-de-Llano, LA, 2010) |
| " Dosing stopped at contrast venography, 12 to 15 days after surgery." | 6.74 | Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. ( Caprini, JA; Clements, ML; Comp, PC; Davidson, BL; Francis, CW; Friedman, RJ; Ginsberg, JS; Hantel, S; Huo, MH; Lieberman, JR; Muntz, JE; Raskob, GE; Schnee, JM, 2009) |
| "Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio." | 6.61 | Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019) |
| "Rivaroxaban is a potential option for patients with cancer and VTE." | 6.58 | Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis. ( Chen, D; Xing, J; Yin, X, 2018) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Cancer is a major risk factor for the development of venous thromboembolism (VTE)." | 6.44 | Management of venous thromboembolism in patients with cancer: role of dalteparin. ( Linkins, LA, 2008) |
| "Dalteparin was not stopped in any women." | 5.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| " Due to its antiplatelet and cardioprotective properties, aspirin has been proposed as an agent that could reduce mortality when used as venous thromboembolism (VTE) prophylaxis following these procedures." | 5.69 | Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial. ( Ackerman, IN; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, PL; Lieu, D; Lorimer, M; MacDessi, SJ; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2023) |
| " We assessed for an effect modification of thromboprophylaxis (dalteparin or unfractionated heparin [UFH]) by sex on thrombotic (deep venous thrombosis [DVT], pulmonary embolism [PE], VTE) and mortality outcomes in a secondary analysis of the Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT)." | 5.69 | Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial. ( Bhuptani, P; Burns, KEA; Cook, DJ; Crowther, MA; Finfer, S; Heels-Ansdell, D; Kahn, SR; Lauzier, F; Mehta, S; Ostermann, M; Thabane, L, 2023) |
| "Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery." | 5.62 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. ( Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 5.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "The results of this randomized controlled trial demonstrate that patients with surgical orthopaedic trauma prefer an oral anticoagulant for postoperative venous thromboembolism chemoprophylaxis and suggest that rivaroxaban may be a viable option." | 5.51 | A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma. ( Chase, CB; Downes, K; John, MP; Mir, HR; Streufert, BD, 2022) |
| " We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study." | 5.51 | Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022) |
| "In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months." | 5.51 | Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. ( Aquilanti, S; Bertoletti, L; Brebion, N; Brisot, D; Bura-Rivière, A; Burnod, A; Charles-Nelson, A; Chatellier, G; Constans, J; Couturaud, F; Elias, A; Falvo, N; Girard, P; Grange, C; Laporte, S; Mahé, I; Meyer, G; Mismetti, P; Pernod, G; Planquette, B; Ray, V; Roy, PM; Sanchez, O; Sevestre, MA; Timar-David, M, 2022) |
| " We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old." | 5.51 | A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022) |
| "The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)." | 5.48 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 5.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 5.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| " Of the eight papers comparing chemical prophylaxis medications in patients with hip or lower limb injuries, fondaparinux and enoxaparin were found to be significantly superior to placebo in respect of prevention of DVT, with no increased risk of bleeding." | 5.41 | The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis. ( Jin, J; MacCormick, AD; Peng, S; Zhang, M, 2023) |
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 5.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study." | 5.41 | Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021) |
| "A VTE prophylaxis protocol using anti-Xa-based dalteparin dosage adjustment in high-risk trauma patients was associated with decreased VTE." | 5.40 | Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. ( Athota, KP; Besl, KM; Droege, CA; Droege, ME; Ernst, NE; Hanseman, DJ; Keegan, SP; Kramer, EA; Lemmink, JA; Lutomski, DM; Mueller, EW; Robinson, BR, 2014) |
| "Apixaban is a direct factor Xa inhibitor that has been shown in clinical trial use to safely reduce the composite of VTE and mortality rates in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA); however, the cost-effectiveness of apixaban treatment in Canadian settings has not been studied." | 5.39 | A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. ( El-Hadi, W; Kadambi, A; Patterson, J; Raymond, V; Revankar, N, 2013) |
| "Fondaparinux is an effective and safe alternative." | 5.36 | Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. ( Ageno, W; Capri, S; Imberti, D; Moia, M; Palareti, G; Piovella, F; Scannapieco, G, 2010) |
| "A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial." | 5.36 | Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. ( Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010) |
| "Paraplegia (as opposed to tetraplegia) was the only risk factor identified for VTE." | 5.35 | Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study. ( Anderson, D; Douglas, JA; Pike, J; Short, C; Thompson, K; Worley, S, 2008) |
| "In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin." | 5.34 | Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. ( Cucherat, M; Deygas, B; Duverger, D; Fisher, W; Girard, P; Laporte, S; Llau, J; Martínez-Martín, J; Mismetti, P; Mouret, P; Presles, E; Rosencher, N; Samama, CM, 2020) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 5.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 5.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "In the 'Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism' (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients with cancer." | 5.34 | Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. ( de Jong, LA; Hulst, MV; Postma, MJ; van der Velden, AWG, 2020) |
| "Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin." | 5.30 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. ( Ageno, W; Cohen, AT; Gibson, CM; Goldhaber, SZ; Hernandez, A; Hull, RD; Lopes, RD; Yee, MK, 2019) |
| "To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients." | 5.30 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jafarizade, M; Kahe, F; Kalayci, A; Liu, Y; Sharfaei, S, 2019) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 5.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 5.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| " Thus, we compared the efficacy and safety of fondaparinux and nadroparin on the prophylaxis of venous thromboembolism (VTE) after MIE." | 5.27 | Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial. ( Shen, Y; Song, J; Tan, L; Wu, W; Xuan, L; Zhong, M, 2018) |
| "Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding." | 5.27 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018) |
| "In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE." | 5.27 | Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. ( Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI, 2018) |
| "Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin." | 5.24 | Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. ( Arbetter, D; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S; Lopes, RD, 2017) |
| " APEX investigated the efficacy of extended-duration betrixaban versus standard-duration enoxaparin to prevent a composite of symptomatic deep-vein thrombosis (proximal or distal), nonfatal pulmonary embolism, or venous thromboembolism (VTE)-related death in acute medically ill patients (n = 7513)." | 5.24 | Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. ( Arbetter, DF; Cohen, AT; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jain, P; Michalak, N; Yee, MK, 2017) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 5.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism." | 5.22 | Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016) |
| "Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE)." | 5.22 | Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism: Initial Experience in a Single Center. ( Fukuda, JM; Guerra, JC; Krutman, M; Kuzniec, S; Ramacciotti, E; Teivelis, M; Varella, AY; Wolosker, N, 2016) |
| "Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial." | 5.22 | Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. ( Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI, 2016) |
| " Direct comparisons show that DOACs significantly decrease recurrent venous thromboembolism (VTE) events compared with dalteparin (odds ratio [OR], 0." | 5.22 | Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. ( Badgett, RG; Bryce, AH; Fuentes, HE; He, H; Liu, H; Marshall, AL; McBane, RD; Montori, V; Murad, MH; Naqvi, SAA; Padranos, L; Riaz, IB; Sipra, QR; Tafur, AJ; Vandvik, PO; Wysokinski, WE, 2022) |
| "In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0." | 5.22 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. ( Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S, 2016) |
| "The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for preventing venous thromboembolism (VTE) after lumbar spine surgery." | 5.20 | Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. ( Du, W; Liu, J; Shen, B; Wang, J; Zhao, C; Zheng, Y, 2015) |
| "To evaluate the effect of prestudy heparin on the efficacy and safety of rivaroxaban relative to enoxaparin/VKA, the 3-month incidence of recurrent VTE, and the 14-day incidence of major and nonmajor clinically relevant bleeding were compared in patients who did and did not receive prestudy heparin." | 5.20 | Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. ( Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC, 2015) |
| "The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)." | 5.20 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015) |
| "In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism-related death, with significantly less bleeding." | 5.20 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. ( Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J, 2015) |
| "Major bleeding was less frequent during dalteparin therapy beyond 6 months." | 5.20 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 5.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 5.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "Rivaroxaban demonstrated superior efficacy and a similar safety profile to enoxaparin for the prevention of venous thromboembolism in the phase III RECORD programme in patients undergoing elective hip or knee replacement surgery." | 5.19 | A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. ( Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M, 2014) |
| "We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months." | 5.19 | Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 5.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials." | 5.17 | Oral apixaban for the treatment of acute venous thromboembolism. ( Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI, 2013) |
| "Venous thromboembolism (VTE) has a significant impact on healthcare costs but is largely preventable with anticoagulant prophylaxis using low-molecular-weight heparins (LMWHs), such as enoxaparin or dalteparin." | 5.17 | Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. ( Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M, 2013) |
| "Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear." | 5.17 | Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013) |
| " The phase III RECORD programme compared rivaroxaban with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement surgery in more than 12,500 patients." | 5.17 | Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). ( Berkowitz, SD; Homering, M; Llau, JV; Loewe, A; Mueck, W; Rosencher, N, 2013) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 5.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Co-medication use with rivaroxaban or enoxaparin resulted in non-significant increases in bleeding events." | 5.16 | Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. ( Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N, 2012) |
| "Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding." | 5.16 | A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012) |
| "In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2." | 5.15 | Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. ( Goldhaber, SZ; Haas, SK; Kakkar, AK; Knabb, RM; Leizorovicz, A; Merli, G; Weitz, JI, 2011) |
| "A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme)." | 5.14 | Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. ( Bandel, TJ; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG, 2009) |
| " Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use." | 5.14 | Apixaban or enoxaparin for thromboprophylaxis after knee replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Portman, RJ; Raskob, GE, 2009) |
| "In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding." | 5.14 | Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 5.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| " Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use." | 5.14 | Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Ramirez, LM; Raskob, GE, 2010) |
| "The aim of the EXTEND study was to assess safety and efficacy of extended administration (35 days) of ximelagatran or enoxaparin for the prevention of venous thromboembolism after elective hip replacement and hip fracture surgery." | 5.14 | Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. ( Agnelli, G; Andersson, M; Bergqvist, D; Boberg, B; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Jensen, E; Lassen, MR; Mouret, P; Rosencher, N, 2009) |
| "We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty." | 5.13 | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. ( Ageno, W; Bandel, TJ; Borris, LC; Lassen, MR; Lieberman, JR; Misselwitz, F; Rosencher, N; Turpie, AG, 2008) |
| "Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty." | 5.13 | Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. ( Brenner, B; Dahl, OE; Eriksson, BI; Haas, S; Kakkar, AK; Misselwitz, F; Mouret, P; Muntz, J; Pap, AF; Soglian, AG, 2008) |
| "Aspirin is perceived to be non-inferior to enoxaparin, a low-molecular-weight heparin, for the prevention of venous thromboembolism (VTE) following elective arthroplasty of the hip or knee and is recommended in clinical guidelines internationally." | 5.12 | Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis. ( An, VVG; Farey, JE; Harris, IA; Karunaratne, S; Sidhu, V, 2021) |
| "According to the available data, Apixaban, Edoxaban, and Darexaban are better than any anticoagulants in the prevention of VTE and bleeding during total knee or total hip arthroplasty." | 5.12 | Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. ( Feng, W; Huang, D; Lu, A; Wang, X, 2021) |
| "Heparins and warfarin are currently used as venous thromboembolism (VTE) prophylaxis in surgery." | 5.12 | The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. ( Ansell, J; Davidson, BL; Deitchman, D; Gallus, A; Lassen, MR; Pineo, G, 2007) |
| "Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin." | 5.05 | Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 5.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| " Initial studies of extended thromboprophylaxis in acutely ill medical patients with enoxaparin, rivaroxaban and apixaban showed little to no benefit towards VTE reduction that was consistently outweighed by increased bleeding." | 4.98 | Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis. ( Burnett, AE; Fletcher, ML; Mahan, CE; Spyropoulos, AC, 2018) |
| "The meta-analysis indicated that rivaroxaban prophylaxis was associated with lower rates of symptomatic venous thromboembolism (VTE) (relative risk[RR]:0." | 4.98 | Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis. ( Huang, HF; Li, SS; Tian, XB; Xie, Q; Yang, XT, 2018) |
| " This study aims to use a network meta-analysis to compare effects of 9 anticoagulant drugs (edoxaban, dabigatan, apixaban, rivaroxaban, warfarin, heparin, bemiparin, ximelagatran, and enoxaparin) in preventing postoperative complications in arthroplasty patients." | 4.95 | Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. ( Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX, 2017) |
| " The RR of major/clinically relevant bleeding was lowest for apixaban 2." | 4.95 | Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. ( Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT, 2017) |
| " The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events." | 4.95 | Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. ( Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J, 2017) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 4.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "To systematically review the efficacy and safety of fondaparinux and enoxaparin in the prevention of venous thromboembolism (VTE) after major orthopedic surgery." | 4.89 | [Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis]. ( Li, H; Shi, Z; Wang, J; Xiao, J, 2013) |
| "Dabigatran 150 mg twice daily was shown to be superior to warfarin in preventing stroke in subjects with nonvalvular atrial fibrillation (SPAF) in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial." | 4.89 | Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. ( Clemens, A; Fraessdorf, M; Friedman, J, 2013) |
| "Low-molecular-weight heparins and fondaparinux are the most economically attractive drugs for venous thromboembolism prevention in hospitalized patients." | 4.88 | Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. ( Cook, DJ; Fowler, RA; Geerts, WH; Pinto, R; Thirugnanam, S, 2012) |
| "Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism (VTE)." | 4.88 | Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. ( Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N, 2012) |
| "In order to compare the effect of oral apixaban (a factor Xa inhibitor) with subcutaneous enoxaparin on major venous thromboembolism and major and non-major clinically relevant bleeding after total knee and hip replacement, we conducted a pooled analysis of two previously reported double-blind randomised studies involving 8464 patients." | 4.88 | Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. ( Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramirez, LM; Raskob, GE; Wright, RT, 2012) |
| "Randomised controlled trials of rivaroxaban, dabigatran, or apixaban compared with enoxaparin for prophylaxis against venous thromboembolism after total hip or knee replacement." | 4.88 | Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. ( Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E, 2012) |
| "We searched for reports of randomized controlled trials on rivaroxaban versus enoxaparin in venous thromboembolism prophylaxis after knee- or hip-joint replacement in the Cochrane library, Embase, Pubmed, the Ovid database, and Chinese databases including VIP, CNKI, and CBM." | 4.87 | A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. ( Banghua, L; Jin, C; Turun, S; Ying, N; Yuan, Y; Zhenhui, L, 2011) |
| "Primary efficacy (any VTE+all-cause mortality) and safety (major bleeding) outcomes in enoxaparin arms largely differed across similarly designed rivaroxaban and dabigatran trials (differences in venography adjudication and bleeding events definitions)." | 4.86 | Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. ( Kolundzic, R; Trkulja, V, 2010) |
| "Oral dabigatran was as effective as subcutaneous enoxaparin in reducing the risk of major VTE and VTE-related mortality after hip or knee arthroplasty and has a similar bleeding profile." | 4.86 | Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. ( Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM, 2010) |
| "Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE)." | 4.85 | Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. ( Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of dabigatran etexilate (DBG) for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip and knee surgery based upon a review of the manufacturer's submission to the NICE as part of the single technology appraisal (STA) process." | 4.85 | Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. ( Carroll, C; Holmes, M; Papaioannou, D, 2009) |
| "Aspirin and enoxaparin are commonly used for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA)." | 4.31 | Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty. ( Ackerman, I; Adie, S; Bastiras, D; Buchbinder, R; Harris, IA; Naylor, JM; Sidhu, V, 2023) |
| "Rivaroxaban chemoprophylaxis following TKA and THA was associated with an increased risk of bleeding and prothrombotic complications compared to aspirin and enoxaparin." | 4.31 | Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. ( Christ, AB; Heckmann, ND; Kang, HP; Lieberman, JR; Mayfield, CK; Mills, ES; Piple, AS; Wang, JC, 2023) |
| " Of the 7 readmissions in the enoxaparin group, one was due to bleeding requiring transfusion; there were no readmissions for bleeding in the apixaban group." | 4.31 | Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. ( Covens, A; Geerts, W; Gien, LT; Kupets, R; Lin, Y; Spénard, E; Vicus, D, 2023) |
| "To compare the safety and efficacy of oral apixaban with that of injectable enoxaparin after robot-assisted radical cystectomy (RARC) for venous thromboembolism (VTE) thromboprophylaxis." | 4.31 | Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy. ( Attalla, K; Elkun, Y; Geduldig, J; Lavallee, E; Mehrazin, R; Rich, JM; Sfakianos, JP; Wiklund, P, 2023) |
| "In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA)." | 4.12 | Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. ( Bavalia, R; Bistervels, IM; Coppens, M; Gebel, M; Lensing, AWA; Middeldorp, S; Prins, MH, 2022) |
| " The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin) and MARINER (Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk) trials evaluated whether rivaroxaban compared with enoxaparin or placebo could prevent venous thromboembolism without increased bleeding." | 4.12 | Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. ( Ageno, W; Albers, GW; Barnathan, ES; Cohen, AT; Elliott, CG; Halperin, JL; Hiatt, WR; Lipardi, C; Lu, W; Maynard, G; Raskob, GE; Spiro, TE; Spyropoulos, AC; Steg, PG; Sugarmann, C; Weitz, JI, 2022) |
| " The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
| " We included patients aged ≥ 18 years with incident stroke diagnosis and assessed prophylactic use of anticoagulants in the 30 days following hospital discharge including low-molecular-weight heparin (enoxaparin ≤40 mg/day, dalteparin ≤5000 IU/day), unfractionated heparin ≤5000 IU/ twice daily or 3 times a day, apixaban 2." | 4.12 | Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019. ( Cuker, A; Dawwas, GK; Hennessy, S; Rothstein, A, 2022) |
| "We evaluated the risks of VTE recurrence and treatment-related major bleeding according to the cancer stage in patients with VTE and solid cancer randomised to apixaban or dalteparin in the Caravaggio study." | 4.12 | Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. ( Agnelli, G; Becattini, C; Brenner, B; Cohen, AT; Connors, JM; Gussoni, G; Huisman, M; Munoz, A; Sanchez, O; Verso, M, 2022) |
| " This study aims to evaluate whether in clinical practice there is an increase in the occurrence of bleeding in patients with renal insufficiency (RI) during treatment or prophylaxis with dalteparin, and to analyse the risk factors potentially influencing the appearance of such bleeding events." | 4.12 | Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin. ( Corregidor Luna, L; Díaz Gómez, E; García Díaz, B; Iglesias-Peinado, I; Suárez Del Olmo, D, 2022) |
| "This article describes the population pharmacokinetics (PK) of dalteparin in pediatric patients with venous thromboembolism (VTE)." | 4.02 | Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. ( Damle, B; Jani, D; Jen, F; Sherman, N; Sweeney, K, 2021) |
| "To determine the effect and safety of sequential treatment with the low-molecular-weight heparin dalteparin and the direct oral anticoagulants rivaroxaban in patients with cancer- associated venous thromboembolism (VTE)." | 4.02 | Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism. ( Chen, L; Chen, Q; Zhu, M; Zhuang, Z, 2021) |
| " The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared with current SoC (enoxaparin overlapped with warfarin) for the treatment of acute deep vein thrombosis (DVT) in China." | 3.96 | Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. ( Wu, J; Yang, L, 2020) |
| " The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients." | 3.96 | Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin." | 3.96 | Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. ( Huh, JW; Jo, KW; Lee, JH; Lee, JS; Oh, YM, 2020) |
| " Food and Drug Administration (FDA) approved dalteparin sodium for the treatment of symptomatic venous thromboembolism (VTE) to reduce the risk of recurrence in pediatric patients 1 month of age and older." | 3.96 | FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients. ( Ande, A; De Claro, RA; Farrell, A; Hariharan, S; Liu, C; Merino, M; Pazdur, R; Reaman, G; Richardson, N; Zvada, S, 2020) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 3.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "This study was a retrospective pilot analysis of adult patients with gynecologic malignancies who received either rivaroxaban, warfarin or low molecular weight heparin for treatment of venous thromboembolism at Augusta University Medical Center from 1 July 2013 to 30 June 2015." | 3.91 | Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. ( Gandhi, AS; Signorelli, JR, 2019) |
| " The purpose of this study was to compare the safety and efficacy of rivaroxaban to enoxaparin for the prevention of VTE in patients with multisystem injuries." | 3.91 | The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population. ( Kingdon, LK; Miller, EM; Savage, SA, 2019) |
| "Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy." | 3.88 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018) |
| " Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days." | 3.88 | Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. ( Cohoon, KP; De Sanctis, Y; Haskell, L; McBane, RD; Spiro, TE, 2018) |
| "A real-world US database analysis was conducted to evaluate the hospital resource utilization and costs of patients hospitalized for venous thromboembolism (VTE) treated with warfarin versus apixaban." | 3.88 | Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. ( Deitelzweig, S; Guo, JD; Gupta, A; Hlavacek, P; Lin, J; Lingohr-Smith, M; Mardekian, J; Marshall, A; Menges, B; Nadkarni, A; Pan, X; Rosenblatt, L; Wygant, G, 2018) |
| " The risk of readmission resulting from bleeding and venous thromboembolism (VTE) has also not been determined for patients undergoing THA or TKA when treated with low-molecular-weight heparin (LMWH) alone compared with mechanical prophylaxis plus aspirin (ASA)." | 3.88 | Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA. ( Arsoy, D; Giori, NJ; Woolson, ST, 2018) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| "To analyze the cost-utility of oral dabigatran etexilate, enoxaparin sodium injection, and no intervention for venous thromboembolism (VTE) prophylaxis after total hip or knee replacement (THR/TKR) surgery among Thai patients." | 3.85 | A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Kotirum, S, 2017) |
| "Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up CLINICAL TRIAL REGISTRATION: URL: http://www." | 3.85 | Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). ( Arbetter, D; Bandman, O; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S, 2017) |
| "The aim of this study was to evaluate the cost-effectiveness of rivaroxaban and apixaban versus enoxaparin for the universal prophylaxis of venous thromboembolism (VTE) and associated long-term complications in Chinese patients after total hip replacement (THR)." | 3.85 | Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. ( Gu, X; Lin, H; Wu, B; Xu, Z; Yan, X, 2017) |
| " The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban." | 3.85 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017) |
| "To evaluate the occurrence of bleeding and venous thromboembolic (VTE) events in patients receiving rivaroxaban, warfarin, or warfarin with the addition of enoxaparin during the immediate postoperative period following major orthopedic surgery." | 3.85 | Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. ( Cieri, NE; Hassan, AK; Kusmierski, K; Lackie, C; Van Opdorp, A, 2017) |
| "Rivaroxaban is a cost-effective alternative to enoxaparin for VTE prophylaxis in patients undergoing THR and TKR." | 3.85 | Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. ( Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS, 2010) |
| "The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg daily with commonly used doses of enoxaparin and demonstrated similar rates of VTE and bleeding." | 3.83 | Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin. ( Cluck, D; Cornett, L; El-Bazouni, H; Freshour, J; Odle, B; Ricket, AL; Stewart, DW; Wood, RC, 2016) |
| "01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)." | 3.83 | Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016) |
| "Apixaban and enoxaparin are indicated for preventing venous thromboembolism (VTE)." | 3.83 | Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. ( Gu, X; Lin, H; Wu, B; Yan, X; Zhou, L, 2016) |
| "Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment, although its suppression of the endogenous clot-dissolution complex APC:PS may ultimately lead to longer time-to-clot dissolution profiles, resulting in increased risk of re-thrombosis." | 3.83 | Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network. ( Biliouris, K; Hartmann, S; Lesko, LJ; Nowak-Göttl, U; Trame, MN, 2016) |
| "We report a case of femoral nerve palsy occurring as a result of spontaneous bilateral iliopsoas haematomas in an elderly patient on treatment dose dalteparin for a suspected pulmonary embolus." | 3.83 | Femoral nerve palsy associated with bilateral spontaneous iliopsoas haematomas: a complication of venous thromboembolism therapy. ( Kent, M; Podger, H, 2016) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 3.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012." | 3.81 | Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. ( Charters, MA; Dobson, C; Frisch, NB; Les, CM; Silverton, CD; Wessell, NM, 2015) |
| "This study focused on the clinical outcomes in multiple myeloma (MM) patients with venous thromboembolism (VTE) who received low-molecular-weight heparin (dalteparin) therapy." | 3.81 | Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, M; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH, 2015) |
| " The primary analysis compared the temporal course of event rates and rate differences between rivaroxaban and enoxaparin prophylaxis for symptomatic venous thromboembolism plus all-cause mortality (efficacy events) versus nonfatal major bleeding (safety events)." | 3.80 | Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. ( Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z, 2014) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 3.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "Recurrent venous thromboembolism (VTE) occurs in some patients despite treatment with the standard drugs, warfarin and low-molecular-weight heparin (LMWH)." | 3.80 | Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis. ( Thachil, J, 2014) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 3.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "Our experience with rivaroxaban in elective hip and knee arthroplasty showed no significant difference in the incidence of VTE or major bleeding." | 3.79 | Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. ( Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H, 2013) |
| "Fondaparinux and enoxaparin are useful for preventing venous thromboembolism after total knee arthroplasty (TKA), but both drugs have associated complications." | 3.79 | Safety of fondaparinux versus enoxaparin after TKA in Japanese patients. ( Hosaka, K; Ishii, T; Ryu, K; Saito, S; Sumino, T; Suzuki, G; Suzuki, T; Tokuhashi, Y, 2013) |
| "To evaluate the consistency of the antithrombotic efficacy and bleeding risk of apixaban 2." | 3.79 | Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. ( Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramacciotti, E; Ramirez, LM; Raskob, GE; Wang, L, 2013) |
| "This study compared the effectiveness of a change from enoxaparin to dalteparin for the prophylaxis of patients at risk of venous thromboembolism (VTE)." | 3.78 | Comparative effectiveness of dalteparin and enoxaparin in a hospital setting. ( Carson, W; Choe, Y; Faria, C; Parks, C; Powers, A; Schilling, B; Simons, WR, 2012) |
| " A lifetime model evaluated the cost effectiveness of rivaroxaban, dabigatran etexilate and enoxaparin sodium for the prophylaxis of venous thromboembolism after total hip replacement." | 3.78 | Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting. ( Barry, M; McCullagh, L; Walsh, C, 2012) |
| " In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12,729), the incidence of complications, including bleeding and adverse events related to surgery (such as wound infection, wound dehiscence and haemarthrosis) are reported." | 3.78 | The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. ( Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG, 2012) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 3.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "Four phase III studies compared oral rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA or TKA)." | 3.77 | Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. ( Bandel, TJ; Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG; Westermeier, T, 2011) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 3.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "The objective of this analysis was the evaluation of the outcomes and costs associated with rivaroxaban and enoxaparin for the prevention of postsurgical venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) and total knee replacement (TKR) from the US payer perspective." | 3.77 | Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. ( Diamantopoulos, A; Duran, A; Forster, F; Kwong, L; Lees, M; Sengupta, N, 2011) |
| "Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement." | 3.76 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010) |
| "Rates of VTE and bleeding events did not differ significantly between dabigatran etexilate and enoxaparin." | 3.75 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. ( Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2009) |
| "In the initial treatment of venous thromboembolism (VTE) fondaparinux, a pentasaccharide, is a good alternative to heparin." | 3.75 | Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2009) |
| "To evaluate the cost effectiveness of rivaroxaban and dabigatran etexilate compared with enoxaparin sodium for the prophylaxis of venous thromboembolism in patients undergoing elective THR and TKR in the Irish healthcare setting." | 3.75 | A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. ( Barry, M; McCullagh, L; Tilson, L; Walsh, C, 2009) |
| " Within the treatment group, patients who received dalteparin, enoxaparin, and UFH were significantly more likely to experience coded thrombocytopenia than those in the no treatment group." | 3.74 | Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. ( Farrelly, EM; Happe, LE; Sarnes, MW; Stanford, RH, 2008) |
| "This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE)." | 3.74 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. ( Hyers, TM; Spyropoulos, AC, 2007) |
| "The safety outcome was any on-treatment bleeding event." | 3.30 | Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial. ( Bao, Y; Chen, C; Chen, L; Chen, Q; Jiang, C; Jiang, G; Li, J; Liu, X; She, Y; Shen, L; Xu, L; Yang, Y; Zhao, M, 2023) |
| "We aimed to evaluate the effectiveness and safety of enoxaparin compared with UFH when used at their standard/intermediate dosing in COVID-19 patients." | 3.30 | Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence. ( Abraham, I; Al Saeed, J; Al-Bassam, S; Al-Makki, S; Alamer, A; AlLehaibi, LH; Almulhim, A; Alomar, M; Alrwaili, NR; Alsheef, M; Alsultan, S, 2023) |
| "This study aimed to compare the efficacy in reaching prophylactic anti-Xa levels and adverse effects profile of the 2 weight-based enoxaparin dosing protocols." | 3.30 | Comparison of postpartum anti-Xa levels following enoxaparin administration to prevent venous thromboembolism using 2 weight-based protocols: a randomized controlled trial. ( Eitam, H; Haj, R; Kassabri, R; Massalha, M; Nachum, Z; Yefet, E, 2023) |
| "The study INHIXACOVID19 was registred on ClinicalTrials." | 3.30 | Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19. ( Bignami, EG; Brambilla, P; Castagna, A; Cosmi, B; Cristini, F; De Stefano, G; Di Perri, G; Drago, F; Fornaro, G; Frattima, S; Giannella, M; Grandone, E; Lupi, M; Mazzaferri, F; Montineri, A; Pan, A; Patacca, A; Romagnoli, A; Rozzini, R; Salvetti, M; Stella, A; Testa, S; Viale, P, 2023) |
| "Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery." | 3.30 | Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. ( Wang, CC; Wu, T; Zhang, GQ; Zhang, LT; Zhou, LB, 2023) |
| "To compare the pharmacokinetic profiles of intravenous (IV) versus subcutaneous (SC) route of administration of LMWH." | 3.11 | Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial. ( De Schryver, N; Eeckhoudt, S; Gérard, L; Laterre, PF; Serck, N; Wittebole, X, 2022) |
| "No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis." | 3.11 | Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. ( Agostinis, M; Antolini, L; Barberis, D; Birocchi, S; Bonacchini, L; Carioti, G; Cattaneo, M; Gazzaniga, G; Grazia Valsecchi, M; Massaini, G; Merli, M; Morici, N; Podda, G; Saverio Serino, F; Trezzi, M, 2022) |
| "To evaluate fixed compared with weight-based enoxaparin dosing to achieve prophylactic anti-Xa levels after cesarean delivery." | 3.11 | Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. ( Allshouse, AA; Branch, DW; Bruno, AM; Campbell, HM; Lim, MY; Metz, TD; Silver, RM, 2022) |
| "Apixaban is a safe alternative to conventionally used enoxaparin for chemoprophylaxis in patients undergoing THA or TKA." | 3.11 | Apixaban or enoxaparin: Which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients? ( Banerjee, S; Elhence, A; Garg, PK; Kunal, K, 2022) |
| "Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2." | 3.11 | Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022) |
| "Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment." | 3.11 | Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study. ( Charalambakis, N; Kosmas, C; Lianos, E; Liatsos, AN; Mazlimoglou, E; Papageorgiou, G; Pouliakis, A; Simeonidis, D; Xynogalos, S; Ziras, N, 2022) |
| " Optimal thromboprophylaxis dosing in high-risk patients is unknown." | 3.01 | Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. ( Agrawal, N; Anderson, VE; Bonaca, M; Cohen, M; Cohoon, KP; Diab, W; Giannis, D; Gianos, E; Goldin, M; Halperin, JL; Hsia, J; Khanijo, S; Lesser, ML; Lewis, PA; Lund, JM; Mignatti, A; Ochani, K; Rahman, H; Sharifova, G; Sison, CP; Spyropoulos, AC; Tafur, A; Wang, J; Weitz, JI, 2021) |
| " The dose-response relationship with twice-daily milvexian was significant (one-sided P<0." | 3.01 | Milvexian for the Prevention of Venous Thromboembolism. ( Ageno, W; Gailani, D; Hylek, EM; Lassen, MR; Mahaffey, KW; Notani, RS; Raskob, GE; Roberts, R; Segers, A; Strony, J; Weitz, JI, 2021) |
| "To review the evidence cited in recent consensus documents providing recommendations for drug dosing for venous thromboembolism (VTE) prophylaxis in obese trauma patients." | 3.01 | Pharmacologic venous thromboembolism prophylaxis in obese trauma patients. ( Barletta, JF; Erstad, BL, 2023) |
| "Our results indicate that ODE, used after the initial TDE treatment period, is as safe and efficacious as TDE maintenance for the treatment of pediatric VTE." | 3.01 | Once-daily Compared With Twice-daily Enoxaparin Maintenance Therapy Appears Safe and Efficacious in Pediatric Venous Thromboembolism. ( Addy, K; Brown, D; Gibson, A; Hashmi, SS; Menon, N; Montanez, N; Rodriguez, N; Srivaths, L, 2023) |
| " A fixed Enoxaparin dosing regimen is the standard of care for chemoprophylaxis in most institutions; however, breakthrough venous thromboembolism events are still reported." | 3.01 | The efficacy of various Enoxaparin dosing regimens in general surgery patients: A systematic review. ( Al Tannir, AH; Biesboer, EA; de Moya, MA; Figueroa, J; Harding, E; Morris, RS; Murphy, PB; Pokrzywa, CJ, 2023) |
| " There is no standard venous thromboembolism (VTE) prophylaxis for both dosing and duration of anticoagulation following laparoscopic sleeve gastrectomy." | 3.01 | Adding a Preoperative Dose of LMWH may Decrease VTE Following Bariatric Surgery. ( Abdelsalam, AM; Aisha, HAA; ElAnsary, AMSE; Elfergany, HM; Nassef, SA; Salman, MA, 2021) |
| "Short-term (3 days) use of enoxaparin was shown to be effective and safe for VTE prophylaxis, comparable to regular use (at least 7 days), in postoperative management of gastric cancer surgery." | 3.01 | Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study. ( Fujiwara, T; Hinotsu, S; Kagawa, S; Kakiuchi, Y; Kikuchi, S; Kuroda, S; Kuwada, K; Nishizaki, M; Tsumura, T; Watanabe, M, 2021) |
| " This prospective, randomized, pilot study sought to explore the association between AT-III and anti-Xa goal attainment and to preliminarily evaluate two enoxaparin dosage adjustment strategies in patients with subprophylactic anti-Xa." | 3.01 | Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial. ( Athota, K; Dowd, JR; Droege, CA; Droege, ME; Elterman, J; Ernst, NE; Gomaa, D; Hanseman, D; Mueller, EW; Philpott, CD; Robinson, BHR; Wakefield, D; Webb, ML, 2021) |
| "Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding." | 3.01 | Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. ( Agnelli, G; Bauersachs, R; Becattini, C; Cohen, AT; Connors, JM; Dentali, F; Falvo, N; Giustozzi, M; Huisman, M; Ruperez Blanco, AB; Szmit, S, 2021) |
| " In the IV group, anti-Xa decrease half-life was 1." | 2.94 | Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ( Cihlar, R; Papiez, A; Penka, M; Sramek, V; Suk, P, 2020) |
| "Venous thromboembolism is an important patient safety issue in thoracic surgery patients." | 2.94 | Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. ( Barnett, S; Bertolaccini, C; Fleming, KI; Lin, J; Moulton, L; Pannucci, CJ; Stringham, J; Varghese, TK, 2020) |
| "Hospitalized patients with cancer are at an increased risk of developing venous thromboembolism (VTE)." | 2.94 | Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. ( Bauer, KA; Bockorny, B; Joyce, R; Khorana, AA; Neuberg, D; Peereboom, D; Puligandla, M; Roopkumar, J; Schlechter, BL; Sharda, AV; Zwicker, JI, 2020) |
| " Secondary outcomes included incidence of venous thromboembolic events, adverse events, medication adherence, participant quality of life, and medication satisfaction." | 2.94 | Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. ( Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ, 2020) |
| "Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050)." | 2.94 | Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial. ( Amano, T; Funakoshi, T; Homma, S; Ichikawa, N; Kamachi, H; Kawamura, H; Maeda, Y; Ohno, Y; Takahashi, N; Taketomi, A; Yokota, R; Yoshida, T, 2020) |
| "Enoxaparin dosing recommendations for morbidly obese patients are lacking." | 2.90 | Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. ( Alexander, BR; Curry, MA; Evans, KS; Kempton, CL; LaFollette, JA; Tran, RH, 2019) |
| "This study aimed to assess whether low-molecular-weight heparin (LMWH) is effective and safe in preventing postoperative venous thromboembolism (VTE) in patients undergoing esophageal cancer surgery." | 2.90 | Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. ( Hirata, S; Matsuhashi, N; Sakuratani, T; Shimokawa, T; Tanaka, H; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2019) |
| " Patients were significantly more likely to achieve an in-range peak aFXa with real-time dose adjustment as opposed to fixed dosing alone (85." | 2.90 | Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ( Bertolaccini, CB; Fleming, KI; Huang, LC; Pannucci, CJ; Pickron, TB; Prazak, AM, 2019) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 2.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| " Future research should examine the impact of weight-based once daily enoxaparin dosing versus twice daily enoxaparin dosing on prophylaxis adequacy." | 2.87 | Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure. ( Fleming, KI; Holoyda, K; Moulton, L; Pannucci, CJ; Prazak, AM; Varghese, TK, 2018) |
| " Weight-based twice-daily enoxaparin dosing may optimize the risks and benefits of prophylactic anticoagulation after plastic and reconstructive surgery." | 2.87 | The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding. ( Agarwal, J; Fleming, KI; Momeni, A; Pannucci, CJ; Prazak, AM; Rockwell, WB, 2018) |
| " In addition, the incidence of all enoxaparin treatment- and operation-related adverse events was investigated." | 2.87 | Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety. ( Baba, H; Baba, Y; Hiyoshi, Y; Imamura, Y; Ishimoto, T; Iwatsuki, M; Miyamoto, Y; Watanabe, M; Yoshida, N, 2018) |
| " In conclusion, this study suggests that 40 mg once daily of Ce, a biosimilar enoxaparin, is as effective and safe as the branded Sanofi enoxaparin in the prophylaxis of VTE in patients submitted to major abdominal surgery at risk for VTE." | 2.87 | Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial. ( Afiune, JB; Agati, L; Aguiar, VCR; Araujo, GR; Assao, VT; Caffaro, RA; Caltabiano, TB; Castelli, V; Colnago, EMDS; Correa, JA; Costa, AJV; DalAcqua, LZ; Davila, R; de Lima, TAM; de Souza, DG; Ferreira, U; Fugii, EY; Magella, FM; Matheus, WE; Mussalem, JS; Neto, SG; Osvaldt, AB; Pazetto, LE; Ramacciotti, E; Raymundo, SRO; Rodrigues, DG; Russeff, GJDS; Sato, DY; Toffoletto, O; Volpiani, GG, 2018) |
| " Asymptomatic deep vein thrombosis (DVT) diagnosed with compression ultrasound (CUS) is a common endpoint in trials assessing the efficacy of anticoagulants to prevent venous thromboembolism (VTE), but the relationship of asymptomatic thrombus to mortality remains uncertain." | 2.87 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. ( Chi, G; Cohen, AT; Datta, S; Gibson, CM; Goldhaber, SZ; Gurin, M; Haroian, N; Harrington, RA; Hernandez, AF; Hull, RD; Kalayci, A; Korjian, S; Nafee, T; Qamar, I; Yee, MK, 2018) |
| "Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk." | 2.87 | Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018) |
| "RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality." | 2.87 | Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018) |
| "Among 94 patients, weight-based dosing ranged from 0." | 2.84 | Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis. ( Fleming, KI; Hunt, MM; Pannucci, CJ; Prazak, AM, 2017) |
| "Dabigatran is an effective oral alternative to enoxaparin for thromboprophylaxis as demonstrated by the RE-NOVATE II study global results." | 2.84 | Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study. ( Babhulkar, S; Clemens, A; Dadi, A; Iyer, R; Kamath, S; Malhotra, R; Mody, B; Mutha, S; Reddy, G; Sanjib, KB; Shah, V; Shetty, N; Tapasvi, S; Wadhwa, M, 2017) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 2.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| "Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7." | 2.84 | Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017) |
| " Analysis 3 compared standard dosing to dose adjustment with the primary outcome being anti-Xa adequacy; secondary outcomes were VTE, pulmonary embolism, and bleeding complications." | 2.82 | Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis. ( Anantha, RV; Connell, M; Kung, JY; Parker, A; Raffael, K; Strickland, M; Verhoeff, K, 2022) |
| "Trauma patients are at high risk of developing venous thromboembolism (VTE), and standard dosing enoxaparin regimens may be inadequate for prophylaxis." | 2.82 | The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis. ( Cole, E; Ebeid, A; Stallwood-Hall, C, 2022) |
| "This manuscript establishes inadequate enoxaparin dosing as a plausible mechanism for breakthrough VTE in surgical patients, and identifies anticoagulant dose adequacy as a novel target for process improvement measures." | 2.82 | Low Anti-Factor Xa Level Predicts 90-Day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials. ( Bertolaccini, C; Fleming, KI; Huang, LC; Momeni, A; Pannucci, CJ; Pickron, TB; Prazak, AM; Stringham, J; Varghese, TK, 2022) |
| "There were 23 patients with hemophilia, 18 (78%) with hemophilia A and 5 (22%) with hemophilia B, who underwent high-risk surgeries (39% THR and 61% TKA)." | 2.82 | Thromboprophylaxis and Incidence of Venous Thromboembolism in Patients With Hemophilia A or B Who Underwent High-Risk Orthopedic Surgeries. ( Akbar, SA; Doll, DC; Dong, X; Freter, CE; Holm, L; Hopkins, T; Hossain, AM; Kale, G; Kim, D; Naidzionak, U; Raza, S, 2016) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | 2.82 | Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| "To evaluate the effectiveness of TEG-adjusted prophylactic enoxaparin dosing among trauma and surgical patients." | 2.82 | Thrombelastography-Based Dosing of Enoxaparin for Thromboprophylaxis in Trauma and Surgical Patients: A Randomized Clinical Trial. ( Arbabi, S; Bulger, EM; Connelly, CR; Erickson, AS; Fair, KA; Hart, KD; Holcomb, JB; Louis, SG; Moore, LJ; Rick, EA; Schreiber, MA; Simeon, EC; Van, PY, 2016) |
| " This analysis supports dosing patients with renal impairment in accordance with patients with normal renal function; however, anti-Xa monitoring could be considered to further support safety in selected patients, particularly those with very severe renal impairment." | 2.82 | A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. ( Abreu, P; Feugère, G; Heissler, J; Jen, F; Ruiz, MT; Woodruff, S, 2016) |
| "The incidence of symptomatic VTE (deep vein thrombosis and pulmonary embolism) events was lower (0/377) in participants who received bemiparin than in those who received no pharmacologic intervention (12/380, 3." | 2.80 | Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. ( Al Tawil, NG; Alalaf, SK; Ali, MS; Jawad, AK; Jawad, RK, 2015) |
| "Body weight is a better predictor of anti-Xa levels compared to lean body weight." | 2.80 | Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. ( Brandjes, DP; Celik, F; Gerdes, VE; Hooijberg, JH; Huitema, AD; van de Laar, AW, 2015) |
| "A total of 10 cancer patients with VTE treated with the LMWH enoxaparin at a standard dose of 1 mg/kg every 12 h were enrolled." | 2.80 | Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ( Gabizon, AA; Na'amad, M; Nasser, NJ; Weinberg, I, 2015) |
| "Our current dosing practice of 40 mg SC for individuals with a BMI ≤50 kg/m(2) and 60 mg for individuals with a BMI ≥50 kg/m(2) resulted in anti-factor Xa activity that was sufficient for adequate thromboprophylaxis in adolescent bariatric surgical patients." | 2.80 | Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study. ( Mushtaq, A; Nadler, EP; van den Anker, JN; Vaughns, JD; Ziesenitz, VC, 2015) |
| "Advanced pancreatic cancer (APC), in addition to its high mortality, accounts for the highest rates of venous thromboembolic events (VTEs)." | 2.80 | Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. ( Bischoff, S; Denecke, T; Deutschinoff, G; Dörken, B; Grunewald, M; Hahnfeld, S; Müller, L; Oettle, H; Opitz, B; Pelzer, U; Reitzig, PC; Riess, H; Sinn, M; Stauch, M; Stieler, JM, 2015) |
| "1 IU/mL was considered subtherapeutic and the final dosage requirement was recorded." | 2.80 | Standard Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis Is Not Sufficient for Most Patients Within a Trauma Intensive Care Unit. ( Ahmed, N; Allen, J; Brevard, SB; Frotan, AM; Gonzalez, RP; Replogle, WH; Rostas, JW; Simmons, JD; Thacker, D, 2015) |
| "This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty." | 2.79 | Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). ( Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014) |
| "Venous thromboembolism is an important complication following major abdominal surgery." | 2.79 | Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. ( Agnelli, G; Fisher, W; George, D; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Murphy, J; Turpie, AG, 2014) |
| " There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs." | 2.79 | Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014) |
| " Dosing of patients with extreme body weights has not been well studied, especially dosing of low weight patients." | 2.78 | Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms. ( Acuña, MP; Aizman, A; Cerda, J; Ernst, D; Mellado, R; Moya, P; Rojas, L, 2013) |
| " While dosing of LMWH based on weight alone is standard for most non-pregnant patients, there is no data on the utility of this approach in pregnancy." | 2.78 | Weight-adjusted dosing of tinzaparin in pregnancy. ( Gibson, PS; Jiang, X; Mansoor, A; Newell, K; Ross, S; Sam, DX; Tang, S, 2013) |
| "Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery." | 2.77 | Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. ( Gallerani, M; Imberti, D; Manfredini, R, 2012) |
| " We prospectively compared three enoxaparin dosing regimens for the achievement of goal peak anti-Factor Xa levels in medically ill patients (n 5 31) with extreme obesity (body mass index (BMI) ‡ 40 kg/m2)." | 2.77 | Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. ( Freeman, A; Horner, T; Pendleton, RC; Rondina, MT, 2012) |
| "Edoxaban is an oral direct factor (F)Xa inhibitor in advanced stages of clinical development." | 2.77 | Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. ( Halim, AB; He, L; Lee, F; Matsushima, N; Mendell, J; Worland, V; Zahir, H; Zhang, G, 2012) |
| " However, a delay in dosing could occur for clinical or logistical reasons." | 2.77 | Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. ( Clemens, A; Dahl, OE; Eriksson, BI; Hantel, S; Kurth, AA; Rosencher, N, 2012) |
| "Venous thromboembolism is a frequent complication in critically ill patients that has a negative impact on patient outcomes." | 2.77 | Bioactivity of enoxaparin in critically ill patients with normal renal function. ( Gouya, G; Heinz, G; Kapiotis, S; Locker, G; Madl, C; Palkovits, S; Stella, A; Wolzt, M, 2012) |
| "Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism." | 2.77 | Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. ( Agnelli, G; Chaudhari, U; Fisher, W; George, DJ; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Turpie, AG, 2012) |
| " The goal of this study was to determine whether enoxaparin for early venous thromboembolism (VTE) prophylaxis is safe for hemodynamically stable patients with TBIs." | 2.76 | Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage. ( Davidson, MA; Guillamondegui, O; Koehler, DM; Shipman, J, 2011) |
| "Our purpose was to describe anti-Xa levels, dosage requirements, and complications associated with enoxaparin treatment doses in patients with morbid obesity." | 2.76 | Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. ( Deal, EN; Hollands, JM; Reichley, RM; Riney, JN; Skrupky, LP; Smith, JR, 2011) |
| "Non-surgical cancer patients are at high thrombotic risk." | 2.75 | The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. ( Eichinger, S; Kaider, A; Kranz, A; Kyrle, PA; Quehenberger, P; Schmid, R; Traby, L, 2010) |
| "Major bleeding was not significantly different between enoxaparin and placebo in either group." | 2.75 | Does ambulation modify venous thromboembolism risk in acutely ill medical patients? ( Amin, AN; Girard, F; Samama, MM, 2010) |
| "In acutely ill medical patients of at least 40 years of age, thromboprophylaxis with certoparin 3000 IU daily is effective and safe in comparison with 7500 IU twice daily UFH." | 2.75 | An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. ( Abletshauser, C; Bramlage, P; Greinacher, A; Haas, S; Riess, H; Schellong, SM; Schwanebeck, U; Sieder, C, 2010) |
| " These assays may provide useful markers to guide appropriate dalteparin (and other low-molecular weight heparin) dosing schedules to optimize anticancer effects of dalteparin in APC." | 2.75 | Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. ( Echrish, H; Ettelaie, C; Gardiner, E; Greenman, J; Li, C; Madden, LA; Maraveyas, A, 2010) |
| "Edoxaban is a new oral direct factor Xa inhibitor." | 2.75 | Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. ( Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010) |
| "Symptomatic acute pulmonary embolism treatment with full therapeutic doses of tinzaparin for 6 months is a feasible alternative to conventional treatment with vitamin K antagonists." | 2.75 | Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. ( Colomé-Nafria, E; Golpe, R; Leiro-Fernández, V; Méndez-Marote, L; Núñez-Delgado, JM; Palacios-Bartolomé, A; Pérez-de-Llano, LA, 2010) |
| "The aim of this study was to evaluate the pharmacodynamic parameters of two doses of the LMWH parnaparin administered to patients undergoing bariatric surgery." | 2.74 | Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). ( Baldini, E; Cini, M; De Paoli, M; Guerra, M; Imberti, D; Legnani, C; Nicolini, A; Palareti, G; Zanardi, A, 2009) |
| " Dosing stopped at contrast venography, 12 to 15 days after surgery." | 2.74 | Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. ( Caprini, JA; Clements, ML; Comp, PC; Davidson, BL; Francis, CW; Friedman, RJ; Ginsberg, JS; Hantel, S; Huo, MH; Lieberman, JR; Muntz, JE; Raskob, GE; Schnee, JM, 2009) |
| "There are limited data on appropriate dosing of low-molecular-weight heparins (LMWHs) for venous thromboembolism (VTE) prophylaxis in bariatric surgery." | 2.73 | Prophylaxis of thromboembolism in bariatric surgery with parnaparin. ( Cuocolo, A; De Caterina, M; Ferrari, P; Forestieri, P; Formato, A; Pilone, V; Quarto, G; Ruocco, A, 2007) |
| " We evaluated three dosage regimens of postoperative enoxaparin in Japanese patients undergoing elective total hip or knee arthroplasty." | 2.73 | Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. ( Fuji, T; Fujita, S; Niwa, S; Ochi, T, 2008) |
| "Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer." | 2.73 | Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). ( Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J, 2008) |
| "Children with acute lymphoblastic leukemia (ALL) have a substantial risk for thromboembolism (TE) that is related to L-asparaginase-induced antithrombin (AT) deficiency and placement of central venous lines." | 2.73 | Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. ( Hager, J; Klein-Franke, A; Kropshofer, G; Meister, B; Strasak, AM; Streif, W, 2008) |
| "A significant dose-response effect for VTE was observed for SR123781A (p < 0." | 2.73 | SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. ( Dahl, O; Lassen, MR; Mismetti, P; Turpie, AG; Zielske, D, 2008) |
| " Little consensus exists regarding who should receive extended enoxaparin thromboprophylaxis or how they should be dosed, namely whether to use weight-based or BMI-stratified dosing strategies." | 2.72 | Risk factors for postdischarge venous thromboembolism among bariatric surgery patients and the evolving approach to extended thromboprophylaxis with enoxaparin. ( Dumon, KR; Garcia Whitlock, AE; O'Connor, K; Tewksbury, C; Williams, NN, 2021) |
| "In THA patients, the rate of deep vein thrombosis (DVT) was lower with factor Xa inhibitors than LMWH." | 2.61 | Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( Cheng, K; Jia, J; Liang, Q; Sun, G; Wang, Q; Wang, Z; Wu, J, 2019) |
| "Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio." | 2.61 | Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019) |
| "En cas de MTEV liée au cancer, les héparines de bas poids moléculaire (HBPM) et en particulier la daltéparine, ont longtemps représenté le traitement de référence." | 2.61 | [Direct oral anticoagulants in the treatment of cancer-associated thrombosis]. ( Marti, C; Righini, M; Robert-Ebadi, H; Rossel, A; Stebler-Fontaine, L, 2019) |
| "No significant increase in major intracranial hemorrhage (p = 0." | 2.58 | Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. ( Khan, NR; Lee, SL; Patel, PG; Sharpe, JP; Sorenson, J, 2018) |
| "Rivaroxaban is a potential option for patients with cancer and VTE." | 2.58 | Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis. ( Chen, D; Xing, J; Yin, X, 2018) |
| "Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE." | 2.58 | Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018) |
| "Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding." | 2.58 | Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. ( Bauersachs, R; Martínez-Zapata, MJ; Mathioudakis, AG; Mousa, SA, 2018) |
| "The current debate over the optimal Enoxaparin prophylactic dosing strategies in obese patients centre around whether it should be based on the actual weight of the patient (i." | 2.55 | Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed. ( Ball, P; He, Z; Morrissey, H, 2017) |
| "We carried out a dose-response model-based meta-analysis to assess venous thromboembolism (VTE) and bleeding with factor Xa (FXa) inhibitors (apixaban, edoxaban, rivaroxaban) and a thrombin inhibitor (dabigatran) compared with European (EU) (40 mg q." | 2.55 | Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. ( Boyd, RA; DiCarlo, L; Mandema, JW, 2017) |
| " Inadequate enoxaparin dosing has been correlated with both asymptomatic and symptomatic VTE events." | 2.55 | Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis. ( Pannucci, CJ; Prazak, AM; Scheefer, M, 2017) |
| "To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population." | 2.55 | Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. ( Gales, MA; Horyna, TJ; Sandmann, EA; Walker, CK, 2017) |
| "Apixaban is a NOAC that selectively inhibits the coagulation factor Xa; it is approved for the prevention of VTE after total hip replacement and total knee replacement surgery." | 2.52 | Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review. ( Benedetti, R; Caforio, M; Imberti, D; Maniscalco, P; Porcellini, G, 2015) |
| "Multiple studies have addressed deep vein thrombosis chemoprophylaxis timing in traumatic brain injuries." | 2.52 | Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: an evidence-based review. ( Abdel-Aziz, H; Dunham, CM; Hileman, BM; Malik, RJ, 2015) |
| " With regard to dosage, for in-hospital treatment the higher dosage of 40 mg twice daily as opposed to 30 mg seems to significantly reduce the incidence of VTE without significantly affecting bleeding rate." | 2.52 | Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: A best evidence topic. ( Khan, OA; Knight, WR; McGlone, ER; Parker, SG; Sufi, P, 2015) |
| "Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis." | 2.52 | Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. ( Chen, M; Chen, S; Deng, Z; Feng, W; Kong, G; Liu, S; Liu, Z; Wang, H; Wu, K; Wu, Y, 2015) |
| "For patients with active cancer (N = 759), the analysis on the efficacy outcomes demonstrated a trend in favour of NOAC (OR 0." | 2.50 | Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. ( Larsen, TB; Lip, GY; Nielsen, PB; Rasmussen, LH; Skjøth, F, 2014) |
| "Compared with patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE." | 2.50 | Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Kahale, L; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I, 2014) |
| "No major bleeding was observed in the patients treated with LMWH or warfarin and in less than 1% of those treated with aspirin." | 2.50 | Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. ( Di Nisio, M; Otten, HM; Porreca, E; Rutjes, AW, 2014) |
| " Of note, for both filters and augmented pharmacologic dosing strategies, patients at highest risk for VTE were more likely to receive more intensive interventions, limiting our ability to attribute outcomes to prophylactic strategies used." | 2.49 | Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. ( Brotman, DJ; Chelladurai, Y; Haut, ER; Kebede, S; Prakasa, KR; Segal, JB; Sharma, R; Shermock, K; Shihab, HM; Singh, S, 2013) |
| "To evaluate the appropriate dosing of enoxaparin as a venous thromboembolism (VTE) prophylaxis in hospitalized obese patients." | 2.49 | Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients. ( Alsharhan, M; Cooper, MR; Durand, C; Willett, KC, 2013) |
| " However, very few studies compare different dosing regimens of the LMWH itself." | 2.48 | Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: a literature summary. ( Diaz, AH; Gilreath, JA; Rodgers, GM, 2012) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Dabigatran etexilate is an oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration for the prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation." | 2.47 | Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. ( Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R, 2011) |
| "Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)." | 2.47 | Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011) |
| "Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)." | 2.47 | Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011) |
| "Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)." | 2.47 | Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011) |
| "An association between cancer and thrombosis has been recognized since 1865." | 2.46 | Bemiparin in oncology. ( Lecumberri Villamediana, R; Monreal Bosch, M; Prandoni, P; Vignoli, A, 2010) |
| "Rivaroxaban is a newly developed oral medicine that direct inhibits factor Xa for the prevention and treatment of thromboembolic disorders." | 2.46 | Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. ( Cao, YB; Jiang, YY; Shen, H; Zhang, JD, 2010) |
| " Selection of the appropriate dosage is strongly recommended." | 2.45 | Safety evaluation of enoxaparin in currently approved indications. ( Meneveau, N, 2009) |
| "Cancer is a major risk factor for the development of venous thromboembolism (VTE)." | 2.44 | Management of venous thromboembolism in patients with cancer: role of dalteparin. ( Linkins, LA, 2008) |
| " Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown." | 1.91 | Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. ( Endeman, H; Hunfeld, NGM; Kruip, MJHA; Preijers, T; Romano, LGR, 2023) |
| "7-280) and relative bioavailability of 40." | 1.91 | Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing? ( Diepstraten, J; Kruip, MJHA; Ter Heine, R; van der Heiden, PLJ; van Rongen, A; Zijlstra, MP, 2023) |
| "The optimal enoxaparin dosing strategy to achieve venous thromboembolism (VTE) prophylaxis in trauma patients remains unclear." | 1.91 | One size does not fit all: Sex bias in pharmacologic venous thromboembolism prophylaxis. ( Berndtson, AE; Borst, JM; Box, K; Costantini, TW; Doucet, JJ; Godat, LN; Kirchberg, TN; Modi, RN; Smith, AM, 2023) |
| "This single-center study suggests that DOACs are both safe and efficacious for the treatment of VTE in children with cancer." | 1.91 | Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients. ( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023) |
| " Utilization of closed incision negative pressure wound therapy for the treatment of postoperative wound drainage did not differ between dosing groups." | 1.91 | Administration of Prophylactic Enoxaparin on the Morning of Surgery Does Not Increase Risk of Blood Transfusion or Wound Drainage Following Internal Fixation of Geriatric Femur Fractures. ( Boakye, LAT; Cluts, LM; Moloney, GB; Palmeri, C, 2023) |
| " capped (< 1 mg/kg) enoxaparin dosing regimen." | 1.91 | Management of venous thromboembolism in morbidly obese patients: a 10-year review. ( Donarelli, C; Ho, P; Khattak, Z; Kwok, A; Lai, J; Lim, HY; Lui, B; Wee, B, 2023) |
| "For discriminating arterial and venous thrombosis, there was no significant difference between the ADA vs." | 1.91 | External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Loffredo, L; Pignatelli, P; Spagnoli, A; Vestri, A; Violi, F, 2023) |
| " There is concern whether body mass index (BMI)-based enoxaparin dosing consistently achieves prophylactic targets in patients with severe obesity." | 1.91 | Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients. ( Chang, CK; Herrmann, DJ; Higgins, RM; Kindel, T; Peppard, WJ; Rein, L, 2023) |
| "Guidelines for enoxaparin dosing after trauma recommend an initial dose of 40 mg twice daily for most patients and then adjusting by anti-Xa levels." | 1.91 | Creatinine Clearance May Predict Goal Enoxaparin Dose in Trauma. ( Dhillon, NK; Drevets, P; Fierro, NM; Ley, EJ; Park, G; Stupinski, J, 2023) |
| " VTE prophylaxis with weight-based enoxaparin dosing may be more effective than the standard dosing regimen for overweight and obese patients; however, weight-based dosing is not practiced routinely." | 1.91 | Evaluating Adequacy of VTE Prophylaxis Dosing with Enoxaparin for Overweight and Obese Patients on an Orthopedic-Medical Trauma Comanagement Service. ( Dailey, H; Jovin, F; Perrin, A; Sheth, H; Smith, R; Snyder, V, 2023) |
| " Emerging literature supports anti-factor Xa (AFXa) monitoring for patients on enoxaparin (LMWH), although a significant knowledge gap remains regarding the optimal dosing and monitoring in EGS patients." | 1.91 | Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients. ( Al Tannir, AH; Biesboer, EA; de Moya, M; Figueroa, J; Morris, RS; Murphy, PB; Pokrzywa, CJ, 2023) |
| " The BV dosing was as follows: patients with a BV of 3 to 4." | 1.91 | Evaluation of a novel blood volume-based enoxaparin dosing guideline for venous thromboembolism prophylaxis in trauma patients. ( Carver, TW; Herrmann, DJ; Holschbach, L; Hubbard, S; Langenstroer, EA; O'Keefe, MM; Peppard, WJ; Rein, L, 2023) |
| "The incidence of pulmonary embolism (2." | 1.91 | Early venous thromboembolism prophylaxis in patients with trauma intracranial hemorrhage: Analysis of the prospective multicenter Consortium of Leaders in Traumatic Thromboembolism study. ( Chien, CY; Inaba, K; Knudson, MM; Martin, MJ; Matsushima, K; Moore, EE; Sauaia, A; Schellenberg, M; Wu, YT, 2023) |
| " Adequate dosing was defined as enoxaparin 30 mg or 40 mg twice daily." | 1.91 | Inadequate Venous Thromboembolism Chemoprophylaxis Is Associated With Higher Venous Thromboembolism Rates Among Trauma Patients With Epidurals. ( Alexander, J; Dhillon, NK; Fierro, NM; Ikonte, C; Ley, EJ; Mason, R; Muniz, T; Siletz, AE, 2023) |
| " To evaluate the safety of this dosing regimen, data was then compared to patients from our institution with similar TBI profiles who had received 5,000 units (U) of subcutaneous heparin (SQH) prophylaxis." | 1.91 | Early administration of high dose enoxaparin after traumatic brain injury. ( Cho, YW; Cripps, M; DeAtkine, E; Fesmire, A; Park, C; Scrushy, M; Wan, B; Zhu, M, 2023) |
| "The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
| "All patients with newly diagnosed endometrial cancer who underwent minimally invasive staging surgery from January 1, 2017 to December 31, 2020 were identified retrospectively, and clinicopathologic and outcome data were obtained through chart review." | 1.91 | Prophylactic anticoagulation after minimally invasive hysterectomy for endometrial cancer: a cost-effectiveness analysis. ( Bell, S; Berger, J; Garrett, A; Kim, H; Lesnock, J; Orellana, T; Rosiello, A; Rush, S; Smith, K, 2023) |
| "Dalteparin was not stopped in any women." | 1.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| "History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration." | 1.91 | Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin. ( Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S, 2023) |
| " A population pharmacodynamic model was developed using non-linear mixed-effects modelling." | 1.72 | Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels. ( Diepstraten, J; Franssen, CFM; Jaspers, TCC; Khorsand, N; Koomen, JV; Lukens, MV; Maat, B; Meijer, CE; Touw, DJ; van den Bemt, PMLA; Vleming, LJ, 2022) |
| " After observing higher than expected VTE rates within our center's Trauma Quality Improvement Program data, we instituted a change in our VTE prophylaxis protocol, moving to enoxaparin dosing titrated by anti-Xa levels." | 1.72 | Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients. ( Collier, BR; Faulks, ER; Gates, RS; Gillen, JR; Lollar, DI; Smith, J, 2022) |
| "Anti-Xa-guided enoxaparin dosing for VTE prophylaxis in neurosurgical patients may help prevent major bleeding." | 1.72 | Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. ( Cua, S; May, CC; Powers, CJ; Smetana, KS, 2022) |
| " We investigated whether our dosage regimen of enoxaparin resulted in similar serum aFXa levels in female and male patients undergoing bariatric surgery." | 1.72 | Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. ( Duprée, A; Izbicki, J; Lautenbach, A; Mann, O; von Kroge, P; Wagner, J; Wolter, S; Wruck, H, 2022) |
| "The aim of this study was to evaluate the effectiveness of a body mass index (BMI)-based enoxaparin prophylaxis dosing protocol at achieving target anti-factor Xa (anti-Xa) concentrations in the trauma population." | 1.72 | Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients. ( Carver, TW; Herrmann, DJ; Hubbard, S; O'Keefe, MM; Peppard, WJ; Prom, A; Rein, LE, 2022) |
| "Despite standard thromboprophylaxis, venous thrombosis is common in critically ill patients with COVID-19." | 1.72 | [Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis]. ( Bonelli, I; Hunter, M; López Saubidet, I; Lurbet, MF; Mandó, F; Parodi, J; Rodríguez, PO, 2022) |
| " To further mechanistically explore obesity-associated differences in anti-Xa concentration, a pediatric physiologically-based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity." | 1.72 | Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity. ( Carreño, FO; Edginton, AN; Gerhart, JG; Gonzalez, D; Hornik, CP; Kirkpatrick, CM; Kumar, KR; Lee, CR; Loop, MS; Sinha, J, 2022) |
| " Weight-based enoxaparin dosing was administered using a pharmacy-driven protocol, which later included a low molecular weight, anti-Xa level directed-dose adjustment strategy." | 1.72 | Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children. ( Bennett, E; Delgado-Corcoran, C; Faustino, EV; Heyrend, C; Pannucci, CJ; Wilcox, R, 2022) |
| " Patients received standard fixed enoxaparin dosing at 30 mg twice daily in head and neck (H&N) and 40 mg daily in breast reconstructions." | 1.72 | Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients. ( Acarturk, TO; Ambani, SW; Bengur, FB; Cruz, C; Gimbel, ML; Kubik, MW; Manders, EK; Nguyen, VT; Solari, MG; Sridharan, S; Varelas, LJ, 2022) |
| " Standard trauma prophylaxis dosing with enoxaparin 30 mg twice daily may be inadequate to prevent VTEs." | 1.72 | Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients. ( Bellfi, LT; Boudreau, R; Greiffenstein, P; Hunt, JP; Marr, A; Mosier, W; Rueb, N; Schoen, J; Smith, A; Stuke, L; Zimmerman, SA, 2022) |
| "Aspirin 81 mg was cost-effective if the initial symptomatic VTE rates decreased by an absolute risk reduction (ARR) of 0." | 1.72 | Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty. ( Aynardi, MC; Bonaddio, V; Kirchner, GJ; Koroneos, Z; Lorenz, FJ; Manto, KM; Martinazzi, BJ; Stauch, CM, 2022) |
| "Obesity is a well-recognised risk factor for venous thromboembolism, and increased dosing of pharmacological prophylaxis is recommended in obese inpatients." | 1.72 | Improving compliance with venous thromboembolism prophylaxis guidelines in obese inpatients. ( Bortz, H; Chee, A; McFadyen, JD; Yip, J, 2022) |
| "venous thromboembolism is a complication among admitted medical and surgical patients." | 1.72 | Evaluation of venous thromboembolism (VTE) risk assessment and thrombo-prophylaxis practices in hospitalized medical and surgical patients at Aga Khan Hospital Dar es Salaam: single-centre retrospective study. ( Adebayo, P; Ali, A; Hameed, K; Ismail, A; Jadawji, N; Jusabani, A; Kiviri, W; Zehri, AA, 2022) |
| " Anti-Xa activity in critically ill patients achieved with standard dosing of low-molecular-weight heparins (LMWH) is often below the target of 0." | 1.72 | Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. ( Benes, J; Cerny, V; Jobanek, J; Skulec, R, 2022) |
| "The evaluation criteria for dosage of low-molecular-weight heparin (LMWH) for pregnant women at high risk of venous thromboembolism (VTE) remain unclear." | 1.72 | Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women. ( Guo, L; Luo, Y; Mu, L; Xiao, S; Ye, Z; Zhang, J, 2022) |
| "Thrombosis was associated with increasing age (median: 74." | 1.72 | Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. ( Akinosoglou, K; Chatzistamati, A; Dimakopoulou, V; Efraimidis, G; Golemi, F; Kaiafa, G; Konstantinidou, A; Liontos, A; Markatis, E; Milionis, H; Mitsianis, A; Panagopoulos, P; Papanikolaou, IC; Papazoglou, D; Pavlaki, M; Pouliakis, A; Randou, E; Samaras, V; Savopoulos, C; Savvanis, S; Triantafyllidis, C; Vadala, C; Varela, K; Xarras, P, 2022) |
| "Real word data on the efficacy and safety of long-term use of tinzaparin for the treatment of cancer-associated thrombosis (CAT) are scarce." | 1.72 | Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. ( Cajfinger, F; Crichi, B; Farge, D; Frere, C; Janus, N; Le Maignan, C; Marjanovic, Z; Rueda-Camino, JA; Spiess, N, 2022) |
| "The overall purpose of this study was to describe the impact of a tinzaparin weight-band dosing table for VTE prophylaxis on wound healing, thrombosis, and bleeding outcomes in patients undergoing total joint arthroplasty." | 1.72 | Impact of Weight-Band Dosing of Tinzaparin for Venous Thromboembolism Prophylaxis on Persistent Wound Drainage in Adult Patients Undergoing Hip and Knee Arthroplasty. ( Antle, O; Cooper, C; Dersch-Mills, D; Kenny, A; Lowerison, J, 2022) |
| " We hypothesized that weight-based dosing would result in appropriate prophylaxis more reliably than fixed dosing." | 1.62 | Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. ( Ayoung-Chee, P; Bukur, M; DiMaggio, CJ; Frangos, SG; Marshall, GT; Moore, S; Rodier, SG; Tandon, M, 2021) |
| " Enoxaparin dosing and corresponding anti-factor Xa levels were collected." | 1.62 | Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit. ( Abdel-Rasoul, M; Magers, J; Prusakov, P; Song, D, 2021) |
| "The aim of this study was to evaluate the adequacy of prophylactic dosing of enoxaparin in patients with severe obesity by performing an antifactor Xa (AFXa) assay." | 1.62 | Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. ( Aminian, A; Brethauer, SA; Cetin, D; Daigle, CR; Karas, LA; Nor Hanipah, Z; Schauer, PR, 2021) |
| " Enoxaparin dosing was nearly double the recommended starting doses for secondary thromboprophylaxis." | 1.62 | Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. ( Dobbie, LJ; Eskell, L; Lamb, A; Ramage, IJ; Reynolds, BC, 2021) |
| " At 21 days, the incidence rate of death and clinical deterioration were lower in patients on higher doses than in those on the standard dosage (hazard ratio 0." | 1.62 | Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. ( Abbattista, M; Aliberti, S; Artoni, A; Blasi, F; Carrafiello, G; Ciavarella, A; De Zan, V; Folli, C; Gori, A; Grasselli, G; Ierardi, AM; Martinelli, I; Monzani, V; Panigada, M; Peyvandi, F, 2021) |
| "Standard fixed-dose enoxaparin dosing regimens may not provide adequate prophylaxis against venous thromboembolism among obese hospitalized patients." | 1.62 | Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. ( Davis, S; Gibson, CM; Hall, C; Schillig, JM, 2021) |
| " The evidence suggests a need to evaluate different dosing protocols among burns patients in order to improve AFXa levels, with the aim of decreasing incidence of VTE in high-risk patients." | 1.62 | Venous thromboembolism in burns patients: Are we underestimating the risk and underdosing our prophylaxis? ( Bortz, H; Cleland, H; Harms, KA; Lo, C; Lu, P; Paul, E, 2021) |
| " Enoxaparin is traditionally dosed using weight." | 1.62 | Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy. ( Andrick, B; Graham, J; Grassi, S; Hart, K; Manikowski, J, 2021) |
| "Common VTE risk factors included cancer (46." | 1.62 | Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study. ( Johnson, SA; Jones, AE; Lai, N; Witt, DM, 2021) |
| " Our objective was to evaluate the efficacy of enoxaparin dosed 40 mg twice daily in achieving prophylactic plasma anti-Xa levels in obese burn patients." | 1.62 | Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients. ( Jones, S; King, B; McKinzie, BP; Nizamani, R; Williams, FN, 2021) |
| "The use of initial weight-based enoxaparin dosing in trauma patients routinely achieved the prespecified target anti-Xa goal." | 1.62 | Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients. ( Huang, E; Martinez-Quinones, P; Robinson, T; Taylor, A; Waller, J; White, C, 2021) |
| "Odds of venous thromboembolism were not statistically significant between all three study medications." | 1.62 | A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision. ( Cornett, B; Dziadkowiec, O; Harkness, W; Hassan, S; Hicks, ME; Kopstein, M; Scherbak, D; Watts, PJ, 2021) |
| "Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery." | 1.62 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. ( Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021) |
| "Treatment with dalteparin or dabigatran was associated with a decreased 90-day risk of VTE following primary TKA surgery compared with treatment with rivaroxaban." | 1.62 | Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study. ( Gromov, K; Jensen, TB; Jimenez-Solem, E; Olesen, JB; Overgaard, S; Petersen, J; Schelde, AB, 2021) |
| " Joseph's Healthcare Hamilton utilizes a weight-adjusted tinzaparin dosage (50 to 75 units/kg rounded to nearest pre-filled syringe) for postoperative VTE prophylaxis." | 1.62 | Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more. ( Anvari, M; Crowther, MA; Douketis, JD; Eshaghpour, A; Ikesaka, RT; Li, A; Siegal, DM; Tiboni, M; Tseng, EK, 2021) |
| "VTE was defined as symptomatic deep vein thrombosis or pulmonary embolism and was confirmed via radiological imaging or autopsy." | 1.56 | Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study. ( Cannegieter, SC; Koopmans, RJ; Koot, RW; Vleggeert-Lankamp, CLA, 2020) |
| "Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited." | 1.56 | Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. ( Antonio, M; Domènech, P; Peñafiel, J; Peris, J; Pina, E; Rosselló, E; Tebe, C, 2020) |
| " Standard prophylactic enoxaparin dosing was 40 mg SC daily, unless amended by the treating clinician." | 1.56 | The ATLANTIC study: Anti-Xa level assessment in trauma intensive care. ( Fitzgerald, M; Martin, EL; Rakhra, S; Udy, A, 2020) |
| " The purpose of this study was to assess the impact of the route of administration and dosage regimen on the compliance to the prescription." | 1.56 | Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study. ( Bautista, M; Bonilla, G; Castro, J; Llinás, A; Moreno, JP, 2020) |
| " Incidence of in-hospital VTE and major bleeding after changes in enoxaparin dosing were monitored." | 1.56 | Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients. ( Kramme, K; Munene, G; Sarraf, P, 2020) |
| " Various prophylaxis dosing strategies have been investigated." | 1.56 | Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients. ( Barber, A; Chen, SL; Jones, E; Mason, SW; Moll, S; Northam, K, 2020) |
| " The patient developed a left thigh hematoma requiring surgical evacuation 1 month after initiation of weight-based dosing of enoxaparin." | 1.56 | Successful Long-term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve. ( Bathini, VG; Korapati, S; Mathew, C; Wang, X, 2020) |
| " Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters." | 1.56 | Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020) |
| " More studies are needed on the prophylactic use and dosing of enoxaparin in patients undergoing LAGB procedures to provide high-level evidence." | 1.56 | Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study. ( Curtain, C; Hussain, Z; Mirkazemi, C; Peterson, GM; Zaidi, STR, 2020) |
| "This study evaluated the safety of early anti-factor Xa assay-guided enoxaparin dosing for chemoprophylaxis in patients with TBI." | 1.56 | Early Anti-Xa Assay-Guided Low Molecular Weight Heparin Chemoprophylaxis Is Safe in Adult Patients with Acute Traumatic Brain Injury. ( Berry, CD; Bukur, M; DiMaggio, CJ; Frangos, SG; Huang, PP; Kim, M; Klein, MJ; Moore, S; Rodier, SG; Tandon, M, 2020) |
| "Empirically dosed enoxaparin is routinely given in the postoperative period for venous thromboembolism (VTE) prophylaxis after radical cystectomy (RC)." | 1.56 | Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. ( Ambani, SN; Corona, LE; Hafez, K; Herrel, LA; Kaffenberger, SD; Montgomery, JS; Morgan, TM; Qin, Y; Singhal, U; Weizer, AZ, 2020) |
| "Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days." | 1.56 | Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020) |
| "4 ml was started subcutaneously after the PCD was removed from the patient and the same dosage of nadroparin was given daily for 15 days following the bariatric operation." | 1.51 | A New Protocol for Venous Thromboembolism Prophylaxis in Bariatric Surgery. ( Abuoglu, HH; Müftüoğlu, MAT; Odabaşı, M, 2019) |
| "1." | 1.51 | Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism. ( Fleming, KI; Higgins, TF; Jones, DL; Jones, WA; Pannucci, CJ; Rothberg, DL; Zhang, Y, 2019) |
| "Hypoalbuminemia is a common finding and independent predictor for unfavorable prognosis." | 1.51 | Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Liu, Y, 2019) |
| "In patients with renal failure, enoxaparin 20 mg SC daily resulted in a 5." | 1.51 | Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. ( Chamoun, N; Karaoui, LR; Salameh, P; Tawil, S, 2019) |
| "Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained." | 1.51 | Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019) |
| "High rates of postpartum hemorrhage are reported in our cohort." | 1.51 | Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism. ( Cox, S; Eslick, R; McLintock, C, 2019) |
| " However, fixed prophylactic doses of enoxaparin in low-weight patients may be close to the weight-based dosing recommended for VTE treatment." | 1.51 | Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients. ( Bahjri, K; Cotton, A; Geslani, V; Hong, L; Yam, L, 2019) |
| "The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)." | 1.48 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018) |
| "Adults with active cancer and an acute VTE were included." | 1.48 | Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients. ( Anselmo, L; Borrego, ME; Burnett, A; Fuller, K; Jakeman, B; Malecki, S, 2018) |
| "Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)." | 1.48 | Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018) |
| "The efficacy of anti-factor Xa (anti-Xa)-guided dosing of thromboprophylaxis after trauma remains controversial." | 1.48 | Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. ( Dharmaraja, A; Eidelson, SA; Karcutskie, CA; Lama, G; Lineen, EB; Martin, AG; Namias, N; Padiadpu, AB; Patel, J; Proctor, KG; Schulman, CI, 2018) |
| "The incidence of venous thromboembolism has increased in patients following cancer surgery despite the increased use of prophylactic anticoagulants, suggesting standard doses may be inadequate." | 1.48 | Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. ( Baumgartner, JM; Block, S; Costantini, TW; Lowy, AM; McKenzie, S, 2018) |
| " We sought to investigate if prophylactic enoxaparin dosed by anti-Xa trough levels could reduce clinically evident VTE in trauma patients with lower extremity or pelvic injury." | 1.48 | Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose? ( Barmparas, G; Dhillon, NK; Gewertz, BL; Gillette, E; Ley, EJ; Mason, R; Smith, EJT, 2018) |
| "Dabigatran etexilate is an oral anticoagulant recognized as noninferior to LMWH." | 1.48 | Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. ( Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M, 2018) |
| " An enoxaparin venous thromboembolism (VTE) prophylaxis protocol implemented in October 2015 provided weight-adjusted initial dosing parameters with subsequent dose titration to achieve targeted anti-factor Xa levels." | 1.48 | Improving Pharmacologic Prevention of VTE in Trauma: IMPACT-IT QI Project. ( Adams, E; Bethea, A; Chumbe, JT; Lucente, FC; Samanta, D, 2018) |
| "Standard low-molecular-weight heparin dosing may be suboptimal for venous thromboembolism prophylaxis." | 1.48 | Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. ( Clark, AT; Cripps, MW; Cunningham, HB; Eastman, AL; Huang, E; Imran, JB; Kacir, CD; Koshy, JP; Madni, TD; Minshall, CT; Rizk, P; Taveras, LR, 2018) |
| "Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies." | 1.48 | Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018) |
| "However, risk of increased intracranial hemorrhage in traumatic brain injury (TBI) population is of concern." | 1.48 | The impact of enoxaparin administration in relationship to hemorrhage in mild traumatic brain injury. ( Becker, G; Dhir, T; Kaplan, M; Kriza, C; Leung, P; McGreen, B; Minimo, C; Patel, N; Randhawa, S; Samuel, S; Weiss, E; Wolanin, K, 2018) |
| "In the Hokusai VTE Cancer study, 1050 patients with cancer and acute VTE were randomized to oral edoxaban or subcutaneous dalteparin for at least 6 months and up to 12 months." | 1.48 | [Treatment of cancer-associated venous thromboembolism]. ( Di Nisio, M, 2018) |
| "National guidelines have been developed to ensure correct dosing of tinzaparin for women delivered by caesarean delivery (CD) to reduce the risk of venous thromboembolism." | 1.48 | Tinzaparin thromboprophylaxis prescribing practice after caesarean delivery 2009-2014. ( Maguire, PJ; McGuire, M; McNicholl, M; Power, KA; Sheehan, SR; Turner, MJ, 2018) |
| " Once-daily dosing was associated with a lower bleeding risk as compared with twice-daily." | 1.46 | Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. ( Biedermann, JS; Cannegieter, SC; Kruip, MJHA; Lijfering, WM; Reitsma, PH; van der Meer, FJM; van Rein, N; Vermaas, HW; Wiersma, N, 2017) |
| "Based on pharmacodynamic data, the majority of plastic surgery patients receive inadequate enoxaparin prophylaxis using fixed dosing." | 1.46 | Inadequate Enoxaparin Dosing Predicts 90-Day Venous Thromboembolism Risk among Plastic Surgery Inpatients: An Examination of Enoxaparin Pharmacodynamics. ( Agarwal, J; Fleming, KI; Ghanem, M; Momeni, A; Pannucci, CJ; Rockwell, WB, 2017) |
| "Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation." | 1.46 | Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. ( Mantia, C; Neuberg, D; Puligandla, M; Uhlmann, EJ; Weber, GM; Zwicker, JI, 2017) |
| " Extended anticoagulation after oncologic liver surgery is safe and effective." | 1.46 | Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. ( Aloia, TA; Davis, CH; Day, RW; Kim, BJ; Kroll, MH; Narula, N; Tzeng, CWD, 2017) |
| " Data regarding the appropriate dosing strategy in this special population is limited." | 1.46 | Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. ( Eldar, SM; Gelikas, S; Lahat, G, 2017) |
| "No previous studies have established the optimal antifactor Xa (anti-Xa) level to guide thromboprophylaxis (TPX) dosing with enoxaparin in trauma patients." | 1.46 | Relation of antifactor-Xa peak levels and venous thromboembolism after trauma. ( Dharmaraja, A; Eidelson, SA; Karcutskie, CA; Lineen, EB; Martin, AG; Namias, N; Patel, J; Proctor, KG; Schulman, CI, 2017) |
| "The rate of VTE recurrences was similar in both subgroups." | 1.46 | Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. ( Bascuñana, J; Bergmann, JF; Bortoluzzi, C; Ferrazzi, P; Giorgi-Pierfranceschi, M; López-Reyes, R; López-Sáez, JB; Monreal, M; Suriñach, JM; Trujillo-Santos, J, 2017) |
| " The primary outcome was the incidence of symptomatic pulmonary embolism after surgery, and the secondary outcome was the incidence of bleeding as an adverse effect of enoxaparin injection." | 1.46 | Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery. ( Adachi, T; Eguchi, S; Fujita, F; Hidaka, M; Imamura, H; Kitasato, A; Kuroki, T; Soyama, A; Takatsuki, M; Tanaka, T, 2017) |
| "Adherence to FDA-approved dosing for the direct oral anticoagulants (DOACs) based on renal function, hepatic function, and concomitant medications in a real-world setting has not been evaluated." | 1.46 | Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. ( Bohm, N; Duckett, A; Fisher, S; Tran, E, 2017) |
| "We report our experience dosing and monitoring enoxaparin with anti-factor Xa activity (anti-FXaA) levels for venous thromboembolism prophylaxis in trauma patients (TP)." | 1.43 | Non-weight-based enoxaparin dosing subtherapeutic in trauma patients. ( Beilman, GJ; Chapman, SA; Irwin, ED; Reicks, P, 2016) |
| " There is limited evidence to support current dosing and monitoring strategies of enoxaparin in this population." | 1.43 | Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. ( Allen, J; Barras, M; Fagermo, N; Lust, K; Martin, JH; Petrie, S, 2016) |
| "Empiric enoxaparin dosing is inadequate for most trauma patients, leading to below target initial anti-Xa levels and requiring dose adjustment for optimal venous thromboembolism prophylaxis." | 1.43 | If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. ( Berndtson, AE; Box, K; Coimbra, R; Costantini, TW; Lane, J, 2016) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 1.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| "Sex effects on VTE after trauma are unclear." | 1.43 | Does sex matter? Effects on venous thromboembolism risk in screened trauma patients. ( Berndtson, AE; Coimbra, R; Costantini, TW; Kobayashi, L; Smith, AM, 2016) |
| " The VTE rate when enoxaparin sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described." | 1.43 | Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. ( Barmparas, G; Chung, K; Dhillon, N; Gewertz, BL; Harada, MY; Ko, A; Ley, EJ; Margulies, DR; Mason, R; Yim, DA, 2016) |
| " Dosage was adjusted to a prophylactic peak anti-Xa level of 0." | 1.43 | Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. ( Ginzburg, E; Karcutskie, CA; Lieberman, HM; Lineen, EB; Namias, N; Riggi, G; Singer, GA; Vaghaiwalla, TM, 2016) |
| " The usage of enoxaparin for venous thromboembolism prophylaxis is safe for Japanese patients after gastrectomy." | 1.43 | Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients. ( Kusanagi, H; Yanagita, T, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 1.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "In the group with renal failure 12 patients had a GFR between 30 and 50 ml/min/1." | 1.42 | No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency. ( Atiq, F; Leebeek, FW; van den Bemt, PM; van Gelder, T; Versmissen, J, 2015) |
| "Early enoxaparin-based anticoagulation may be a safe option in trauma patients with blunt solid organ injury." | 1.42 | Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe? ( Friese, RS; Green, DJ; Gries, L; Harrison, C; Joseph, B; Kulvatunyou, N; Lubin, D; O'Keeffe, T; Pandit, V; Rhee, P; Tang, A; Zangbar, B, 2015) |
| " No adverse events from this dosing were observed during the duration of therapy." | 1.42 | Achievement of therapeutic anti-Xa levels in a proven heparin-resistant patient through the use of nontraditional high-dose enoxaparin. ( Conwall, K; Krajewski, KC; Krajewski, MP; Smith, K, 2015) |
| "The median time from trauma to filter insertion was 2days and low molecular weight heparin at prophylactic dose was initiated in 92% once the filter was inserted." | 1.42 | The use of optional inferior vena cava filters of type Optease in trauma patients--a single type of filter in a single Medical Center. ( Grossman, E; Khaitovich, B; Kleinbaum, Y; Lavan, O; Rimon, U; Salomon, O; Segal, B; Simon, D; Steinberg, DM, 2015) |
| "To assess the risk for intracranial hemorrhage associated with the administration of therapeutic doses of low-molecular-weight heparin, we performed a matched, retrospective cohort study of 293 patients with cancer with brain metastases (104 with therapeutic enoxaparin and 189 controls)." | 1.42 | Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. ( Campigotto, F; Coletti, E; Donato, J; Neuberg, D; Uhlmann, EJ; Weber, GM; Zwicker, JI, 2015) |
| "To compare the adequacy of venous thromboembolism prophylaxis based on anti-Xa concentrations between weight-based enoxaparin dosing and body mass index (BMI)-stratified dosing in morbidly obese women after cesarean delivery." | 1.42 | Enoxaparin dosing after cesarean delivery in morbidly obese women. ( LaCoursiere, DY; Overcash, RT; Somers, AT, 2015) |
| " However, evidence suggests decreased bioavailability of enoxaparin in critically ill patients." | 1.42 | Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved. ( Becher, RD; Borgerding, EM; Farrah, JP; Kilgo, P; Lauer, C; Miller, PR; Nunez, JM; Rebo, GJ; Stirparo, JJ, 2015) |
| "LMWH seems to be safe and efficacious for both management and prophylaxis of VTEs in pediatric neurosurgery." | 1.42 | The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients. ( Briceño, V; Fridley, J; Gonda, DD; Jea, A; Lam, SK; Luerssen, TG; Ryan, SL, 2015) |
| " Adverse events, based on the Common Terminology Criteria for Adverse Events, Version 4, were recorded." | 1.42 | Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan. ( Eguchi, F; Goto, M; Miyamoto, S; Nakahara, H; Ogawa, M; Sanui, A; Satoh, S; Takashima, T; Tatsumura, M; Yoshizato, T, 2015) |
| "The Michigan Trauma Quality Improvement Program (MTQIP) is a collaborative quality initiative sponsored by Blue Cross Blue Shield of Michigan and Blue Care Network (BCBSM/BCN)." | 1.42 | Reduction in Venous Thromboembolism Events: Trauma Performance Improvement and Loop Closure Through Participation in a State-Wide Quality Collaborative. ( Cherry-Bukowiec, JR; Hemmila, MR; Jakubus, JL; Machado-Aranda, DA; Napolitano, LM; Park, PK; Raghavendran, K; To, KB; Wahl, WL, 2015) |
| "Dabigatran has demonstrated similar efficacy and safety to enoxaparin for VTE prevention in patients undergoing hip and knee arthroplasty, and to warfarin for the treatment of VTE." | 1.42 | The evolving role of dabigatran etexilate in clinical practice. ( Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA, 2015) |
| " These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer." | 1.42 | Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. ( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015) |
| " Thirty patients undergoing unilateral or bilateral total knee replacement, admitted to the intensive care unit on a therapeutic dosage of subcutaneous enoxaparin (30-mg injections administered twice daily), were included into the study." | 1.42 | Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery. ( Kaso, G; Tekkesin, M; Tekkesin, N, 2015) |
| " Correct dosing is critical to prevent bleeding or thrombosis." | 1.40 | Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. ( Antonijoan, RM; Ayani, I; Ballester, MR; Borrell, M; Fontcuberta, J; Gich, I; Gutierro, I; Martinez-Gonzalez, J; Rico, S, 2014) |
| "Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown." | 1.40 | Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. ( Deal, EN; Gage, BF; Milligan, PE; Thoelke, MS; Wang, TF; Wong, CA, 2014) |
| "To demonstrate that low-molecular-weight heparin (enoxaparin) can be used in critically ill pediatric patients to achieve target anti-factor Xa concentrations and determine appropriate dosing corrected for age and illness severity." | 1.40 | Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*. ( Abu-Sultaneh, S; Hanson, SJ; Havens, PL; Hoffmann, RG; Punzalan, RC; Schloemer, NJ; Yan, K, 2014) |
| " The objective of this retrospective study was to determine if 40-mg daily dosing would increase the incidence of VTE." | 1.40 | Epidural placement does not result in an increased incidence of venous thromboembolism in combat-wounded patients. ( Caruso, JD; Elster, EA; Rodriguez, CJ, 2014) |
| "A VTE prophylaxis protocol using anti-Xa-based dalteparin dosage adjustment in high-risk trauma patients was associated with decreased VTE." | 1.40 | Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. ( Athota, KP; Besl, KM; Droege, CA; Droege, ME; Ernst, NE; Hanseman, DJ; Keegan, SP; Kramer, EA; Lemmink, JA; Lutomski, DM; Mueller, EW; Robinson, BR, 2014) |
| "Dalteparin 5000 U/day was used in both groups." | 1.40 | The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. ( Dzieciuchowicz, L; Krasińska, B; Krasiński, Z; Pawlaczyk, K; Staniszewski, R; Szpurek, D; Urbanek, T; Wójcicka, K, 2014) |
| " We investigated two different dosing regimens; fixed dose and weight-adjusted dose on the anticoagulant effects of the LMWH tinzaparin used for thromboprophylaxis in obese pregnant women." | 1.40 | Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women. ( Higgins, JR; Ismail, SK; Norris, L; O'Shea, S, 2014) |
| "Venous thromboembolism and subsequent pulmonary embolism are frequent and sometimes fatal complications in patients after surgical interventions." | 1.39 | [Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study]. ( Guschmann, M; Kaiser, J; Rübenacker, S, 2013) |
| "Patients undergoing elective colorectal cancer surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database." | 1.39 | Is extended thromboprophylaxis necessary in elective colorectal cancer surgery? ( Chandra, R; Hunter, RA; Lawrence, MJ; Melino, G; Moore, J; Thomas, M, 2013) |
| "Apixaban is a direct factor Xa inhibitor that has been shown in clinical trial use to safely reduce the composite of VTE and mortality rates in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA); however, the cost-effectiveness of apixaban treatment in Canadian settings has not been studied." | 1.39 | A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. ( El-Hadi, W; Kadambi, A; Patterson, J; Raymond, V; Revankar, N, 2013) |
| " The physiological changes associated with pregnancy alter the pharmacokinetic profile of low-molecular-weight heparins, which has led to controversy and subsequent variation in practice, when pregnant women with venous thromboembolism are treated with low-molecular-weight heparins." | 1.39 | Population pharmacokinetics of enoxaparin during the antenatal period. ( Arya, R; Davies, JG; Green, B; Marsh, MS; Patel, JP; Patel, RK, 2013) |
| " Enoxaparin was administered after caesarean section using the Royal College of Obstetricians and Gynaecologists weight-adjusted dosing guidelines." | 1.39 | Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study. ( Casey, E; Hiscock, RJ; Newell, PA; Simmons, SW; Walker, SP, 2013) |
| " In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens." | 1.39 | Use of enoxaparin in end-stage renal disease. ( Coppola, B; Lai, S, 2013) |
| "Increased perioperative thromboprophylaxis dosage does not increase pericardial effusion rates or mortality in proximal aortic surgery." | 1.39 | NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta. ( Bryan, AJ; Davies, A; Hussain, A; Rahman, IA, 2013) |
| "Limited data exist regarding the efficacy of weight-based dosing of low-molecular weight heparin for venous thromboembolism (VTE) prophylaxis in obese trauma patients." | 1.39 | Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. ( Bickford, A; Bledsoe, J; Dickerson, J; Johnston, R; Majercik, S; Smith, K; White, T, 2013) |
| " The aim of this study was to test the hypothesis that higher dosing (40 mg twice daily) would improve peak anti-Xa levels and decrease venous thromboembolism." | 1.39 | Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer? ( Hall, ST; Kopelman, TR; O'Neill, PJ; Pieri, PG; Pressman, MS; Quan, A; Salomone, JP; Wells, JR, 2013) |
| "We hypothesized that many trauma patients would be subtherapeutic on the standard prophylactic dose of enoxaparin." | 1.39 | Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. ( Bansal, V; Box, K; Coimbra, R; Costantini, TW; Doucet, J; Fortlage, D; Min, E; Tran, V; Winfield, RD, 2013) |
| " Thrombotic storm was defined as newly diagnosed multisite venous thromboembolism (VTE) with acute thrombus progression despite conventional or higher than conventional dosing of heparin or low molecular weight heparin." | 1.38 | Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. ( Gibson, E; Goldenberg, NA; Knoll, CM; Manco-Johnson, MJ; Mourani, PM; Soep, J; Wang, M, 2012) |
| "Venous thromboembolism was significantly associated with pelvic fractures, intensive care unit stay, and central venous catheters (P = ." | 1.38 | Increased use of enoxaparin in pediatric trauma patients. ( Askegard-Giesmann, JR; Kenney, BD; O'Brien, SH; Wang, W, 2012) |
| "Among patients with cancer-related VTE, 59." | 1.38 | Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012) |
| "In short-term (up to 2 weeks) treatment, bleeding and VTE were more frequent than in long-term treatment." | 1.37 | Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation. ( Kienitz, C; Lang, A; Rollnik, JD; Wetzel, P, 2011) |
| "Weight-based dosing for enoxaparin is recommended in the 2008 American College of Chest Physicians (ACCP) guidelines for venous thromboembolism (VTE) prophylaxis." | 1.37 | Increased enoxaparin dosing is required for obese children. ( Dunlap, M; Johnson, PN; Lewis, TV; Nebbia, AM, 2011) |
| "To evaluate dosing requirements and monitoring patterns of low-molecular-weight heparin (LMWH) when used in high-risk pregnancy." | 1.37 | Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. ( Chevalier, AB; Hibbard, JU; Kominiarek, MA; Nutescu, EA; Shapiro, NL, 2011) |
| " Few standards exist for delineating the optimal dosing strategy for VTE prevention in obese patients, especially in the setting of major surgery or trauma." | 1.37 | Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. ( Barton, RG; Kimball, EJ; Ludwig, KP; Mone, M; Simons, HJ, 2011) |
| "Frequent occurrence of low antifactor Xa levels observed in this study demonstrated the inadequacy of standard dosing of enoxaparin for VTE prophylaxis in many patients with acute burns." | 1.37 | Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. ( Cochran, A; Faraklas, I; Lin, H; Saffle, J, 2011) |
| "Venous thromboembolism is a major patient safety issue." | 1.37 | Postoperative enoxaparin prevents symptomatic venous thromboembolism in high-risk plastic surgery patients. ( Bailey, SH; Dreszer, G; Hamill, JB; Hoxworth, RE; Hume, KM; Kalliainen, LK; Pannucci, CJ; Portschy, PR; Pusic, AL; Rubin, JP; Wachtman, CF; Wilkins, EG, 2011) |
| " For those records documenting tinzaparin use and pregnancy outcome, information was extracted into a standardised case report form; these were reviewed for adverse events, which were submitted for adjudication by independent experts in obstetric medicine and haematology." | 1.37 | Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. ( Borg, JY; Greer, IA; Nelson-Piercy, C; Powrie, R; Rodger, M; Stinson, J; Talbot, DJ, 2011) |
| "Nadroparin is both safe and effective for the treatment of DVT during pregnancy and puerperium." | 1.36 | Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium. ( Antonijević, N; Djordjević, V; Ilić, V; Kovac, M; Lazić, R; Mitić, G; Novakov-Mikić, A; Povazan, L; Salatić, I, 2010) |
| "Venous thromboembolism is a common and potentially fatal complication in patients with advanced cancer." | 1.36 | Thromboprophylaxis during chemotherapy in patients with advanced cancer. ( Agnelli, G; Verso, M, 2010) |
| " We completed a pharmacokinetic study in morbidly obese, medically-ill patients to determine if weight-based dosing of enoxaparin for VTE prophylaxis was feasible, without excessive levels of anticoagulation, as determined by peak anti-Xa levels." | 1.36 | Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. ( Draper, L; Pendleton, RC; Rodgers, GM; Rondina, MT; Wheeler, M, 2010) |
| "Hospitalized cancer patients are at an increased risk for venous thromboembolism (VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated." | 1.36 | Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. ( Liu, CY; Reeves, D, 2010) |
| "Fondaparinux is an effective and safe alternative." | 1.36 | Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. ( Ageno, W; Capri, S; Imberti, D; Moia, M; Palareti, G; Piovella, F; Scannapieco, G, 2010) |
| "Venous thromboembolism is a relatively frequently occurring complication in critically ill patients admitted to the ICU despite prophylactic treatment with subcutaneous low molecular weight heparin." | 1.36 | Adequate thromboprophylaxis in critically ill patients. ( Levi, M, 2010) |
| "A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial." | 1.36 | Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. ( Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010) |
| "There are limited data on appropriate dosing of low-molecular-weight heparins (LMWH) for venous thromboembolism (VTE) prophylaxis in bariatric surgery." | 1.36 | Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. ( Picard, F; Simoneau, MD; Vachon, A, 2010) |
| "To evaluate the safety of individually dosed low molecular weight heparin (LMWH) for prophylaxis and treatment of thromboembolic complications in pregnancy." | 1.36 | Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin. ( Andersen, AS; Bergholt, T; Berthelsen, JG, 2010) |
| " They analyzed rates of documented symptomatic venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) confirmed by objective methods, major bleeding, death, thrombocytopenia, and other adverse events." | 1.35 | Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. ( Fontcuberta, J; Gómez-Outes, A; Martínez-González, J; Otero-Fernández, R; Rocha, E, 2008) |
| " Although VTE prophylaxis is recommended in bariatric surgery, data with regard to monitoring and appropriate dosing of low-molecular-weight heparin are limited." | 1.35 | Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. ( Kuhl, DA; Lee, MD; Madan, AK; Simone, EP; Tichansky, DS, 2008) |
| "We discuss the cases of 2 patients with prostate cancer who were taking Dr." | 1.35 | Prostasol and venous thromboembolism. ( Bubley, G; Clement, J, 2008) |
| "Trauma patients at a Level I Trauma Center found to be nonambulatory or otherwise high risk were placed on a protocol of lower-extremity (LE) compression devices and subcutaneous enoxaparin as soon as feasible after admission." | 1.35 | Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population. ( Adams, RC; Berenguer, C; Hamrick, M; Ochsner, MG; Senkowski, C, 2008) |
| "Fondaparinux was associated with significantly lower costs and fewer VTEs compared to enoxaparin without an increase in bleed rates or all-cause inpatient mortality." | 1.35 | Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. ( Farias-Eisner, R; Franklin, M; Happe, LE; Horblyuk, R; Lunacsek, OE, 2009) |
| "Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways." | 1.35 | Fondaparinux: an overview. ( Banerjee, P; Goyal, D; Lip, GY; Nadar, SK; Shantsila, E, 2009) |
| "Limited data exist regarding efficacy and dosing of low-molecular-weight heparins, including enoxaparin, for morbidly obese patients." | 1.35 | Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. ( Kuhl, DA; Lee, MD; Madan, AK; Rowan, BO; Tichansky, DS, 2008) |
| "Paraplegia (as opposed to tetraplegia) was the only risk factor identified for VTE." | 1.35 | Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study. ( Anderson, D; Douglas, JA; Pike, J; Short, C; Thompson, K; Worley, S, 2008) |
| "Venous thromboembolism is a common and life-threatening complication in patients with advanced cancer." | 1.34 | Thromboprophylaxis during chemotherapy after advanced cancer. ( Agnelli, G; Verso, M, 2007) |
| "Dalteparin was associated with a lower rate of major bleeding events than was fondaparinux, but there were no significant differences in such events among fondaparinux, enoxaparin, and unfractionated heparin." | 1.34 | Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. ( Farrelly, E; Happe, LE; Peeples, PJ; Sarnes, MW; Shorr, AF; Stanford, RH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 94 (10.01) | 29.6817 |
| 2010's | 555 (59.11) | 24.3611 |
| 2020's | 290 (30.88) | 2.80 |
| Authors | Studies |
|---|---|
| De Schryver, N | 1 |
| Serck, N | 1 |
| Eeckhoudt, S | 1 |
| Laterre, PF | 1 |
| Wittebole, X | 1 |
| Gérard, L | 1 |
| Jaspers, TCC | 1 |
| Meijer, CE | 1 |
| Vleming, LJ | 1 |
| Franssen, CFM | 1 |
| Diepstraten, J | 2 |
| Lukens, MV | 1 |
| van den Bemt, PMLA | 1 |
| Maat, B | 1 |
| Khorsand, N | 1 |
| Touw, DJ | 1 |
| Koomen, JV | 1 |
| Apostu, D | 1 |
| Berechet, B | 1 |
| Oltean-Dan, D | 1 |
| Mester, A | 1 |
| Petrushev, B | 1 |
| Popa, C | 1 |
| Gherman, ML | 1 |
| Tigu, AB | 1 |
| Tomuleasa, CI | 1 |
| Barbu-Tudoran, L | 1 |
| Benea, HRC | 1 |
| Piciu, D | 1 |
| Romano, LGR | 2 |
| Hunfeld, NGM | 2 |
| Kruip, MJHA | 4 |
| Endeman, H | 2 |
| Preijers, T | 2 |
| van Rongen, A | 1 |
| Zijlstra, MP | 1 |
| van der Heiden, PLJ | 1 |
| Ter Heine, R | 2 |
| Zhao, M | 1 |
| Bao, Y | 2 |
| Jiang, C | 1 |
| Chen, L | 2 |
| Xu, L | 1 |
| Liu, X | 2 |
| Li, J | 2 |
| Yang, Y | 1 |
| Jiang, G | 1 |
| She, Y | 1 |
| Chen, Q | 2 |
| Shen, L | 1 |
| Chen, C | 1 |
| Cihlar, R | 1 |
| Sramek, V | 1 |
| Papiez, A | 1 |
| Penka, M | 1 |
| Suk, P | 1 |
| Koopmans, RJ | 1 |
| Cannegieter, SC | 2 |
| Koot, RW | 1 |
| Vleggeert-Lankamp, CLA | 1 |
| van der Veen, L | 1 |
| Segers, M | 1 |
| van Raay, JJ | 1 |
| Gerritsma-Bleeker, CL | 1 |
| Brouwer, RW | 1 |
| Veeger, NJ | 1 |
| van Hulst, M | 1 |
| van Rein, N | 1 |
| Biedermann, JS | 1 |
| van der Meer, FJM | 1 |
| Wiersma, N | 1 |
| Vermaas, HW | 1 |
| Reitsma, PH | 1 |
| Lijfering, WM | 1 |
| Mihaljević, Z | 1 |
| Dimnjaković, D | 1 |
| Tripković, B | 1 |
| Buljan, M | 1 |
| Aljinović, A | 1 |
| Delimar, D | 1 |
| Bićanić, G | 1 |
| Schijns, W | 1 |
| Deenen, MJ | 1 |
| Aarts, EO | 1 |
| Homan, J | 1 |
| Janssen, IMC | 1 |
| Berends, FJ | 1 |
| Kaasjager, KAH | 1 |
| Song, J | 2 |
| Xuan, L | 1 |
| Wu, W | 1 |
| Shen, Y | 1 |
| Tan, L | 1 |
| Zhong, M | 1 |
| Abuoglu, HH | 1 |
| Müftüoğlu, MAT | 1 |
| Odabaşı, M | 1 |
| Hanna-Sawires, RG | 1 |
| Groen, JV | 1 |
| Klok, FA | 2 |
| Tollenaar, RAEM | 1 |
| Mesker, WE | 1 |
| Swijnenburg, RJ | 1 |
| Vahrmeijer, AL | 1 |
| Bonsing, BA | 1 |
| Mieog, JSD | 1 |
| Heckmann, M | 1 |
| Thermann, H | 1 |
| Heckmann, F | 1 |
| Atiq, F | 1 |
| van den Bemt, PM | 1 |
| Leebeek, FW | 1 |
| van Gelder, T | 1 |
| Versmissen, J | 1 |
| Ageno, W | 14 |
| Bosch, J | 1 |
| Cucherat, M | 2 |
| Eikelboom, JW | 3 |
| Ofosu, FA | 1 |
| Kistler, U | 1 |
| Kramers-de Quervain, I | 1 |
| Munzinger, U | 1 |
| Kucher, N | 1 |
| Crowther, MA | 6 |
| Cook, DJ | 4 |
| Mitić, G | 1 |
| Kovac, M | 2 |
| Povazan, L | 1 |
| Djordjević, V | 2 |
| Ilić, V | 1 |
| Salatić, I | 1 |
| Lazić, R | 1 |
| Antonijević, N | 1 |
| Novakov-Mikić, A | 1 |
| Agnelli, G | 25 |
| Verso, M | 7 |
| Bednarek, W | 1 |
| Karowicz-Bilińska, A | 1 |
| Kotarski, J | 1 |
| Nowak-Markwitz, E | 1 |
| Oszukowski, P | 1 |
| Paszkowski, T | 1 |
| Poreba, R | 1 |
| Spaczyński, M | 1 |
| Teliga-Czajkowska, J | 1 |
| Barni, S | 2 |
| Gasparini, G | 1 |
| LaBianca, R | 1 |
| Khorana, AA | 10 |
| Perunicic, J | 1 |
| Antonijevic, NM | 1 |
| Miljic, P | 1 |
| Mikovic, D | 1 |
| Djokic, M | 1 |
| Mrdovic, I | 1 |
| Nikolic, A | 1 |
| Vasiljevic, Z | 1 |
| Weber, C | 1 |
| Merminod, T | 1 |
| Herrmann, FR | 1 |
| Zulian, GB | 1 |
| van Ommen, CH | 1 |
| van den Dool, EJ | 1 |
| Peters, M | 1 |
| Kaplunov, OA | 1 |
| Kaplunov, KO | 1 |
| Petrikov, AS | 1 |
| Imberti, D | 9 |
| Baldini, E | 2 |
| Pierfranceschi, MG | 2 |
| Nicolini, A | 2 |
| Cartelli, C | 1 |
| De Paoli, M | 2 |
| Boni, M | 1 |
| Filippucci, E | 1 |
| Cariani, S | 1 |
| Bottani, G | 1 |
| Du, W | 1 |
| Zhao, C | 1 |
| Wang, J | 4 |
| Liu, J | 1 |
| Shen, B | 2 |
| Zheng, Y | 1 |
| Bugamelli, S | 1 |
| Zangheri, E | 1 |
| Montebugnoli, M | 1 |
| Guerra, L | 1 |
| Legnani, C | 1 |
| Cini, M | 1 |
| Guerra, M | 1 |
| Zanardi, A | 1 |
| Palareti, G | 2 |
| Camporese, G | 2 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Forestieri, P | 1 |
| Quarto, G | 1 |
| De Caterina, M | 1 |
| Cuocolo, A | 1 |
| Pilone, V | 1 |
| Formato, A | 1 |
| Ruocco, A | 1 |
| Ferrari, P | 1 |
| McKeage, K | 1 |
| Keating, GM | 1 |
| Sagüillo, K | 1 |
| Pérez-Flecha, F | 1 |
| Almeida, F | 1 |
| Picón, M | 1 |
| Acero, J | 1 |
| Galeano-Valle, F | 1 |
| Pérez-Rus, G | 1 |
| Demelo-Rodríguez, P | 1 |
| Ordieres-Ortega, L | 1 |
| Ortega-Morán, L | 1 |
| Muñoz-Martín, AJ | 1 |
| Medina-Molina, S | 1 |
| Alvarez-Sala-Walther, LA | 1 |
| Del-Toro-Cervera, J | 1 |
| Gao, JH | 1 |
| Chu, XC | 1 |
| Wang, LL | 1 |
| Ning, B | 1 |
| Zhao, CX | 1 |
| Muñoz-Atienza, V | 1 |
| Gil-Rendo, A | 1 |
| Amo-Salas, M | 1 |
| Núñez-Guerrero, P | 1 |
| Martín-Fernández, J | 1 |
| Pina, E | 1 |
| Antonio, M | 1 |
| Peris, J | 1 |
| Rosselló, E | 1 |
| Domènech, P | 1 |
| Peñafiel, J | 1 |
| Tebe, C | 1 |
| San Norberto García, EM | 1 |
| Merino, B | 1 |
| Taylor, JH | 1 |
| Vizcaíno, I | 1 |
| Vaquero, C | 1 |
| Rico, S | 1 |
| Antonijoan, RM | 1 |
| Ballester, MR | 1 |
| Gutierro, I | 1 |
| Ayani, I | 1 |
| Martinez-Gonzalez, J | 5 |
| Borrell, M | 1 |
| Fontcuberta, J | 2 |
| Gich, I | 1 |
| Alalaf, SK | 2 |
| Jawad, RK | 2 |
| Muhammad, PR | 1 |
| Ali, MS | 2 |
| Al Tawil, NG | 2 |
| Jawad, AK | 1 |
| Vila, L | 1 |
| Rodríguez, C | 2 |
| Rodríguez-Mañas, L | 1 |
| Gómez-Huelgas, R | 1 |
| Veiga-Fernández, F | 1 |
| Ruiz, GM | 1 |
| González, JM | 1 |
| Kakkar, VV | 2 |
| Balibrea, JL | 1 |
| Prandoni, P | 7 |
| Monreal Bosch, M | 1 |
| Vignoli, A | 1 |
| Lecumberri Villamediana, R | 1 |
| Abad Rico, JI | 1 |
| Lozano Sánchez, FS | 1 |
| Rocha, E | 2 |
| Fontcuberta Boj, J | 1 |
| Otero-Fernández, R | 1 |
| Gómez-Outes, A | 4 |
| Shao, J | 1 |
| Chen, QH | 1 |
| Sarangi, SN | 1 |
| Gaballah, M | 1 |
| Nolfi-Donegan, D | 1 |
| Battaglia, M | 1 |
| Amin, S | 1 |
| Amodio, J | 1 |
| Acharya, SS | 1 |
| Gates, RS | 1 |
| Lollar, DI | 1 |
| Collier, BR | 1 |
| Smith, J | 1 |
| Faulks, ER | 1 |
| Gillen, JR | 1 |
| Spyropoulos, AC | 13 |
| Goldin, M | 2 |
| Giannis, D | 2 |
| Diab, W | 2 |
| Khanijo, S | 2 |
| Mignatti, A | 2 |
| Gianos, E | 2 |
| Cohen, M | 3 |
| Sharifova, G | 2 |
| Lund, JM | 2 |
| Tafur, A | 3 |
| Lewis, PA | 2 |
| Cohoon, KP | 2 |
| Rahman, H | 2 |
| Sison, CP | 2 |
| Lesser, ML | 2 |
| Ochani, K | 2 |
| Agrawal, N | 1 |
| Hsia, J | 1 |
| Anderson, VE | 2 |
| Bonaca, M | 2 |
| Halperin, JL | 3 |
| Weitz, JI | 19 |
| May, CC | 1 |
| Cua, S | 1 |
| Smetana, KS | 1 |
| Powers, CJ | 1 |
| Raskob, GE | 21 |
| Spiro, TE | 8 |
| Lu, W | 3 |
| Yuan, Z | 2 |
| Levitan, B | 2 |
| Suh, E | 2 |
| Barnathan, ES | 3 |
| Marini, CP | 1 |
| Lewis, E | 1 |
| Petrone, P | 1 |
| Zenilman, A | 1 |
| Lu, Z | 1 |
| Rivera, A | 1 |
| McNelis, J | 1 |
| Strony, J | 1 |
| Gailani, D | 1 |
| Hylek, EM | 2 |
| Lassen, MR | 23 |
| Mahaffey, KW | 1 |
| Notani, RS | 1 |
| Roberts, R | 1 |
| Segers, A | 8 |
| Schroeppel, TJ | 1 |
| Clement, LP | 1 |
| Douville, AA | 1 |
| Schmoekel, NH | 1 |
| Stassinopoulos, J | 1 |
| Decker, C | 1 |
| Stillman, ZE | 1 |
| Rodriquez, J | 1 |
| Brockman, VP | 1 |
| Hennessy, E | 1 |
| Heise, H | 1 |
| Khan, AD | 1 |
| Chua, CXK | 1 |
| Tan, JHI | 1 |
| Bin Abd Razak, HR | 1 |
| Feimster, J | 1 |
| Slack, D | 1 |
| Nimeri, A | 1 |
| Dunn, AS | 1 |
| Morici, N | 2 |
| Podda, G | 1 |
| Birocchi, S | 1 |
| Bonacchini, L | 1 |
| Merli, M | 1 |
| Trezzi, M | 1 |
| Massaini, G | 1 |
| Agostinis, M | 1 |
| Carioti, G | 1 |
| Saverio Serino, F | 1 |
| Gazzaniga, G | 1 |
| Barberis, D | 1 |
| Antolini, L | 1 |
| Grazia Valsecchi, M | 1 |
| Cattaneo, M | 2 |
| Di Micco, P | 2 |
| Imbalzano, E | 1 |
| Russo, V | 2 |
| Attena, E | 1 |
| Mandaliti, V | 1 |
| Orlando, L | 1 |
| Lombardi, M | 1 |
| Di Micco, G | 1 |
| Annunziata, S | 1 |
| Piccinocchi, G | 1 |
| Pacelli, W | 1 |
| Del Guercio, M | 1 |
| Gorosabel Calzada, M | 1 |
| Hernández Matías, A | 1 |
| Andonaegui de la Madriz, A | 1 |
| León Ledesma, R | 1 |
| Alonso-Lamberti Rizo, L | 1 |
| Salazar Carrasco, A | 1 |
| Ruiz de Adana, JC | 1 |
| Jover Navalón, JM | 1 |
| Wagner, J | 1 |
| Wruck, H | 1 |
| Lautenbach, A | 1 |
| von Kroge, P | 1 |
| Wolter, S | 1 |
| Mann, O | 1 |
| Izbicki, J | 1 |
| Duprée, A | 1 |
| Tewksbury, C | 2 |
| Garcia Whitlock, AE | 2 |
| O'Connor, K | 2 |
| Dumon, K | 1 |
| Williams, N | 1 |
| Jizzini, M | 1 |
| Akhtar, OS | 1 |
| Atwood, K | 1 |
| Ji, W | 1 |
| Pleskow, J | 1 |
| Bat, T | 1 |
| Balderman, S | 1 |
| Kalayci, A | 4 |
| Gibson, CM | 17 |
| Hernandez, AF | 14 |
| Hull, RD | 15 |
| Cohen, AT | 32 |
| Fitzgerald, C | 1 |
| Hussain, SD | 1 |
| Chi, G | 10 |
| Alkhalfan, F | 3 |
| Harrington, RA | 12 |
| Goldhaber, SZ | 23 |
| O'Keefe, MM | 2 |
| Carver, TW | 2 |
| Herrmann, DJ | 3 |
| Prom, A | 1 |
| Hubbard, S | 2 |
| Rein, LE | 1 |
| Peppard, WJ | 3 |
| Wehmeyer, A | 1 |
| Coetzee, R | 1 |
| McCartney, J | 1 |
| Verhoeff, K | 3 |
| Raffael, K | 1 |
| Connell, M | 3 |
| Kung, JY | 1 |
| Strickland, M | 3 |
| Parker, A | 1 |
| Anantha, RV | 3 |
| Swanson, E | 3 |
| Bistervels, IM | 2 |
| Bavalia, R | 1 |
| Gebel, M | 4 |
| Lensing, AWA | 1 |
| Middeldorp, S | 7 |
| Prins, MH | 10 |
| Coppens, M | 1 |
| Leeds, IL | 1 |
| Sklow, B | 1 |
| Gorgun, E | 1 |
| Liska, D | 1 |
| Lightner, AL | 1 |
| Hull, TL | 1 |
| Steele, SR | 1 |
| Holubar, SD | 1 |
| Bouget, J | 1 |
| Balusson, F | 1 |
| Kerbrat, S | 1 |
| Roy, PM | 2 |
| Viglino, D | 1 |
| Lacut, K | 1 |
| Pavageau, L | 1 |
| Oger, E | 1 |
| Lipardi, C | 2 |
| Albers, GW | 2 |
| Elliott, CG | 1 |
| Hiatt, WR | 2 |
| Maynard, G | 1 |
| Steg, PG | 1 |
| Sugarmann, C | 1 |
| Hunter, M | 1 |
| Lurbet, MF | 1 |
| Parodi, J | 1 |
| Mandó, F | 1 |
| Bonelli, I | 1 |
| Rodríguez, PO | 1 |
| López Saubidet, I | 1 |
| Gerhart, JG | 1 |
| Carreño, FO | 1 |
| Loop, MS | 1 |
| Lee, CR | 1 |
| Edginton, AN | 1 |
| Sinha, J | 1 |
| Kumar, KR | 1 |
| Kirkpatrick, CM | 1 |
| Hornik, CP | 1 |
| Gonzalez, D | 1 |
| Sochet, AA | 1 |
| Morrison, JM | 1 |
| Jaffray, J | 1 |
| Godiwala, N | 1 |
| Wilson, HP | 1 |
| Thornburg, CD | 1 |
| Bhat, RV | 1 |
| Zia, A | 1 |
| Lawrence, C | 1 |
| Kudchadkar, SR | 1 |
| Hamblin, F | 2 |
| Russell, CJ | 1 |
| Streiff, MB | 5 |
| Amankwah, EK | 1 |
| Goldenberg, NA | 5 |
| Bennett, E | 1 |
| Delgado-Corcoran, C | 1 |
| Pannucci, CJ | 19 |
| Wilcox, R | 2 |
| Heyrend, C | 1 |
| Faustino, EV | 1 |
| Ebeid, A | 1 |
| Cole, E | 1 |
| Stallwood-Hall, C | 1 |
| de Brito, AFS | 1 |
| Brito, NC | 1 |
| Tanaka, SKT | 1 |
| Ferreira, VL | 1 |
| Ferreira Júnior, ABS | 1 |
| Riveros, BS | 1 |
| Nita, ME | 1 |
| Centers, GI | 1 |
| Hege, KM | 1 |
| Nitu, ME | 1 |
| Cristea, IA | 1 |
| Yabrodi, M | 1 |
| Schade Willis, TM | 1 |
| Bhai, H | 1 |
| Faustino, EVS | 1 |
| Ambani, SW | 1 |
| Bengur, FB | 2 |
| Varelas, LJ | 1 |
| Nguyen, VT | 1 |
| Cruz, C | 1 |
| Acarturk, TO | 1 |
| Manders, EK | 1 |
| Kubik, MW | 1 |
| Sridharan, S | 2 |
| Gimbel, ML | 2 |
| Solari, MG | 2 |
| Vincent, LE | 1 |
| Talanker, MM | 1 |
| Butler, DD | 1 |
| Zhang, X | 1 |
| Podbielski, JM | 1 |
| Wang, YW | 2 |
| Chen-Goodspeed, A | 1 |
| Hernandez Gonzalez, SL | 1 |
| Fox, EE | 1 |
| Cotton, BA | 3 |
| Wade, CE | 3 |
| Cardenas, JC | 3 |
| Modi, RN | 2 |
| Borst, JM | 2 |
| Kirchberg, TN | 2 |
| Box, K | 4 |
| Smith, AM | 3 |
| Godat, LN | 3 |
| Doucet, JJ | 2 |
| Costantini, TW | 7 |
| Berndtson, AE | 4 |
| Stitzel, HJ | 1 |
| Hue, JJ | 1 |
| Elshami, M | 1 |
| McCaulley, L | 1 |
| Hoehn, RS | 1 |
| Rothermel, LD | 1 |
| Ammori, JB | 1 |
| Hardacre, JM | 1 |
| Winter, JM | 1 |
| Ocuin, LM | 1 |
| Abatzis-Papadopoulos, M | 1 |
| Tigkiropoulos, K | 1 |
| Nikas, S | 1 |
| Papoutsis, I | 1 |
| Kostopoulou, O | 1 |
| Stavridis, K | 1 |
| Karamanos, D | 1 |
| Lazaridis, I | 1 |
| Saratzis, N | 1 |
| Metcalf, KB | 1 |
| Du, JY | 1 |
| Ochenjele, G | 1 |
| Bellfi, LT | 1 |
| Zimmerman, SA | 1 |
| Boudreau, R | 1 |
| Mosier, W | 1 |
| Smith, A | 1 |
| Rueb, N | 1 |
| Hunt, JP | 1 |
| Stuke, L | 1 |
| Greiffenstein, P | 1 |
| Schoen, J | 1 |
| Marr, A | 1 |
| Mohamed, AS | 1 |
| Ahmad, HM | 1 |
| Abdul-Raheem, ASA | 1 |
| Kamel, FMM | 1 |
| Khames, A | 1 |
| Mady, AF | 1 |
| Martinazzi, BJ | 1 |
| Kirchner, GJ | 1 |
| Stauch, CM | 1 |
| Lorenz, FJ | 1 |
| Manto, KM | 1 |
| Bonaddio, V | 1 |
| Koroneos, Z | 1 |
| Aynardi, MC | 1 |
| AlLehaibi, LH | 1 |
| Alomar, M | 1 |
| Almulhim, A | 1 |
| Al-Makki, S | 1 |
| Alrwaili, NR | 1 |
| Al-Bassam, S | 1 |
| Alsultan, S | 1 |
| Al Saeed, J | 1 |
| Alsheef, M | 1 |
| Abraham, I | 1 |
| Alamer, A | 1 |
| Dawwas, GK | 1 |
| Cuker, A | 3 |
| Rothstein, A | 1 |
| Hennessy, S | 2 |
| Sidhu, VS | 4 |
| Kelly, TL | 2 |
| Pratt, N | 2 |
| Graves, SE | 2 |
| Buchbinder, R | 3 |
| Adie, S | 4 |
| Cashman, K | 2 |
| Ackerman, I | 2 |
| Bastiras, D | 3 |
| Brighton, R | 2 |
| Burns, AWR | 2 |
| Chong, BH | 2 |
| Clavisi, O | 2 |
| Cripps, M | 3 |
| Dekkers, M | 2 |
| de Steiger, R | 2 |
| Dixon, M | 2 |
| Ellis, A | 2 |
| Griffith, EC | 2 |
| Hale, D | 3 |
| Hansen, A | 2 |
| Harris, A | 2 |
| Hau, R | 2 |
| Horsley, M | 3 |
| James, D | 2 |
| Khorshid, O | 2 |
| Kuo, L | 2 |
| Lewis, P | 1 |
| Lieu, D | 3 |
| Lorimer, M | 2 |
| MacDessi, S | 1 |
| McCombe, P | 2 |
| McDougall, C | 2 |
| Mulford, J | 2 |
| Naylor, JM | 4 |
| Page, RS | 2 |
| Radovanovic, J | 2 |
| Solomon, M | 2 |
| Sorial, R | 2 |
| Summersell, P | 2 |
| Tran, P | 2 |
| Walter, WL | 2 |
| Webb, S | 2 |
| Wilson, C | 2 |
| Wysocki, D | 2 |
| Harris, IA | 8 |
| Bruno, AM | 1 |
| Allshouse, AA | 2 |
| Campbell, HM | 1 |
| Branch, DW | 2 |
| Lim, MY | 1 |
| Silver, RM | 2 |
| Metz, TD | 2 |
| Westerman, ME | 1 |
| Bree, KK | 1 |
| Msaouel, P | 1 |
| Kukreja, JB | 1 |
| Mantaring, C | 1 |
| Rukundo, I | 1 |
| Gonzalez, MG | 1 |
| Gregg, JR | 1 |
| Casteel, KN | 1 |
| Matin, SF | 1 |
| Deokar, K | 1 |
| Kaliya, M | 1 |
| Vachhani, K | 1 |
| Singhal, S | 1 |
| Parekh, A | 1 |
| Shafiei, M | 1 |
| Sabouri, M | 1 |
| Aminmansour, B | 1 |
| Rezvani, M | 1 |
| Mahmoodkhani, M | 1 |
| Rahmani, P | 1 |
| Karami, B | 1 |
| Sourani, A | 1 |
| Foroughi, M | 1 |
| Chee, A | 1 |
| Bortz, H | 2 |
| Yip, J | 1 |
| McFadyen, JD | 1 |
| Scheuermann, A | 1 |
| Liegl, M | 1 |
| Simpson, P | 1 |
| Branchford, B | 1 |
| Malec, L | 1 |
| Ismail, A | 1 |
| Jadawji, N | 1 |
| Adebayo, P | 1 |
| Jusabani, A | 1 |
| Hameed, K | 1 |
| Zehri, AA | 1 |
| Kiviri, W | 1 |
| Ali, A | 1 |
| Saadoun, R | 1 |
| Moroni, EA | 1 |
| Surucu, Y | 1 |
| Veit, JA | 1 |
| Khan, NI | 1 |
| Daniels, K | 1 |
| Rothenberger, SD | 1 |
| Kubik, M | 1 |
| Haut, ER | 5 |
| Moore, EE | 2 |
| Knudson, MM | 3 |
| Kandula, V | 1 |
| Shah, PV | 1 |
| Thirunavu, VM | 1 |
| Yerneni, K | 1 |
| Karras, C | 1 |
| Abecassis, ZA | 1 |
| Hopkins, B | 1 |
| Bloch, O | 1 |
| Potts, MB | 1 |
| Jahromi, BS | 1 |
| Tate, MC | 1 |
| Zohar, N | 1 |
| Ellis, MH | 1 |
| Dichtwald, S | 1 |
| Meyer, A | 1 |
| Zohar, E | 1 |
| Ifrach, N | 1 |
| Payne, A | 1 |
| Richardson, P | 1 |
| Muthayya, P | 1 |
| Maradei-Pereira, JAR | 3 |
| Sauma, ML | 3 |
| Demange, MK | 3 |
| John, MP | 3 |
| Streufert, BD | 3 |
| Downes, K | 3 |
| Chase, CB | 3 |
| Mir, HR | 3 |
| Whipple, MO | 3 |
| Erstad, BL | 3 |
| Barletta, JF | 3 |
| Gibson, A | 3 |
| Montanez, N | 3 |
| Addy, K | 3 |
| Hashmi, SS | 3 |
| Brown, D | 3 |
| Rodriguez, N | 3 |
| Menon, N | 3 |
| Srivaths, L | 3 |
| Garcia, D | 5 |
| Moloney, GB | 2 |
| Boakye, LAT | 2 |
| Cluts, LM | 2 |
| Palmeri, C | 2 |
| Shapiro, AJ | 2 |
| Bigam, DL | 2 |
| Wee, B | 2 |
| Lui, B | 2 |
| Lai, J | 2 |
| Khattak, Z | 2 |
| Kwok, A | 3 |
| Donarelli, C | 2 |
| Ho, P | 2 |
| Lim, HY | 2 |
| Masjedi, M | 1 |
| Azadikhah, S | 1 |
| Zand, F | 1 |
| Asmarian, N | 1 |
| Sabetian, G | 1 |
| Ostovan, M | 1 |
| Naderi-Boldaji, V | 1 |
| Violi, F | 1 |
| Pignatelli, P | 1 |
| Vestri, A | 1 |
| Spagnoli, A | 1 |
| Loffredo, L | 1 |
| Sakon, C | 1 |
| Nikirk, M | 1 |
| O'Brien, ARW | 1 |
| Marturano, MN | 1 |
| Khan, AR | 1 |
| DeBlieux, P | 1 |
| Wang, H | 3 |
| Ross, SW | 2 |
| Cunningham, KW | 1 |
| Sing, RF | 1 |
| Thomas, BW | 1 |
| Samuel, S | 3 |
| To, C | 1 |
| Ling, Y | 1 |
| Zhang, K | 1 |
| Jiang, X | 2 |
| Bernstam, EV | 1 |
| Hsu, CH | 1 |
| Chen, CH | 1 |
| Hsu, NC | 1 |
| Hsu, CC | 1 |
| Hsu, CJ | 1 |
| Wei, JC | 1 |
| DeMik, DE | 1 |
| Mont, MA | 1 |
| Dunbar, M | 1 |
| Walker, R | 1 |
| Kim, RG | 1 |
| Sidhu, V | 3 |
| Joo, PY | 1 |
| Modrak, M | 1 |
| Park, N | 1 |
| Brand, J | 1 |
| Rubin, LE | 1 |
| Grauer, JN | 1 |
| Bernstein, JA | 1 |
| Alsehly, AA | 1 |
| Wang, TF | 8 |
| Carrier, M | 13 |
| Kulkarni, NS | 1 |
| Piple, AS | 1 |
| Wang, JC | 1 |
| Kang, HP | 1 |
| Mills, ES | 1 |
| Mayfield, CK | 1 |
| Lieberman, JR | 3 |
| Christ, AB | 1 |
| Heckmann, ND | 1 |
| Spénard, E | 1 |
| Geerts, W | 3 |
| Lin, Y | 1 |
| Gien, LT | 1 |
| Kupets, R | 1 |
| Covens, A | 1 |
| Vicus, D | 1 |
| Chang, CK | 1 |
| Higgins, RM | 1 |
| Rein, L | 2 |
| Kindel, T | 1 |
| Park, G | 1 |
| Dhillon, NK | 3 |
| Fierro, NM | 2 |
| Drevets, P | 1 |
| Stupinski, J | 1 |
| Ley, EJ | 4 |
| Perrin, A | 1 |
| Sheth, H | 1 |
| Snyder, V | 1 |
| Dailey, H | 1 |
| Jovin, F | 1 |
| Smith, R | 3 |
| Li, W | 1 |
| Dunn, K | 1 |
| Cortes, J | 1 |
| Nguyen, T | 1 |
| Moussa, D | 1 |
| Kumar, A | 1 |
| Dao, T | 1 |
| Beeson, J | 1 |
| Choi, HA | 1 |
| McCullough, LD | 1 |
| Pokrzywa, CJ | 2 |
| Biesboer, EA | 2 |
| Figueroa, J | 2 |
| Al Tannir, AH | 2 |
| de Moya, M | 1 |
| Morris, RS | 2 |
| Murphy, PB | 2 |
| Griffin, M | 1 |
| Lip, GYH | 2 |
| Vaduganathan, M | 1 |
| Bikdeli, B | 2 |
| Haj, R | 1 |
| Massalha, M | 1 |
| Eitam, H | 1 |
| Kassabri, R | 1 |
| Yefet, E | 1 |
| Nachum, Z | 2 |
| Rich, JM | 1 |
| Elkun, Y | 1 |
| Geduldig, J | 1 |
| Lavallee, E | 1 |
| Mehrazin, R | 1 |
| Attalla, K | 1 |
| Wiklund, P | 1 |
| Sfakianos, JP | 1 |
| Harding, E | 1 |
| de Moya, MA | 1 |
| Langenstroer, EA | 1 |
| Holschbach, L | 1 |
| Ackerman, IN | 1 |
| Lewis, PL | 1 |
| MacDessi, SJ | 1 |
| Wu, YT | 1 |
| Chien, CY | 1 |
| Matsushima, K | 1 |
| Schellenberg, M | 1 |
| Inaba, K | 1 |
| Sauaia, A | 1 |
| Martin, MJ | 1 |
| Ebell, MH | 1 |
| Muniz, T | 1 |
| Siletz, AE | 1 |
| Alexander, J | 1 |
| Ikonte, C | 1 |
| Mason, R | 3 |
| Grubic, N | 1 |
| Canney, M | 1 |
| Delluc, A | 2 |
| Hundemer, GL | 1 |
| Knoll, G | 1 |
| Lazo-Langner, A | 1 |
| Massicotte-Azarniouch, D | 1 |
| Tanuseputro, P | 1 |
| Sood, MM | 1 |
| Reiter, AJ | 1 |
| Prinz, J | 1 |
| Li, Y | 1 |
| Nagle, AP | 1 |
| Hungness, ES | 1 |
| Teitelbaum, EN | 1 |
| Cho, YW | 1 |
| Scrushy, M | 1 |
| Zhu, M | 3 |
| DeAtkine, E | 1 |
| Wan, B | 1 |
| Fesmire, A | 1 |
| Park, C | 1 |
| Ehsan, M | 1 |
| Jafar, U | 1 |
| Butt, M | 1 |
| Naveed, A | 1 |
| Umer, M | 1 |
| Ayyan, M | 1 |
| Mustafa, B | 1 |
| Awan, RU | 1 |
| Rajput, RV | 1 |
| Sharron, MP | 1 |
| Pavuluri, P | 1 |
| Hansen, H | 1 |
| Ansusinha, E | 1 |
| DeBiasi, R | 1 |
| Majumdar, S | 1 |
| Diab, Y | 1 |
| Nasich, LL | 1 |
| Hoffman, R | 1 |
| Keren-Politansky, A | 1 |
| Jabareen, A | 1 |
| Kalish, Y | 2 |
| Schliamser, L | 1 |
| Brenner, B | 9 |
| Nadir, Y | 1 |
| Tsai, SW | 1 |
| Chang, WL | 1 |
| Pai, FY | 1 |
| Chou, TA | 1 |
| Chen, CF | 1 |
| Wu, PK | 1 |
| Chen, WM | 1 |
| Karahan, F | 1 |
| Ünal, S | 1 |
| Tezol, Ö | 1 |
| Sürmeli Döven, S | 1 |
| Durak, F | 1 |
| Alakaya, M | 1 |
| Mısırlıoğlu, M | 1 |
| Yeşil, E | 1 |
| Kıllı, İ | 1 |
| Kurt, H | 1 |
| Altunköprü, G | 1 |
| Alexander, M | 1 |
| Harris, S | 1 |
| Underhill, C | 1 |
| Torres, J | 1 |
| Sharma, S | 1 |
| Lee, N | 1 |
| Wong, H | 1 |
| Eek, R | 1 |
| Michael, M | 1 |
| Tie, J | 1 |
| Rogers, J | 1 |
| Heriot, AG | 1 |
| Ball, D | 1 |
| MacManus, M | 1 |
| Wolfe, R | 1 |
| Solomon, BJ | 1 |
| Burbury, K | 1 |
| Palmieri, A | 1 |
| Hicks, V | 1 |
| Aikman, N | 1 |
| Borowsky, M | 1 |
| Haggerty, A | 1 |
| ElSahwi, K | 1 |
| Marshall, S | 1 |
| Tsveybel, K | 1 |
| Boukedes, S | 1 |
| Chepuri, R | 1 |
| Coppolino, A | 1 |
| El-Chemaly, S | 1 |
| Hartigan, P | 1 |
| Kennedy, J | 1 |
| Keshk, M | 1 |
| Klibaner-Schiff, E | 1 |
| Lee, S | 2 |
| Mallidi, H | 1 |
| Sharma, N | 1 |
| Thaniyavarn, T | 1 |
| Young, J | 1 |
| Townsend, K | 1 |
| Goldberg, H | 1 |
| Peng, S | 1 |
| Zhang, M | 1 |
| Jin, J | 1 |
| MacCormick, AD | 1 |
| Cosmi, B | 1 |
| Giannella, M | 1 |
| Fornaro, G | 1 |
| Cristini, F | 1 |
| Patacca, A | 1 |
| Castagna, A | 1 |
| Mazzaferri, F | 1 |
| Testa, S | 1 |
| Pan, A | 1 |
| Lupi, M | 1 |
| Brambilla, P | 1 |
| Montineri, A | 1 |
| Frattima, S | 1 |
| Bignami, EG | 1 |
| Salvetti, M | 1 |
| De Stefano, G | 1 |
| Grandone, E | 1 |
| Di Perri, G | 1 |
| Rozzini, R | 1 |
| Stella, A | 2 |
| Romagnoli, A | 1 |
| Drago, F | 1 |
| Viale, P | 1 |
| Wang, C | 3 |
| Ning, YC | 1 |
| Song, LP | 1 |
| Li, PJ | 1 |
| Wang, FH | 1 |
| Ding, MX | 1 |
| Jiang, L | 1 |
| Wang, M | 2 |
| Pei, QQ | 1 |
| Hu, SM | 1 |
| Bell, S | 1 |
| Orellana, T | 1 |
| Garrett, A | 1 |
| Smith, K | 3 |
| Kim, H | 2 |
| Rosiello, A | 1 |
| Rush, S | 1 |
| Berger, J | 1 |
| Lesnock, J | 1 |
| Dziri, C | 1 |
| Ben Hmida, W | 1 |
| Dougaz, W | 1 |
| Khalfallah, M | 1 |
| Samaali, I | 1 |
| Jerraya, H | 1 |
| Bouasker, I | 1 |
| Nouira, R | 1 |
| Rose, M | 1 |
| Pang, N | 1 |
| Conway, S | 1 |
| Osman, I | 1 |
| Atamna, A | 1 |
| Elis, A | 1 |
| Lopes, RD | 2 |
| Yee, MK | 7 |
| Hernandez, A | 1 |
| Seo, WW | 1 |
| Park, MS | 1 |
| Kim, SE | 1 |
| Lee, JH | 4 |
| Park, DG | 1 |
| Han, KR | 1 |
| Oh, DJ | 1 |
| Hyon, MS | 1 |
| Rodier, SG | 2 |
| Bukur, M | 2 |
| Moore, S | 2 |
| Frangos, SG | 2 |
| Tandon, M | 2 |
| DiMaggio, CJ | 2 |
| Ayoung-Chee, P | 1 |
| Marshall, GT | 1 |
| Rottenstreich, A | 1 |
| Karlin, A | 1 |
| Levin, G | 1 |
| Rottenstreich, M | 1 |
| Lobastov, K | 1 |
| Dementieva, G | 1 |
| Soshitova, N | 1 |
| Bargandzhiya, A | 1 |
| Barinov, V | 1 |
| Laberko, L | 1 |
| Rodoman, G | 1 |
| Jones, DL | 1 |
| Jones, WA | 1 |
| Fleming, KI | 11 |
| Higgins, TF | 1 |
| Rothberg, DL | 1 |
| Zhang, Y | 1 |
| Vasilakis, V | 1 |
| Klein, GM | 1 |
| Trostler, M | 1 |
| Mukit, M | 1 |
| Marquez, JE | 1 |
| Dagum, AB | 1 |
| Khan, SU | 1 |
| Song, D | 1 |
| Magers, J | 1 |
| Abdel-Rasoul, M | 1 |
| Prusakov, P | 1 |
| Huang, Q | 2 |
| Xing, SX | 1 |
| Zeng, Y | 1 |
| Si, HB | 1 |
| Zhou, ZK | 1 |
| Pelargos, PE | 1 |
| Dunn, IF | 1 |
| Jacobson, B | 1 |
| Rambiritch, V | 1 |
| Paek, D | 1 |
| Sayre, T | 1 |
| Naidoo, P | 1 |
| Shan, J | 1 |
| Leisegang, R | 1 |
| Rakhra, S | 1 |
| Martin, EL | 1 |
| Fitzgerald, M | 1 |
| Udy, A | 1 |
| Yun, R | 1 |
| Sciubba, DM | 1 |
| Lewin, JJ | 1 |
| Lau, BD | 3 |
| Shermock, KM | 3 |
| Kraus, PS | 3 |
| Popoola, VO | 1 |
| Dalpoas, SE | 1 |
| Bilal, S | 1 |
| Zhao, G | 1 |
| Qu, S | 1 |
| Xiong, T | 1 |
| Yao, X | 1 |
| Wu, B | 3 |
| Moreno, JP | 1 |
| Bautista, M | 1 |
| Castro, J | 1 |
| Bonilla, G | 1 |
| Llinás, A | 1 |
| Kramme, K | 1 |
| Sarraf, P | 1 |
| Munene, G | 1 |
| Mason, SW | 1 |
| Barber, A | 1 |
| Jones, E | 1 |
| Chen, SL | 1 |
| Moll, S | 1 |
| Northam, K | 1 |
| Wang, X | 3 |
| Mathew, C | 1 |
| Korapati, S | 1 |
| Bathini, VG | 1 |
| Bauersachs, R | 16 |
| Becker, B | 1 |
| Berkowitz, SD | 6 |
| Freitas, MCS | 1 |
| Metzig, C | 1 |
| De Sanctis, Y | 3 |
| Xu, J | 1 |
| Argenti, D | 1 |
| Yang, H | 1 |
| Albanese, J | 1 |
| Karri, JV | 1 |
| Vincent, S | 1 |
| Cap, AP | 1 |
| Krantz, EN | 1 |
| Philpott, CD | 3 |
| Droege, ME | 4 |
| Mueller, EW | 4 |
| Ernst, NE | 4 |
| Garber, PM | 1 |
| Tsuei, BJ | 1 |
| Goodman, MD | 2 |
| Droege, CA | 4 |
| Murphy, RF | 1 |
| Williams, D | 1 |
| Hogue, GD | 1 |
| Spence, DD | 1 |
| Epps, H | 1 |
| Chambers, HG | 1 |
| Shore, BJ | 1 |
| Lee, YR | 1 |
| van Oosterom, N | 1 |
| Winckel, K | 1 |
| Barras, M | 2 |
| Bertolaccini, C | 3 |
| Moulton, L | 2 |
| Stringham, J | 2 |
| Barnett, S | 1 |
| Lin, J | 9 |
| Varghese, TK | 3 |
| Miyamoto, K | 1 |
| Komatsu, H | 1 |
| Nagaya, Y | 1 |
| Tsukihara, S | 1 |
| Sarugami, M | 1 |
| Osaku, D | 1 |
| Taniguchi, F | 1 |
| Harada, T | 1 |
| Kanamori, Y | 1 |
| Mahlab-Guri, K | 1 |
| Otman, MS | 1 |
| Replianski, N | 1 |
| Rosenberg-Bezalel, S | 1 |
| Rabinovich, I | 1 |
| Sthoeger, Z | 1 |
| Mula, V | 1 |
| Parikh, S | 1 |
| Suresh, S | 1 |
| Bottle, A | 1 |
| Loeffler, M | 1 |
| Alam, M | 1 |
| Rosenfield, LK | 1 |
| Limsakun, T | 1 |
| Dishy, V | 1 |
| Mendell, J | 2 |
| Pizzagalli, F | 1 |
| Pav, J | 1 |
| Kochan, J | 1 |
| Vandell, AG | 1 |
| Rambaran, C | 1 |
| Kobayashi, F | 1 |
| Orihashi, Y | 1 |
| Warren, V | 1 |
| McPhillips, P | 1 |
| Zhou, J | 2 |
| Lee, JK | 1 |
| Koo, JW | 1 |
| Jeong, SY | 1 |
| Choi, S | 1 |
| Park, KC | 1 |
| Hwang, KT | 1 |
| Samama, CM | 2 |
| Laporte, S | 6 |
| Rosencher, N | 9 |
| Girard, P | 5 |
| Llau, J | 1 |
| Mouret, P | 7 |
| Fisher, W | 6 |
| Martínez-Martín, J | 1 |
| Duverger, D | 1 |
| Deygas, B | 1 |
| Presles, E | 1 |
| Mismetti, P | 10 |
| Kubicek, P | 1 |
| Boughalem, E | 1 |
| Frere, C | 2 |
| Aleidan, FAS | 1 |
| Aljarba, GA | 1 |
| Aldakhil, AA | 1 |
| Allehyani, BI | 1 |
| Yahia, MA | 1 |
| Alghtani, NE | 1 |
| Badri, M | 1 |
| Alaklabi, AA | 1 |
| Alsuhaibani, A | 1 |
| Ní Cheallaigh, S | 1 |
| Fleming, A | 1 |
| Dahly, D | 1 |
| Kehoe, E | 1 |
| O'Byrne, JM | 1 |
| McGrath, B | 1 |
| O'Connell, C | 2 |
| Sahm, LJ | 1 |
| Hussain, Z | 1 |
| Peterson, GM | 1 |
| Mirkazemi, C | 1 |
| Curtain, C | 1 |
| Zaidi, STR | 1 |
| Kim, M | 2 |
| Klein, MJ | 1 |
| Berry, CD | 1 |
| Huang, PP | 1 |
| Zwicker, JI | 5 |
| Roopkumar, J | 1 |
| Puligandla, M | 2 |
| Schlechter, BL | 1 |
| Sharda, AV | 1 |
| Peereboom, D | 1 |
| Joyce, R | 1 |
| Bockorny, B | 1 |
| Neuberg, D | 3 |
| Bauer, KA | 1 |
| Artifoni, M | 1 |
| Danic, G | 1 |
| Gautier, G | 1 |
| Gicquel, P | 1 |
| Boutoille, D | 1 |
| Raffi, F | 1 |
| Néel, A | 1 |
| Lecomte, R | 1 |
| Marietta, M | 1 |
| Tripodi, A | 1 |
| Sharathkumar, AA | 1 |
| Rashki Kemmak, A | 1 |
| Abutorabi, A | 1 |
| Alipour, V | 1 |
| Diver, E | 1 |
| Guntupalli, SR | 2 |
| Brennecke, A | 2 |
| Behbakht, K | 1 |
| Tayebnejad, A | 2 |
| Breed, CA | 1 |
| Babayan, LM | 1 |
| Cheng, G | 1 |
| Ramzan, AA | 1 |
| Wheeler, LJ | 1 |
| Corr, BR | 1 |
| Lefkowits, C | 1 |
| Sheeder, J | 2 |
| Matsuo, K | 2 |
| Flink, D | 1 |
| Carbajal-Mamani, SL | 1 |
| Dideban, B | 1 |
| Schweer, D | 1 |
| Balavage, KT | 1 |
| Chuang, L | 1 |
| Wang, Y | 2 |
| Wang, S | 1 |
| Amaro, B | 1 |
| Cardenas-Goicoechea, J | 1 |
| Dall, CP | 1 |
| Shaw, N | 1 |
| Egan, J | 1 |
| Carvalho, FL | 1 |
| Galloway, LAS | 1 |
| Krasnow, R | 1 |
| Stamatakis, L | 1 |
| Corona, LE | 1 |
| Singhal, U | 1 |
| Hafez, K | 1 |
| Herrel, LA | 1 |
| Kaffenberger, SD | 1 |
| Montgomery, JS | 1 |
| Morgan, TM | 1 |
| Weizer, AZ | 1 |
| Qin, Y | 1 |
| Ambani, SN | 1 |
| Farey, JE | 1 |
| An, VVG | 1 |
| Karunaratne, S | 1 |
| Santoliquido, A | 1 |
| Porfidia, A | 1 |
| Nesci, A | 1 |
| De Matteis, G | 2 |
| Marrone, G | 1 |
| Porceddu, E | 1 |
| Cammà, G | 1 |
| Giarretta, I | 1 |
| Fantoni, M | 1 |
| Landi, F | 1 |
| Gasbarrini, A | 1 |
| Pola, R | 1 |
| D'Alfonso, ME | 1 |
| Lo Monaco, MR | 1 |
| Kamachi, H | 1 |
| Homma, S | 1 |
| Kawamura, H | 1 |
| Yoshida, T | 1 |
| Ohno, Y | 1 |
| Ichikawa, N | 1 |
| Yokota, R | 1 |
| Funakoshi, T | 1 |
| Maeda, Y | 1 |
| Takahashi, N | 1 |
| Amano, T | 1 |
| Taketomi, A | 1 |
| Trimaille, A | 1 |
| Curtiaud, A | 1 |
| Marchandot, B | 1 |
| Matsushita, K | 1 |
| Sato, C | 1 |
| Leonard-Lorant, I | 1 |
| Sattler, L | 1 |
| Grunebaum, L | 1 |
| Ohana, M | 1 |
| Von Hunolstein, JJ | 1 |
| Andres, E | 1 |
| Goichot, B | 1 |
| Danion, F | 1 |
| Kaeuffer, C | 1 |
| Poindron, V | 1 |
| Ohlmann, P | 1 |
| Jesel, L | 1 |
| Morel, O | 1 |
| Moll, M | 1 |
| Zon, RL | 1 |
| Sylvester, KW | 1 |
| Chen, EC | 1 |
| Cheng, V | 1 |
| Connell, NT | 1 |
| Fredenburgh, LE | 1 |
| Baron, RM | 1 |
| Cho, MH | 1 |
| Woolley, AE | 1 |
| Connors, JM | 7 |
| Sbeit, W | 1 |
| Kadah, A | 1 |
| Shafrir, A | 1 |
| Kalisky, I | 1 |
| Mahamid, M | 1 |
| Hazou, W | 1 |
| Katz, L | 1 |
| Mari, A | 1 |
| Khoury, T | 1 |
| Yang, L | 2 |
| Wu, J | 2 |
| Haac, BE | 1 |
| O'Hara, NN | 1 |
| Manson, TT | 1 |
| Slobogean, GP | 1 |
| Castillo, RC | 1 |
| O'Toole, RV | 1 |
| Stein, DM | 1 |
| Mower, S | 1 |
| Thompson, S | 1 |
| Obitsu, T | 1 |
| Tanaka, N | 1 |
| Oyama, A | 1 |
| Ueno, T | 1 |
| Saito, M | 3 |
| Yamaguchi, T | 2 |
| Takagi, A | 1 |
| Rikiyama, T | 1 |
| Unno, M | 2 |
| Naitoh, T | 2 |
| Glickman, A | 1 |
| Vahtera, A | 1 |
| Szanto, T | 1 |
| Lassila, R | 1 |
| Valkonen, M | 1 |
| Sivula, M | 1 |
| Huhtala, H | 1 |
| Pettilä, V | 1 |
| Kuitunen, A | 1 |
| Abdelsalam, AM | 1 |
| ElAnsary, AMSE | 1 |
| Salman, MA | 1 |
| Nassef, SA | 1 |
| Elfergany, HM | 1 |
| Aisha, HAA | 1 |
| Talasaz, AH | 1 |
| Rashidi, F | 1 |
| Sharif-Kashani, B | 1 |
| Farrokhpour, M | 1 |
| Bakhshandeh, H | 1 |
| Sezavar, H | 1 |
| Dabbagh, A | 1 |
| Beigmohammadi, MT | 1 |
| Payandemehr, P | 1 |
| Yadollahzadeh, M | 1 |
| Riahi, T | 1 |
| Khalili, H | 1 |
| Jamalkhani, S | 1 |
| Rezaeifar, P | 1 |
| Abedini, A | 1 |
| Lookzadeh, S | 1 |
| Shahmirzaei, S | 1 |
| Tahamtan, O | 1 |
| Matin, S | 1 |
| Amin, A | 1 |
| Parhizgar, SE | 1 |
| Jimenez, D | 2 |
| Gupta, A | 2 |
| Madhavan, MV | 1 |
| Parikh, SA | 1 |
| Monreal, M | 8 |
| Hadavand, N | 1 |
| Hajighasemi, A | 1 |
| Maleki, M | 2 |
| Sadeghian, S | 1 |
| Mohebbi, B | 1 |
| Piazza, G | 3 |
| Kirtane, AJ | 1 |
| Krumholz, HM | 1 |
| Sadeghipour, P | 1 |
| Cattelan, AM | 1 |
| Carrozzi, L | 1 |
| Leone, L | 1 |
| Filippi, L | 1 |
| De Gaudenzi, E | 1 |
| Villalta, S | 1 |
| Pesavento, R | 1 |
| Cardillo, G | 1 |
| Viggiano, GV | 1 |
| Mangiacapra, S | 1 |
| Cavalli, A | 1 |
| Fontanella, A | 3 |
| Agrusta, F | 1 |
| Bellizzi, A | 1 |
| Amitrano, M | 1 |
| Iannuzzo, M | 1 |
| Sacco, C | 1 |
| Lodigiani, C | 1 |
| Karas, LA | 1 |
| Nor Hanipah, Z | 1 |
| Cetin, D | 1 |
| Schauer, PR | 1 |
| Brethauer, SA | 1 |
| Daigle, CR | 1 |
| Aminian, A | 1 |
| Atallah, B | 1 |
| Sadik, ZG | 1 |
| Salem, N | 1 |
| El Nekidy, WS | 1 |
| Almahmeed, W | 1 |
| Park, WM | 1 |
| Cherfan, A | 1 |
| Hamed, F | 1 |
| Mallat, J | 1 |
| Van der Merwe, M | 1 |
| Julyan, M | 1 |
| Du Plessis, JM | 1 |
| Bhatt, H | 1 |
| Singh, S | 2 |
| Huang, LC | 2 |
| Pickron, TB | 2 |
| Prazak, AM | 7 |
| Momeni, A | 5 |
| Dobbie, LJ | 1 |
| Lamb, A | 1 |
| Eskell, L | 1 |
| Ramage, IJ | 1 |
| Reynolds, BC | 1 |
| Fantoni, C | 1 |
| Bertù, L | 1 |
| Faioni, EM | 1 |
| Froiio, C | 1 |
| Mariani, N | 1 |
| Paciaroni, M | 1 |
| Alberti, A | 1 |
| Becattini, C | 9 |
| Guercini, F | 1 |
| Martini, G | 1 |
| Tassi, R | 1 |
| Marotta, G | 1 |
| Venti, M | 1 |
| Acciarresi, M | 1 |
| Mosconi, MG | 1 |
| Marcheselli, S | 1 |
| Fratticci, L | 1 |
| D'Amore, C | 1 |
| Versino, M | 1 |
| De Lodovici, ML | 1 |
| Carimati, F | 1 |
| Pezzini, A | 1 |
| Padovani, A | 1 |
| Corea, F | 1 |
| Scoditti, U | 1 |
| Denti, L | 1 |
| Tassinari, T | 1 |
| Silvestrelli, G | 1 |
| Ciccone, A | 1 |
| Caso, V | 1 |
| Osborne, SA | 1 |
| Masci, PP | 1 |
| Du, QS | 1 |
| Daniel, RA | 1 |
| Desilva, K | 1 |
| Vitetta, L | 1 |
| Zhao, KN | 1 |
| Seymour, RB | 1 |
| Hamadé, A | 1 |
| Woehl, B | 1 |
| Harzallah, I | 1 |
| Talbot, M | 1 |
| Tousch, J | 1 |
| Jambert, L | 1 |
| Veeranki, SP | 1 |
| Xiao, Z | 1 |
| Levorsen, A | 1 |
| Sinha, M | 1 |
| Shah, BR | 1 |
| Yamashita, S | 1 |
| Nishi, M | 1 |
| Ikemoto, T | 1 |
| Yoshikawa, K | 1 |
| Higashijima, J | 1 |
| Tokunaga, T | 1 |
| Takasu, C | 1 |
| Kashihara, H | 1 |
| Eto, S | 1 |
| Yoshimoto, T | 1 |
| Shimada, M | 1 |
| Martinelli, I | 2 |
| Ciavarella, A | 1 |
| Abbattista, M | 1 |
| Aliberti, S | 1 |
| De Zan, V | 1 |
| Folli, C | 1 |
| Panigada, M | 1 |
| Gori, A | 1 |
| Artoni, A | 1 |
| Ierardi, AM | 1 |
| Carrafiello, G | 1 |
| Monzani, V | 1 |
| Grasselli, G | 1 |
| Blasi, F | 1 |
| Peyvandi, F | 1 |
| Hall, C | 1 |
| Davis, S | 1 |
| Schillig, JM | 1 |
| Rajaratnam, N | 1 |
| Patel, JP | 3 |
| Roberts, LN | 2 |
| Czuprynska, J | 1 |
| Patel, RK | 3 |
| Arya, R | 3 |
| Lu, P | 1 |
| Harms, KA | 1 |
| Paul, E | 1 |
| Lo, C | 1 |
| Cleland, H | 1 |
| Hart, K | 1 |
| Andrick, B | 1 |
| Grassi, S | 1 |
| Manikowski, J | 1 |
| Graham, J | 1 |
| Lai, N | 1 |
| Jones, AE | 1 |
| Johnson, SA | 1 |
| Witt, DM | 1 |
| Feng, W | 2 |
| Huang, D | 1 |
| Lu, A | 1 |
| Tseng, EK | 3 |
| Nieuwlaat, R | 1 |
| Angchaisuksiri, P | 1 |
| Blair, C | 1 |
| Dane, K | 1 |
| Davila, J | 1 |
| DeSancho, MT | 2 |
| Diuguid, D | 1 |
| Griffin, DO | 1 |
| Kahn, SR | 7 |
| Lee, AI | 1 |
| Neumann, I | 2 |
| Pai, A | 1 |
| Pai, M | 1 |
| Righini, M | 2 |
| Sanfilippo, KM | 1 |
| Siegal, D | 1 |
| Skara, M | 1 |
| Touri, K | 1 |
| Akl, EA | 7 |
| Bou Akl, I | 1 |
| Boulos, M | 1 |
| Brignardello-Petersen, R | 1 |
| Charide, R | 1 |
| Chan, M | 1 |
| Dearness, K | 1 |
| Darzi, AJ | 1 |
| Kolb, P | 1 |
| Colunga-Lozano, LE | 1 |
| Mansour, R | 1 |
| Morgano, GP | 1 |
| Morsi, RZ | 1 |
| Noori, A | 1 |
| Piggott, T | 1 |
| Qiu, Y | 1 |
| Roldan, Y | 1 |
| Schünemann, F | 1 |
| Stevens, A | 1 |
| Solo, K | 1 |
| Ventresca, M | 1 |
| Wiercioch, W | 1 |
| Mustafa, RA | 1 |
| Schünemann, HJ | 2 |
| Qian, C | 1 |
| Huhtakangas, J | 1 |
| Juvela, S | 2 |
| Bode, MK | 1 |
| Tatlisumak, T | 1 |
| Savolainen, M | 1 |
| Numminen, H | 1 |
| Ollikainen, J | 1 |
| Luostarinen, L | 1 |
| Kupila, L | 1 |
| Tetri, S | 2 |
| Snoga, JL | 1 |
| Benitez, RM | 1 |
| Kim, S | 1 |
| Creager, O | 1 |
| Lusk, KA | 1 |
| DeBiase, C | 1 |
| Giuliano, CA | 1 |
| Doshi, M | 1 |
| Ganoff, M | 1 |
| Alexander Paxton, R | 1 |
| Runner, RP | 2 |
| Shau, DN | 1 |
| Staley, CA | 2 |
| Roberson, JR | 2 |
| McKinzie, BP | 1 |
| Nizamani, R | 1 |
| Jones, S | 2 |
| King, B | 1 |
| Williams, FN | 1 |
| Oh, HJ | 1 |
| Ryu, KH | 1 |
| Park, BJ | 1 |
| Yoon, BH | 1 |
| Scarduelli, C | 1 |
| Inglese, F | 1 |
| Beccaria, M | 1 |
| Spreafico, F | 1 |
| Garuti, M | 1 |
| Pecoriello, A | 1 |
| Cervi, G | 1 |
| Greco, G | 1 |
| Scarduelli, S | 1 |
| Lucchini, G | 1 |
| De Donno, G | 1 |
| Borghi, C | 1 |
| Mol, BW | 1 |
| Agarwal, J | 4 |
| Rockwell, WB | 4 |
| Mendenhall, SD | 1 |
| Goodwin, I | 1 |
| Gociman, B | 1 |
| Williams, NN | 1 |
| Dumon, KR | 1 |
| Cohoon, K | 1 |
| Kittelson, JM | 2 |
| Dale, RA | 1 |
| Briggler, R | 1 |
| Matherne, E | 1 |
| Johnson, C | 1 |
| Boehmer, K | 1 |
| Farrar, JE | 1 |
| Makley, AT | 3 |
| Deichstetter, KM | 1 |
| Taylor, A | 1 |
| Huang, E | 2 |
| Waller, J | 1 |
| White, C | 1 |
| Martinez-Quinones, P | 1 |
| Robinson, T | 1 |
| Kuroda, S | 2 |
| Kikuchi, S | 2 |
| Kakiuchi, Y | 1 |
| Watanabe, M | 2 |
| Kuwada, K | 1 |
| Tsumura, T | 1 |
| Nishizaki, M | 2 |
| Kagawa, S | 2 |
| Hinotsu, S | 2 |
| Fujiwara, T | 2 |
| Dai, JC | 1 |
| Morgan, TN | 1 |
| Kusin, S | 1 |
| Kommidi, V | 1 |
| Garbens, A | 1 |
| Cadeddu, JA | 1 |
| Gahan, JC | 1 |
| Webb, ML | 1 |
| Athota, K | 1 |
| Wakefield, D | 1 |
| Dowd, JR | 1 |
| Gomaa, D | 1 |
| Robinson, BHR | 1 |
| Hanseman, D | 1 |
| Elterman, J | 1 |
| Elias, A | 2 |
| Morgenstern, Y | 1 |
| Braun, E | 1 |
| Tzoran, I | 1 |
| Marshall, AM | 1 |
| Trussell, TM | 1 |
| Yee, AM | 1 |
| Malone, MP | 1 |
| Benes, J | 1 |
| Skulec, R | 1 |
| Jobanek, J | 1 |
| Cerny, V | 1 |
| Watts, PJ | 1 |
| Kopstein, M | 1 |
| Harkness, W | 1 |
| Cornett, B | 1 |
| Dziadkowiec, O | 1 |
| Hicks, ME | 1 |
| Hassan, S | 1 |
| Scherbak, D | 1 |
| Rahbar, E | 1 |
| Ali Hasan, M | 1 |
| Azeez Alsaadi, M | 1 |
| Tahseen Mehsen, J | 1 |
| Ortiz, RM | 1 |
| Golijanin, B | 1 |
| O'Rourke, TK | 1 |
| Sobel, DW | 1 |
| Pillsbury, L | 1 |
| T Tucci, C | 1 |
| Caffery, P | 1 |
| Golijanin, D | 1 |
| Kunal, K | 1 |
| Banerjee, S | 1 |
| Garg, PK | 1 |
| Elhence, A | 1 |
| Chong, MJ | 1 |
| Chiam, C | 1 |
| Verhamme, P | 7 |
| Yi, BA | 1 |
| Salter, J | 1 |
| Bloomfield, D | 1 |
| Büller, HR | 16 |
| Chen, KB | 1 |
| Huang, Y | 1 |
| Chen, J | 1 |
| Ghanem, M | 1 |
| He, Z | 1 |
| Morrissey, H | 1 |
| Ball, P | 1 |
| Boyd, RA | 1 |
| DiCarlo, L | 1 |
| Mandema, JW | 1 |
| Mantia, C | 1 |
| Uhlmann, EJ | 2 |
| Weber, GM | 2 |
| Hwang, HG | 1 |
| Koo, SM | 1 |
| Uh, ST | 1 |
| Kim, YK | 1 |
| Fan, JL | 1 |
| Roberts, LE | 1 |
| Scheurer, ME | 1 |
| Yee, DL | 1 |
| Shah, MD | 1 |
| Lee-Kim, YJ | 1 |
| Bala, A | 2 |
| Huddleston, JI | 2 |
| Goodman, SB | 2 |
| Maloney, WJ | 2 |
| Amanatullah, DF | 2 |
| Stensland, KD | 1 |
| Katz, EG | 1 |
| Canes, D | 1 |
| Tang, Y | 1 |
| Wang, K | 1 |
| Shi, Z | 2 |
| Yang, P | 1 |
| Dang, X | 1 |
| Cafri, G | 1 |
| Paxton, EW | 1 |
| Chen, Y | 1 |
| Cheetham, CT | 1 |
| Gould, MK | 3 |
| Sluggett, J | 1 |
| Bini, SA | 1 |
| Khatod, M | 1 |
| Whiting, DR | 1 |
| Robison, E | 1 |
| Heyborne, K | 1 |
| Valdez, C | 1 |
| Korjian, S | 5 |
| Daaboul, Y | 4 |
| Jain, P | 3 |
| Arbetter, D | 2 |
| Hull, R | 9 |
| Gold, A | 6 |
| Alzghari, SK | 1 |
| Seago, SE | 1 |
| Garza, JE | 1 |
| Hashimie, YF | 1 |
| Baty, KA | 1 |
| Evans, MF | 1 |
| Shaver, C | 1 |
| Herrington, JD | 1 |
| Turpie, AGG | 1 |
| Curnutte, JT | 1 |
| Sáez-Giménez, B | 1 |
| Berastegui, C | 1 |
| Sintes, H | 1 |
| Perez-Miranda, J | 1 |
| Figueredo, A | 1 |
| López Meseguer, M | 1 |
| Monforte, V | 1 |
| Bravo, C | 1 |
| Santamaría, A | 2 |
| Ramon, MA | 1 |
| Gómez-Ollés, S | 1 |
| Roman, A | 1 |
| Miano, TA | 1 |
| Christie, JD | 1 |
| Martin, N | 1 |
| Smith, B | 1 |
| Guo, W | 1 |
| Arbetter, DF | 2 |
| Michalak, N | 1 |
| Kim, BJ | 1 |
| Day, RW | 1 |
| Davis, CH | 1 |
| Narula, N | 1 |
| Kroll, MH | 1 |
| Tzeng, CWD | 1 |
| Aloia, TA | 1 |
| Newall, F | 1 |
| Gelikas, S | 1 |
| Eldar, SM | 1 |
| Lahat, G | 1 |
| Hunt, MM | 1 |
| Fuller, K | 1 |
| Malecki, S | 1 |
| Anselmo, L | 1 |
| Borrego, ME | 1 |
| Jakeman, B | 1 |
| Burnett, A | 1 |
| Xiang, E | 1 |
| Ahuja, T | 1 |
| Raco, V | 1 |
| Cirrone, F | 1 |
| Green, D | 1 |
| Papadopoulos, J | 1 |
| Ozturk, G | 1 |
| Akpinar, P | 1 |
| Karamanlioglu, AD | 1 |
| Ozkan, FU | 1 |
| Aktas, I | 1 |
| Karcutskie, CA | 3 |
| Dharmaraja, A | 2 |
| Patel, J | 3 |
| Eidelson, SA | 2 |
| Padiadpu, AB | 1 |
| Martin, AG | 2 |
| Lama, G | 1 |
| Lineen, EB | 3 |
| Namias, N | 3 |
| Schulman, CI | 2 |
| Proctor, KG | 2 |
| Schomburg, J | 1 |
| Krishna, S | 1 |
| Soubra, A | 1 |
| Cotter, K | 1 |
| Fan, Y | 1 |
| Brown, G | 1 |
| Konety, B | 1 |
| Ek, L | 1 |
| Gezelius, E | 1 |
| Bergman, B | 1 |
| Bendahl, PO | 1 |
| Anderson, H | 1 |
| Sundberg, J | 1 |
| Wallberg, M | 1 |
| Falkmer, U | 1 |
| Verma, S | 1 |
| Belting, M | 1 |
| Signorelli, JR | 1 |
| Gandhi, AS | 1 |
| Mahan, CE | 1 |
| Burnett, AE | 1 |
| Fletcher, ML | 1 |
| Nafee, T | 3 |
| Kerneis, M | 2 |
| Wiest, C | 1 |
| Khan, NR | 1 |
| Patel, PG | 1 |
| Sharpe, JP | 1 |
| Lee, SL | 1 |
| Sorenson, J | 1 |
| Baumgartner, JM | 1 |
| McKenzie, S | 1 |
| Block, S | 1 |
| Lowy, AM | 1 |
| Amin, AN | 4 |
| Nicklaus, MD | 1 |
| Ludwig, SL | 1 |
| Kettle, JK | 1 |
| Smith, EJT | 1 |
| Gillette, E | 1 |
| Barmparas, G | 2 |
| Gewertz, BL | 2 |
| Yang, LS | 1 |
| Alukaidey, S | 1 |
| Croucher, K | 1 |
| Dowling, D | 1 |
| Holoyda, K | 1 |
| Haskell, L | 4 |
| McBane, RD | 4 |
| Senay, A | 1 |
| Trottier, M | 1 |
| Delisle, J | 1 |
| Banica, A | 1 |
| Benoit, B | 1 |
| Laflamme, GY | 1 |
| Malo, M | 1 |
| Nguyen, H | 1 |
| Ranger, P | 1 |
| Fernandes, JC | 1 |
| Yoshida, N | 2 |
| Baba, Y | 1 |
| Miyamoto, Y | 1 |
| Iwatsuki, M | 1 |
| Hiyoshi, Y | 1 |
| Ishimoto, T | 1 |
| Imamura, Y | 1 |
| Baba, H | 2 |
| Kelecy, MW | 1 |
| Shutt, T | 1 |
| Rostas, J | 1 |
| Martin, RCG | 1 |
| Luce, EA | 1 |
| Bethea, A | 1 |
| Adams, E | 1 |
| Lucente, FC | 1 |
| Samanta, D | 1 |
| Chumbe, JT | 1 |
| Imran, JB | 1 |
| Madni, TD | 1 |
| Clark, AT | 1 |
| Rizk, P | 1 |
| Minshall, CT | 1 |
| Taveras, LR | 1 |
| Cunningham, HB | 1 |
| Eastman, AL | 2 |
| Koshy, JP | 1 |
| Kacir, CD | 1 |
| Cripps, MW | 2 |
| Groff, H | 1 |
| Azboy, I | 1 |
| Parvizi, J | 1 |
| Ramacciotti, E | 6 |
| Ferreira, U | 1 |
| Costa, AJV | 1 |
| Raymundo, SRO | 1 |
| Correa, JA | 1 |
| Neto, SG | 1 |
| Osvaldt, AB | 1 |
| Agati, L | 1 |
| Aguiar, VCR | 1 |
| Davila, R | 1 |
| Caltabiano, TB | 1 |
| Magella, FM | 1 |
| Volpiani, GG | 1 |
| Castelli, V | 1 |
| Caffaro, RA | 1 |
| DalAcqua, LZ | 1 |
| Matheus, WE | 1 |
| Sato, DY | 1 |
| Russeff, GJDS | 1 |
| de Souza, DG | 1 |
| Pazetto, LE | 1 |
| de Lima, TAM | 1 |
| Colnago, EMDS | 1 |
| Fugii, EY | 1 |
| Mussalem, JS | 1 |
| Assao, VT | 1 |
| Toffoletto, O | 1 |
| Rodrigues, DG | 1 |
| Afiune, JB | 1 |
| Araujo, GR | 1 |
| Xing, J | 1 |
| Yin, X | 1 |
| Chen, D | 7 |
| Bhalla, V | 1 |
| Abdel-Latif, A | 1 |
| Bhalla, M | 1 |
| Ziada, K | 1 |
| Williams, MV | 1 |
| Smyth, SS | 1 |
| Marques de Marino, P | 1 |
| Rial Horcajo, R | 1 |
| Garcia Grandal, T | 1 |
| Sanchez Hervas, L | 1 |
| Serrano Hernando, FJ | 1 |
| Herraiz Martinez, MA | 1 |
| Coronado Martin, PJ | 1 |
| Liu, Y | 2 |
| Karaoui, LR | 1 |
| Tawil, S | 1 |
| Salameh, P | 1 |
| Chamoun, N | 1 |
| Dhir, T | 1 |
| Weiss, E | 1 |
| Wolanin, K | 1 |
| Randhawa, S | 1 |
| Minimo, C | 1 |
| Becker, G | 1 |
| McGreen, B | 1 |
| Kriza, C | 1 |
| Patel, N | 1 |
| Kaplan, M | 1 |
| Leung, P | 1 |
| Travis, R | 1 |
| Mir, M | 1 |
| Jafarizade, M | 2 |
| Ganti, A | 1 |
| Kazmi, SH | 1 |
| Ghaffarpasand, E | 1 |
| Pitliya, A | 1 |
| Datta, S | 2 |
| Sharfaei, S | 2 |
| Alihashemi, M | 1 |
| Elsaiey, A | 1 |
| Qamar, I | 2 |
| Jahansouz, M | 1 |
| Talib, U | 1 |
| Kahe, F | 2 |
| Habibi, S | 1 |
| Abdelwahed, M | 1 |
| Tariq, F | 1 |
| Kaur, M | 1 |
| Younes, A | 1 |
| Walia, SS | 1 |
| Singh, A | 1 |
| Dildar, SM | 1 |
| Afzal, MK | 1 |
| Einerson, BD | 1 |
| Yu, Z | 1 |
| Shan, P | 1 |
| Yang, X | 1 |
| Lou, XJ | 1 |
| Hase, EA | 1 |
| Barros, VIPVL | 1 |
| Igai, AMK | 1 |
| Francisco, RPV | 1 |
| Zugaib, M | 1 |
| Ng, QX | 1 |
| Seng, C | 1 |
| Ho, CYX | 1 |
| Yeo, WS | 1 |
| Gurin, M | 1 |
| Haroian, N | 1 |
| Deitelzweig, S | 2 |
| Guo, JD | 1 |
| Hlavacek, P | 1 |
| Wygant, G | 1 |
| Rosenblatt, L | 1 |
| Pan, X | 2 |
| Mardekian, J | 2 |
| Lingohr-Smith, M | 1 |
| Menges, B | 1 |
| Marshall, A | 2 |
| Nadkarni, A | 1 |
| Petersen, PB | 1 |
| Kehlet, H | 1 |
| Jørgensen, CC | 1 |
| Huang, HF | 1 |
| Li, SS | 1 |
| Yang, XT | 1 |
| Xie, Q | 1 |
| Tian, XB | 1 |
| Bassiri-Tehrani, B | 1 |
| Karanetz, I | 1 |
| Bernik, SF | 1 |
| Dec, W | 1 |
| Lehman, JC | 1 |
| Lerman, OZ | 1 |
| Curry, MA | 1 |
| LaFollette, JA | 1 |
| Alexander, BR | 1 |
| Evans, KS | 1 |
| Tran, RH | 1 |
| Kempton, CL | 1 |
| Guy, H | 1 |
| Laskier, V | 1 |
| Fisher, M | 1 |
| Neuman, WR | 1 |
| Bucior, I | 1 |
| Moriuchi, K | 1 |
| Chigusa, Y | 1 |
| Kondoh, E | 1 |
| Murakami, R | 1 |
| Ueda, Y | 1 |
| Mogami, H | 1 |
| Mandai, M | 1 |
| Garmi, G | 2 |
| Zafran, N | 1 |
| Okopnik, M | 1 |
| Gavish, I | 2 |
| Romano, S | 2 |
| Salim, R | 2 |
| Bailly, J | 1 |
| Jacobson, BF | 1 |
| Louw, S | 1 |
| Gottschalk, MB | 1 |
| Pour, AE | 1 |
| Sun, G | 2 |
| Wang, Q | 1 |
| Liang, Q | 1 |
| Jia, J | 1 |
| Cheng, K | 1 |
| Wang, Z | 2 |
| Brunetti, L | 1 |
| Wassef, A | 1 |
| Sadek, R | 1 |
| Deshpande, K | 1 |
| Ziegler, J | 1 |
| Na, SS | 1 |
| Riley, P | 1 |
| Kagan, L | 1 |
| Miller, KM | 1 |
| Brenner, MJ | 1 |
| Boyle, E | 1 |
| Reid, J | 1 |
| O'Donnell, M | 1 |
| Harkin, D | 1 |
| Badger, S | 1 |
| Haughton, B | 1 |
| Haughton, J | 1 |
| George Norman, J | 1 |
| Navid, A | 1 |
| Allport, K | 1 |
| Andrews, M | 1 |
| Mannan, K | 1 |
| Livesey, J | 1 |
| Bertoletti, L | 5 |
| Murgier, M | 1 |
| Stelfox, HT | 1 |
| Nadi, S | 1 |
| Vreugdenburg, TD | 1 |
| Atukorale, Y | 1 |
| Ma, N | 1 |
| Maddern, G | 1 |
| Rovers, M | 1 |
| Murasko, MJ | 1 |
| Burk, DR | 1 |
| Cox, S | 1 |
| Eslick, R | 1 |
| McLintock, C | 1 |
| Rodarte, RRP | 1 |
| Guimarães, JAM | 1 |
| Franco, JS | 1 |
| Fonseca, L | 1 |
| Nascimento, V | 1 |
| Aramburu, JPG | 1 |
| Barretto, JM | 1 |
| Tanaka, Y | 1 |
| Yamada, A | 1 |
| Hirata, S | 1 |
| Tanaka, H | 1 |
| Sakuratani, T | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 1 |
| Shimokawa, T | 1 |
| Yoshida, K | 1 |
| de Almeida, RL | 2 |
| Rodrigues, CC | 1 |
| Melo E Silva, CA | 1 |
| Beraldo, PSS | 2 |
| Amado, VM | 2 |
| Yam, L | 1 |
| Bahjri, K | 1 |
| Geslani, V | 1 |
| Cotton, A | 1 |
| Hong, L | 1 |
| Arcelus, JI | 2 |
| Bertolaccini, CB | 1 |
| Stepien, K | 1 |
| Nowak, K | 2 |
| Zalewski, J | 1 |
| Pac, A | 1 |
| Undas, A | 1 |
| Eguchi, H | 1 |
| Kawamoto, K | 1 |
| Tsujie, M | 1 |
| Yukawa, M | 1 |
| Kubota, M | 1 |
| Asaoka, T | 1 |
| Takeda, Y | 1 |
| Noda, T | 1 |
| Shimizu, J | 1 |
| Nagano, H | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Wilsey, HA | 1 |
| Pandya, K | 1 |
| Beavers, C | 1 |
| Xiaoshu, L | 1 |
| Ather, A | 1 |
| Alshouimi, RA | 1 |
| Al Rammah, SM | 1 |
| Alzahrani, MY | 1 |
| Badreldin, HA | 1 |
| Al Yami, MS | 1 |
| Almohammed, OA | 1 |
| Kerr, DL | 1 |
| Butler, S | 1 |
| Read, AC | 1 |
| Gonzaga, BPM | 1 |
| Dalen, JE | 1 |
| Stein, PD | 1 |
| Plitt, JL | 1 |
| Jaswal, N | 1 |
| Alpert, JS | 1 |
| Ohta, H | 1 |
| Miyake, T | 1 |
| Shimizu, T | 1 |
| Sonoda, H | 1 |
| Ueki, T | 1 |
| Kaida, S | 1 |
| Iida, H | 1 |
| Tani, M | 1 |
| Morris, MC | 1 |
| Kassam, F | 1 |
| Bercz, A | 1 |
| Beckmann, N | 1 |
| Schumacher, F | 1 |
| Gulbins, E | 1 |
| Di Minno, G | 1 |
| Cimminiello, C | 2 |
| Polo Friz, H | 1 |
| Scaglione, F | 1 |
| Trepanier, M | 1 |
| Alhassan, N | 1 |
| Sabapathy, CA | 1 |
| Liberman, AS | 1 |
| Charlebois, P | 1 |
| Stein, BL | 1 |
| S Feldman, L | 1 |
| Lee, L | 1 |
| Kingdon, LK | 1 |
| Miller, EM | 1 |
| Savage, SA | 1 |
| Amirsadri, M | 1 |
| Mousavi, S | 1 |
| Karimipour, A | 1 |
| Tardy, B | 1 |
| Buchmuller, A | 1 |
| Ni Ainle, F | 2 |
| Wysokinski, WE | 4 |
| Houghton, DE | 2 |
| Casanegra, AI | 1 |
| Vlazny, DT | 1 |
| Bott-Kitslaar, DM | 1 |
| Froehling, DA | 1 |
| Hodge, DO | 1 |
| Peterson, LG | 1 |
| Nakagawa, K | 2 |
| Watanabe, J | 1 |
| Ota, M | 1 |
| Suwa, Y | 1 |
| Suzuki, S | 1 |
| Suwa, H | 1 |
| Momiyama, M | 1 |
| Ishibe, A | 1 |
| Saigusa, Y | 1 |
| Yamanaka, T | 1 |
| Kunisaki, C | 1 |
| Endo, I | 1 |
| Rübenacker, S | 1 |
| Kaiser, J | 1 |
| Guschmann, M | 1 |
| Sindali, K | 1 |
| Rose, B | 1 |
| Soueid, H | 1 |
| Jeer, P | 1 |
| Saran, D | 1 |
| Shrivastava, R | 1 |
| Lim, SY | 1 |
| Jeon, K | 1 |
| Kim, HJ | 2 |
| Kim, SM | 2 |
| Ha, JM | 1 |
| Um, SW | 1 |
| Koh, WJ | 1 |
| Chung, MP | 1 |
| Kwon, OJ | 1 |
| Suh, GY | 1 |
| Kwok, CS | 2 |
| Pradhan, S | 1 |
| Yeong, JK | 1 |
| Loke, YK | 2 |
| Li, H | 1 |
| Xiao, J | 1 |
| Zeidan, AM | 1 |
| Ahmed, SR | 1 |
| Hobson, DB | 2 |
| Carolan, H | 1 |
| Lambrianidi, C | 1 |
| Horn, PB | 1 |
| Tinoco, G | 1 |
| Siddiqui, S | 1 |
| Felicissimo, P | 1 |
| Hosaka, K | 1 |
| Saito, S | 1 |
| Ishii, T | 1 |
| Sumino, T | 1 |
| Ryu, K | 1 |
| Suzuki, G | 1 |
| Suzuki, T | 1 |
| Tokuhashi, Y | 1 |
| Alameddine, R | 1 |
| Husari, A | 1 |
| Derksen, RJ | 1 |
| Mulder, WM | 1 |
| Mulder, JW | 1 |
| Vink, R | 1 |
| Sohne, M | 1 |
| Chan, KE | 1 |
| Thadhani, RI | 1 |
| Maddux, FW | 1 |
| Brotman, DJ | 1 |
| Shihab, HM | 1 |
| Prakasa, KR | 1 |
| Kebede, S | 1 |
| Sharma, R | 1 |
| Shermock, K | 1 |
| Chelladurai, Y | 1 |
| Segal, JB | 1 |
| Ganetsky, VS | 1 |
| Efird, LE | 1 |
| Lehmann, CU | 1 |
| Pinto, BL | 1 |
| Ross, PA | 1 |
| Chandra, R | 1 |
| Melino, G | 1 |
| Thomas, M | 1 |
| Lawrence, MJ | 1 |
| Hunter, RA | 1 |
| Moore, J | 1 |
| Cohen, A | 7 |
| Curto, M | 2 |
| Gallus, AS | 8 |
| Johnson, M | 2 |
| Masiukiewicz, U | 1 |
| Pak, R | 2 |
| Thompson, J | 2 |
| Keith, JN | 1 |
| Chong, TW | 1 |
| Davar, D | 1 |
| Moore, AG | 1 |
| Morris, A | 1 |
| Revankar, N | 1 |
| Patterson, J | 1 |
| Kadambi, A | 1 |
| Raymond, V | 2 |
| El-Hadi, W | 1 |
| Green, B | 2 |
| Marsh, MS | 2 |
| Davies, JG | 2 |
| Cohen, AA | 1 |
| Rider, T | 1 |
| Hiscock, RJ | 1 |
| Casey, E | 1 |
| Simmons, SW | 1 |
| Walker, SP | 1 |
| Newell, PA | 1 |
| Folkerts, K | 1 |
| Diamantopoulos, A | 5 |
| Brosa, M | 1 |
| Lai, S | 1 |
| Coppola, B | 1 |
| Décousus, H | 4 |
| Grosso, MA | 3 |
| Mercuri, M | 1 |
| Schellong, SM | 8 |
| Schwocho, L | 2 |
| Shi, M | 3 |
| Wells, P | 4 |
| Rahman, IA | 1 |
| Hussain, A | 1 |
| Davies, A | 1 |
| Bryan, AJ | 1 |
| Martinuzzo, ME | 1 |
| Barrera, LH | 1 |
| D 'adamo, MA | 1 |
| Otaso, JC | 1 |
| Gimenez, MI | 1 |
| Oyhamburu, J | 1 |
| Lim, GB | 1 |
| Bickford, A | 1 |
| Majercik, S | 1 |
| Bledsoe, J | 1 |
| Johnston, R | 1 |
| Dickerson, J | 1 |
| White, T | 1 |
| Yusen, RD | 3 |
| Tapson, VF | 5 |
| Samama, MM | 4 |
| Chen, M | 3 |
| Deslandes, B | 1 |
| Turpie, AG | 18 |
| Pelzer, U | 3 |
| Sinn, M | 2 |
| Stieler, J | 2 |
| Riess, H | 6 |
| Sasaki, H | 1 |
| Ishida, K | 1 |
| Shibanuma, N | 1 |
| Tei, K | 1 |
| Tateishi, H | 1 |
| Toda, A | 1 |
| Yamashiro, Y | 1 |
| Matsumoto, T | 1 |
| Kuroda, R | 1 |
| Kurosaka, M | 1 |
| Milligan, PE | 1 |
| Wong, CA | 1 |
| Deal, EN | 2 |
| Thoelke, MS | 1 |
| Gage, BF | 2 |
| Eriksson, BI | 16 |
| Renfurm, RW | 1 |
| Kashiwa, M | 1 |
| Clemens, A | 7 |
| Fraessdorf, M | 1 |
| Friedman, J | 1 |
| Haas, S | 8 |
| Kreutz, R | 1 |
| Mantovani, LG | 1 |
| Pattanayak, CW | 1 |
| Holberg, G | 1 |
| Jamal, W | 1 |
| Schmidt, A | 1 |
| van Eickels, M | 1 |
| Gionis, MN | 1 |
| Ioannou, CV | 1 |
| Katsamouris, AN | 1 |
| Katonis, P | 1 |
| Balalis, K | 1 |
| Sfyridaki, K | 1 |
| Elalamy, I | 1 |
| Gerotziafas, GT | 1 |
| Kopelman, TR | 1 |
| O'Neill, PJ | 1 |
| Pieri, PG | 1 |
| Salomone, JP | 1 |
| Hall, ST | 1 |
| Quan, A | 1 |
| Wells, JR | 1 |
| Pressman, MS | 1 |
| Willett, KC | 1 |
| Alsharhan, M | 1 |
| Durand, C | 1 |
| Cooper, MR | 1 |
| Yassin, M | 1 |
| Mitchell, C | 1 |
| Diab, M | 1 |
| Senior, C | 1 |
| Bandle, J | 2 |
| Shackford, SR | 2 |
| Sise, CB | 2 |
| Kakkar, AK | 13 |
| George, D | 2 |
| Murphy, J | 1 |
| Lawson, F | 2 |
| Haft, JI | 1 |
| Thomé, S | 1 |
| Desanctis, YH | 1 |
| Homering, M | 7 |
| Hu, D | 3 |
| Mebazaa, A | 3 |
| Merli, G | 6 |
| Schellong, S | 3 |
| Burton, P | 1 |
| Rojas, L | 1 |
| Aizman, A | 1 |
| Ernst, D | 1 |
| Acuña, MP | 1 |
| Moya, P | 1 |
| Mellado, R | 1 |
| Cerda, J | 1 |
| Gritsiouk, Y | 1 |
| Hegsted, DA | 1 |
| Schlesinger, P | 1 |
| Gardiner, SK | 1 |
| Gubler, KD | 1 |
| Harrington, R | 2 |
| Kitt, MM | 1 |
| Lorenz, TJ | 1 |
| Hankey, GJ | 1 |
| Changolkar, A | 1 |
| Menditto, L | 1 |
| Shah, M | 1 |
| Puto, K | 1 |
| Farrelly, E | 4 |
| Yi, X | 1 |
| Zhang, B | 1 |
| Chi, W | 1 |
| Hayashi, H | 1 |
| Morikawa, T | 1 |
| Yoshida, H | 1 |
| Motoi, F | 1 |
| Okada, T | 1 |
| Mizuma, M | 1 |
| Katayose, Y | 1 |
| Traynor, K | 1 |
| Campbell, W | 1 |
| Pierson, J | 1 |
| Cohen-Shohet, R | 1 |
| Mast, BA | 1 |
| Friedman, RJ | 7 |
| Berlin, JA | 1 |
| Weinstein, RB | 1 |
| DiBattiste, PM | 1 |
| Davidson, BL | 5 |
| Verheijen, S | 1 |
| Lensing, AW | 7 |
| Brighton, TA | 2 |
| Lyons, RM | 1 |
| Rehm, J | 1 |
| Camden, R | 1 |
| Ludwig, S | 1 |
| Avendaño-Solá, C | 1 |
| Terleira-Fernández, AI | 2 |
| Vargas-Castrillón, E | 2 |
| Schloemer, NJ | 1 |
| Abu-Sultaneh, S | 1 |
| Hanson, SJ | 1 |
| Yan, K | 1 |
| Hoffmann, RG | 1 |
| Punzalan, RC | 1 |
| Havens, PL | 1 |
| Robinson, S | 2 |
| Zincuk, A | 1 |
| Larsen, UL | 1 |
| Ekstrøm, C | 1 |
| Toft, P | 1 |
| Joseph, B | 1 |
| Pandit, V | 1 |
| Harrison, C | 1 |
| Lubin, D | 1 |
| Kulvatunyou, N | 1 |
| Zangbar, B | 1 |
| Tang, A | 1 |
| O'Keeffe, T | 1 |
| Green, DJ | 1 |
| Gries, L | 1 |
| Friese, RS | 1 |
| Rhee, P | 1 |
| Pastorek, RA | 1 |
| Bernstein, IH | 1 |
| Scott, WW | 1 |
| Madden, CJ | 2 |
| Rickert, KL | 1 |
| Wolf, SE | 2 |
| Phelan, HA | 2 |
| Shantsila, E | 2 |
| Lip, GY | 4 |
| Schellong, SW | 1 |
| Caruso, JD | 1 |
| Elster, EA | 1 |
| Rodriguez, CJ | 1 |
| Raza, S | 1 |
| Kale, G | 1 |
| Kim, D | 1 |
| Akbar, SA | 1 |
| Holm, L | 1 |
| Naidzionak, U | 1 |
| Hossain, AM | 1 |
| Dong, X | 1 |
| Doll, DC | 1 |
| Freter, CE | 1 |
| Hopkins, T | 1 |
| Song, KY | 1 |
| Yoo, HM | 1 |
| Kim, EY | 1 |
| Kim, JI | 1 |
| Yim, HW | 1 |
| Jeon, HM | 1 |
| Park, CH | 1 |
| Fuji, T | 3 |
| Wang, CJ | 1 |
| Fujita, S | 2 |
| Kawai, Y | 1 |
| Kimura, T | 1 |
| Tachibana, S | 1 |
| Migita, K | 1 |
| Bito, S | 1 |
| Nakamura, M | 2 |
| Miyata, S | 1 |
| Kakizaki, H | 1 |
| Nakayama, Y | 1 |
| Matsusita, T | 1 |
| Furuichi, I | 1 |
| Sasazaki, Y | 1 |
| Tanaka, T | 2 |
| Yoshida, M | 1 |
| Kaneko, H | 1 |
| Abe, I | 1 |
| Mine, T | 1 |
| Ihara, K | 1 |
| Kuratsu, S | 1 |
| Saisho, K | 1 |
| Miyahara, H | 1 |
| Segata, T | 1 |
| Nakagawa, Y | 1 |
| Kamei, M | 1 |
| Torigoshi, T | 1 |
| Motokawa, S | 1 |
| Königsbrügge, O | 1 |
| Langer, M | 1 |
| Hayde, M | 1 |
| Ay, C | 2 |
| Pabinger, I | 2 |
| Maniscalco, P | 1 |
| Caforio, M | 1 |
| Porcellini, G | 1 |
| Benedetti, R | 1 |
| Kuz'min, VV | 1 |
| Buzov, DA | 1 |
| Nudel'man, SV | 1 |
| Golubkov, NA | 1 |
| Parker, RI | 1 |
| Celik, F | 1 |
| Huitema, AD | 1 |
| Hooijberg, JH | 1 |
| van de Laar, AW | 1 |
| Brandjes, DP | 1 |
| Gerdes, VE | 1 |
| Nwulu, U | 1 |
| Brooks, H | 1 |
| Richardson, S | 1 |
| McFarland, L | 1 |
| Coleman, JJ | 1 |
| Bahl, V | 1 |
| Shuman, AG | 1 |
| Hu, HM | 1 |
| Jackson, CR | 1 |
| Alaniz, C | 1 |
| Chepeha, DB | 1 |
| Bradford, CR | 1 |
| Nasser, NJ | 1 |
| Na'amad, M | 1 |
| Weinberg, I | 1 |
| Gabizon, AA | 1 |
| Krajewski, KC | 1 |
| Conwall, K | 1 |
| Krajewski, MP | 1 |
| Oswald, E | 1 |
| Velik-Salchner, C | 1 |
| Innerhofer, P | 1 |
| Tauber, H | 1 |
| Auckenthaler, T | 1 |
| Ulmer, H | 1 |
| Streif, W | 2 |
| Larsen, TB | 2 |
| Nielsen, PB | 1 |
| Skjøth, F | 1 |
| Rasmussen, LH | 2 |
| Patel, AA | 1 |
| Ogden, K | 1 |
| Mody, SH | 1 |
| Bookhart, B | 1 |
| Daley, MJ | 1 |
| Ali, S | 1 |
| Brown, CV | 1 |
| Fuorlo, M | 1 |
| Montalto, M | 1 |
| Landolfi, R | 1 |
| Müller, K | 1 |
| Pap, ÁF | 3 |
| Tewes, MC | 1 |
| Giuliani, J | 1 |
| Martelli, S | 1 |
| Piacentini, P | 1 |
| Bonetti, A | 1 |
| Mushtaq, A | 1 |
| Vaughns, JD | 1 |
| Ziesenitz, VC | 1 |
| Nadler, EP | 1 |
| van den Anker, JN | 1 |
| Charters, MA | 1 |
| Frisch, NB | 1 |
| Wessell, NM | 1 |
| Dobson, C | 1 |
| Les, CM | 1 |
| Silverton, CD | 1 |
| Ma, G | 1 |
| Zhang, R | 1 |
| Wu, X | 1 |
| Wang, D | 1 |
| Ying, K | 1 |
| Lavan, O | 1 |
| Rimon, U | 1 |
| Simon, D | 1 |
| Khaitovich, B | 1 |
| Segal, B | 1 |
| Grossman, E | 1 |
| Kleinbaum, Y | 1 |
| Steinberg, DM | 1 |
| Salomon, O | 1 |
| Holländer, SW | 1 |
| Sifft, A | 1 |
| Hess, S | 1 |
| Klingen, HJ | 1 |
| Djalali, P | 1 |
| Birk, D | 1 |
| Abdel-Aziz, H | 1 |
| Dunham, CM | 1 |
| Malik, RJ | 1 |
| Hileman, BM | 1 |
| Azık, F | 1 |
| Gökçebay, DG | 1 |
| Tavil, B | 1 |
| Işık, P | 1 |
| Tunç, B | 1 |
| Uçkan, D | 1 |
| Thirugnanam, S | 1 |
| Pinto, R | 3 |
| Geerts, WH | 3 |
| Fowler, RA | 3 |
| Donato, J | 1 |
| Campigotto, F | 1 |
| Coletti, E | 1 |
| Opitz, B | 2 |
| Deutschinoff, G | 1 |
| Stauch, M | 1 |
| Reitzig, PC | 1 |
| Hahnfeld, S | 1 |
| Müller, L | 1 |
| Grunewald, M | 1 |
| Stieler, JM | 1 |
| Denecke, T | 1 |
| Bischoff, S | 1 |
| Oettle, H | 2 |
| Dörken, B | 2 |
| Dang, JD | 1 |
| Davis, LE | 1 |
| Overcash, RT | 1 |
| Somers, AT | 1 |
| LaCoursiere, DY | 1 |
| Nunez, JM | 1 |
| Becher, RD | 1 |
| Rebo, GJ | 1 |
| Farrah, JP | 1 |
| Borgerding, EM | 1 |
| Stirparo, JJ | 1 |
| Lauer, C | 1 |
| Kilgo, P | 1 |
| Miller, PR | 1 |
| Gonda, DD | 1 |
| Fridley, J | 1 |
| Ryan, SL | 1 |
| Briceño, V | 1 |
| Lam, SK | 1 |
| Luerssen, TG | 1 |
| Jea, A | 1 |
| Nagata, C | 1 |
| Tanabe, H | 1 |
| Takakura, S | 1 |
| Narui, C | 1 |
| Yanaihara, N | 1 |
| Okamoto, A | 1 |
| Kleiner, MT | 1 |
| Ahmed, AA | 1 |
| Huser, A | 1 |
| Mooar, P | 1 |
| Torg, J | 1 |
| Goto, M | 1 |
| Yoshizato, T | 1 |
| Tatsumura, M | 1 |
| Takashima, T | 1 |
| Ogawa, M | 1 |
| Nakahara, H | 1 |
| Satoh, S | 1 |
| Sanui, A | 1 |
| Eguchi, F | 1 |
| Miyamoto, S | 1 |
| Machado-Aranda, DA | 1 |
| Jakubus, JL | 1 |
| Wahl, WL | 1 |
| Cherry-Bukowiec, JR | 1 |
| To, KB | 1 |
| Park, PK | 1 |
| Raghavendran, K | 1 |
| Napolitano, LM | 1 |
| Hemmila, MR | 1 |
| Kreuziger, LB | 1 |
| Kooistra, HA | 1 |
| Sahin, K | 1 |
| Meijer, K | 1 |
| Hellenbart, E | 1 |
| Drambarean, B | 1 |
| Lee, J | 1 |
| Nutescu, EA | 2 |
| Atmakusuma, TD | 1 |
| Tambunan, KL | 1 |
| Sukrisman, L | 1 |
| Effendi, S | 1 |
| Rachman, A | 1 |
| Setiawati, A | 1 |
| Rinaldi, I | 1 |
| Mulansari, NA | 1 |
| Rajabto, W | 1 |
| Nasution, SA | 1 |
| Aninditha, T | 1 |
| Sedono, R | 1 |
| Sugiarto, A | 1 |
| Pitoyo, CW | 1 |
| Paramitha, D | 1 |
| Astoro, NW | 1 |
| Nasution, IR | 1 |
| Olson, EJ | 1 |
| Calvo, RY | 1 |
| Dunne, CE | 1 |
| Van Gent, JM | 1 |
| Zander, AL | 1 |
| Sikand, H | 1 |
| Bongiovanni, MS | 1 |
| Sise, MJ | 1 |
| Rostas, JW | 1 |
| Brevard, SB | 1 |
| Ahmed, N | 1 |
| Allen, J | 2 |
| Thacker, D | 1 |
| Replogle, WH | 1 |
| Gonzalez, RP | 1 |
| Frotan, AM | 1 |
| Simmons, JD | 1 |
| Holmstrom, B | 1 |
| Ashrani, A | 3 |
| Bockenstedt, PL | 1 |
| Chesney, C | 1 |
| Eby, C | 1 |
| Fanikos, J | 2 |
| Fenninger, RB | 1 |
| Fogerty, AE | 1 |
| Gao, S | 1 |
| Hendrie, P | 1 |
| Kuderer, N | 1 |
| Lee, A | 1 |
| Lee, JT | 1 |
| Lovrincevic, M | 1 |
| Millenson, MM | 1 |
| Neff, AT | 1 |
| Ortel, TL | 3 |
| Paschal, R | 1 |
| Shattil, S | 1 |
| Siddiqi, T | 1 |
| Smock, KJ | 2 |
| Soff, G | 2 |
| Yee, GC | 1 |
| Zakarija, A | 1 |
| McMillian, N | 1 |
| Engh, AM | 1 |
| Parker, SG | 1 |
| McGlone, ER | 1 |
| Knight, WR | 1 |
| Sufi, P | 1 |
| Khan, OA | 1 |
| Lee, TC | 1 |
| Yamabe, T | 1 |
| Wu, K | 1 |
| Liu, Z | 1 |
| Kong, G | 1 |
| Deng, Z | 1 |
| Chen, S | 1 |
| Wu, Y | 1 |
| Liu, S | 1 |
| Di Nisio, M | 9 |
| Rutjes, AW | 2 |
| Tekkesin, N | 1 |
| Tekkesin, M | 1 |
| Kaso, G | 1 |
| Phatak, H | 1 |
| Sanders, P | 1 |
| Thompson, JR | 1 |
| Levi, M | 2 |
| Beyer-Westendorf, J | 4 |
| van Bellen, B | 1 |
| Bounameaux, H | 3 |
| Trajanovic, M | 1 |
| Lam, P | 1 |
| Wells, PS | 5 |
| Rostagno, C | 1 |
| Wolosker, N | 2 |
| Varella, AY | 1 |
| Fukuda, JM | 1 |
| Teivelis, M | 1 |
| Kuzniec, S | 1 |
| Krutman, M | 2 |
| Guerra, JC | 1 |
| Quon, P | 1 |
| Le, HH | 1 |
| Mtibaa, M | 1 |
| Moshyk, A | 1 |
| Hachey, KJ | 1 |
| Sterbling, H | 1 |
| Choi, DS | 1 |
| Pinjic, E | 1 |
| Hewes, PD | 1 |
| Munoz, J | 1 |
| McAneny, D | 1 |
| Tripodis, Y | 1 |
| Fernando, HC | 1 |
| Litle, VR | 1 |
| Ricket, AL | 1 |
| Stewart, DW | 1 |
| Wood, RC | 1 |
| Cornett, L | 1 |
| Odle, B | 1 |
| Cluck, D | 1 |
| Freshour, J | 1 |
| El-Bazouni, H | 1 |
| Moon, YW | 1 |
| Lim, SJ | 1 |
| Kim, DW | 2 |
| Park, YS | 1 |
| Chapman, SA | 1 |
| Irwin, ED | 1 |
| Reicks, P | 1 |
| Beilman, GJ | 1 |
| Campbell, PM | 1 |
| Ippoliti, C | 1 |
| Parmar, S | 1 |
| Schulman, S | 4 |
| Ning, GZ | 1 |
| Kan, SL | 1 |
| Chen, LX | 1 |
| Shangguan, L | 1 |
| Feng, SQ | 1 |
| Zhou, Y | 1 |
| Bonilla, GA | 2 |
| Bautista, MP | 2 |
| Petrie, S | 1 |
| Lust, K | 1 |
| Fagermo, N | 1 |
| Martin, JH | 1 |
| Malhotra, R | 1 |
| Babhulkar, S | 1 |
| Sanjib, KB | 1 |
| Dadi, A | 1 |
| Iyer, R | 2 |
| Kamath, S | 1 |
| Mody, B | 1 |
| Mutha, S | 1 |
| Reddy, G | 1 |
| Shah, V | 2 |
| Shetty, N | 1 |
| Tapasvi, S | 1 |
| Wadhwa, M | 1 |
| Desai, A | 2 |
| Calixte, R | 1 |
| Aparnath, M | 1 |
| Hindenburg, A | 1 |
| Salzman, S | 1 |
| Mathew, JP | 1 |
| Cygan, LD | 1 |
| Weizberg, M | 1 |
| Hahn, B | 1 |
| Lane, J | 1 |
| Coimbra, R | 3 |
| King, DA | 1 |
| Pow, RE | 1 |
| Dickison, DM | 1 |
| Vale, PR | 1 |
| Kobayashi, L | 1 |
| Castellucci, LA | 1 |
| Shaw, J | 1 |
| Giulivi, A | 1 |
| Edwards, C | 1 |
| Patel, R | 1 |
| Cook, K | 1 |
| Napolitano, M | 1 |
| Padberg, FT | 1 |
| Ko, A | 1 |
| Harada, MY | 1 |
| Chung, K | 1 |
| Yim, DA | 1 |
| Dhillon, N | 1 |
| Margulies, DR | 1 |
| Braverman, M | 1 |
| Connelly, CR | 1 |
| Van, PY | 1 |
| Hart, KD | 1 |
| Louis, SG | 1 |
| Fair, KA | 1 |
| Erickson, AS | 1 |
| Rick, EA | 1 |
| Simeon, EC | 1 |
| Bulger, EM | 1 |
| Arbabi, S | 1 |
| Holcomb, JB | 1 |
| Moore, LJ | 1 |
| Schreiber, MA | 1 |
| Singer, GA | 1 |
| Riggi, G | 1 |
| Vaghaiwalla, TM | 1 |
| Lieberman, HM | 1 |
| Ginzburg, E | 1 |
| Gutierrez, C | 1 |
| Llinas, AM | 1 |
| Monsalvo, DJ | 1 |
| Vedovati, MC | 2 |
| Riera-Mestre, A | 1 |
| Mueller, K | 1 |
| Kubitza, D | 1 |
| Schneider, J | 1 |
| Pisters, R | 1 |
| Fedacko, J | 1 |
| Fontes-Carvalho, R | 1 |
| Radzak, KN | 1 |
| Wages, JJ | 1 |
| Hall, KE | 1 |
| Nakasone, CK | 1 |
| Pariser, JJ | 1 |
| Pearce, SM | 1 |
| Anderson, BB | 1 |
| Packiam, VT | 1 |
| Prachand, VN | 1 |
| Smith, ND | 1 |
| Steinberg, GD | 1 |
| Yan, X | 2 |
| Gu, X | 2 |
| Zhou, L | 1 |
| Lin, H | 4 |
| Bleker, SM | 1 |
| Sisson, M | 1 |
| Sharfman, ZT | 1 |
| Campbell, JC | 1 |
| Spitzer, AI | 1 |
| Hartmann, S | 1 |
| Biliouris, K | 1 |
| Lesko, LJ | 1 |
| Nowak-Göttl, U | 1 |
| Trame, MN | 1 |
| Greig, SL | 1 |
| Garnock-Jones, KP | 1 |
| Scheefer, M | 1 |
| Kotirum, S | 1 |
| Chongmelaxme, B | 1 |
| Chaiyakunapruk, N | 1 |
| Rondina, MT | 3 |
| Ridsdale, S | 1 |
| Martin, V | 1 |
| Payne, JH | 1 |
| Schmidt-Braekling, T | 1 |
| Pearle, AD | 1 |
| Mayman, DJ | 1 |
| Westrich, GH | 1 |
| Waldstein, W | 1 |
| Boettner, F | 1 |
| Venker, BT | 1 |
| Ganti, BR | 1 |
| Lee, ED | 1 |
| Nunley, RM | 1 |
| Schinzel, H | 2 |
| Samuel, NG | 1 |
| Seifert, CF | 1 |
| Joshi, SS | 1 |
| Chen, DY | 1 |
| Halaby, R | 2 |
| Bandman, O | 2 |
| Negm, O | 1 |
| Abou Saif, S | 1 |
| El Gharib, M | 1 |
| Yousef, M | 1 |
| Abd-Elsalam, S | 1 |
| Hanify, JM | 1 |
| Dupree, LH | 1 |
| Johnson, DW | 1 |
| Ferreira, JA | 1 |
| Tao, DL | 1 |
| Bien, JY | 1 |
| DeLoughery, TG | 1 |
| Shatzel, JJ | 1 |
| Xu, Z | 1 |
| Pignataro, BS | 1 |
| Nishinari, K | 1 |
| Cavalcante, RN | 1 |
| Centofanti, G | 1 |
| Yazbek, G | 1 |
| Bomfim, GAZ | 1 |
| Fonseca, IYI | 1 |
| Teivelis, MP | 1 |
| Sanches, SM | 1 |
| Cieri, NE | 1 |
| Kusmierski, K | 1 |
| Lackie, C | 1 |
| Van Opdorp, A | 1 |
| Hassan, AK | 1 |
| Trujillo-Santos, J | 1 |
| Bergmann, JF | 2 |
| Bortoluzzi, C | 1 |
| López-Reyes, R | 1 |
| Giorgi-Pierfranceschi, M | 1 |
| López-Sáez, JB | 2 |
| Ferrazzi, P | 1 |
| Bascuñana, J | 1 |
| Suriñach, JM | 1 |
| Jones, CE | 1 |
| Hollis, RH | 1 |
| Gullick, AA | 1 |
| Wahl, T | 1 |
| Richman, JS | 1 |
| Graham, LA | 1 |
| Lucy, AT | 1 |
| Chu, DI | 1 |
| Morris, MS | 1 |
| Xie, J | 1 |
| Ma, J | 1 |
| Yue, C | 1 |
| Pei, F | 1 |
| Walker, CK | 1 |
| Sandmann, EA | 1 |
| Horyna, TJ | 1 |
| Gales, MA | 1 |
| Imamura, H | 1 |
| Adachi, T | 1 |
| Kitasato, A | 1 |
| Soyama, A | 1 |
| Hidaka, M | 1 |
| Fujita, F | 1 |
| Takatsuki, M | 1 |
| Kuroki, T | 1 |
| Eguchi, S | 1 |
| Yanagita, T | 1 |
| Kusanagi, H | 1 |
| Lu, SP | 1 |
| Leeds, JM | 1 |
| Tran, E | 1 |
| Duckett, A | 1 |
| Fisher, S | 1 |
| Bohm, N | 1 |
| Ginsberg, JS | 1 |
| Comp, PC | 1 |
| Francis, CW | 4 |
| Huo, MH | 2 |
| Muntz, JE | 1 |
| Clements, ML | 1 |
| Hantel, S | 4 |
| Schnee, JM | 3 |
| Caprini, JA | 3 |
| Froimson, MI | 1 |
| Murray, TG | 1 |
| Fazekas, AF | 1 |
| Borris, LC | 2 |
| Huisman, MV | 6 |
| Bandel, TJ | 4 |
| Beckmann, H | 1 |
| Muehlhofer, E | 1 |
| Misselwitz, F | 7 |
| Lohrmann, J | 1 |
| Becker, RC | 2 |
| Dahl, OE | 10 |
| Muntz, J | 1 |
| Soglian, AG | 1 |
| Simone, EP | 1 |
| Madan, AK | 2 |
| Tichansky, DS | 2 |
| Kuhl, DA | 2 |
| Lee, MD | 2 |
| Clement, J | 1 |
| Bubley, G | 1 |
| Raftopoulos, I | 1 |
| Martindale, C | 1 |
| Cronin, A | 1 |
| Steinberg, J | 1 |
| Fishmann, A | 1 |
| Adams, RC | 1 |
| Hamrick, M | 1 |
| Berenguer, C | 1 |
| Senkowski, C | 1 |
| Ochsner, MG | 1 |
| Fox, NS | 1 |
| Laughon, SK | 1 |
| Bender, SD | 1 |
| Saltzman, DH | 1 |
| Rebarber, A | 1 |
| Ochi, T | 1 |
| Niwa, S | 1 |
| Depew, AJ | 1 |
| Hu, CK | 1 |
| Nguyen, AC | 1 |
| Driessen, N | 1 |
| Comp, P | 1 |
| Happe, LE | 4 |
| Sarnes, M | 2 |
| Deitelzweig, SB | 1 |
| Becker, R | 1 |
| Benner, J | 1 |
| Norwood, SH | 2 |
| Berne, JD | 1 |
| Rowe, SA | 1 |
| Villarreal, DH | 1 |
| Ledlie, JT | 1 |
| Schuman, EP | 1 |
| Shedd, GC | 1 |
| Franklin, C | 1 |
| Schumacher, AM | 1 |
| Green, DE | 1 |
| Lotke, PA | 1 |
| ten Cate, H | 1 |
| Hamulyak, K | 1 |
| McKenna, GS | 1 |
| Karthikesalingam, A | 1 |
| Walsh, SR | 1 |
| Tang, TY | 1 |
| Quick, CR | 1 |
| Hilbig, A | 1 |
| Scholten, T | 1 |
| Kauschat-Brüning, D | 1 |
| Bramlage, P | 6 |
| Villalba, JC | 1 |
| Granero Xiberta, J | 1 |
| Soler Minoves, JM | 1 |
| Garcia Nuño, L | 1 |
| Díaz, G | 1 |
| Iglesias, A | 1 |
| César, J | 1 |
| García-Avello, A | 1 |
| Martí, D | 1 |
| Escobar, C | 1 |
| Vidal, R | 1 |
| Sueiro, A | 1 |
| Reade, H | 1 |
| Sultanzadeh, J | 1 |
| Mallinson, R | 1 |
| Eikelboom, JE | 1 |
| Wolowacz, SE | 3 |
| Roskell, NS | 3 |
| Plumb, JM | 4 |
| Hacobian, M | 1 |
| Shetty, R | 1 |
| Niles, CM | 1 |
| Gerhard-Herman, M | 1 |
| Vallurupalli, N | 1 |
| Baroletti, S | 1 |
| McKean, SC | 1 |
| Sonis, J | 1 |
| Parasuraman, S | 1 |
| Kosowsky, JM | 1 |
| Kim, KS | 1 |
| Brophy, GM | 1 |
| Maciver, F | 1 |
| Beard, SM | 1 |
| Robinson, PA | 2 |
| Dolan, G | 2 |
| Brenkel, IJ | 2 |
| de Maistre, E | 1 |
| Terriat, B | 1 |
| Lesne-Padieu, AS | 1 |
| Abello, N | 1 |
| Bouchot, O | 1 |
| Steinmetz, EF | 1 |
| Wheeler, M | 1 |
| Rodgers, GM | 3 |
| Draper, L | 1 |
| Pendleton, RC | 3 |
| Farias-Eisner, R | 1 |
| Horblyuk, R | 1 |
| Franklin, M | 1 |
| Lunacsek, OE | 1 |
| van Doormaal, FF | 1 |
| Gallus, A | 5 |
| Piovella, F | 3 |
| Reeves, D | 1 |
| Liu, CY | 1 |
| Harenberg, J | 3 |
| Nitschmann, S | 1 |
| Gent, M | 3 |
| Nadar, SK | 1 |
| Goyal, D | 1 |
| Banerjee, P | 1 |
| Cindolo, L | 1 |
| Salzano, L | 1 |
| Mirone, V | 1 |
| Imbimbo, C | 1 |
| Longo, N | 1 |
| Kakkos, SK | 4 |
| Reddy, DJ | 1 |
| Lenhart, G | 1 |
| Schulman, KL | 2 |
| Pineo, G | 6 |
| Portman, RJ | 1 |
| Kase, CS | 1 |
| Bladin, C | 1 |
| Fieschi, C | 1 |
| Gabbai, AA | 1 |
| O'Riordan, W | 1 |
| Pineo, GF | 5 |
| Famularo, G | 1 |
| Gasbarrone, L | 1 |
| Minisola, G | 1 |
| De Simone, C | 1 |
| McCullagh, L | 2 |
| Tilson, L | 1 |
| Walsh, C | 2 |
| Barry, M | 2 |
| Holmes, M | 1 |
| Carroll, C | 1 |
| Papaioannou, D | 1 |
| Ferrufino, CP | 1 |
| Hussein, M | 1 |
| Battleman, D | 1 |
| Meneveau, N | 1 |
| Gresham, C | 1 |
| Levine, M | 2 |
| Ruha, AM | 1 |
| Capri, S | 1 |
| Scannapieco, G | 1 |
| Moia, M | 1 |
| Suárez-Gea, ML | 2 |
| Pozo-Hernández, C | 1 |
| Johnson, BH | 1 |
| Byrne, M | 3 |
| Reynolds, JV | 1 |
| O'Donnell, JS | 1 |
| Keogan, M | 1 |
| White, B | 2 |
| Murphy, S | 1 |
| Maher, SG | 1 |
| Pidgeon, GP | 1 |
| Noack, H | 2 |
| Verma, AK | 1 |
| Kälebo, P | 1 |
| Wetherill, G | 1 |
| Wilpshaar, JW | 1 |
| Meems, L | 1 |
| Saxer, F | 1 |
| Dick, W | 1 |
| Wiseman, DN | 1 |
| Harrison, J | 1 |
| Fareed, J | 2 |
| Hornick, P | 1 |
| Motte, S | 1 |
| Claes, N | 1 |
| Verhaeghe, R | 1 |
| Hermans, C | 1 |
| Trkulja, V | 1 |
| Kolundzic, R | 1 |
| Kurth, AA | 4 |
| Traby, L | 1 |
| Kaider, A | 1 |
| Schmid, R | 1 |
| Kranz, A | 1 |
| Quehenberger, P | 1 |
| Kyrle, PA | 1 |
| Eichinger, S | 1 |
| Nwachukwu, U | 1 |
| Liang, J | 2 |
| Brant, R | 2 |
| Lang, A | 1 |
| Kienitz, C | 1 |
| Wetzel, P | 1 |
| Rollnik, JD | 1 |
| Quinlan, DJ | 2 |
| Bergqvist, D | 3 |
| Kent, DM | 1 |
| Lindenauer, PK | 1 |
| Nicol, P | 1 |
| Vicaut, E | 1 |
| Leil, TA | 1 |
| Feng, Y | 1 |
| Zhang, L | 1 |
| Paccaly, A | 1 |
| Mohan, P | 1 |
| Pfister, M | 1 |
| Lees, M | 4 |
| Forster, F | 3 |
| Ananthapavan, J | 1 |
| McDonald, H | 1 |
| Cao, YB | 1 |
| Zhang, JD | 1 |
| Shen, H | 1 |
| Jiang, YY | 1 |
| Monz, BU | 1 |
| Girard, F | 1 |
| Salvo, JP | 1 |
| Troxell, CR | 1 |
| Duggan, DP | 1 |
| Wagner, W | 1 |
| Cao, C | 1 |
| Kupfer, S | 1 |
| Raskob, G | 5 |
| Spaeder, J | 1 |
| Zufferey, PJ | 1 |
| Dudley, RR | 1 |
| Aziz, I | 1 |
| Bonnici, A | 1 |
| Saluja, RS | 1 |
| Lamoureux, J | 1 |
| Kalmovitch, B | 1 |
| Gursahaney, A | 1 |
| Razek, T | 1 |
| Marcoux, J | 1 |
| Huang, J | 1 |
| Cao, Y | 1 |
| Liao, C | 1 |
| Wu, L | 1 |
| Gao, F | 1 |
| Jones, JW | 1 |
| Nieto, JA | 2 |
| Valle, R | 1 |
| Dentali, F | 2 |
| Gianni, M | 1 |
| Squizzato, A | 2 |
| Carson, MP | 1 |
| Kuo, YH | 1 |
| Westermeier, T | 1 |
| Stern, L | 2 |
| Subrahmanian, T | 2 |
| Annemans, L | 2 |
| Ramirez, LM | 3 |
| Salottolo, K | 1 |
| Offner, P | 1 |
| Levy, AS | 1 |
| Mains, CW | 1 |
| Slone, DS | 1 |
| Bar-Or, D | 1 |
| Hermansson, K | 1 |
| Liotier, J | 1 |
| Kleber, FX | 1 |
| Chapelle, C | 2 |
| Moulin, N | 1 |
| Yokote, R | 1 |
| Matsubara, M | 1 |
| Hirasawa, N | 1 |
| Hagio, S | 1 |
| Ishii, K | 1 |
| Takata, C | 1 |
| Sasaki, S | 1 |
| Miyakoshi, N | 1 |
| Matsuura, H | 1 |
| Saito, H | 1 |
| Nakanishi, T | 1 |
| Kudo, Y | 1 |
| Fujiya, T | 1 |
| Shimada, Y | 1 |
| Koehler, DM | 1 |
| Shipman, J | 1 |
| Davidson, MA | 1 |
| Guillamondegui, O | 1 |
| Lewis, TV | 1 |
| Johnson, PN | 1 |
| Nebbia, AM | 1 |
| Dunlap, M | 1 |
| Lereun, C | 1 |
| Rasul, F | 1 |
| Sengupta, N | 3 |
| Turun, S | 1 |
| Banghua, L | 1 |
| Yuan, Y | 1 |
| Zhenhui, L | 1 |
| Ying, N | 1 |
| Jin, C | 1 |
| Jameson, SS | 1 |
| Sanders, RD | 1 |
| Reed, MR | 1 |
| Hollands, JM | 1 |
| Riney, JN | 1 |
| Skrupky, LP | 1 |
| Smith, JR | 1 |
| Reichley, RM | 1 |
| Iqbal, Z | 1 |
| Kwong, LM | 2 |
| Stark, JE | 1 |
| Smith, WJ | 1 |
| Kučera, T | 1 |
| Malý, R | 1 |
| Urban, K | 1 |
| Sponer, P | 1 |
| Howard, L | 1 |
| Salooja, N | 1 |
| Maratea, D | 1 |
| Fadda, V | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Anaissie, EJ | 1 |
| Coleman, EA | 1 |
| Goodwin, JA | 1 |
| Kennedy, RL | 1 |
| Lockhart, KD | 1 |
| Stewart, CB | 1 |
| Coon, SK | 1 |
| Bailey, C | 1 |
| Barlogie, B | 1 |
| Jaber, RM | 1 |
| Zumsteg, JM | 1 |
| Golgotiu, V | 1 |
| Spratke, LM | 1 |
| Wilkins, EG | 3 |
| Tarricone, R | 1 |
| Abedi, N | 1 |
| Papp, A | 1 |
| Vorob'eva, NM | 1 |
| Panchenko, EP | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Ermolina, OV | 1 |
| Balakhonova, TV | 1 |
| Kirienko, AI | 1 |
| Willard, RN | 1 |
| Muñiz, AE | 1 |
| Chuidian, F | 1 |
| Larocca, A | 1 |
| Cavallo, F | 1 |
| Bringhen, S | 1 |
| Di Raimondo, F | 1 |
| Falanga, A | 2 |
| Evangelista, A | 1 |
| Cavalli, M | 1 |
| Stanevsky, A | 1 |
| Corradini, P | 1 |
| Pezzatti, S | 1 |
| Patriarca, F | 1 |
| Cavo, M | 1 |
| Peccatori, J | 1 |
| Catalano, L | 1 |
| Carella, AM | 1 |
| Cafro, AM | 1 |
| Siniscalchi, A | 1 |
| Crippa, C | 1 |
| Petrucci, MT | 1 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Di Toritto, TC | 1 |
| Boccadoro, M | 1 |
| Nagler, A | 1 |
| Palumbo, A | 1 |
| Montero Ruiz, E | 1 |
| Baldominos Utrilla, G | 1 |
| López Álvarez, J | 1 |
| Santolaya Perrin, R | 1 |
| Wachtman, CF | 2 |
| Dreszer, G | 2 |
| Bailey, SH | 2 |
| Portschy, PR | 2 |
| Hamill, JB | 2 |
| Hume, KM | 2 |
| Hoxworth, RE | 2 |
| Kalliainen, LK | 2 |
| Rubin, JP | 2 |
| Pusic, AL | 2 |
| Shapiro, NL | 1 |
| Kominiarek, MA | 1 |
| Chevalier, AB | 1 |
| Hibbard, JU | 1 |
| Rollins, KE | 1 |
| Peters, CJ | 1 |
| Safranek, PM | 1 |
| Ford, H | 1 |
| Baglin, TP | 1 |
| Hardwick, RH | 1 |
| Diaz, AH | 1 |
| Gilreath, JA | 1 |
| Blombery, PA | 1 |
| Carson, W | 1 |
| Schilling, B | 1 |
| Simons, WR | 1 |
| Parks, C | 1 |
| Choe, Y | 2 |
| Faria, C | 1 |
| Powers, A | 1 |
| Rodrigues, JN | 1 |
| Agarwal, R | 1 |
| Ramoutar, D | 1 |
| Weightman, L | 1 |
| Raurell, A | 1 |
| Ludwig, KP | 1 |
| Simons, HJ | 1 |
| Mone, M | 1 |
| Barton, RG | 1 |
| Kimball, EJ | 1 |
| Demaria, J | 1 |
| Lillo-Le Louët, A | 1 |
| Caliandro, R | 1 |
| Le Guillou, JL | 1 |
| Crespin, M | 1 |
| de Sanctis, A | 1 |
| Stern, JB | 1 |
| Duran, A | 2 |
| Kwong, L | 2 |
| Faraklas, I | 1 |
| Saffle, J | 1 |
| Cochran, A | 1 |
| Leizorovicz, A | 1 |
| Haas, SK | 1 |
| Knabb, RM | 1 |
| Hohmann, V | 1 |
| Rao, A | 1 |
| Seger, AC | 1 |
| Catapane, E | 1 |
| Chen, X | 2 |
| Parakh, R | 1 |
| Marciniak, CM | 1 |
| Kaplan, J | 1 |
| Welty, L | 1 |
| Migliaccio-Walle, K | 1 |
| Rublee, D | 1 |
| Simon, TA | 2 |
| Wright, RT | 1 |
| Elsaid, KA | 1 |
| Collins, CM | 1 |
| Wright, R | 1 |
| Kawabata, H | 1 |
| Yang, ZY | 1 |
| Mao, C | 1 |
| Jin-Ling, TJ | 1 |
| Dranitsaris, G | 4 |
| Jelincic, V | 1 |
| Espada, NG | 1 |
| Merino, RG | 1 |
| González, TC | 1 |
| Kakkar, A | 2 |
| Gallerani, M | 1 |
| Manfredini, R | 1 |
| Millar, JA | 1 |
| Lett, JE | 1 |
| Bagley, LJ | 1 |
| Densie, IK | 1 |
| Freeman, A | 1 |
| Horner, T | 1 |
| Manco-Johnson, MJ | 1 |
| Soep, J | 1 |
| Gibson, E | 1 |
| Knoll, CM | 1 |
| Mourani, PM | 1 |
| Askegard-Giesmann, JR | 1 |
| O'Brien, SH | 2 |
| Wang, W | 1 |
| Kenney, BD | 1 |
| Zahir, H | 1 |
| Matsushima, N | 1 |
| Halim, AB | 1 |
| He, L | 1 |
| Zhang, G | 4 |
| Lee, F | 1 |
| Worland, V | 1 |
| Long, X | 1 |
| Lin, C | 1 |
| Zhao, R | 1 |
| Zindel, S | 1 |
| Stock, S | 1 |
| Müller, D | 1 |
| Stollenwerk, B | 1 |
| Springmann, V | 1 |
| Martineau, J | 1 |
| Stewart, JA | 1 |
| Komari, N | 1 |
| McLeod, A | 2 |
| Strulovitch, C | 1 |
| Blostein, M | 1 |
| Faucher, JP | 1 |
| Gamble, G | 1 |
| Gordon, W | 1 |
| Kagoma, PK | 1 |
| Miron, MJ | 1 |
| Laverdière, D | 1 |
| Game, M | 1 |
| Mills, A | 1 |
| Cain, K | 1 |
| Schmeler, KM | 1 |
| Langley, G | 1 |
| Max, O | 1 |
| Ramirez, PT | 1 |
| Levenback, CF | 1 |
| Dufour, B | 1 |
| Toussaint-Hacquard, M | 1 |
| Kearney-Schwartz, A | 1 |
| Manckoundia, MD | 1 |
| Laurain, MC | 1 |
| Joly, L | 1 |
| Deibener, J | 1 |
| Wahl, D | 1 |
| Lecompte, T | 1 |
| Benetos, A | 1 |
| Perret-Guillaume, C | 1 |
| Albertsen, IE | 1 |
| Overvad, TF | 1 |
| Li, XM | 1 |
| Sun, SG | 1 |
| Zhang, WD | 1 |
| Aldy, K | 1 |
| Brakenridge, SC | 1 |
| Nakonezny, PA | 1 |
| Chason, DP | 1 |
| Arbique, GM | 1 |
| Berne, J | 1 |
| Minei, JP | 1 |
| Takeuchi, M | 1 |
| Marx, S | 1 |
| Marder, VJ | 1 |
| Schulze, A | 1 |
| Wehling, M | 1 |
| Weiss, C | 1 |
| Pryor, HI | 1 |
| Singleton, A | 1 |
| Lin, E | 1 |
| Lin, P | 1 |
| Vaziri, K | 1 |
| Encke, A | 1 |
| Weber, AA | 1 |
| Paar, WD | 1 |
| Zumberg, M | 1 |
| Gouya, G | 1 |
| Palkovits, S | 1 |
| Kapiotis, S | 1 |
| Madl, C | 1 |
| Locker, G | 1 |
| Wolzt, M | 1 |
| Heinz, G | 1 |
| Min, E | 1 |
| Tran, V | 1 |
| Winfield, RD | 1 |
| Fortlage, D | 1 |
| Doucet, J | 1 |
| Bansal, V | 1 |
| Wang, L | 1 |
| Gómez Arrayas, I | 1 |
| Suárez Fernández, C | 1 |
| Gómez Cerezo, JF | 1 |
| Betegón Nicolás, L | 1 |
| de Salas-Cansado, M | 1 |
| Rubio-Terrés, C | 1 |
| Llau, JV | 1 |
| Mueck, W | 1 |
| Loewe, A | 1 |
| Yoshida, Rde A | 1 |
| Yoshida, WB | 1 |
| Maffei, FH | 1 |
| El Dib, R | 1 |
| Nunes, R | 1 |
| Rollo, HA | 1 |
| Tapson, V | 1 |
| Meister, B | 1 |
| Kropshofer, G | 1 |
| Klein-Franke, A | 1 |
| Strasak, AM | 1 |
| Hager, J | 1 |
| Shorr, AF | 2 |
| Happe, L | 1 |
| Mody-Patel, N | 1 |
| Ma, Q | 1 |
| Ball, ST | 1 |
| Pinsorsnak, P | 1 |
| Amstutz, HC | 1 |
| Schmalzried, TP | 1 |
| Ansell, J | 1 |
| Deitchman, D | 1 |
| Sarnes, MW | 2 |
| Peeples, PJ | 1 |
| Stanford, RH | 2 |
| Farrelly, EM | 1 |
| Martins, HS | 1 |
| Scalabrini-Neto, A | 1 |
| Velasco, IT | 1 |
| Rowan, BO | 1 |
| Kinori, M | 1 |
| Saar, N | 1 |
| Justo, D | 1 |
| Almog, R | 1 |
| Chauleur, C | 1 |
| Quenet, S | 1 |
| Varlet, MN | 1 |
| Seffert, P | 1 |
| Dahl, O | 1 |
| Zielske, D | 1 |
| Hakala, J | 1 |
| Saloheimo, P | 1 |
| Pyhtinen, J | 1 |
| Rusanen, H | 1 |
| Savolainen, ER | 1 |
| Hillbom, M | 1 |
| Muir, KW | 1 |
| Andersson, M | 1 |
| Bylock, A | 1 |
| Jensen, E | 1 |
| Boberg, B | 1 |
| Suljevic, I | 1 |
| Basic, S | 1 |
| Surkovic, I | 1 |
| Turan, M | 1 |
| Musija, E | 1 |
| Walenga, JM | 1 |
| Kaiser, PC | 1 |
| Prechel, MM | 1 |
| Hoppensteadt, D | 1 |
| Jeske, WP | 1 |
| Bacher, P | 1 |
| Kretzschmar, A | 1 |
| Donadini, MP | 1 |
| Guasti, L | 1 |
| Greinacher, A | 1 |
| Schwanebeck, U | 1 |
| Sieder, C | 3 |
| Abletshauser, C | 3 |
| Tebbe, U | 2 |
| Gerlach, HE | 2 |
| Melzer, N | 1 |
| Muñoz, A | 5 |
| Franco, L | 1 |
| Mahé, I | 3 |
| Gussoni, G | 5 |
| Hamulyak, EN | 1 |
| Lambert, C | 3 |
| Suero, MR | 1 |
| Torbicki, A | 3 |
| Schelde, AB | 1 |
| Petersen, J | 1 |
| Jensen, TB | 1 |
| Gromov, K | 1 |
| Overgaard, S | 1 |
| Olesen, JB | 1 |
| Jimenez-Solem, E | 1 |
| Planquette, B | 1 |
| Charles-Nelson, A | 1 |
| Grange, C | 1 |
| Pernod, G | 1 |
| Couturaud, F | 2 |
| Falvo, N | 3 |
| Sevestre, MA | 1 |
| Ray, V | 1 |
| Burnod, A | 2 |
| Brebion, N | 1 |
| Timar-David, M | 1 |
| Aquilanti, S | 1 |
| Constans, J | 1 |
| Bura-Rivière, A | 1 |
| Brisot, D | 1 |
| Chatellier, G | 1 |
| Sanchez, O | 4 |
| Meyer, G | 14 |
| Xiao, S | 1 |
| Luo, Y | 1 |
| Guo, L | 1 |
| Zhang, J | 1 |
| Mu, L | 1 |
| Ye, Z | 1 |
| van der Heijden, CDCC | 1 |
| Kooistra, EJ | 1 |
| Brüggemann, RJ | 1 |
| Walburgh Schmidt, JWJ | 1 |
| de Grouw, EPLM | 1 |
| Frenzel, T | 1 |
| Pickkers, P | 1 |
| Leentjens, J | 1 |
| Huisman, M | 3 |
| Hartman, LR | 1 |
| Nurmeev, I | 1 |
| Svirin, P | 1 |
| Wolter, KD | 1 |
| Yan, JL | 1 |
| Jani, D | 2 |
| Sherman, N | 2 |
| Raithel, M | 1 |
| Haibach, M | 1 |
| Kremenevski, I | 1 |
| Arnold, E | 1 |
| Ringwald, J | 1 |
| Novak, P | 1 |
| Novak, A | 1 |
| Šabović, M | 1 |
| Kozak, M | 1 |
| Zhou, LB | 1 |
| Wang, CC | 1 |
| Zhang, LT | 1 |
| Wu, T | 1 |
| Zhang, GQ | 1 |
| Burns, KEA | 1 |
| Heels-Ansdell, D | 4 |
| Thabane, L | 2 |
| Lauzier, F | 1 |
| Mehta, S | 3 |
| Ostermann, M | 1 |
| Bhuptani, P | 1 |
| Finfer, S | 4 |
| Arce-Huamani, MA | 1 |
| Barboza, JJ | 1 |
| Martínez-Herrera, JF | 1 |
| Torres-Roman, JS | 1 |
| Maguiña, JL | 1 |
| Aschenbrenner, DS | 1 |
| Le-Rademacher, JG | 2 |
| Zemla, T | 1 |
| Perepu, U | 1 |
| Anderson, D | 2 |
| Gundabolu, K | 1 |
| Kuzma, C | 1 |
| Perez Botero, J | 1 |
| Leon Ferre, RA | 2 |
| Henkin, S | 2 |
| Lenz, CJ | 2 |
| Vishnu, P | 1 |
| Loprinzi, CL | 2 |
| Mulder, FI | 2 |
| Bosch, FTM | 1 |
| Kraaijpoel, N | 2 |
| Beenen, LFM | 1 |
| van Es, N | 4 |
| Jo, KW | 1 |
| Huh, JW | 1 |
| Oh, YM | 1 |
| Lee, JS | 1 |
| Stebler-Fontaine, L | 1 |
| Rossel, A | 1 |
| Marti, C | 1 |
| Robert-Ebadi, H | 1 |
| Park, JY | 1 |
| van Bergen, EDP | 1 |
| Huisman, A | 1 |
| Welsing, PMJ | 1 |
| de Winter, MA | 1 |
| Rookmaaker, MB | 1 |
| Kaasjager, HAH | 1 |
| Nijkeuter, M | 1 |
| Meenks, SD | 1 |
| Foudraine, NA | 1 |
| Broen, K | 1 |
| le Noble, JLML | 1 |
| Janssen, PKC | 1 |
| Sueiro, MR | 1 |
| Campanini, M | 2 |
| Vescovo, G | 3 |
| Miranda, S | 1 |
| Levesque, H | 1 |
| Riaz, IB | 2 |
| Marshall, AL | 2 |
| Badgett, RG | 2 |
| Damle, B | 1 |
| Jen, F | 2 |
| Sweeney, K | 1 |
| Merino, M | 1 |
| Richardson, N | 1 |
| Reaman, G | 1 |
| Ande, A | 1 |
| Zvada, S | 1 |
| Liu, C | 1 |
| Hariharan, S | 1 |
| De Claro, RA | 1 |
| Farrell, A | 1 |
| Pazdur, R | 1 |
| Stattin, K | 1 |
| Lipcsey, M | 1 |
| Andersson, H | 1 |
| Pontén, E | 1 |
| Bülow Anderberg, S | 1 |
| Gradin, A | 1 |
| Larsson, A | 1 |
| Lubenow, N | 1 |
| von Seth, M | 1 |
| Rubertsson, S | 1 |
| Hultström, M | 1 |
| Frithiof, R | 1 |
| Díaz Gómez, E | 1 |
| Suárez Del Olmo, D | 1 |
| Corregidor Luna, L | 1 |
| Iglesias-Peinado, I | 1 |
| García Díaz, B | 1 |
| Young, G | 1 |
| de Jong, LA | 1 |
| van der Velden, AWG | 1 |
| Hulst, MV | 1 |
| Postma, MJ | 1 |
| Zhuang, Z | 1 |
| Mandalà, M | 1 |
| Fuentes, HE | 1 |
| Naqvi, SAA | 1 |
| He, H | 1 |
| Sipra, QR | 1 |
| Tafur, AJ | 1 |
| Padranos, L | 1 |
| Vandvik, PO | 1 |
| Montori, V | 1 |
| Bryce, AH | 1 |
| Liu, H | 1 |
| Murad, MH | 1 |
| Giustozzi, M | 1 |
| Ruperez Blanco, AB | 1 |
| Szmit, S | 1 |
| Maraziti, G | 1 |
| Manfellotto, D | 1 |
| Sanchez, A | 1 |
| McBane Ii, R | 1 |
| Perez-Botero, J | 1 |
| Kovacs, MJ | 3 |
| Mercuri, MF | 2 |
| Yeo, E | 1 |
| Hakoum, MB | 1 |
| Kahale, LA | 1 |
| Tsolakian, IG | 1 |
| Matar, CF | 1 |
| Yosuico, VE | 1 |
| Terrenato, I | 5 |
| Sperati, F | 5 |
| Barba, M | 5 |
| Schünemann, H | 5 |
| Arsoy, D | 1 |
| Giori, NJ | 1 |
| Woolson, ST | 1 |
| Young, AM | 1 |
| Thirlwall, J | 1 |
| Chapman, O | 1 |
| Lokare, A | 1 |
| Hill, C | 1 |
| Dunn, JA | 1 |
| Lyman, GH | 2 |
| Hutchinson, C | 1 |
| MacCallum, P | 1 |
| Hobbs, FDR | 1 |
| Petrou, S | 1 |
| Dale, J | 1 |
| Poole, CJ | 1 |
| Maraveyas, A | 3 |
| Abdel-Razeq, H | 1 |
| Finianos, A | 1 |
| Taher, AT | 1 |
| Noble, S | 1 |
| Lee, AYY | 5 |
| Grosso, M | 1 |
| Hernandez, CR | 1 |
| Abreu de Sousa, J | 1 |
| Hellgren, M | 1 |
| Mistafa, O | 1 |
| Woodruff, S | 4 |
| Feugère, G | 2 |
| Abreu, P | 2 |
| Heissler, J | 2 |
| Weitz, J | 1 |
| Buller, H | 1 |
| Miyazaki, Y | 1 |
| Sase, K | 1 |
| Hasegawa, K | 1 |
| Morimoto, T | 1 |
| Menakaya, CU | 1 |
| Pennington, N | 1 |
| Muthukumar, N | 1 |
| Joel, J | 1 |
| Ramirez Jimenez, AJ | 1 |
| Shaw, CJ | 1 |
| Mohsen, A | 1 |
| Anderson, DR | 2 |
| Dunbar, MJ | 2 |
| Bohm, ER | 1 |
| Belzile, E | 1 |
| Zukor, D | 1 |
| Gofton, W | 1 |
| Gross, P | 1 |
| Pelet, S | 1 |
| Crowther, M | 2 |
| MacDonald, S | 1 |
| Kim, P | 1 |
| Pleasance, S | 1 |
| Davis, N | 1 |
| Andreou, P | 1 |
| Kovacs, M | 1 |
| Rodger, MA | 3 |
| Ramsay, T | 2 |
| Vendittoli, PA | 1 |
| Steinberg, DI | 1 |
| Granziera, S | 1 |
| Markun, S | 1 |
| Besl, KM | 1 |
| Lemmink, JA | 1 |
| Kramer, EA | 1 |
| Athota, KP | 1 |
| Keegan, SP | 1 |
| Lutomski, DM | 1 |
| Hanseman, DJ | 1 |
| Robinson, BR | 1 |
| Thachil, J | 1 |
| Kahale, L | 1 |
| Muti, P | 4 |
| Krasiński, Z | 1 |
| Szpurek, D | 1 |
| Staniszewski, R | 1 |
| Dzieciuchowicz, L | 1 |
| Pawlaczyk, K | 1 |
| Krasińska, B | 1 |
| Wójcicka, K | 1 |
| Urbanek, T | 1 |
| Hague, WM | 1 |
| Kingdom, J | 1 |
| Karovitch, A | 1 |
| Sermer, M | 1 |
| Clement, AM | 1 |
| Coat, S | 1 |
| Chan, WS | 1 |
| Said, J | 1 |
| Rey, E | 1 |
| Khurana, R | 1 |
| Demers, C | 1 |
| Solymoss, S | 2 |
| Hinshaw, K | 1 |
| Dwyer, J | 1 |
| Smith, G | 1 |
| McDonald, S | 1 |
| Newstead-Angel, J | 1 |
| Khandelwal, M | 1 |
| Le Gal, G | 2 |
| Greer, IA | 2 |
| Keely, E | 1 |
| Rosene-Montella, K | 1 |
| Walker, M | 1 |
| Kulkarni, R | 1 |
| Wallace, A | 1 |
| Burr, S | 1 |
| Mittmann, N | 2 |
| Guyatt, G | 3 |
| Krahn, M | 2 |
| Chan, B | 2 |
| Ormanidhi, O | 2 |
| Arabi, Y | 2 |
| Qushmaq, I | 2 |
| Rocha, MG | 2 |
| Dodek, P | 2 |
| McIntyre, L | 2 |
| Hall, R | 2 |
| Ferguson, ND | 3 |
| Marshall, JC | 2 |
| Doig, CJ | 2 |
| Muscedere, J | 2 |
| Jacka, MJ | 2 |
| Klinger, JR | 2 |
| Vlahakis, N | 2 |
| Orford, N | 2 |
| Seppelt, I | 2 |
| Skrobik, YK | 2 |
| Sud, S | 2 |
| Cade, JF | 2 |
| Cooper, J | 2 |
| Cook, D | 2 |
| Phillips, P | 1 |
| James, AH | 1 |
| Konkle, BA | 1 |
| Pastores, SM | 1 |
| Kessler, CM | 1 |
| Selby, R | 1 |
| Kreder, HJ | 1 |
| Kaus, L | 1 |
| Sealey, F | 1 |
| Gillespie, MA | 1 |
| Lyle, CA | 1 |
| Li, G | 1 |
| Levine, MAH | 1 |
| Holbrook, A | 1 |
| Lamontagne, F | 1 |
| Walter, SD | 1 |
| Arabi, YM | 1 |
| Bellomo, R | 1 |
| Cooper, DJ | 1 |
| Lee, SE | 1 |
| Jeon, YW | 1 |
| Yoon, JH | 1 |
| Cho, BS | 1 |
| Eom, KS | 1 |
| Kim, YJ | 1 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Min, CK | 1 |
| Shaya, SA | 1 |
| Saldanha, LJ | 1 |
| Vaezzadeh, N | 1 |
| Ni, R | 1 |
| Gross, PL | 2 |
| Podger, H | 1 |
| Kent, M | 1 |
| Little, MT | 1 |
| Ruiz, MT | 1 |
| Shane, L | 1 |
| Burgers, L | 1 |
| Kuderer, NM | 1 |
| Wun, T | 1 |
| Rubens, D | 1 |
| Hobbs, S | 1 |
| Peterson, D | 1 |
| Baran, A | 1 |
| Kaproth-Joslin, K | 1 |
| Shane, LG | 1 |
| Galanaud, JP | 2 |
| Stemer, G | 1 |
| Debourdeau, P | 2 |
| Plante, S | 1 |
| Belzile, EL | 1 |
| Fréchette, D | 1 |
| Lefebvre, J | 1 |
| Linkins, LA | 1 |
| Simoneau, MD | 1 |
| Vachon, A | 1 |
| Picard, F | 1 |
| Worley, S | 1 |
| Short, C | 1 |
| Pike, J | 1 |
| Douglas, JA | 1 |
| Thompson, K | 1 |
| Stumpo, C | 1 |
| Bartle, W | 1 |
| Goldman, MC | 1 |
| Griffiths, GO | 1 |
| Burns, S | 1 |
| Noble, SI | 1 |
| Macbeth, FR | 1 |
| Cohen, D | 1 |
| Maughan, TS | 1 |
| Andersen, AS | 1 |
| Berthelsen, JG | 1 |
| Bergholt, T | 1 |
| Schmid, P | 1 |
| Brodmann, D | 1 |
| Fischer, AG | 1 |
| Wuillemin, WA | 1 |
| Ettelaie, C | 2 |
| Echrish, H | 1 |
| Li, C | 1 |
| Gardiner, E | 2 |
| Greenman, J | 1 |
| Madden, LA | 1 |
| Haines, ST | 1 |
| Dager, WE | 1 |
| Trujillo, TC | 1 |
| Puskas, D | 1 |
| Bocanegra, T | 1 |
| Brzezková, R | 1 |
| Frýba, V | 1 |
| Chrz, K | 1 |
| Krska, Z | 1 |
| Kvasnicka, J | 1 |
| Pillai, AR | 1 |
| Olujohungbe, A | 1 |
| Evans, MR | 1 |
| Main, NJ | 1 |
| Hunt, BJ | 1 |
| Green, L | 1 |
| Lawrie, AS | 1 |
| Patel, S | 2 |
| Hossain, F | 1 |
| Chitolie, A | 1 |
| Mackie, IJ | 1 |
| Haddad, FS | 1 |
| Machin, SJ | 1 |
| Vasireddi, SR | 3 |
| Gunukula, S | 3 |
| Blackburn, TK | 1 |
| Java, KR | 1 |
| Lowe, D | 1 |
| Brown, JS | 1 |
| Rogers, SN | 1 |
| Waters, J | 1 |
| Roy, R | 1 |
| Fyfe, D | 1 |
| Propper, D | 1 |
| Lofts, F | 1 |
| Sgouros, J | 1 |
| Wedgwood, K | 1 |
| Bozas, G | 1 |
| Rathbun, SW | 1 |
| Aston, CE | 1 |
| Whitsett, TL | 1 |
| Krafft, A | 1 |
| Bauersachs, RM | 1 |
| Dudenhausen, J | 1 |
| Faridi, A | 1 |
| Fischer, T | 1 |
| Fung, S | 1 |
| Geisen, U | 1 |
| Herchenhan, E | 1 |
| Keller, F | 1 |
| Kemkes-Matthes, B | 1 |
| Spannagl, M | 1 |
| Thaler, CJ | 1 |
| Akinosoglou, K | 1 |
| Savopoulos, C | 1 |
| Pouliakis, A | 2 |
| Triantafyllidis, C | 1 |
| Markatis, E | 1 |
| Golemi, F | 1 |
| Liontos, A | 1 |
| Vadala, C | 1 |
| Papanikolaou, IC | 1 |
| Dimakopoulou, V | 1 |
| Xarras, P | 1 |
| Varela, K | 1 |
| Kaiafa, G | 1 |
| Mitsianis, A | 1 |
| Chatzistamati, A | 1 |
| Randou, E | 1 |
| Savvanis, S | 1 |
| Pavlaki, M | 1 |
| Efraimidis, G | 1 |
| Samaras, V | 1 |
| Papazoglou, D | 1 |
| Konstantinidou, A | 1 |
| Panagopoulos, P | 1 |
| Milionis, H | 1 |
| Xynogalos, S | 1 |
| Simeonidis, D | 1 |
| Papageorgiou, G | 1 |
| Charalambakis, N | 1 |
| Lianos, E | 1 |
| Mazlimoglou, E | 1 |
| Liatsos, AN | 1 |
| Kosmas, C | 1 |
| Ziras, N | 1 |
| Crichi, B | 1 |
| Rueda-Camino, JA | 1 |
| Cajfinger, F | 1 |
| Spiess, N | 1 |
| Janus, N | 1 |
| Le Maignan, C | 1 |
| Marjanovic, Z | 1 |
| Farge, D | 1 |
| Amerali, M | 1 |
| Politou, M | 1 |
| Auer, RC | 1 |
| Ott, M | 1 |
| Karanicolas, P | 1 |
| Brackstone, MR | 1 |
| Ashamalla, S | 1 |
| Weaver, J | 1 |
| Tagalakis, V | 1 |
| Boutros, M | 1 |
| Stotland, P | 1 |
| Marulanda, AC | 1 |
| Moloo, H | 1 |
| Jayaraman, S | 1 |
| Spadafora, S | 1 |
| MacLellan, S | 1 |
| Trottier, D | 1 |
| Jonker, D | 2 |
| Asmis, T | 2 |
| Mallick, R | 1 |
| Pecarskie, A | 1 |
| Karathanos, C | 3 |
| Georgiadis, G | 3 |
| Ioannou, C | 3 |
| Vasdekis, S | 3 |
| Chatzis, D | 3 |
| Latzios, P | 3 |
| Giannoukas, AD | 3 |
| Makedonov, I | 1 |
| Kahn, S | 1 |
| Abdulrehman, J | 1 |
| Helfer, H | 1 |
| Siguret, V | 1 |
| Yeung, J | 1 |
| Dix, CHK | 1 |
| Ritchie, AG | 1 |
| Kow, M | 1 |
| Chen, VMY | 1 |
| Li, A | 1 |
| Eshaghpour, A | 1 |
| Douketis, JD | 2 |
| Anvari, M | 2 |
| Tiboni, M | 2 |
| Siegal, DM | 2 |
| Ikesaka, RT | 1 |
| Falchero, L | 1 |
| Cloarec, N | 1 |
| Monnet, I | 1 |
| Tomasini, P | 1 |
| Boulon, C | 1 |
| Boutruche, B | 1 |
| Scotté, F | 1 |
| Lamblin, A | 1 |
| Cooper, C | 1 |
| Antle, O | 1 |
| Lowerison, J | 1 |
| Dersch-Mills, D | 1 |
| Kenny, A | 1 |
| Maguire, PJ | 1 |
| McGuire, M | 1 |
| Power, KA | 1 |
| McNicholl, M | 1 |
| Sheehan, SR | 1 |
| Turner, MJ | 1 |
| Dimakakos, EP | 1 |
| Vathiotis, I | 1 |
| Syrigos, K | 1 |
| Kamphuisen, PW | 5 |
| Janas, MS | 5 |
| Jarner, MF | 5 |
| Novo-Veleiro, I | 1 |
| Alvela-Suárez, L | 1 |
| Costa-Grille, A | 1 |
| Suárez-Dono, J | 1 |
| Ferrón-Vidan, F | 1 |
| Pose-Reino, A | 1 |
| Kolesar, E | 1 |
| Handa, P | 1 |
| Labianca, RF | 1 |
| Mantovani, L | 1 |
| Lee, AY | 2 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 1 |
| McAuliffe, F | 1 |
| Byrne, B | 2 |
| Matikas, A | 1 |
| Vardakis, N | 1 |
| Souglakos, J | 1 |
| Georgoulias, V | 1 |
| Ismail, SK | 2 |
| Norris, L | 2 |
| O'Shea, S | 1 |
| Higgins, JR | 2 |
| Noel-Savina, E | 1 |
| Descourt, R | 1 |
| André, M | 1 |
| Leroyer, C | 1 |
| Parent, F | 1 |
| Deruelle, P | 1 |
| Jilwan, F | 1 |
| Boyer-Neumann, C | 1 |
| Wolf, M | 1 |
| Simonneau, G | 1 |
| Goertz, L | 1 |
| Schneider, SW | 1 |
| Desch, A | 1 |
| Mayer, FT | 1 |
| Koett, J | 1 |
| Karampinis, I | 1 |
| Bohlmann, MK | 1 |
| Umansky, V | 1 |
| Bauer, AT | 1 |
| Martínez-Zapata, MJ | 1 |
| Mathioudakis, AG | 1 |
| Mousa, SA | 1 |
| Wong, A | 1 |
| Appleby, N | 1 |
| Regan, C | 1 |
| Hassan, T | 1 |
| Milner, M | 1 |
| Sullivan, AO | 1 |
| O'Donnell, J | 1 |
| Perry, SL | 1 |
| Bohlin, C | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Vredenburgh, JJ | 1 |
| Cook, R | 1 |
| Poon, MC | 1 |
| Pérez-de-Llano, LA | 1 |
| Leiro-Fernández, V | 1 |
| Golpe, R | 1 |
| Núñez-Delgado, JM | 1 |
| Palacios-Bartolomé, A | 1 |
| Méndez-Marote, L | 1 |
| Colomé-Nafria, E | 1 |
| Nelson-Piercy, C | 1 |
| Powrie, R | 1 |
| Borg, JY | 1 |
| Rodger, M | 1 |
| Talbot, DJ | 1 |
| Stinson, J | 1 |
| Auer, R | 1 |
| Scheer, A | 1 |
| Boushey, R | 1 |
| Muttukrishna, S | 1 |
| Romera, A | 1 |
| Pérez de Llano, LA | 1 |
| Gibson, PS | 1 |
| Newell, K | 1 |
| Sam, DX | 1 |
| Mansoor, A | 1 |
| Tang, S | 1 |
| Ross, S | 1 |
| Hyers, TM | 1 |
| Zheng, J | 1 |
| Zhao, Y | 1 |
| Xiang, Y | 1 |
| Jin, Y | 1 |
| Fisher, WD | 1 |
| George, DJ | 2 |
| Heller, S | 1 |
| Krause, M | 1 |
| Porreca, E | 1 |
| Otten, HM | 1 |
| Chen, YW | 1 |
| Chaudhari, U | 1 |
| Gras, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients: a Randomized Controlled Trial[NCT04982055] | Phase 4 | 60 participants (Actual) | Interventional | 2015-04-08 | Completed | ||
| A Randomized Pilot Study Comparing the Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery[NCT01431456] | Phase 3 | 148 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer[NCT03646409] | 542 participants (Actual) | Observational | 2018-06-11 | Completed | |||
| Assessing Women's Preferences for Postpartum Thromboprophylaxis: the PREFER-PostPartum[NCT05318547] | 52 participants (Anticipated) | Interventional | 2022-05-13 | Recruiting | |||
| Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial[NCT01588171] | 7,020 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958] | 150 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)[NCT04401293] | Phase 3 | 257 participants (Actual) | Interventional | 2020-04-26 | Completed | ||
| Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study[NCT00571649] | Phase 3 | 8,101 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk[NCT02111564] | Phase 3 | 12,024 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surger[NCT03891524] | Phase 2 | 1,242 participants (Actual) | Interventional | 2019-06-17 | Completed | ||
| Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study[NCT02886533] | 6,484 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial[NCT04354155] | Phase 2 | 40 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery[NCT04305756] | 146 participants (Actual) | Interventional | 2020-06-12 | Completed | |||
| Patient Adherence to Venous Thromboembolism Prophylaxis in Orthopaedic Trauma Patients: A Randomized, Controlled Trial Comparing Subcutaneous Enoxaparin & Oral Rivaroxaban[NCT04169269] | Phase 4 | 128 participants (Anticipated) | Interventional | 2020-01-13 | Recruiting | ||
| A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr[NCT03276143] | Phase 2 | 813 participants (Actual) | Interventional | 2017-09-21 | Completed | ||
| Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients[NCT03251963] | Phase 2 | 131 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688] | Phase 1 | 22 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004] | Phase 1 | 18 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery[NCT02401594] | Phase 3 | 3,608 participants (Actual) | Interventional | 2015-12-08 | Terminated (stopped due to Remaining outdated treatments and additional costs too high for new manufacturing) | ||
| A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients[NCT02706249] | Phase 2 | 50 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Role of Ischemia Modified Albumin in Patients With COVID-19[NCT05286268] | 194 participants (Anticipated) | Observational | 2022-04-06 | Recruiting | |||
| A Multicenter, Open-label, Prospective, Randomized, Active-controlled Study on the Efficacy and Safety of Oral Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis After Major Gynecological Cancer Surgery.[NCT04999176] | Phase 3 | 440 participants (Anticipated) | Interventional | 2020-10-22 | Recruiting | ||
| The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design[NCT02366871] | Phase 2 | 400 participants (Actual) | Interventional | 2015-04-28 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00440193] | Phase 3 | 3,449 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients[NCT01573169] | Phase 3 | 73 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to The trial has been terminated prematurely after the randomization of 73 patients due to a lack of funding.) | ||
| Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients: A Prospective Randomized Trial of Standard Enoxaparin Versus Two Anti-Xa Adjusted Dosing Strategies[NCT02412982] | Phase 4 | 103 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| The Prevalence and Incidence of Deep Venous Thrombosis in General ICU Patients Receiving Enoxaparine Prophylaxis[NCT03286985] | 200 participants (Actual) | Observational | 2017-09-01 | Completed | |||
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization[NCT00077753] | Phase 4 | 4,726 participants | Interventional | 2002-02-28 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.[NCT00457002] | Phase 3 | 6,758 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer[NCT00717938] | Phase 3 | 390 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Optimization of Enoxaparin Prophylaxis Using Real-time Anti-Factor Xa Levels in Major Reconstructive Surgery Patients[NCT02687204] | Phase 1 | 118 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Enoxaparin Metabolism in Reconstructive Surgery Patients[NCT02411292] | Phase 2 | 110 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial[NCT02600260] | 7,212 participants (Actual) | Interventional | 2014-12-01 | Completed | |||
| Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty[NCT01557725] | 4,924 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose[NCT02704052] | Early Phase 1 | 116 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Title: EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients[NCT03243708] | 90,537 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| Patient-Centered Education Bundle to Decrease Patient Refusal of Venous Thromboembolism (VTE) Prophylaxis[NCT02402881] | 19,652 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Educating Nurses About Venous Thromboembolism Prevention[NCT02301793] | 933 participants (Actual) | Interventional | 2014-04-01 | Completed | |||
| Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of Venous Thromboembolism (VTE) Prophylaxis: A Crossover, Cluster Randomized Controlled Trial[NCT03367364] | 9,657 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism[NCT00643201] | Phase 3 | 5,614 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism[NCT03988842] | Phase 4 | 4 participants (Actual) | Interventional | 2019-07-25 | Terminated (stopped due to COVID-19 pandemic) | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women[NCT02829957] | Phase 2/Phase 3 | 19 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)[NCT02942576] | Phase 3 | 632 participants (Actual) | Interventional | 2017-03-21 | Completed | ||
| Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan[NCT02952599] | 352 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)[NCT03977363] | 25 participants (Actual) | Observational [Patient Registry] | 2020-01-27 | Terminated (stopped due to Halted Prematurely) | |||
| Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe[NCT02943993] | 2,809 participants (Actual) | Observational | 2016-04-06 | Completed | |||
| A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B[NCT02798471] | Phase 3 | 290 participants (Actual) | Interventional | 2017-03-27 | Completed | ||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism ([NCT00986154] | Phase 3 | 8,292 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery[NCT00902928] | Phase 2/Phase 3 | 1,992 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee[NCT00831714] | 19,076 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery[NCT00679588] | Phase 3 | 4,413 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study[NCT03048032] | 1,566 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients[NCT01448746] | Phase 3 | 682 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | ||
| A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2)[NCT01203098] | Phase 2 | 264 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase[NCT00716898] | 25 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery[NCT01587781] | 12 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Effectiveness and Safety Evaluation of Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis: A Prospective, Single-center, Single-arm, Phase II Clinical Study[NCT04677192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-01-31 | Not yet recruiting | ||
| Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome[NCT01068795] | 144 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Thrombelastography Based Dosing of Enoxaparin for Thromboprophylaxis: a Prospective Randomized Trial[NCT00990236] | 185 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00439777] | Phase 3 | 4,833 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)[NCT04406389] | Phase 4 | 14 participants (Actual) | Interventional | 2020-10-13 | Terminated (stopped due to Low accrual) | ||
| A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642] | 20 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?[NCT02900170] | 8 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement[NCT00329628] | Phase 3 | 4,541 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.[NCT00361894] | Phase 3 | 2,531 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement.[NCT00332020] | Phase 3 | 2,457 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses[NCT02856295] | Phase 4 | 136 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707] | Phase 4 | 1,200 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | ||
| An Efficacy and Safety Study of Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression Treated With Stent Implantation (PLICTS)：A Prospective Randomized Controlled Trial[NCT04067505] | Phase 3 | 224 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | ||
| A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery[NCT00371683] | Phase 3 | 3,608 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke[NCT00077805] | Phase 4 | 0 participants | Interventional | 2003-08-31 | Completed | ||
| Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin[NCT00353678] | Phase 2 | 1,141 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)[NCT00452530] | Phase 3 | 3,221 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement[NCT00641732] | Phase 2 | 1,045 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study[NCT00439725] | Phase 3 | 1,197 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis[NCT03191305] | 50 participants (Anticipated) | Interventional | 2017-08-31 | Not yet recruiting | |||
| A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Antic[NCT00423319] | Phase 3 | 5,407 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD[NCT03277001] | 438 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | |||
| International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings[NCT00622648] | Phase 4 | 8,329 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00697099] | Phase 3 | 2,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery[NCT00721760] | Phase 3 | 1,003 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery[NCT00718224] | Phase 3 | 1,150 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial[NCT01853202] | 40 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneo[NCT00168805] | Phase 3 | 2,101 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818] | Phase 3 | 3,494 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin[NCT03299296] | Phase 3 | 100 participants (Actual) | Interventional | 2017-01-01 | Enrolling by invitation | ||
| A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00338897] | Phase 2/Phase 3 | 1,090 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| "The EXTEND Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergo[NCT00206089] | Phase 3 | 3,300 participants | Interventional | 2005-09-30 | Terminated (stopped due to Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.) | ||
| An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients[NCT00311753] | Phase 3 | 342 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412] | Phase 3 | 3,254 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.[NCT02746185] | Phase 3 | 159 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES[NCT00952380] | Phase 2 | 38 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism[NCT02585713] | Phase 3 | 300 participants (Actual) | Interventional | 2015-11-20 | Completed | ||
| Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406] | Phase 3 | 1,168 participants (Actual) | Interventional | 2017-04-13 | Active, not recruiting | ||
| Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19[NCT04316884] | 300 participants (Anticipated) | Observational | 2020-03-12 | Recruiting | |||
| CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study[NCT02583191] | Phase 3 | 246 participants (Actual) | Interventional | 2016-03-23 | Terminated (stopped due to Recruitment was not as expected.) | ||
| Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)[NCT02744092] | 811 participants (Actual) | Interventional | 2016-12-13 | Completed | |||
| A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancrea[NCT03139487] | Phase 2 | 176 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855] | 240 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682] | Phase 3 | 1,046 participants (Actual) | Interventional | 2015-07-16 | Completed | ||
| TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.[NCT00967382] | Phase 3 | 292 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism[NCT01274637] | Phase 3 | 62 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention[NCT00187408] | Phase 4 | 700 participants | Interventional | 2002-08-31 | Completed | ||
| A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients[NCT00876915] | Phase 3 | 218 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to slow enrollment and lack of continuing funds) | ||
| FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer[NCT00519805] | Phase 3 | 2,200 participants (Anticipated) | Interventional | 2007-08-31 | Recruiting | ||
| Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function[NCT00264693] | 96 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM][NCT00462852] | Phase 2 | 120 participants (Anticipated) | Interventional | 2003-04-30 | Completed | ||
| Management of Superficial Thrombophlebitis[NCT00264381] | Phase 4 | 72 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients[NCT04248348] | 600 participants (Anticipated) | Observational | 2018-12-01 | Recruiting | |||
| A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer[NCT01455831] | Phase 3 | 616 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025] | Phase 3 | 900 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Weight-Adjusted Dosing of Tinzaparin in Pregnancy[NCT00851864] | Phase 4 | 13 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery[NCT00709904] | Phase 3 | 469 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study[NCT02025894] | 3,032 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy[NCT00694382] | Phase 3 | 3,212 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Risk of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Day 30 ± 2 days. (NCT04401293)
Timeframe: Day 30 ± 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 25 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 31 |
The composite of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Hospital Day 10 + 4 (NCT04401293)
Timeframe: Day 10 + 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 2 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 3 |
Risk of major bleeding defined using the International Society of Thrombosis and Haemostasis (ISTH) criteria (NCT04401293)
Timeframe: Day 30 ± 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 6 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 2 |
Need for Intubation will be based on monitoring of patient conditions. (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 17 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 21 |
Progression to Acute Respiratory Distress Syndrome (ARDS) based on monitoring of patient conditions. (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 11 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 6 |
Need for Re-hospitalization will be based on monitoring of patient conditions. (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 1 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 3 |
"Sepsis-induced coagulopathy (SIC) score predicts likelihood of sepsis-induced coagulopathy based on ISTH guidelines.~The score uses the following domains:~Platelets, K/uL (thousands per microliter)~INR (International Normalized Ratio)~D-Dimer Level~Fibrinogen~Platelet count > 100 cells x 10^9/L is 0 points, platelet count 50 to 100 cells x 10^9/L is 1 point and Platelet count < 50 cells x 10^9/L is 2 points. INR < 1.3 is 0 points, INR 1.3 to 1.7 is 1 point and INR > 1.7 is 2 points. D-Dimer level < 400 ng/mL is 0 points, D-Dimer level 400-4000 ng/mL is 2 points and D-Dimer level > 4000 ng/mL is 3 points. Fibrinogen level > 100 mg/dL is 0 points and fibrinogen level < 100 mg/dL is 1 point.~Calculated (SIC) scores yields a possible 0 to 6 points, where ≥4 predicts higher mortality rates within 30 days and greater risk of pulmonary embolism." (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | units on a scale (Mean) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 2.35 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 2.31 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.4 |
| Enoxaparin | 5.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.6 |
| Enoxaparin | 9.2 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.7 |
| Enoxaparin | 2.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.0 |
| Enoxaparin | 3.1 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin | 3.9 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 9.4 |
| Enoxaparin | 7.8 |
Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin or transfusion of >=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.8 |
| Enoxaparin | 1.2 |
Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin; or transfusion of >= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.1 |
| Enoxaparin | 1.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.8 |
| Enoxaparin | 4.5 |
All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths. (NCT00571649)
Timeframe: Up to Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Any event | Death (cardiovascular) | Death (other) | VTE related death | |
| Enoxaparin | 6.2 | 1.4 | 3.7 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.7 | 1.4 | 4.3 | 1.0 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Symptomatic non-fatal PE | Symptomatic DVT in lower extremity | Asymptomatic proximal DVT in lower extremity | VTE related death | |
| Enoxaparin | 0.1 | 0.2 | 2.4 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 | 2.4 | 0.1 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Symptomatic non-fatal PE | Symptomatic DVT in lower extremity | Asymptomatic proximal DVT in lower extremity | VTE related death | |
| Enoxaparin | 0.5 | 0.5 | 4.4 | 1.0 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 | 0.4 | 3.5 | 0.6 |
Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category. (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event-Day 10 | Ischemic stroke-Day 10 | Acute MI-Day 10 | Death (cardiovascular)-Day 10 | Any event-Day 35 | Ischemic stroke-Day 35 | Acute MI-Day 35 | Death (cardiovascular)-Day 35 | Any event-Day 90 | Ischemic stroke-Day 90 | Acute MI-Day 90 | Death (cardiovascular)-Day 90 | |
| Enoxaparin | 1.0 | 0.3 | 0.4 | 0.4 | 1.6 | 0.5 | 0.5 | 0.8 | 2.8 | 1.1 | 0.7 | 1.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 1.0 | 0.3 | 0.5 | 0.4 | 1.8 | 0.5 | 0.6 | 0.9 | 2.8 | 0.8 | 0.9 | 1.4 |
Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90 (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| symptomatic VTE (incl. VTE-related death)-Day 10 | symptomatic VTE (non fatal)-Day 10 | symptomatic VTE (incl. VTE-related death)-Day 35 | symptomatic VTE (non fatal)-Day 35 | symptomatic VTE (incl. VTE-related death)-Day 90 | symptomatic VTE (non fatal)-Day 90 | |
| Enoxaparin | 0.6 | 0.3 | 1.4 | 0.7 | 1.9 | 0.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.5 | 1.0 | 0.6 | 1.7 | 0.7 |
Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.19 |
| Placebo | 1.49 |
Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.72 |
| Placebo | 0.77 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.31 |
| Placebo | 1.80 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.58 |
| Placebo | 2.03 |
Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.19 |
| Placebo | 0.42 |
A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days. (NCT02111564)
Timeframe: From randomization to 2 days after the last dose (Day 45)
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.28 |
| Placebo | 0.15 |
Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.84 |
| Placebo | 1.11 |
Apparent clearance of a drug was defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liter per hour (L/h) (Geometric Mean) |
|---|---|
| Overall | 7.72 |
V/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liter (Geometric Mean) |
|---|---|
| Overall | 125 |
Impact of age on CL/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | L/h (Geometric Mean) |
|---|---|
| Age: Less Than or Equal to (<=) 68 Years | 8.70 |
| Age: Greater Than (>) 68 Years | 6.83 |
Impact of weight on CL/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | L/h (Geometric Mean) |
|---|---|
| Weight: <= 82 Kilograms (kg) | 7.04 |
| Weight: Greater Than (>) 82 kg | 8.54 |
Impact of age on V/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| AGE <= 68 Years | 135 |
| AGE >68 Years | 116 |
Impact of weight on V/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| Weight <= 82kg | 109 |
| Weight > 82kg | 145 |
Impact of demographic character (sex) on CL/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liter per hour (L/h) (Geometric Mean) |
|---|---|
| Female | 7.14 |
| Male | 9.32 |
Impact of sex on V/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| Female | 118 |
| Male | 143 |
Impact of renal function on CL/F was assessed. The outcome measure was reported based on CRCL. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | L/h (Geometric Mean) |
|---|---|
| Creatinine Clearance (CRCL): Less Than (<) 90 | 6.71 |
| CRCL: Greater Than or Equal to (>=) 90 | 8.83 |
Impact of renal function on V/F was assessed. The outcome measure is reported based on CRCL. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| CRCL < 90 | 116 |
| CRCL >= 90 | 135 |
Number of participants with deaths (CEC-adjudicated) were reported. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Number of participants with deaths (CEC-adjudicated) were reported. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 1 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 2 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 4 |
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 1 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 2 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 4 |
Number of participants with nonfatal PE (adjudicated by CEC) were reported. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 1 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Number of participants with nonfatal PE (adjudicated by CEC) were reported. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 1 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 7 |
| JNJ-70033093 50 mg Once Daily + Placebo | 30 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 27 |
| JNJ-70033093 50 mg BID | 14 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 |
| JNJ-70033093 100 mg + Placebo BID | 12 |
| JNJ-70033093 200 mg BID | 10 |
| Enoxaparin 40 mg Once Daily | 54 |
Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 7 |
| JNJ-70033093 50 mg Once Daily + Placebo | 30 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 27 |
| JNJ-70033093 50 mg BID | 14 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 |
| JNJ-70033093 100 mg + Placebo BID | 12 |
| JNJ-70033093 200 mg BID | 10 |
| Enoxaparin 40 mg Once Daily | 54 |
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate. (NCT03891524)
Timeframe: Up to 14 days
| Intervention | proportion of participants (Number) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0.35 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0.21 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0.20 |
| JNJ-70033093 50 mg BID | 0.13 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0.09 |
| JNJ-70033093 100 mg + Placebo BID | 0.09 |
| JNJ-70033093 200 mg BID | 0.07 |
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate. (NCT03891524)
Timeframe: Up to 14 days
| Intervention | proportion of participants (Number) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0.02 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0.01 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0.01 |
| JNJ-70033093 50 mg BID | 0.01 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0.01 |
| JNJ-70033093 100 mg + Placebo BID | 0.01 |
| JNJ-70033093 200 mg BID | 0.01 |
Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 12 | 12 |
| JNJ-70033093 100 mg + Placebo BID | 7 | 7 |
| JNJ-70033093 200 mg BID | 6 | 6 |
| JNJ-70033093 200 mg Once Daily + Placebo | 11 | 11 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 2 | 2 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 7 | 7 |
| JNJ-70033093 50 mg Once Daily + Placebo | 8 | 8 |
Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: Epistaxis, Gastrointestinal bleed,Hematuria,Bruising/ecchymosis,Hemoptysis,Hematoma. (NCT03891524)
Timeframe: Up to Day 14, Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 5 | 5 |
| JNJ-70033093 100 mg + Placebo BID | 1 | 1 |
| JNJ-70033093 200 mg BID | 1 | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 1 | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 2 | 2 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 | 2 |
Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 4 | 4 |
| JNJ-70033093 100 mg + Placebo BID | 1 | 1 |
| JNJ-70033093 200 mg BID | 1 | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 1 | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 2 | 2 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 | 2 |
Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 50 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 10 | 1 |
| JNJ-70033093 200 mg BID | 10 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 26 | 2 |
| JNJ-70033093 25 mg Once Daily + Placebo | 7 | 0 |
| JNJ-70033093 50 mg BID | 13 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 27 | 2 |
Number of participants with distal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 50 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 10 | 1 |
| JNJ-70033093 200 mg BID | 10 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 26 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 7 | 0 |
| JNJ-70033093 50 mg BID | 13 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 27 | 2 |
Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 1 | 1 |
| JNJ-70033093 100 mg + Placebo BID | 0 | 0 |
| JNJ-70033093 200 mg BID | 0 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 0 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 | 0 |
Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 5 | 5 |
| JNJ-70033093 100 mg + Placebo BID | 1 | 1 |
| JNJ-70033093 200 mg BID | 1 | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 1 | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 2 | 2 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 | 2 |
Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 8 | 8 |
| JNJ-70033093 100 mg + Placebo BID | 7 | 7 |
| JNJ-70033093 200 mg BID | 4 | 5 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 | 9 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 2 | 2 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 5 | 5 |
| JNJ-70033093 50 mg Once Daily + Placebo | 6 | 6 |
Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 1 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 | 0 |
| JNJ-70033093 200 mg BID | 0 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 0 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 | 0 |
Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 1 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 | 0 |
| JNJ-70033093 200 mg BID | 0 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 0 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 | 0 |
To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by number of participants with confirmed HA-VTE. (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 2 |
"The safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis will be measured by cumulative incidence (number of participants) of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following:~fatal bleeding;~clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period;~retroperitoneal, pulmonary, or central nervous system bleeding;~bleeding requiring surgical intervention in an operating suite;~bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition);~bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite." (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 0 |
The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4-hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (<12 and those >12 years of age). (NCT04354155)
Timeframe: 4 hours post initial dose
| Intervention | mg/kg (Median) | |
|---|---|---|
| Children 12 years or older | Children less than 12 years | |
| Thromboprophylaxis | 0.5 | 0.52 |
Bleeding events requiring alteration in the course of care within 90 days of surgery (NCT03251963)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fixed Dose Enoxaparin | 1 |
| Weight Tiered Enoxaparin | 3 |
Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery (NCT03251963)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fixed Dose Enoxaparin | 1 |
| Weight Tiered Enoxaparin | 0 |
Number of patients with in range initial peak Xa level (NCT03251963)
Timeframe: 36 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fixed Dose Enoxaparin | 27 |
| Weight Tiered Enoxaparin | 27 |
Comparing number of symptomatic VTE (data collected prior to unblinding) for the standard dose (Arm A) versus intermediate dose enoxaparin (Arm B). (NCT02706249)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| A: Standard Dose Enoxaparin | 0 |
| B: Weight Adjusted Enoxaparin | 0 |
Number of major hemorrhage in weight-adjusted enoxaparin arm and standard-dose enoxaparin arm (NCT02706249)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| A: Standard Dose Enoxaparin | 1 |
| B: Weight Adjusted Enoxaparin | 0 |
To investigate the numbers of VTE in hospitalized cancer patients receiving standard dose (NCT02706249)
Timeframe: 17 days only measured in Arm A (Standard dose enoxaparin)
| Intervention | participants (Number) |
|---|---|
| A: Standard Dose Enoxaparin | 2 |
Participants were monitored for up to 28 days. This was measured through self-report, patient diaries, and the return of all medication bottles/syringes. This was the number of participants that did not miss more than 2 days of study medication over 28 days (less than 4 pills or 2 injections missed). (NCT02366871)
Timeframe: Day 1 post-op/standard of care first dose of medication to Day 28 (+/- 4 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 173 |
| Subcutaneous Enoxaparin | 164 |
Participants were monitored for up to 90 days. This is the number of participants with bleeding events that did not meet the ISTH criteria but still required intervention. This is the number of participants who had at least one non-major bleeding event during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care first dose of medication to day 90 (+/- 14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 12 |
| Subcutaneous Enoxaparin | 19 |
The International Society on Thrombosis and Hemostasis criteria (ISTH) will be used to assess incidence of major bleeding. Participants were monitored for up to 90 days. This is the number of participants who have had at least one major bleeding incidence during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care first medication dose to day 90 (+/-14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 1 |
| Subcutaneous Enoxaparin | 1 |
Participants were monitored for up to 90 days. Both DVTs and PEs will be measured using the Wells criteria, ultrasound, and/or CT. This is the number of participants who had at least one DVT or PE during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care to day first dose of medication 90 (+/- 14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 2 |
| Subcutaneous Enoxaparin | 3 |
This was measured through a validated health survey (SF-8™) provided by a healthcare company (Optum®), which measured overall physical and mental well-being, with responses ranging from none to very, not at all to extremely, etc. Change was calculated as the difference at baseline versus 28 days post op. The score was 0-100 and a higher score was considered a better outcome. (NCT02366871)
Timeframe: At baseline, and visit 4, which is 28 days (+/- 4 days) post-op/standard of care
| Intervention | score on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| physical score-baseline | physical score-visit 4 | Physical change | mental score-baseline | mental score-visit 4 | Mental change | |
| Oral Apixaban | 50.7 | 39.2 | -5.9 | 50.7 | 50.7 | 0.8 |
| Subcutaneous Enoxaparin | 49.7 | 38.5 | -6.2 | 49.7 | 49.3 | 0.0 |
Participants were monitored at the 28 (+/- 4) day post-op visit. This was measured through administering a participant satisfaction questionnaire ranging from strongly agree to strongly disagree.This is the number of participants that completed the questionnaire in response to agreeing it was difficult to remember to take the medication, agreeing that there was pain associated with the medication, and agreeing that the medication was easy to use. (NCT02366871)
Timeframe: On visit 4, which is 28 days (+/- 4 days) post-op/standard of care
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Difficult remembering to take medication72102815 | Difficult remembering to take medication72102814 | Pain associated with taking the medication72102814 | Pain associated with taking the medication72102815 | Was medication easy to take72102814 | Was medication easy to take72102815 | |||||||||||||
| Agree | Neutral | Disagree | ||||||||||||||||
| Oral Apixaban | 23 | |||||||||||||||||
| Subcutaneous Enoxaparin | 23 | |||||||||||||||||
| Oral Apixaban | 16 | |||||||||||||||||
| Subcutaneous Enoxaparin | 15 | |||||||||||||||||
| Oral Apixaban | 149 | |||||||||||||||||
| Subcutaneous Enoxaparin | 149 | |||||||||||||||||
| Oral Apixaban | 4 | |||||||||||||||||
| Subcutaneous Enoxaparin | 92 | |||||||||||||||||
| Oral Apixaban | 10 | |||||||||||||||||
| Subcutaneous Enoxaparin | 25 | |||||||||||||||||
| Oral Apixaban | 173 | |||||||||||||||||
| Subcutaneous Enoxaparin | 70 | |||||||||||||||||
| Oral Apixaban | 186 | |||||||||||||||||
| Subcutaneous Enoxaparin | 110 | |||||||||||||||||
| Oral Apixaban | 2 | |||||||||||||||||
| Subcutaneous Enoxaparin | 21 | |||||||||||||||||
| Oral Apixaban | 0 | |||||||||||||||||
| Subcutaneous Enoxaparin | 56 | |||||||||||||||||
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.1 |
| Enoxaparin/VKA | 1.1 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.9 |
| Enoxaparin/VKA | 4.2 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.3 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.6 |
| Enoxaparin/VKA | 4.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.1 |
| Enoxaparin/VKA | 8.1 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.6 |
| Enoxaparin/VKA | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 1.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Enoxaparin/VKA | 0.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 3.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.2 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 5.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 3.0 | 1.1 | 1.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.4 | 1.0 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.07 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.8 | 0.6 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0 | 0.07 | 0 | 0.3 | 0.6 | 0.07 | 0.07 | 1.3 | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.3 | 0 | 1.0 | 1.6 | 0.3 | 0.2 | 2.0 | 1.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.06 | 0.2 | 0.06 | 1.2 | 0.8 | 0.06 | 0.1 | 1.8 | 0.9 |
symptomatic and asymptomatic intra and extracranial bleedings (NCT01573169)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 1 |
| Standard Therapy | 3 |
"modified Rankin Scale (mRS) equal to and greater than 3.~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead." (NCT01573169)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 27 |
| Standard Therapy | 30 |
mortality of any cause (NCT01573169)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 7 |
| Standard Therapy | 6 |
Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination (NCT01573169)
Timeframe: 10 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 6 |
| Standard Therapy | 7 |
Serum AT-III (% activity) will be compared between the control group and the intervention group patients (combined) after the third dose of enoxaparin 30 mg every 12 hours once initiated at the discretion of the trauma service per current VTE prophylaxis protocol (NCT02412982)
Timeframe: After third dose of enoxaparin 30mg q12h, which will typically be on Day 2 of enoxaparin
| Intervention | Percent AT-III activity (%) (Median) |
|---|---|
| Control Group | 87 |
| Intervention Group | 82 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.36 |
| Enoxaparin 40 mg | 2.12 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.22 |
| Enoxaparin 40 mg | 0.24 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.22 |
| Enoxaparin 40 mg | 0.24 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.40 |
| Enoxaparin 40 mg | 2.50 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 6.44 |
| Enoxaparin 40 mg | 6.50 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.71 |
| Enoxaparin 40 mg | 2.93 |
Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.00 |
| Enoxaparin 40 mg | 0.15 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.15 |
| Enoxaparin 40 mg | 0.49 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.15 |
| Enoxaparin 40 mg | 0.37 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 3.11 |
| Enoxaparin 40 mg | 3.46 |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day
| Intervention | Event rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 1.73 |
| Enoxaparin 40 mg | 1.61 |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 1.66 |
| Enoxaparin 40 mg | 1.51 |
Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 6.44 |
| Enoxaparin 40 mg | 6.63 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.06 |
| Enoxaparin 40 mg | 0.09 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of drug to last dose of drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 7.73 |
| Enoxaparin 40 mg | 6.81 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 7.16 |
| Enoxaparin 40 mg | 6.83 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%): (Number) |
|---|---|
| Apixaban 2.5 mg | 2.26 |
| Enoxaparin 40 mg | 1.90 |
VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.71 |
| Enoxaparin 40 mg | 3.06 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.67 |
| Enoxaparin 40 mg | 2.08 |
Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.47 |
| Enoxaparin 40 mg | 0.19 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.40 |
| Enoxaparin 40 mg | 0.80 |
Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) | |||
|---|---|---|---|---|
| MI or stoke (N=3183, 3216) | MI (N=3184, 3217) | Stroke (N=3183, 3216) | Thrombocytopenia (N=3184, 3217) | |
| Apixaban 2.5 mg | 0.38 | 0.22 | 0.16 | 0.19 |
| Enoxaparin 40 mg | 0.37 | 0.12 | 0.25 | 0.09 |
Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Day of Discharge from Hospital (N=1607, 1625) | Day 30 of Treatment + 2 (N=2227,2301) | |
| Apixaban 2.5 mg | -1.0 | 0.0 |
| Enoxaparin 40 mg | -0.4 | -0.5 |
Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | bpm (Mean) | |
|---|---|---|
| Hospital Discharge (N=1606,1622) | Day 30 of treatment (N=2225,2299) | |
| Apixaban 2.5 mg | -5.4 | -4.0 |
| Enoxaparin 40 mg | -5.1 | -4.3 |
Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Discharge from Hospital (N=1607, 1625) | Day 30 of Treatment + 2 (N=2227, 2301) | |
| Apixaban 2.5 mg | -3.0 | -2.3 |
| Enoxaparin 40 mg | -2.4 | -2.9 |
Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths. (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations Due to AE | Deaths | |
| Apixaban 2.5 mg | 1871 | 611 | 244 | 290 | 131 |
| Enoxaparin 40 mg | 1910 | 601 | 221 | 262 | 133 |
Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Neurologic AEs | Neurologic SAEs | Liver-related AEs | Liver-related SAEs | |
| Apixaban 2.5 mg | 45 | 5 | 127 | 9 |
| Enoxaparin 40 mg | 42 | 1 | 142 | 12 |
Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of >3*Upper Limit of Normal (ULN) for ALT and AST and elevation of >2*ULN for Bilirubin. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST Elevation >3*ULN (N=2831, 2863) | ALT Elevation >3*ULN (N=2827, 2861) | AST + ALT >3*ULN on same date (N= 2827, 2861) | TBili >2*ULN (N= 2853, 2884) | ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855) | ALT>3*ULN + TBili >2*ULN (N=2817, 2853) | |
| Apixaban 2.5 mg | 23 | 22 | 14 | 13 | 2 | 0 |
| Enoxaparin 40 mg | 28 | 32 | 13 | 14 | 2 | 2 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if PreRx < LLN then use < 0.75* PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if PreRx < LLN then use < 0.75*PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if PreRx < LLN then use < 0.95*PreRx or > ULN if PreRx > ULN then use > 1.05*PreRx or < LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Calcium < 0.8*LLN (N=2861, 2893) | Calcium > 1.2*ULN (N=2861, 2893) | Chloride < 0.9*LLN (N=2861, 2886) | Chloride > 1.1*ULN (N=2861, 2886) | Bicarbonate < 0.75*LLN (N=2831, 2855) | Bicarbonate > 1.25*ULN (N=2831, 2855) | Potassium < 0.9*LLN (N=2851, 2878) | Potassium > 1.1*ULN (N=2851, 2878) | Sodium < 0.95*LLN (N=2862, 2888) | Sodium > 1.05*ULN (N=2862, 2888) | |
| Apixaban 2.5 mg | 6 | 3 | 25 | 5 | 5 | 6 | 61 | 140 | 23 | 9 |
| Enoxaparin 40 mg | 8 | 3 | 25 | 1 | 6 | 4 | 58 | 137 | 25 | 6 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if PreRx < LLN then use 0.9* PreRx or > ULN if PreRx > ULN then use 1.1 *PreRx or
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Glucose Fasting <0.9*LLN (N=284,287) | Glucose Fasting > 1.5*ULN (N=284,287) | Total Protein < 0.9 *LLN (N=2864, 2890) | Total Protein > 1.1*ULN (N=2864, 2890) | Creatine kinase >5*ULN U/L(N=2856, 2888) | Uric acid > 1.5* ULN (N=2862, 2889) | |
| Apixaban 2.5 mg | 5 | 39 | 78 | 16 | 8 | 47 |
| Enoxaparin 40 mg | 3 | 30 | 51 | 8 | 10 | 44 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: >2 g/dL decrease compared to PreRx value or value <=8 g/dL; Hematocrit: <0.75*PreRx; Erythrocytes: <0.75*PreRx c/µL; Leukocytes: <0.75*LLN or > 1.25*ULN, if PreRx
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin >2 g/dL decrease (N=2835, 2871) | Hematocrit <0.75*PreRx (N=2688, 2722) | Platelet Count < 100*10^9 c/L (N=2761, 2799) | Erythrocytes <0.75*PreRx c/µL (N=2697, 2730) | Leukocytes <0.75*LLN (N= 2835, 2869) | Leukocytes > 1.25*ULN (N=2835, 2869) | Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24) | Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24) | Abs Monocytes > 2000/MM^3 (N= 19, 25) | |
| Apixaban 2.5 mg | 133 | 23 | 9 | 28 | 64 | 331 | 1 | 4 | 1 |
| Enoxaparin 40 mg | 98 | 17 | 7 | 16 | 55 | 283 | 1 | 2 | 0 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Alkaline phosphatase U/L > 2*ULN(N=2866, 2895) | ALT U/L > 3*ULN (N=2827, 2861) | AST U/L > 3*ULN (N=2831, 2863) | Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821) | Bilirubin Total mg/dL > 2*ULN (N=2853, 2884) | BUN mg/dL > 1.5*ULN (N=2864, 2891) | Creatinine mg/dL > 1.5*ULN (N=2862, 2892) | |
| Apixaban 2.5 mg | 35 | 23 | 24 | 123 | 17 | 194 | 150 |
| Enoxaparin 40 mg | 47 | 33 | 29 | 106 | 15 | 188 | 156 |
Bleeding events requiring alteration in the course of care within 90 days of surgery (NCT02411292)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin Metabolism | 3 |
Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery (NCT02411292)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low aFXa Level | 5 |
| In-Range or High aFXa Level | 0 |
This is the number of participants with VTE events as documented in the electronic health record. (NCT02402881)
Timeframe: 15 Months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Pre-Intervention | Post-Intervention | |
| Control | 14 | 17 |
| Intervention | 7 | 6 |
This is the percentage of venous thromboembolism (VTE) prophylaxis doses that were not administered for any reason as documented in the electronic health record by a nurse. (NCT02402881)
Timeframe: 15 Months
| Intervention | Percentage of nonadministration (Number) | |
|---|---|---|
| Pre-Intervention | Post-Intervention | |
| Control | 13.6 | 13.3 |
| Intervention | 9.1 | 5.6 |
This is the percentage of VTE prophylaxis doses that were not administered for any reason as documented in the electronic health record by a nurse (NCT02301793)
Timeframe: (Baseline); approximately 3 months later (Post-Education)
| Intervention | percentage of nonadministration (Number) | |
|---|---|---|
| Pre-Education | Post-Education | |
| Contemporary Education Format | 10.8 | 9.2 |
| Traditional Education Format | 14.5 | 13.5 |
Did the intervention decrease rates of patient refusal of VTE prophylaxis medication doses among hospitalized patients? (NCT02301793)
Timeframe: Baseline; approximately 3 months later (post education)
| Intervention | percentage of patient refused doses (Number) | |
|---|---|---|
| Pre-Education | Post-Education | |
| Contemporary Education Format | 5.6 | 5.1 |
| Traditional Education Format | 7.3 | 7.0 |
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0385 |
| Enoxaparin + Warfarin | 0.0800 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0322 |
| Enoxaparin + Warfarin | 0.0395 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0234 |
| Enoxaparin + Warfarin | 0.0292 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0280 |
| Enoxaparin + Warfarin | 0.0448 |
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0699 |
| Enoxaparin + Warfarin | 0.1261 |
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0226 |
| Enoxaparin + Warfarin | 0.0269 |
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0056 |
| Enoxaparin + Warfarin | 0.0182 |
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0430 |
| Enoxaparin + Warfarin | 0.0971 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1170 |
| Enoxaparin + Warfarin | 0.1878 |
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0084 |
| Enoxaparin + Warfarin | 0.0133 |
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0104 |
| Enoxaparin + Warfarin | 0.0095 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1502 |
| Enoxaparin + Warfarin | 0.2514 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0046 |
| Enoxaparin + Warfarin | 0.0061 |
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0157 |
| Enoxaparin + Warfarin | 0.0198 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0058 |
| Enoxaparin + Warfarin | 0.0087 |
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00643201)
Timeframe: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE or SAE | Discontinued Due to AE or SAE | Death | |
| Apixaban | 1795 | 417 | 415 | 162 | 37 |
| Enoxaparin + Warfarin | 1923 | 410 | 695 | 199 | 44 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Creatine Kinase High (N=2601, 2596) | Uric Acid High (N=2601, 2596) | Total Protein Low (N=2601, 2596) | Total Protein High (N=2601, 2596) | |
| Apixaban | 20 | 6 | 15 | 0 |
| Enoxaparin + Warfarin | 24 | 3 | 16 | 0 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bicarbonate Low (N=2600,2593) | Bicarbonate High (N=2600,2593) | Total Calcium Low (N=2601,2596) | Total Calcium High (N=2601,2596) | Chloride Low Total Calcium Low (N=2601,2596) | Chloride Low Total Calcium High (N=2601,2596) | Potassium Low (N=2601,2596) | Potassium High (N=2601,2596) | Sodium Low (N=2601,2596) | ||
| Apixaban | 44 | 17 | 3 | 12 | 5 | 0 | 26 | 19 | 10 | 4 |
| Enoxaparin + Warfarin | 31 | 11 | 10 | 11 | 3 | 1 | 22 | 22 | 6 | 4 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erthrocytes Low (N=2599, 2593) | Hematocrit Low (N=2588, 2587) | Hemoglobin Low (N=2599, 2593) | Platelet Count Low (N=2594, 2589) | Leukocytes Low (N=2528, 2519) | Leukocytes High (N=2528, 2519) | Absolute Basophils High (N=2594,2589) | Absolute Eosinophils High (N=2594,2589) | Absolute Lyphocytes Low (N=2594,2589) | Absolute Lyphocytes High (N=2594,2589) | Absolute Monocytes High (N=2594,2589) | Absolute Neutrophils Low (N=2594,2589) | |
| Apixaban | 23 | 26 | 96 | 23 | 41 | 26 | 1 | 84 | 94 | 4 | 1 | 9 |
| Enoxaparin + Warfarin | 17 | 20 | 101 | 13 | 41 | 15 | 2 | 79 | 76 | 3 | 2 | 20 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| BUN High (N=517, 523) | Creatinine High (N=2601, 2596) | ALT High (N=2601, 2598) | ALP High (N=2601, 2598) | AST High (N=2601, 2598) | Direct Bilirubin High (N=2601, 2593) | Total Bilirubin High (N=2601, 2597) | |
| Apixaban | 2 | 47 | 52 | 35 | 40 | 28 | 8 |
| Enoxaparin + Warfarin | 7 | 37 | 145 | 27 | 40 | 21 | 7 |
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Blood in Urine High (N=2289, 2273) | Glucose in Urine High (N=2289, 2273) | Leukocyte Esterase in Urine High (N=2289, 2273) | Protein in Urine High (N=2289, 2273) | RBC + WBC in Urine High (N=1685, 1719) | RBC in Urine High (N=1293, 1389) | WBC in Urine High (N=1354, 1361) | |
| Apixaban | 85 | 46 | 105 | 41 | 359 | 111 | 274 |
| Enoxaparin + Warfarin | 127 | 31 | 102 | 50 | 361 | 140 | 263 |
Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes. (NCT02829957)
Timeframe: 3 months
| Intervention | g/dl (Median) |
|---|---|
| Rivaroxaban | 12.8 |
| Apixaban | 13.25 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 1 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 4 |
| Apixaban | 2 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 1, 2, and 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
"Measure Description: A PBAC Score of < 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;~Towels~1 point for each lightly stained towel~5 points or each moderately soiled towel~20 points if the towel is completely saturated with blood~Tampons~1 point for each lightly stained tampon~5 points for each moderately soiled tampon~10 points if the tampon is completely saturated with blood~Clots~1 point for small clots~5 points for large clots" (NCT02829957)
Timeframe: 3 months
| Intervention | score on a scale (Median) |
|---|---|
| Rivaroxaban | 292 |
| Apixaban | 146 |
The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. (NCT02829957)
Timeframe: 3 months
| Intervention | Score (Median) |
|---|---|
| Rivaroxaban | 55.5 |
| Apixaban | 45.6 |
Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability. (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 10 |
| VKA-based Regimen | 3 |
"An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 2 |
"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 2 |
"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.~CV mortality was defined as cardiac or vascular death according to Academic Research Consortium." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 0 |
Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| ETNA-VTE | 100 |
Descriptive statistics were used to report the duration of edoxaban treatment. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Month 1 ongoing | Month 3 ongoing | Month 6 ongoing | Month 12 ongoing | Month 18 ongoing | Participants off edoxaban treatment at 18 months | |
| ETNA-VTE | 2527 | 2346 | 1842 | 1272 | 713 | 1910 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 11.0 | 9.5 | 0 | 15.0 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 18.0 | 44.5 | 8.0 | 16.0 |
Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Recurrent DVT only | Recurrent PE with DVT | Recurrent PE only | All-cause death | Cardiovascular-related death | Venous thromboembolism-related death | Stroke | Systemic embolic event | Hospitalization related to CV | |
| ETNA-VTE | 61 | 7 | 31 | 95 | 23 | 1 | 26 | 2 | 253 |
Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Haemorrhage | Gastrointestinal haemorrhage | Menorrhagia | Epistaxis | Fatigue | Nausea | Dizziness | Rash | Headache | Pruritus | |
| ETNA-VTE | 35 | 12 | 12 | 11 | 8 | 8 | 7 | 7 | 5 | 5 |
Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrent VTE | Recurrent DVT only | Recurrent PE with DVT | Recurrent PE only | All-cause death | CV-related death | VTE-related death | Stroke | Systemic embolic event | Hospitalization-related to cardiovascular | |
| ETNA-VTE | 37 | 27 | 1 | 9 | 50 | 11 | 1 | 15 | 1 | 167 |
Descriptive statistics were used to report the number of participants with bleeding events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with any bleeding events | At least 1 major bleeding event | Clinically relevant non-major bleeding event | Minor | Gastrointestinal bleeding event | Epidural or subdural haematoma bleeding event | Intra-ocular bleeding event | Intra-articular bleeding event | Pleural bleeding event | Other bleeding event | Spontaneous bleeding | Provoked bleeding | Unknown bleeding | |
| ETNA-VTE | 304 | 38 | 82 | 300 | 77 | 4 | 5 | 3 | 1 | 319 | 287 | 115 | 18 |
Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Stroke | Bleeding events | Systemic embolic events | Non-valvular atrial fibrillation | Malignancy | Others | |
| ETNA-VTE | 2 | 75 | 0 | 0 | 0 | 4 |
Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. (NCT02943993)
Timeframe: at Baseline
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Puerperium | Prolonged immobilisation | >5 days in bed | History of major surgery trauma | Known thrombophilic conditions | |
| ETNA-VTE | 9 | 401 | 218 | 359 | 111 |
Descriptive statistics were used to report the number of stroke events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | events (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall treatment: Total number of stroke events | Overall treatment: Ischemic events | Overall treatment: Haemorrhagic events | Overall treatment: Unknown events | On treatment: Total number of stroke events | On treatment: Ischemic events | On treatment: Haemorrhagic events | On treatment: Unknown events | |
| ETNA-VTE | 27 | 17 | 5 | 5 | 16 | 12 | 3 | 1 |
Descriptive statistics were used to report the number of systemic embolic events (SEE). (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Systemic embolic events (Number) | |
|---|---|---|
| Upper/lower extremity | Renal | |
| ETNA-VTE | 1 | 1 |
Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Death due to ADR | Participants with at least 1 ADR | Participants with at least 1 serious ADR | Study discontinuation due to ADR | |
| ETNA-VTE | 2 | 142 | 59 | 0 |
Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | VTE recurrences (Number) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 39 | 28 | 1 | 9 |
Descriptive statistics were used to describe the number of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | VTE recurrences (Number) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 105 | 64 | 7 | 32 |
All bleeding events included major bleeding defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells (RBCs), clinically relevant non-major bleeding defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug), nuisance bleeding, or a combination of bleeding events. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 25 |
| Standard of Care | 24 |
Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 3 |
| Standard of Care | 5 |
Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 8 |
| Standard of Care | 5 |
No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus at baseline and at Month 3. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 21 |
| Standard of Care | 29 |
No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 35 |
| Standard of Care | 47 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 5 |
| Standard of Care | 2 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 7 |
| Standard of Care | 2 |
All-cause mortality is defined as death due to any cause. Adjudicated data are reported for overall all-cause mortality, all-cause mortality by the primary cause of death, and primary cause of death further described by additional specifications. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Participants with adjudicated all-cause mortality | Venous thromboembolism (VTE)-related death | Venous thromboembolism (VTE)-related death: Unexplained death which VTE cannot be ruled out | Other known causes of death | Other known causes of death: Cancer | Other known causes of death: Infectious disease | Other known causes of death: Other | |
| Edoxaban | 2 | 1 | 1 | 1 | 0 | 0 | 1 |
| Standard of Care | 3 | 1 | 1 | 2 | 1 | 1 | 0 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Fatal PE | Non-fatal PE | Deep vein thrombosis (DVT) only | Fatal DVT | Non-fatal DVT | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 0 | 0 | 0 | 5 | 0 | 4 | 1 |
| Standard of Care | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Death as a result of VTE | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 1 | 1 |
| Standard of Care | 1 | 1 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Fatal PE | Non-fatal PE | Deep vein thrombosis (DVT) only | Fatal DVT | Non-fatal DVT | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 1 | 0 | 1 | 6 | 0 | 5 | 1 |
| Standard of Care | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Diagnosis of recurrent VTE requires the confirmation imaging and ≥1 symptom of VTE. Death from VTE is based on diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. No change or extension of thrombotic burden (quantitative diagnostic imaging) of the index qualifying VTE thrombus. Imaging criteria for VTE: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Symptomatic recurrent VTE | PE with or without DVT | DVT only | Death as a result of VTE | Unexplained death which VTE cannot be ruled out | No change or extension of thrombotic burden | |
| Edoxaban | 4 | 0 | 4 | 1 | 1 | 21 |
| Standard of Care | 1 | 1 | 0 | 1 | 1 | 29 |
Deep vein thrombosis was assessed by ultrasonography or magnetic resonance venography (MRV), catheter-related thrombosis was assessed by ultrasonography or echocardiography, sino-venous thrombosis was assessed by brain MRI, and pulmonary embolism was assessed by nuclear ventilation/perfusion (V/Q) scanning. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Main Treatment: Participants with DVT only | Main Treatment: Participants with catheter-related thrombosis | Main Treatment: Participants with cerebral sino-venous DVT thrombosis | Main Treatment: Participants with PE with or without DVT | Extension Treatment: Participants with DVT | Extension Treatment: Participants with catheter-related thrombosis | Extension Treatment: Participants with sino-venous DVT thrombosis | Extension Treatment: Participants with PE | Overall Treatment: Participants with DVT | Overall Treatment: Participants with catheter-related thrombosis | Overall Treatment: Participants with sino-venous DVT thrombosis | Overall Treatment: Participants with PE | |
| Edoxaban | 4 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 5 | 1 | 1 | 1 |
| Standard of Care | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Symptomatic VTE | Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Deep vein thrombosis (DVT) only | |
| Edoxaban | 4 | 0 | 4 |
| Standard of Care | 1 | 1 | 0 |
Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding) occurring during treatment plus 3 days after their last dose for that time period. (NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | participants with an event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 349 |
| Heparin/Warfarin | 423 |
"Symptomatic recurrent Venous Thromboembolism (VTE), i.e., the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE occurring during the Overall Study Period.~Overall Study Period defined as The time from the reference date (randomization date/initial dose of study drug date) to the last study follow-up visit." (NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | number or participants with an event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 130 |
| Heparin/Warfarin | 146 |
(NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | number of participants with event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 228 |
| Heparin/Warfarin | 228 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
(NCT01203098)
Timeframe: 2 weeks
| Intervention | percentage of subjects with bleeds (Number) |
|---|---|
| DU-176b 15 mg | 2.2 |
| DU-176b 30 mg | 1.2 |
| Enoxaparin Sodium 20mg (2000IU) | 2.3 |
"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity DVT confirmed by bilateral venography at the end of study treatment~Definite diagnosis of symptomatic PE~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE" (NCT01203098)
Timeframe: 2 weeks
| Intervention | percent of participants with VTE event (Number) |
|---|---|
| DU-176b 15 mg | 3.8 |
| DU-176b 30 mg | 2.8 |
| Enoxaparin Sodium 20mg (2000IU) | 4.1 |
An ultrasound duplex will be completed at least one time after randomization to determine if the subject has developed a DVT. (NCT00990236)
Timeframe: Through study completion, assessed up to 120 days post randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Exoxaparin 30 mg BID | 6 |
| Enoxaparin Dose Adjusted Based on TEG | 5 |
An increase in bleeding complications will be assessed daily during hospitalization (NCT00990236)
Timeframe: Through study completion, assessed up to 120 days post randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Exoxaparin 30 mg BID | 5 |
| Enoxaparin Dose Adjusted Based on TEG | 13 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.2 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.4 |
| Enoxaparin/VKA | 4.0 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.4 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin/VKA | 4.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 10.3 |
| Enoxaparin/VKA | 11.4 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Enoxaparin/VKA | 0.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Enoxaparin/VKA | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 3.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 2.1 | 0.8 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.6 | 1.2 | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.05 | 0 | 0.5 | 0.1 | 0.09 | 0.05 | 0.7 | 0.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.09 | 0 | 0.09 | 0.5 | 0.2 | 0.09 | 0.3 | 0.8 | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0.04 | 0.2 | 0.1 | 0.8 | 0.7 | 0.2 | 0.1 | 1.5 | 2.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.1 | 0.3 | 0.0 | 1.0 | 0.7 | 0.2 | 0.4 | 1.3 | 1.4 |
Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm (NCT04406389)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intermediate Dose Prophylaxis | 0 |
| Therapeutic Dose Anticoagulation | 2 |
Comparison of length of ICU stay in days between each treatment arm. (NCT04406389)
Timeframe: 6 months
| Intervention | Days (Median) |
|---|---|
| Intermediate Dose Prophylaxis | 25.5 |
| Therapeutic Dose Anticoagulation | 25 |
Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment arm (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | ||
|---|---|---|---|
| Venous Thromboembolism Events | Arterial Thrombosis Events | Microthrombosis Events | |
| Intermediate Dose Prophylaxis | 1 | 1 | 0 |
| Therapeutic Dose Anticoagulation | 0 | 0 | 1 |
Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria. (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | |
|---|---|---|
| Major Bleeding Events | Clinically Relevant Non-Major Bleeding Events | |
| Intermediate Dose Prophylaxis | 1 | 1 |
| Therapeutic Dose Anticoagulation | 1 | 2 |
Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied
| Intervention | cm/s (Mean) | |||
|---|---|---|---|---|
| Delta PVV from before to after Venaflow (Standing) | Delta PVV from before to after Venaflow (Supine) | delta PVV from before to after Activeca (Standing) | delta PVV from before to after Activecare (supine) | |
| 10 Healthy Patients Without THA | 127.9 | 87.1 | 32.6 | 40.5 |
| 10 Patients With THA on Post-Op Day 2 | 155.7 | 86.8 | 41.9 | 37.8 |
Primary endpoint - Incidence of ARN is the primary outcome of this study and this is based on a documentation of AKI (defined as an increase in baseline serum creatinine ≥ 0.3 mg/dL), in the absence of any other obvious etiology for the AKI identified after a standard clinical evaluation and work up by the patient's primary care physician, cardiologist or nephrologist. This incidence will be expressed as a percentage. (NCT02900170)
Timeframe: 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Participants | 0 |
Event rate was number of participants with all-cause death divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 0.19 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.19 |
An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.97 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.40 |
ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.25 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.00 |
ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.19 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.81 |
ICAC adjudicated cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 0.13 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.00 |
ICAC adjudicated VTE, acute clinically overt bleeding events, suspected thrombocytopenia, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 9.90 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 10.60 |
ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.13 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.97 |
ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. VTE includes DVT and PE. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.05 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.73 |
VTE / VTE-related death was defined as the combination of fatal or non-fatal PE, and symptomatic or asymptomatic DVT. A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 8.91 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 8.61 |
A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected proximal DVT and non-fatal PE, and all-cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.05 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.64 |
An Independent Central Adjudication Committee (ICAC) adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). Surgery=Day 1; Randomization/Treatment started on Day of Surgery or the next day (Day 1 or Day 2). A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. Intended Treatment Period=starts on the day of randomization; for treated participants, the period ends at the latter of 2 days after last dose of study drug or 14 days after the first dose of study drug; for randomized participants who were not treated, the period ends 14 days after randomization. (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 8.99 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 8.85 |
ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From first dose to last dose, plus 2 days (12 days, plus 2)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| MI/Stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban 2.5mg BID | 0.06 | 0.06 | 0.00 | 0.00 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.31 | 0.25 | 0.13 | 0.13 |
ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Follow up Period was from the end of the treatment period (last dose) up to 60 days post last dose, Day 72. (NCT00371683)
Timeframe: Last dose of study drug to Day 72 (60 days)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Major Bleeding (n=1563, 1553) | CR N-M Bleeding (n=1563, 1553) | Major or CR N-M Bleeding (n=1563, 1553) | Any Bleeding (n=1563, 1553) | |
| Apixaban 2.5mg BID | 0.13 | 0.26 | 0.38 | 0.90 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.13 | 0.45 | 0.58 | 1.29 |
ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Clinically relevant (CR); Non-Major (N-M) Bleeding. Day 1=Day of surgery. Treatment started (first dose) day of surgery or next day. Treatment continued for 12 days. (NCT00371683)
Timeframe: First dose of study drug to last dose, plus 2 days post last dose
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Major Bleeding (n=1596, 1588) | CR N-M Bleeding (n=1596, 1588) | Major or CR N-M Bleeding(n=1596, 1588) | Any Bleeding (n=1596, 1588) | |
| Apixaban 2.5mg BID | 0.69 | 2.19 | 2.88 | 5.33 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.39 | 2.96 | 4.28 | 6.80 |
An ICAC adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| PE (Fatal or Non-Fatal) (n=1599, 1596) | Non-Fatal PE (n=1599, 1596) | All DVT n=1142, 1122 | Symptomatic DVT (n=1599, 1596) | Asymptomatic DVT (n=1139,1115) | Symptomatic Proximal DVT (n=1599,1596) | Symptomatic Distal DVT (n=1599,1596) | |
| Apixaban 2.5mg BID | 1.00 | 0.88 | 7.79 | 0.19 | 7.55 | 0.13 | 0.06 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.44 | 0.44 | 8.20 | 0.44 | 7.62 | 0.19 | 0.38 |
ICAC adjudicated all venograms and suspected symptomatic DVT. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Proximal DVT (n=1254, 1207) | Distal DVT (n=1146, 1133) | Asymptomatic Proximal DVT (n=1252, 1204) | Asymptomatic Distal DVT (n=1145, 1127) | |
| Apixaban 2.5mg BID | 0.72 | 7.24 | 0.56 | 7.16 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.91 | 8.03 | 0.66 | 7.54 |
A 60-day follow-up period started after the last dose of study drug and continued until the End of Study Visit on Day 72 (60 days ± 3 days, after the last dose of study drug). Event rate was number of participants with the endpoint divided by the number of participants analyzed (%). ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per ISTH guidelines modified for surgical patients. (NCT00371683)
Timeframe: Post last dose of study drug to Day 72 (60 days)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| MI/Stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban 2.5mg BID | 0.06 | 0.06 | 0.00 | 0.00 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.06 | 0.06 | 0.00 | 0.00 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Heart rate was measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Heart rate was measured in beats per minute (bpm). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days
| Intervention | bpm (Mean) | ||||
|---|---|---|---|---|---|
| Heart Rate Day 1 (n=240,237) | Heart Rate Day 2 (n=1575,1574) | Heart Rate Day 3 (n=1490,1498) | Heart Rate Day 4 (n=127,134) | Heart Rate Day 12 (n=1495, 1462) | |
| Apixaban 2.5mg BID | 2.3 | 4.6 | 4.5 | 7.6 | -0.3 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 2.7 | 4.5 | 5.0 | 9.4 | -0.1 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Blood pressures (BP) were measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Systolic and diastolic pressures were measured in millimeters of mercury (mmHg). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days
| Intervention | mmHg (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diastolic BP Day 1 (n=240, 237) | Diastolic BP Day 2 (n=1577, 1574) | Diastolic BP Day 3 (n=1489,1498) | Diastolic BP Day 4 (n=127,134) | Diastolic BP Day 12 (n=1495,1463) | Systolic BP Day 1 (n=240,237) | Systolic BP Day 2 (n=1577,1574) | Systolic BP Day 3 (n=1489,1498) | Systolic BP Day 4 (n=127,134) | Systolic BP Day 12 (n=1495,1463) | |
| Apixaban 2.5mg BID | -0.4 | 1.7 | 2.3 | 0.6 | 7.3 | 1.5 | 5.4 | 4.7 | 2.8 | 9.1 |
| Enoxaparin 30 mg SC Injection q 12 Hours | -0.9 | 1.5 | 2.1 | 0.3 | 7.5 | -0.7 | 4.2 | 4.3 | 1.4 | 8.9 |
Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Potassium: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Calcium: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN If pre-dose > ULN then use > 1.25*predose or < LLN. Chloride: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Sodium: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*predose or >ULN if pre-dose > ULN then use > 1.05*predose or < LLN. Bicarbonate: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN if pre-dose > ULN then use > 1.25*predose or < LLN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Calcium low (n=1569,1562) | Calcium high (n=1569,1562) | Chloride low (n=1568,1562) | Chloride high (n=1568,1562) | Bicarbonate low (n=1568,1561) | Potassium low(n=1568,1559) | Potassium high(n=1568,1559) | Sodium low (n=1568,1562) | Sodium high (n=1568,1562) | |
| Apixaban 2.5mg BID | 1 | 0 | 11 | 0 | 11 | 54 | 26 | 23 | 2 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 5 | 1 | 17 | 1 | 13 | 56 | 20 | 39 | 0 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Hematology profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 2, 3, 4, 12 (end of treatment). Upper limit of normal (ULN); lower limit of normal (LLN). Platelet Count low: < 100,000/mm^3 (or < 100*109 cells/L). Erythrocytes low: < 0.75 *pre-dose. Hemoglobin low: > 2 g/dL decrease compared to pre-dose or Value ≤ 8 g/dL. Hematocrit low: < 0.75*pre-dose . Leukocytes: < 0.75*LLN or > 1.25* ULN, or if pre-dose < LLN then use < 0.8*predose or > ULN if pre-dose > ULN then use > 1.2*predose or < LLN. Lymphocytes (absolute): < 0.750*10^3 cells/µL or > 7.50*10^3 cells/ µL. Eosinophils (absolute) high: > 0.750*10^3 cells/µL. Basophils(absolute) high: > 400/mm^3 (or > 0.4*103 cells/µL). Monocytes (absolute) high: > 2000/mm^3 (or > 2*103 cells/µL). Neutrophils(absolute) high: < 1.0*103 cells/µL. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin low (n=1561,1549) | Hematocrit low (n=1558,1547) | Platelet count low (n=1556,1543) | Erythrocytes low (n=1557,1547) | Leukocytes low(n=1583,1572) | Leukocytes high(n=1583,1572) | Basophils high (n=1577, 1564) | Eosinophils high (n=1577, 1564) | Lymphocytes low (n=1577,1564) | Lymphocytes high (n=1577,1564) | Monocytes high (n=1577,1564) | Neutrophils low (n=1577,1564) | |
| Apixaban 2.5mg BID | 386 | 135 | 6 | 130 | 8 | 214 | 0 | 32 | 125 | 2 | 4 | 4 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 392 | 157 | 9 | 149 | 11 | 210 | 2 | 13 | 117 | 4 | 4 | 5 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Bilirubin (direct) high: > 1.5*ULN. Total bilirubin: : > 2*ULN, Alanine Aminotransferase (ALT) high: > 3*ULN. Alkaline Phosphatase (ALP): > 2*ULN. Aspartate Aminotransferase (AST): > 3*ULN. Creatinine: > 1.5*ULN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| ALP high (n=1573,1563) | ALT high (n=1573,1562) | AST high (n=1573,1562) | Bilirubin direct high (n=1563,1553) | Bilirubin total high(n=1572,1562) | Creatinine high (n=1569,1562) | |
| Apixaban 2.5mg BID | 42 | 33 | 29 | 63 | 2 | 17 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 55 | 45 | 40 | 54 | 8 | 28 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Fasting Glucose: if pre-dose < LLN then use < 0.8*predose; or > ULN if pre-dose > ULN then use > 2.0*predose or
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Fasting Glucose low (n=611, 579) | Fasting Glucose high (n=611, 579) | Total Protein low (n=1568,1562) | CK high (n=1573,1563) | Uric Acid high (n=1567,1562) | |
| Apixaban 2.5mg BID | 8 | 54 | 527 | 52 | 22 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 5 | 28 | 513 | 45 | 12 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00371683)
Timeframe: First dose to last dose, plus 2 days for AEs (12 + 2 days) or plus 30 days for SAEs (12 + 30 days)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| SAE | Bleeding AE | AEs leading to discontinuation | Deaths | |
| Apixaban 2.5mg BID | 123 | 110 | 60 | 3 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 123 | 144 | 58 | 5 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID + Placebo | 1.09 |
| Enoxaparin, 40 mg QD + Placebo | 2.17 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID | 15.06 |
| Enoxaparin, 40 mg QD | 24.37 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs. (NCT00452530)
Timeframe: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| SAE | Bleeding AE | Discontinuations due to AEs | Deaths | |
| Apixaban, 2.5 mg BID + Placebo | 72 | 90 | 40 | 2 |
| Enoxaparin, 40 mg QD + Placebo | 88 | 112 | 44 | 0 |
Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment. (NCT00452530)
Timeframe: Days 1 to 12
| Intervention | Percentage of events/patients evaluated (Number) | |||
|---|---|---|---|---|
| Major bleeding (n=9, 14) | CRNM (n=44, 58) | Major bleeding or CRNM (n=53, 72) | Any bleeding | |
| Apixaban, 2.5 mg BID + Placebo | 0.60 | 2.93 | 3.53 | 6.93 |
| Enoxaparin, 40 mg QD + Placebo | 0.93 | 3.85 | 4.77 | 8.36 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): <0.8*LLN or >1.2*ULN, or if preRx
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium, total (low) (n=1447, 1457) | Chloride, serum (low)(n=1442, 1454) | Bicarbonate (low) (n=1435, 1447) | Potassium, serum (low) (n=1438, 1453) | Potassium, serum (high)(n=1438, 1453) | Sodium, serum (low) (n=1442, 1454) | Sodium, serum (high) (n=1442, 1454) | Glucose, fasting serum (low) (n=715, 713) | Glucose, fasting serum (high) (n=715, 713) | Protein, total (low) (n=1447, 1457 | Creatine kinase (CK) (high) (n=1463, 1476) | Uric acid (high) (n=1446, 1458) | |
| Apixaban, 2.5 mg BID + Placebo | 5 | 1 | 0 | 38 | 34 | 5 | 1 | 8 | 46 | 223 | 66 | 1 |
| Enoxaparin, 40 mg QD + Placebo | 9 | 0 | 3 | 41 | 40 | 10 | 0 | 1 | 25 | 243 | 65 | 2 |
preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4. (NCT00452530)
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Blood, urine (high) (n=1421, 1430) | Glucose, urine (high) (n=1421, 1429) | Protein, urine (high) (n=1421, 1430) | Red blood cells, urine (high) (n=441, 385) | White blood cells, urine (high)(n=441, 386) | |
| Apixaban, 2.5 mg BID + Placebo | 169 | 160 | 60 | 133 | 101 |
| Enoxaparin, 40 mg QD + Placebo | 113 | 154 | 89 | 116 | 102 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): >2 decrease from preRx value or value <=8; hematocrit (%): <0.75*preRx; platelets: <100*10^9 cells/L; erythrocytes (*10^6 cells/μL): <0.75*preRx; leukocytes: <0.75*LLN or >1.25*ULN, or if preRx
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
| Intervention | Participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1424, 1442) | Hematocrit, low n=(1369, 1396) | Platelet count, low (n=1413, 1425) | Erythrocytes, low (n=1368, 1396) | Leukocytes, low (n=1457, 1471) | Leukocytes, high (n=1457, 1471) | Basophils (absolute), high (n=1448, 1465) | Eosinophils (absolute), high (n=1448, 1465) | Lymphocytes (absolute), low (n=1448, 1465) | Lymphocytes (absolute), high (n=1448, 1465) | Monocytes (absolute), high (n=1448, 1465) | Neutrophils (absolute), low (n=1448, 1465) | Alkaline phosphatase (ALP), high (n=1465, 1476) | Alanine aminotransferase (ALT), high (n=1459,1472) | Aspartate aminotransferase (AST) , high (n=1459,14 | Bilirubin, direct (high) (n=1447,1457) | Bilirubin, total (high) (n=1461,1476) | Blood urea nitrogen (BUN) (high)(n=1447,1458) | Creatinine (high) (n=1447,1458) | |
| Apixaban, 2.5 mg BID + Placebo | 1127 | 668 | 7 | 690 | 27 | 193 | 2 | 43 | 203 | 1 | 5 | 5 | 15 | 32 | 34 | 87 | 15 | 15 | 17 |
| Enoxaparin, 40 mg QD + Placebo | 1178 | 723 | 5 | 735 | 26 | 213 | 4 | 60 | 215 | 0 | 2 | 2 | 31 | 26 | 26 | 76 | 9 | 17 | 23 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 |
| Placebo | 0.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.0 |
| Placebo | 0.2 |
Events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral CT scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.0 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound or venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Placebo | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Placebo | 5.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 2.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. For definition of DVT/PE, kindly refer to the link in the Protocol section. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), or lung scintigraphy (for PE), and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Placebo | 7.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. Treatment-emergent events and all events post randomization were reported. Treatment-emergent: after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.2 | 0.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 |
All events adjudicated/confirmed by CIAC blinded to treatment. Clinically relevant bleeding included major bleeding (definition: see outcome 7) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of daily life activities. Treatment-emergent events (after intake of 1st study medication tablet as randomized up to 2 days after stop of study medication ['time window: 2 days']) and all events post randomization were reported (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 1.2 | 1.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.0 | 6.0 |
All events were adjudicated and confirmed by a central independent adjudication committee (CIAC) blinded to treatment. Major bleeding event was overt bleeding associated with a 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Treatment-emergent [after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days)] events and all events post randomization were reported. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.0 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.7 |
All pre-defined vascular events (acute coronary syndromes, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism and vascular death) were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on results/films/images of confirmatory testing, and/or case summaries. On treatment events and all events post randomization were reported. On treatment: after intake of first tablet of study medication as randomized but not more than 1 day after stop of study medication (referred to as time window: 1 day) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| On treatment (time window: 1 day) | All post-randomization | |
| Placebo | 0.7 | 0.7 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.5 | 0.8 |
Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID Plus Placebo | 0.45 |
| Enoxaparin, 40 mg QD Plus Placebo | 1.14 |
Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID Plus Placebo | 1.39 |
| Enoxaparin, 40 mg QD Plus Placebo | 3.86 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Postprocedural hematoma | Operative hemorrhage | Incision site hematoma | Incision site hemorrhage | Postprocedural hemorrhagic | Hematuria traumatic | Periorbital hematoma | Subcutaneous hematoma | Traumatic hematoma | Hematoma | Wound hemorrhage | Hemorrhage | Hematuria | Hemorrhage urinary tract | Urethral hemorrhage | Epistaxis | Hemoptysis | |
| Apixaban, 2.5 mg BID Plus Placebo | 20 | 19 | 14 | 13 | 4 | 1 | 1 | 1 | 0 | 34 | 18 | 13 | 41 | 1 | 0 | 33 | 3 |
| Enoxaparin, 40 mg QD Plus Placebo | 23 | 14 | 10 | 19 | 7 | 1 | 0 | 0 | 1 | 38 | 15 | 13 | 39 | 1 | 2 | 25 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic anemia | Ecchymosis | Petechiae | Hemorrhage subcutaneous | Increased tendency to bruise | Vaginal hemorrhage | Menorrhagia | Uterine hemorrhage | Conjunctival hemorrhage | Hematoma infection | Spinal hematoma | |
| Apixiban, 2.5 mg BID Plus Placebo | 20 | 5 | 2 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 15 | 9 | 2 | 0 | 5 | 0 | 0 | 1 | 0 | 0 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bloody discharge | Catheter site hemorrhage | Injection site hemorrhage | Injection site hematoma | Infusion site hematoma | Vessel puncture site hematoma | Hematocrit decreased | Red blood cell count decreased | Blood urine present | Blood urine | Occult blood positive | Fibrin D dimer increased | Hematochezia | Mallory-Weiss Syndrome | Hematemesis | Melaena | Rectal hemorrhage | Gingival bleeding | Anal hemorrhage | Diarrhea hemorrhagic | Diverticulum intestinal hemorrhagic | Gastrointestinal hemorrhage | Intra-abdominal hematoma | Duodenal ulcer hemorrhage | Hemorrhoidal hemorrhage | Mouth hemorrhage | |
| Apixaban, 2.5 mg BID Plus Placebo | 16 | 6 | 4 | 3 | 1 | 1 | 18 | 14 | 8 | 1 | 1 | 0 | 6 | 4 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 13 | 5 | 10 | 28 | 0 | 0 | 21 | 20 | 6 | 1 | 0 | 1 | 2 | 0 | 2 | 1 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
Treatment guidelines were provided for jaundice and elevated results of liver function tests. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspartate aminotransferase increased | Alanine aminotransferase increased | Gamma-glutamyltransferase increased | Blood bilirubin increased | Bilirubin conjugated increased | Hepatic enzyme increased | Liver function test results abnormal | Transaminases increased | Cholelithiasis | Hepatitis toxic | Cholecystitis acute | Cholestasis | Hyperbilirubinemia | Postcholecystectomy syndrome | Cholecystitis | Hepatic pain | Hepatitis | Hepatomegaly | Jaundice cholestatic | Hypoalbuminemia | Hypoproteinemia | Yellow skin | |
| Apixaban, 2.5 mg BID Plus Placebo | 48 | 40 | 27 | 17 | 11 | 9 | 4 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 67 | 61 | 54 | 7 | 12 | 16 | 9 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: >2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): <0.75*preRx; platelet count (*10^9 cells/L): <100,000/mm^3; erythrocytes (*10^6 cells/μL): <0.75*preRx level; leukocytes (*10^3 cells/μL): < 0.75*LLN or >1.25*ULN, or if preRx LLN use < 0.8*preRx or >ULN if preRx >ULN use >1.2*preRx or
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=2605, 2587) | Hematocrit, low (n=2554, 2536) | Platelet count, low (n=2597, 2576) | Erythrocytes, low (n=2558, 2540) | Leukocytes, low (n=2632, 2617) | Leukocytes, high (n=2632, 2617) | Basophils (absolute), high (n=2629, 2613) | Eosinophils (absolute), high (n=2629, 2613) | Lymphocytes (absolute), low (n=2629, 2613) | Lymphocytes (absolute), high (n=2629, 2613) | Monocytes (absolute), high (n=2629, 2613) | Neutrophils (absolute), low (n=2629, 2613) | |
| Apixaban, 2.5 mg BID Plus Placebo | 2189 | 1274 | 6 | 1310 | 54 | 385 | 1 | 75 | 383 | 3 | 9 | 5 |
| Enoxaparin, 40 mg QD Plus Placebo | 2218 | 1350 | 9 | 1377 | 54 | 360 | 3 | 70 | 382 | 3 | 11 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): >3 *ULN: alkaline phosphatase (ALP) (U/L): >2* ULN; aspartate aminotransferase (ASP) (U/L): >3 *ULN; bilirubin, direct (mg/dL): >2*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN; calcium (mg/dL): < 0.8*LLN or >1.2 *ULN, or if preRx
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, high (n=2631, 2618) | Alanine aminotransferase, high (n=2629, 2616) | Aspartate aminotransferase, high (n=2629, 2616) | Bilirubin, direct, high (n=2622, 2604) | Bilirubin, total, high (n=2630, 2617) | Blood urea nitrogen (BUN), high (n=2618, 2598) | Creatinine, high (n=2618, 2598) | Calcium, total, low (n=2618, 2598) | Calcium, total, high (n=2618, 2598) | Chloride, serum, low (n=2615, 2594) | Bicarbonate, low (n=2615, 2595) | Potassium, serum, low (n=2614, 2594) | Potassium, serum, high (n=2614, 2594) | Sodium, serum, low (n=2615, 2594) | Sodium, serum, high (n=2615, 2594) | |
| Apixaban, 2.5 mg BID Plus Placebo | 55 | 50 | 73 | 145 | 24 | 19 | 21 | 7 | 0 | 6 | 8 | 73 | 61 | 29 | 5 |
| Enoxaparin, 40 mg QD Plus Placebo | 57 | 83 | 73 | 139 | 12 | 17 | 25 | 18 | 1 | 6 | 8 | 73 | 47 | 23 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): <.8*LLN or >1.5*ULN, or if preRx
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, fasting serum, high (n=14, 17) | Protein, total, low (n=2618, 2596) | Protein, total, high (n=2618, 2596) | Creatine kinase, high (n=2630, 2616) | Uric acid, high (n=2618, 2597) | Blood, urine, high (n=2588, 2568) | Glucose, urine, high (n=2588, 2568) | Leukocyte esterase, urine, high (n=21, 41) | Protein, urine (n=2588, 2568) | Red blood cells (RBC), urine, high (n=1310, 1230) | White blood cells (WBC),urine, high (n=1311, 1228) | |
| Apixaban, 2.5 mg BID Plus Placebo | 0 | 747 | 3 | 615 | 2 | 275 | 68 | 0 | 169 | 216 | 217 |
| Enoxaparin, 40 mg QD Plus Placebo | 1 | 752 | 1 | 642 | 3 | 234 | 76 | 4 | 168 | 173 | 229 |
Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paraesthesia | Hypoaesthesia | Burning sensation | Peroneal nerve palsy | Hypotonia | Dysarthria | Paresis | Cervicobrachial syndrome | Coordination abnormal | Hypertonia | Neuropathy peripheral | Peripheral nerve lesion | Radiculitis | Paralysis | Muscular weakness | Nerve injury | Femoral nerve injury | Sciatic nerve injury | Peroneal nerve injury | Diplopia | Gait disturbance | |
| Apixaban, 2.5 mg BID Plus Placebo | 32 | 29 | 7 | 5 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | 2 | 1 | 1 | 0 | 1 | 1 |
| Enoxaparin, 40 mg QD Plus Placebo | 19 | 35 | 5 | 6 | 4 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 11 | 1 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug
| Intervention | Participants (Number) | ||
|---|---|---|---|
| SAEs | Bleeding AEs | Death | |
| Apixaban, 2.5 mg BID Plus Placebo | 18 | 15 | 2 |
| Enoxaparin, 40 mg QD Plus Placebo | 18 | 21 | 0 |
Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Percentage of events/patients evaluted (Number) | |||
|---|---|---|---|---|
| Major bleeding | CRNM | Major or CRNM | Any bleeding | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.82 | 4.08 | 4.83 | 11.71 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.68 | 4.51 | 5.04 | 12.56 |
VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All-cause death | VTE-related death | PE (fatal or nonfatal) | Nonfatal PE | All DVT (n=1944, 1911) | Symptomatic DVT | Asymptomatic DVT (n=1943, 1907) | Proximal DVT (n=2196, 2190) | Distal DVT (1951, 1908) | Symptomatic proximal DVT | Asymptomatic proximal DVT (n=2195, 2187) | Symptomatic distal DVT | Asymptomatic distal DVT (n=1950, 1907) | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.11 | 0.04 | 0.11 | 0.07 | 1.13 | 0.04 | 1.08 | 0.32 | 1.03 | 0.04 | 0.27 | 0.04 | 0.97 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.04 | 0.00 | 0.19 | 0.19 | 3.56 | 0.19 | 3.30 | 0.91 | 2.99 | 0.15 | 0.73 | 0.04 | 2.94 |
Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to <100,000/mm^3 for patients with a baseline value >150,000/mm^3 or a >50% decline, if the baseline value was ≤150,000/mm^3. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percent of events/patients evaluated (Number) | |||
|---|---|---|---|---|
| MI/stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.22 | 0.19 | 0.04 | 0.07 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.26 | 0.11 | 0.15 | 0.11 |
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 18 |
| Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 17 |
| Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 60 |
| Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 61 |
| Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 404.9 |
| Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Transfusions required | Missing | |
| Dabigatran 220mg | 246 | 4 |
| Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
| Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
| Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
| Dabigatran 220mg | 14 | 37 | 98 |
| Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
| Enoxaparin | 4 | 1 | 0 | 2 | 1 |
All cause death, as adjudicated by the VTE events committee (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 13 |
| Dabigatran 150mg | 20 |
| Enoxaparin | 18 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 13 |
| Dabigatran 150mg | 18 |
| Enoxaparin | 17 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 1 |
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Dabigatran 150mg | 3 |
| Enoxaparin | 8 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 182 |
| Dabigatran 150mg | 211 |
| Enoxaparin | 192 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 183 |
| Dabigatran 150mg | 213 |
| Enoxaparin | 193 |
Volume of blood loss for treated and operated patients during surgery. (NCT00168805)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 187 |
| Dabigatran 150mg | 190 |
| Enoxaparin | 191 |
Blood transfusion for treated and operated patients on Day of surgery. (NCT00168805)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Patients with >=1 transfusions | Patients with >=1 non-autologous transfusions | |
| Dabigatran 150mg | 253 | 86 |
| Dabigatran 220mg | 242 | 87 |
| Enoxaparin | 265 | 120 |
Frequency of patients with possible clinically significant abnormalities. (NCT00168805)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(620;645;636) | AST decrease N=(620;645;636) | ALT increase N=(621;645;637) | ALT decrease N=(621;645;637) | Bilirubin increase N=(619;644;635) | Bilirubin decrease N=(619;644;635) | |
| Dabigatran 150mg | 6 | 0 | 21 | 0 | 23 | 0 |
| Dabigatran 220mg | 9 | 0 | 16 | 0 | 19 | 0 |
| Enoxaparin | 9 | 0 | 24 | 0 | 14 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168805)
Timeframe: First administration until 6-10 days
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major | Clinically relevant | Minor | None | |
| Dabigatran 150mg | 9 | 48 | 59 | 587 |
| Dabigatran 220mg | 10 | 40 | 60 | 569 |
| Enoxaparin | 9 | 37 | 69 | 579 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168805)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptotic Deep Vein Thrombosis | symptotic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 150mg | 3 | 1 | 2 | 0 | 0 |
| Dabigatran 220mg | 4 | 0 | 1 | 2 | 1 |
| Enoxaparin | 2 | 0 | 0 | 0 | 2 |
All cause death, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 3 |
| Dabigatran 150mg | 3 |
| Enoxaparin | 0 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 28 |
| Dabigatran 150mg | 38 |
| Enoxaparin | 36 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 23 |
| Dabigatran 150mg | 35 |
| Enoxaparin | 33 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 5 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 3 |
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 6 |
| Dabigatran 150mg | 9 |
| Enoxaparin | 1 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 46 |
| Dabigatran 150mg | 72 |
| Enoxaparin | 57 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 53 |
| Dabigatran 150mg | 75 |
| Enoxaparin | 60 |
Volume of blood loss for treated and operated patients during surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 457 |
| Dabigatran 150mg | 435 |
| Enoxaparin | 463 |
Blood transfusion for treated and operated patients on Day of surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Patients with >=1 transfusions | Patients with >=1 non-autologous transfusions | |
| Dabigatran 150mg | 531 | 266 |
| Dabigatran 220mg | 517 | 259 |
| Enoxaparin | 542 | 286 |
Frequency of patients with possible clinically significant abnormalities. (NCT00168818)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(1103;1097;1103) | AST decrease N=(1103;1097;1103) | ALT increase N=(1103;1098;1103) | ALT decrease N=(1103;1098;1103) | Bilirubin increase N=(1102;1094;1102) | Bilirubin decrease N=(1102;1094;1102) | |
| Dabigatran 150mg | 16 | 0 | 29 | 0 | 24 | 0 |
| Dabigatran 220mg | 11 | 0 | 28 | 0 | 25 | 0 |
| Enoxaparin | 29 | 0 | 59 | 0 | 34 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major | Clinical relevant | Minor | None | |
| Dabigatran 150mg | 15 | 55 | 72 | 1021 |
| Dabigatran 220mg | 23 | 48 | 70 | 1005 |
| Enoxaparin | 18 | 40 | 74 | 1022 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168818)
Timeframe: end of treatment to day 91±7
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptotic Deep Vein Thrombosis | symptotic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 150mg | 4 | 1 | 1 | 0 | 2 |
| Dabigatran 220mg | 1 | 0 | 1 | 0 | 0 |
| Enoxaparin | 5 | 3 | 0 | 1 | 1 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data for day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase
| Intervention | IU/kg (Mean) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 207.50 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 141.85 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 132.40 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 115.06 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 international unit per milliliter (IU/mL). Cumulative data of Day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase
| Intervention | IU/mL (Median) |
|---|---|
| Dalteparin Sodium: All Participants (>= 0 to < 19 Years) | 125 |
During dose adjustment phase, doses were adjusted according to prespecified therapeutic anti-Xa levels in order to achieve target prespecified therapeutic anti-factor Xa levels (0.5 to 1.0 IU/mL). Number of dose adjustments which were done within the specified time window of up to 4 hours post dose on all days (1 to 7) to achieve the prespecified therapeutic anti-Xa levels are reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase
| Intervention | dose adjustment (Median) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 3.5 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0.5 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0.0 |
Criteria:hematology:hemoglobin, hematocrit, erythrocytes less than(<)0.8*lower limit of normal(LLN), platelets <0.5*LLN >1.75*upper limit of normal (ULN),leukocytes <0.6* LLN >1.5* ULN, lymphocytes, lymphocytes/Leukocytes, neutrophils, neutrophils/leukocytes <0.8* LLN >1.2* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes >1.2*ULN, activated partial thromboplastin time, prothrombin time, prothrombin international normalized ratio >1.1* ULN. Clinical chemistry: bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase >3.0*ULN, protein, albumin <0.8* LLN >1.2* ULN, blood urea nitrogen, creatinine >1.3* ULN, sodium <0.95*LLN >1.05*ULN, potassium, chloride, calcium, magnesium <0.9* LLN >1.1* ULN, phosphate <0.8* LLN >1.2* ULN, glucose <0.6*LLN >1.5*ULN, estimated(est) creatinine clearance, est GFR modified and bedside schwartz, >1.0* ULN. Urinalysis: creatinine >1.0*ULN. (NCT00952380)
Timeframe: Baseline up to 104 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 1 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 2 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 8 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 5 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 19 |
Symptomatic VTE defined as new or progressive signs and symptoms as judged by the investigator including but not limited to: objective swelling, pain or tenderness, pitting edema, erythema or cyanosis. Progression of VTE: Progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 1 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Percentage of participants who achieved the prespecified level during the dose adjustment phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase
| Intervention | percentage of participants (Number) |
|---|---|
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 0 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 100.0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 100.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 100.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 85.0 |
Time to achieve the target range (prespecified therapeutic anti- factor Xa levels) was defined as the number of days from the first dose of study drug to the final dose that achieves the target anti-factor Xa level. Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data of Day 1 to 7 is reported. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase
| Intervention | days (Median) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 4.5 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 3.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 2.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 2.0 |
Time to first occurrence of major bleeding event was defined as the time interval (in days) between date of first study treatment and date of documentation of first major bleeding event. A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter, overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration, bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal or intraspinal). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | days (Median) |
|---|---|
| Dalteparin Sodium: All Participants (>= 0 to < 19 Years) | NA |
It was defined as the time interval (in days) between date of first study treatment and date of documentation of first VTE. VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot breaks, loose and travels in the blood, this is called VTE. VTE was confirmed by at least one radiographic test and was defined as any new or progressive VTE whose signs and symptoms (identified by the investigator) included: objective swelling or tenderness, pitting edema, erythema or cyanosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | days (Median) |
|---|---|
| Dalteparin Sodium: All Participants (>= 0 to < 19 Years) | NA |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeter (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 100 | 104.75 | 100 | 103 | 97.75 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeter (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 54 | 54 | 56 | 60 | 63 | 64 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 55 | 55 | 55.30 | 56.60 | 60 | 61 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 172 | 135 | 135 | 135 | 135 | 151.75 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | degree celsius (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 36.60 | 36.70 | 36.90 | 36.50 | 36.60 | 36.70 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 36.70 | 36.85 | 36.40 | 36.50 | 36.70 | 37.15 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 36.50 | 36.80 | 36.70 | 36.60 | 36.80 | 36.75 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 37.00 | 36.70 | 36.70 | 36.50 | 36.60 | 36.90 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 36.80 | 36.80 | 36.70 | 36.70 | 36.60 | 36.80 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR: Baseline | HR: Day 1 | HR: Day 2 | HR: Day 30 | HR: Day 60 | HR: Day 90 | PR: Baseline | PR: Day 1 | PR: Day 2 | PR: Day 30 | PR: Day 60 | PR: Day 90 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 115.00 | 112.00 | 114.00 | 120.50 | 120.00 | 107.00 | 96.50 | 121.00 | 117.00 | 88.00 | 88.00 | 114.00 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 70.00 | 85.00 | 75.00 | 87.50 | 94.50 | 80.00 | 73.00 | 94.50 | 93.00 | 102.00 | 95.00 | 92.00 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||
|---|---|---|---|---|---|---|
| HR: Baseline | HR: Day 1 | HR: Day 2 | HR: Day 30 | HR: Day 60 | HR: Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 148.00 | 146.00 | 136.00 | 138.00 | 132.00 | 122.00 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||
|---|---|---|---|---|---|---|
| PR: Baseline | PR: Day 1 | PR: Day 2 | PR: Day 30 | PR: Day 60 | PR: Day 90 | |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 114.00 | 87.00 | 98.00 | 101.00 | 93.00 | 96.00 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| HR: Baseline | HR: Day 1 | HR: Day 2 | HR: Day 30 | HR: Day 60 | HR: Day 90 | PR: Day 1 | PR: Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 146.00 | 142.00 | 130.00 | 130.00 | 184.00 | 134.00 | 108.00 | 140.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeters (cm) (Median) | |||
|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 55.00 | 56.60 | 60.00 | 61.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeters (cm) (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 54.00 | 54.00 | 60.00 | 63.00 | 64.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeters (cm) (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 110.00 | 115.80 | 107.90 | 115.10 | 115.00 | 109.50 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 133.00 | 134.00 | 142.00 | 140.30 | 139.70 | 140.70 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 166.00 | 166.00 | 166.90 | 167.75 | 168.50 | 166.65 |
Respiratory rate was defined as the number of breaths per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | breaths per minute (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 35.00 | 34.00 | 34.00 | 34.00 | 30.00 | 24.00 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 25.00 | 36.00 | 34.00 | 36.00 | 36.00 | 34.00 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 24.00 | 21.00 | 20.00 | 22.00 | 20.00 | 22.00 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 20.00 | 18.00 | 20.00 | 22.00 | 20.00 | 20.00 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 20.00 | 18.00 | 18.00 | 18.00 | 20.00 | 18.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | millimeters of mercury (mmHg) (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP: Baseline | SBP: Day 1 | SBP: Day 2 | SBP: Day 30 | SBP: Day 60 | SBP: Day 90 | DSBP: Baseline | DSBP: Day 1 | DSBP: Day 2 | DSBP: Day 30 | DSBP: Day 60 | DSBP: Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 101.00 | 97.00 | 94.00 | 77.0 | 74.00 | 76.00 | 60.00 | 61.00 | 48.00 | 53.00 | 51.00 | 53.00 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 50.00 | 105.50 | 75.00 | 77.00 | 102.00 | 105.00 | 41.00 | 57.00 | 53.00 | 61.00 | 57.00 | 55.50 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 110.50 | 112.0 | 107.00 | 112.00 | 101.00 | 97.50 | 66.00 | 65.50 | 60.50 | 64.00 | 60.00 | 60.50 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 96.00 | 111.00 | 112.00 | 109.00 | 118.00 | 116.00 | 67.00 | 66.50 | 70.00 | 68.00 | 67.00 | 67.00 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 117.50 | 113.00 | 119.50 | 118.00 | 117.50 | 116.00 | 65.00 | 64.00 | 65.00 | 69.00 | 67.00 | 69.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | kilograms (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 4.05 | 4.17 | 4.50 | 6.30 | 7.15 | 7.70 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 3.93 | 4.04 | 4.15 | 4.56 | 4.60 | 4.70 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 18.78 | 17.23 | 14.95 | 15.50 | 16.60 | 21.50 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 36.60 | 37.00 | 39.35 | 39.20 | 38.30 | 39.30 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 60.00 | 63.40 | 58.00 | 63.80 | 65.80 | 59.60 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes, ears, nose, throat:Screening | Eyes, ears, nose, throat: Visit 3 | Eyes, ears, nose, throat: Visit 4 | Eyes, ears, nose, throat: Visit 5 | Eyes, ears, nose, throat: Visit 6 | Eyes, ears, nose, throat: Visit 7 | General appearance: Screening | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Skin: Screening | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 4 | 3 | 4 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 2 | 2 | 3 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 2 | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 2 | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 2 | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes: Screening | Eyes: Visit 2 | Eyes: Visit 3 | Eyes: Visit 4 | Eyes: Visit 5 | Eyes: Visit 6 | Eyes: Visit 7 | Eyes, ears, nose, throat:Screening | General appearance: Screening | General appearance: Visit 2 | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 2 | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Nose: Screening | Nose: Visit 2 | Skin: Screening | Skin: Visit 2 | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 2 | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 2 | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 2 | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes: Screening | Eyes: Visit 2 | Eyes: Visit 3 | Eyes: Visit 4 | Eyes: Visit 5 | Eyes: Visit 6 | Eyes: Visit 7 | Eyes, ears, nose, throat:Screening | Eyes, ears, nose, throat: Visit 3 | Eyes, ears, nose, throat: Visit 4 | Eyes, ears, nose, throat: Visit 7 | General appearance: Screening | General appearance: Visit 2 | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 2 | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Nose: Screening | Nose: Visit 2 | Skin: Screening | Skin: Visit 2 | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 2 | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 2 | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 2 | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes: Screening | Eyes: Visit 2 | Eyes: Visit 3 | Eyes: Visit 4 | Eyes: Visit 5 | Eyes: Visit 6 | Eyes: Visit 7 | Eyes, ears, nose, throat:Screening | Eyes, ears, nose, throat: Visit 3 | Eyes, ears, nose, throat: Visit 4 | Eyes, ears, nose, throat: Visit 5 | Eyes, ears, nose, throat: Visit 6 | Eyes, ears, nose, throat: Visit 7 | General appearance: Screening | General appearance: Visit 2 | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 2 | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Nose: Screening | Nose: Visit 2 | Skin: Screening | Skin: Visit 2 | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 0 | 1 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 2 | 0 | 2 | 3 | 4 | 1 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 3 | 10 | 1 | 3 | 8 | 3 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 1 | 2 | 3 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | 5 | 4 | 3 | 5 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 5 | 1 | 3 | 6 | 7 | 5 | 4 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after the last dose of study drug (up to Day 132) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 1 | 0 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 2 | 2 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 7 | 3 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 7 | 3 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 19 | 13 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. The percentage of participants who had anti factor-Xa levels within the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow up phase
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 100.0 | 100.0 | 100.0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 100.0 | 100.0 | 100.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 33.3 | 75.0 | 50.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 93.3 | 81.8 | 72.7 |
Prespecified therapeutic anti-factor Xa range was 0.5-1.0 IU/mL. The percentage of participants who had anti-factor Xa levels outside the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow-up phase
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 0 | 0 | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 | 0 | 0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 66.7 | 25.0 | 50.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 6.7 | 18.2 | 27.3 |
VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. PE is a blood clot in the lungs. Clinical response of progression was defined as progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. Clinical response of regression: Regressed clot burden utilizing the same imaging modality as the screening visit. Clinical response of resolution: Thrombus resolution of the qualifying event measured by repeat imaging at the end of study (EOS) visit. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Progression | Regression | Resolution | No Change | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 0 | 0 | 100.0 | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 | 12.5 | 62.5 | 0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0 | 14.3 | 57.1 | 14.3 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0 | 29.4 | 58.8 | 5.9 |
A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter 24 hours, Overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, Overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration or bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal). A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major or clinically relevant no major bleeding (bleeding resulting in any medical or surgical interventions but which did not meet the criteria for major bleeding). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Major Bleeding | Minor Bleeding | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 0 | 0 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 50.0 | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 | 50.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0 | 57.1 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0 | 40.0 |
The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 0 |
| Arm B (Dalteparin) | 2.1 |
A similar analysis as described for the primary safety analysis will be used. The rate (percentage) of patients experiencing major bleeding or a clinically relevant non-major bleed at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 7.0 |
| Arm B (Dalteparin) | 8.1 |
Analyzed using the same methods described above for the primary endpoint.Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) is defined as the time from randomization to the date the patient experienced the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE). (NCT02585713)
Timeframe: Up to 3 months post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A (Apixaban) | NA |
| Arm B (Dalteparin) | NA |
To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 3-months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 11.2 |
| Randomized Arm 2 (LMWH) | 10.7 |
| Preference Cohort 1 (DOACs) | 10.3 |
| Preference Cohort 2 (LMWH) | 10.5 |
To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 6-months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 11.6 |
| Randomized Arm 2 (LMWH) | 11.3 |
| Preference Cohort 1 (DOACs) | 11.5 |
| Preference Cohort 2 (LMWH) | 10.1 |
To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 3 months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 56.7 |
| Randomized Arm 2 (LMWH) | 53.3 |
| Preference Cohort 1 (DOACs) | 55.8 |
| Preference Cohort 2 (LMWH) | 54.9 |
To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 56.5 |
| Randomized Arm 2 (LMWH) | 54.1 |
| Preference Cohort 1 (DOACs) | 54.9 |
| Preference Cohort 2 (LMWH) | 53.1 |
To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months. Only VTEs that were nonfatal were considered because of the challenges of attributing cause of death in cancer patients to tumor progression vs. VTE. (NCT02744092)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Randomized Arm 1 (DOACs) | 6.1 |
| Randomized Arm 2 (LMWH) | 8.8 |
| Preference Cohort 1 (DOACs) | 7.5 |
| Preference Cohort 2 (LMWH) | 4.1 |
To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months. d. Major bleeding was defined as Grade >=3 on the Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI CTCAE) criteria version 5.0 (i.e., severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living). (NCT02744092)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Randomized Arm 1 (DOACs) | 5.2 |
| Randomized Arm 2 (LMWH) | 5.6 |
| Preference Cohort 1 (DOACs) | 11.5 |
| Preference Cohort 2 (LMWH) | 7.6 |
Change in mental health at 3 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 3-months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | -0.3 |
| Randomized Arm 2 (LMWH) | 0.7 |
| Preference Cohort 1 (DOACs) | 0.3 |
| Preference Cohort 2 (LMWH) | 0.4 |
Change in mental health at 6 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 6-months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 0.3 |
| Randomized Arm 2 (LMWH) | 0.9 |
| Preference Cohort 1 (DOACs) | 1.1 |
| Preference Cohort 2 (LMWH) | -1.9 |
Change in physical health at 3 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 3-month follow-up assessment. (NCT02744092)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 1.8 |
| Randomized Arm 2 (LMWH) | 0.7 |
| Preference Cohort 1 (DOACs) | 3.4 |
| Preference Cohort 2 (LMWH) | -0.3 |
Change in physical health at 6 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 6-month follow-up assessment. (NCT02744092)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 2.4 |
| Randomized Arm 2 (LMWH) | 0.7 |
| Preference Cohort 1 (DOACs) | 2.1 |
| Preference Cohort 2 (LMWH) | -2.8 |
To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE based on survival at 6 months. Mortality was reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form) (NCT02744092)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Randomized Arm 1 (DOACs) | 21.5 |
| Randomized Arm 2 (LMWH) | 18.4 |
| Preference Cohort 1 (DOACs) | 16.3 |
| Preference Cohort 2 (LMWH) | 23.8 |
The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 32 |
| Dalteparin Group | 16 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 67 |
| Dalteparin Group | 71 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 19 |
| Dalteparin Group | 35 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 21 |
| Dalteparin Group | 24 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 41 |
| Dalteparin Group | 59 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 235 |
| Dalteparin Group | 228 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 6 |
| Dalteparin Group | 4 |
"If a subject dies between randomization and late postpartum follow up (Day 90 +/- 7 days) the death will be adjudicated as certain, highly probable, probable, or unlikely due to Pulmonary Embolism (PE) using the following criteria.~Certain: hypotension, hypoxia, cardiac arrest with no other explanation other than PE and autopsy or radiographic confirmation Highly probable: criteria for certain but another disease could have caused the death Probable: other cause suspected based on clinical evidence but 100% certainty not available Unlikely: all other cases." (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
The average number of subjects that are recruited per site per month during a 4 month active recruitment phase at each site. (NCT01274637)
Timeframe: 4 months
| Intervention | participants per site per month (Number) |
|---|---|
| Low Molecular Weight Heparin | 0.9 |
| Control Group | 0.9 |
All subjects who develop thrombocytopenia (platelets less than 80 x 109/L and/or with >50% decrease from baseline) will be investigated for Heparin Induced Thrombocytopenia (HIT) by having ELISA and serotonin release assays to confirm or refute a diagnosis of HIT. HIT will be diagnosed with a positive PF4 (platelet factor 4) HIT ELISA assay. (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
This includes symptomatic Deep Vein Thrombosis or Pulmonary Embolism. Suspected outcomes will be adjudicated by a blinded adjudication committee. (NCT01274637)
Timeframe: From Day 10 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
"Major bleeding meets at least one of the following: Fatal bleeding; Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, retroperitoneal, etc.); Bleeding causing a fall in hemoglobin level of 20 g L-1 (1.24 mmol L-1) or more, or leading to transfusion of two or more units of whole blood or red cells .~Clinically Relevant Non-major Bleeding does not meet the criteria for major bleeding but meets at least one of the following: Hospitalization; Medical intervention; Unscheduled contact with a physician; Discomfort (pain, or impairment of activities of daily life)." (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 3 |
| Control Group | 1 |
This includes symptomatic Deep Vein Thrombosis (DVT) or pulmonary embolism (PE) in the interval between randomization and the last dose of study drug (10 days +/- 3 days) OR asymptomatic proximal DVT detected by compression ultrasound of both legs done within 24hrs of the last dose of study drug (10 days (+/- 3 days) postpartum). Compressed and non-compressed images will be obtained from the calf trifurcation to the inguinal ligament. All suspected outcomes will be adjudicated by a blinded expert adjudication committee. (NCT01274637)
Timeframe: From randomization to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
The percentage of patients who experienced a clinically significant bleeding event were recorded (including major and clinically significant non-major bleeding) over 13 weeks (12 weeks of study and an additional week of observation). Major bleeding was defined as being clinically overt and satisfying one of the following: decrease in hemoglobin of 2.0 g/dL, leading to transfusion of 2 or more units of blood or packed red cells, occurring in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leading to death. Clinically significant non-major bleeding was defined as clinically overt, not meeting criteria for major bleeding and with one of the following characteristics: multiple-source, spontaneous hematoma > 25 cm², epistaxis > 5 mins, macroscopic hematuria not related to instrumentation, spontaneous rectal bleeding, gingival bleeding > 5 mins, hemoptysis, hematemesis or prolonged bleeding (> 5 minutes) after venipuncture. (NCT00876915)
Timeframe: 13 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Dalteparin Injection | 14 |
| No Therapy | 2 |
The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT. (NCT00876915)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Dalteparin Injection | 12 |
| No Therapy | 21 |
Blood samples were obtained to measure the value of D-Dimer at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of D-Dimer
| Intervention | ug/mL (Mean) |
|---|---|
| High Risk | 2.99 |
| Low Risk | 1.87 |
Blood samples were obtained to measure the value of FVIIa at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of FVIIa
| Intervention | pM (Mean) |
|---|---|
| High Risk | 151.2 |
| Low Risk | 148.6 |
Blood samples were obtained to measure the value of Human F12 at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of Human F12
| Intervention | ng/mL (Mean) |
|---|---|
| High Risk | 484.7 |
| Low Risk | 306.3 |
Blood samples were obtained to measure the value of TAT at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TAT
| Intervention | ug/L (Mean) |
|---|---|
| High Risk | 9.89 |
| Low Risk | 12.44 |
Blood samples were obtained to measure the value of Tissue Factor at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients. (NCT00876915)
Timeframe: baseline value of tissue factor
| Intervention | pg/mL (Mean) |
|---|---|
| High Risk | 0.669 |
| Low Risk | 0.187 |
Blood samples were obtained to measure the value of TFPI at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TFPI
| Intervention | pg/mL (Mean) |
|---|---|
| High Risk | 813.6 |
| Low Risk | 738.2 |
Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain (NCT00264381)
Timeframe: Day 1, Day 14
| Intervention | units on a scale (Mean) |
|---|---|
| Ibuprofen 800 mg Tid | -2.28 |
| Dalteparin 200 U/kg Then 10,000 U Daily | -2.23 |
Number of participants with bleeding events related to treatment (NCT00264381)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Ibuprofen 800 mg Tid | 0 |
| Dalteparin 200 U/kg Then 10,000 U Daily | 0 |
Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing (NCT00264381)
Timeframe: Day 14
| Intervention | participants (Number) | |
|---|---|---|
| Thrombosis progression | VTE | |
| Dalteparin 200 U/kg Then 10,000 U Daily | 0 | 0 |
| Ibuprofen 800 mg Tid | 4 | 0 |
Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing. (NCT00264381)
Timeframe: 3 months
| Intervention | participants (Number) | |
|---|---|---|
| Thrombosis progression | VTE | |
| Dalteparin 200 U/kg Then 10,000 U Daily | 4 | 1 |
| Ibuprofen 800 mg Tid | 6 | 0 |
122 reviews available for dalteparin and Thromboembolism, Venous
| Article | Year |
|---|---|
Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis.
Topics: Anticoagulants; Humans; Nadroparin; Randomized Controlled Trials as Topic; Treatment Outcome; Venous | 2016 |
Preventing venous thromboembolism in critically ill patients.
Topics: Clinical Trials as Topic; Critical Illness; Dalteparin; Heparin; Humans; Intensive Care Units; Nadro | 2008 |
Clinical use of parnaparin in major and minor orthopedic surgery: a review.
Topics: Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans | 2008 |
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug | 2009 |
Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.
Topics: Anticoagulants; Cardiovascular Diseases; Chronic Disease; Drug Administration Schedule; Fibrinolytic | 2008 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Lo | 2017 |
Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
Topics: Cost-Benefit Analysis; Factor Xa Inhibitors; Fibrinolytic Agents; Half-Life; Heparin, Low-Molecular- | 2008 |
New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
Topics: Animals; Anticoagulants; Chemistry, Pharmaceutical; Diabetic Foot; Factor Xa Inhibitors; Heparin, Lo | 2010 |
Bemiparin in oncology.
Topics: Anticoagulants; Antineoplastic Agents; Chemotherapy, Adjuvant; Fibrinolytic Agents; Heparin, Low-Mol | 2010 |
Clinical experience with bemiparin.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Surgical Procedures, Oper | 2010 |
New frontiers with bemiparin: use in special populations.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Child; Female; Fibrinolytic Agents; Heparin, Low-Mol | 2010 |
Enoxaparin Versus Direct Oral Anticoagulants for Venous Thromboembolism in Asians Undergoing Total Knee Arthroplasty: A Meta-Analysis and Systematic Review.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Asian People; Enoxaparin; Humans; Venous Thromboemb | 2022 |
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
Topics: Anticoagulants; COVID-19; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weig | 2021 |
Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Molecular Weight; Prospective Stu | 2022 |
The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Administration Schedule; Enoxaparin; Hemorrhage | 2022 |
Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brazil; Cost-Benefi | 2022 |
The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Random | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Pharmacologic venous thromboembolism prophylaxis in obese trauma patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Patients; Venous Thromboembolism | 2023 |
Once-daily Compared With Twice-daily Enoxaparin Maintenance Therapy Appears Safe and Efficacious in Pediatric Venous Thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Child; Enoxaparin; Humans; Prospective Studies; Retrospective Stu | 2023 |
Once-daily Compared With Twice-daily Enoxaparin Maintenance Therapy Appears Safe and Efficacious in Pediatric Venous Thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Child; Enoxaparin; Humans; Prospective Studies; Retrospective Stu | 2023 |
Once-daily Compared With Twice-daily Enoxaparin Maintenance Therapy Appears Safe and Efficacious in Pediatric Venous Thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Child; Enoxaparin; Humans; Prospective Studies; Retrospective Stu | 2023 |
Once-daily Compared With Twice-daily Enoxaparin Maintenance Therapy Appears Safe and Efficacious in Pediatric Venous Thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Child; Enoxaparin; Humans; Prospective Studies; Retrospective Stu | 2023 |
The efficacy of various Enoxaparin dosing regimens in general surgery patients: A systematic review.
Topics: Anticoagulants; Body Mass Index; Child; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; M | 2023 |
Enoxaparin for COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Randomized Controlled Trials as Topic; Venous Thromboe | 2023 |
The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis.
Topics: Adult; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Multiple Trauma; Network Meta-A | 2023 |
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications; | 2020 |
Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analys | 2020 |
Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Heparin, Low-Molecular-Weight; | 2021 |
Low Anti-Factor Xa Level Predicts 90-Day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials.
Topics: Anticoagulants; Enoxaparin; Humans; Postoperative Complications; Postoperative Hemorrhage; Prospecti | 2022 |
PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Hemorrhagic Stroke; Humans; Middle Aged; Venous Thr | 2020 |
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridine | 2021 |
A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Fema | 2021 |
Risk factors for postdischarge venous thromboembolism among bariatric surgery patients and the evolving approach to extended thromboprophylaxis with enoxaparin.
Topics: Aftercare; Anticoagulants; Bariatric Surgery; Enoxaparin; Humans; Male; Patient Discharge; Risk Fact | 2021 |
Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Disease Management; Enoxaparin; Female; Humans; | 2017 |
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hemorrhage; Huma | 2017 |
Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Topics: Age Factors; Anticoagulants; Benzamides; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hospi | 2018 |
Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.
Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Heparin, Low-Molecular-Weight; Intr | 2018 |
Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.
Topics: Anticoagulants; Enoxaparin; Humans; Neoplasms; Rivaroxaban; Venous Thromboembolism | 2018 |
Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
Topics: Administration, Oral; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Hospitalization; Humans; Py | 2018 |
Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Topics: Anticoagulants; Benzamides; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Fa | 2018 |
Surgical Management of Placenta Accreta Spectrum.
Topics: Anticoagulants; Cesarean Section; Enoxaparin; Female; Gestational Age; Humans; Hysterectomy; Magneti | 2018 |
Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis.
Topics: Anticoagulants; Arthroplasty; Enoxaparin; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Ra | 2018 |
Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Middle Aged | 2018 |
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enox | 2019 |
Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Topics: Anticoagulants; Benzamides; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; | 2019 |
Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp | 2019 |
Systematic review of prophylaxis for venous thromboembolism after knee arthroplasty: enoxaparin versus rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Enoxaparin; Humans; Postopera | 2019 |
The use of direct oral anticoagulants for extended duration thromboprophylaxis in medically ill patients: a systematic review and meta-analysis.
Topics: Enoxaparin; Factor Xa Inhibitors; Humans; Length of Stay; Premedication; Risk Factors; Time Factors; | 2019 |
Does the form of venous thromboembolism prophylaxis following primary total knee arthroplasty alter the rate of early reoperation or revision surgery?
Topics: Arthroplasty, Replacement, Knee; Aspirin; Australia; Case-Control Studies; Clinical Decision-Making; | 2019 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
[Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis].
Topics: Enoxaparin; Fondaparinux; Humans; Orthopedic Procedures; Polysaccharides; Randomized Controlled Tria | 2013 |
Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis.
Topics: Anticoagulants; Bariatric Surgery; Comparative Effectiveness Research; Enoxaparin; Heparin, Low-Mole | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies.
Topics: Anticoagulants; Delivery of Health Care; Drug Administration Schedule; Enoxaparin; Heparin; Hospital | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administr | 2013 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution | 2013 |
Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Venous Thromboembolism | 2013 |
Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Enoxaparin; Factor Xa Inhibitors; Humans; Pyra | 2015 |
Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Humans; Neopl | 2014 |
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2015 |
Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: an evidence-based review.
Topics: Anticoagulants; Brain Injuries; Enoxaparin; Humans; Intracranial Hemorrhages; Risk Factors; Venous T | 2015 |
Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Hosp | 2012 |
Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: A best evidence topic.
Topics: Anticoagulants; Bariatric Surgery; Clinical Protocols; Cohort Studies; Enoxaparin; Female; Hemorrhag | 2015 |
Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Humans; Publicat | 2015 |
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low | 2016 |
Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor | 2016 |
Spontaneous, resolving S1Q3T3 in pulmonary embolism: A case report and literature review on prognostic value of electrocardiography score for pulmonary embolism.
Topics: Adult; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Humans; Male; Myocardial Ischem | 2016 |
Apixaban: A Review in Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Hemorrhage; H | 2016 |
Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Monitoring, Intraoperative; Postoperative | 2017 |
Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Fe | 2017 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; H | 2017 |
Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Randomized Controlled Trials a | 2017 |
Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
Topics: Anticoagulants; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2017 |
[Venous thromboembolism and immobilization for medical reason].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux | 2008 |
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2009 |
Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cli | 2009 |
Safety evaluation of enoxaparin in currently approved indications.
Topics: Adult; Animals; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Myocardial Infarction; Posto | 2009 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab | 2010 |
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimi | 2010 |
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cardiology; Clinica | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enox | 2010 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method | 2010 |
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Evidence-Based Medicine; Female; | 2011 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; France; Hemorrhage; Heparin; Humans; | 2011 |
A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2011 |
Enoxaparin: a pharmacologic and clinical review.
Topics: Acute Coronary Syndrome; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecula | 2011 |
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analys | 2011 |
Standard or extended-duration prophylaxis in medical patients? A review of the evidence.
Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Pulmonary Embolism; Randomized Control | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; | 2011 |
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as | 2011 |
Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: a literature summary.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Enoxaparin; Humans; Neoplasms; Treatment Out | 2012 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clini | 2011 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2012 |
Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Female; Humans; Male; Randomized Controlled Trials as Topic; | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2012 |
Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; F | 2012 |
Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Pyrazoles; Pyri | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R | 2012 |
Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interact | 2012 |
Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Topics: Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Elective Surgical Procedures; Enoxaparin; | 2013 |
Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies.
Topics: Clinical Trials as Topic; Drug Evaluation; Heparin, Low-Molecular-Weight; Humans; Thrombosis; Venous | 2013 |
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism | 2023 |
[Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
Topics: Administration, Oral; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; | 2019 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Mol | 2018 |
The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dalteparin; Gastrointestinal Neoplasms; Humans; | 2018 |
Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Postpartum Hemorrhage; Pregnancy; Pregnancy Compl | 2019 |
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weigh | 2014 |
Updates in pediatric venous thromboembolism.
Topics: Anticoagulants; Child; Chronic Disease; Clinical Trials as Topic; Dalteparin; Fibrinolytic Agents; F | 2015 |
Management of venous thromboembolism in patients with cancer: role of dalteparin.
Topics: Anticoagulants; Dalteparin; Drug Costs; Humans; Neoplasms; Quality of Life; Risk Factors; Treatment | 2008 |
Dalteparin as the primary low-molecular-weight heparin on a hospital formulary.
Topics: Acute Coronary Syndrome; Anticoagulants; Dalteparin; Fibrinolytic Agents; Formularies, Hospital as T | 2009 |
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weigh | 2011 |
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Neo | 2011 |
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weigh | 2011 |
Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
Topics: Aged; Anticoagulants; COVID-19; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Pregnancy; T | 2022 |
Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications.
Topics: Fibrinolytic Agents; Hemorrhage; Humans; Renal Elimination; Renal Insufficiency, Chronic; Risk Adjus | 2020 |
The Role of Tinzaparin in Oncology.
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Tinzaparin; Treat | 2018 |
Treatment of venous thromboembolism with tinzaparin in oncological patients.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Tinzaparin; Venous Thromboembolism | 2019 |
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Randomized Contro | 2018 |
Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 2012 |
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Join | 2017 |
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Topics: Adult; Ambulatory Care; Anticoagulants; Antineoplastic Agents; Antithrombins; Child; Hemorrhage; Hep | 2014 |
Semuloparin for the prevention of venous thromboembolic events in cancer patients.
Topics: Animals; Blood Coagulation; Evidence-Based Medicine; Fibrinolytic Agents; Heparin, Low-Molecular-Wei | 2012 |
232 trials available for dalteparin and Thromboembolism, Venous
| Article | Year |
|---|---|
Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial.
Topics: Anticoagulants; Critical Illness; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Prospective Stu | 2022 |
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
Topics: Anticoagulants; Hemorrhage; Humans; Lung Neoplasms; Nadroparin; Rivaroxaban; Thoracic Surgery; Venou | 2023 |
Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors.
Topics: Administration, Intravenous; Aged; Anticoagulants; Critical Illness; Factor Xa; Female; Humans; Inje | 2020 |
Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
Topics: Activities of Daily Living; Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Female; Hum | 2021 |
Influence of Fondaparinux Versus Nadroparin Calcium Thromboprophylaxis on Clinical Parameters Following Total Knee Arthroplasty
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Fondaparinux; | 2016 |
Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anticoagulants; Double-Blind Method; Esophagectomy; Female; Fondaparinux; H | 2018 |
Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Male; Middle Aged; Nadroparin; Neoplasms; P | 2008 |
Nadroparin therapy in pediatric patients with venous thromboembolic disease.
Topics: Adolescent; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Child; Child, Preschool; Dos | 2008 |
Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).
Topics: Adult; Anticoagulants; Bariatric Surgery; Dose-Response Relationship, Drug; Drug Administration Sche | 2014 |
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Lumbar Vertebrae; Middle Aged; Rivaroxab | 2015 |
Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
Topics: Adult; Anticoagulants; Bariatric Surgery; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weigh | 2009 |
Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
Topics: Adult; Anticoagulants; Bariatric Surgery; Blood Coagulation Tests; Body Mass Index; Combined Modalit | 2007 |
Extended use of bemiparin as thromboprophylaxis during bariatric surgery: results of anti-factor Xa activity measurements.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Mass Index; Drug Administration Schedule; Factor Xa; | 2018 |
Low-molecular-weight heparin for prevention of venous thromboembolism after varicose vein surgery in moderate-risk patients: a randomized, controlled trial.
Topics: Adolescent; Aged; Anticoagulants; Combined Modality Therapy; Drug Administration Schedule; Early Amb | 2013 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Gynecologic Surgical Procedures; | 2015 |
Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Heparin, Low-Molecular-Weight; Humans; | 2010 |
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; COVID-19; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; H | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Milvexian for the Prevention of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Dose | 2021 |
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism | 2022 |
Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.
Topics: Anticoagulants; Body Mass Index; Enoxaparin; Hospitalization; Humans; Risk Factors; Venous Thromboem | 2022 |
Optimal Dosing of Prophylactic Enoxaparin after Surgical Procedures: Results of the Double-Blind, Randomized, Controlled FIxed or Variable Enoxaparin (FIVE) Trial.
Topics: Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial.
Topics: Anticoagulants; Child; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Systemic Infla | 2022 |
Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence.
Topics: Adolescent; Anticoagulants; COVID-19; Enoxaparin; Heparin; Humans; Retrospective Studies; Treatment | 2023 |
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Aust | 2022 |
Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial.
Topics: Anticoagulants; Blood Coagulation; Cesarean Section; Enoxaparin; Female; Humans; Pregnancy; Venous T | 2022 |
Comparison between rivaroxaban versus enoxaparin for venous thromboembolism prophylaxis following spine surgeries, a randomized clinical trial.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hematoma; Humans; Male; Middle Aged; Rivaroxaban; Venous | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Orthopedics; Prospective Studies; Rivaroxaban; Venous Thr | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Australia; Drainage; Enoxaparin; Huma | 2023 |
Comparison of postpartum anti-Xa levels following enoxaparin administration to prevent venous thromboembolism using 2 weight-based protocols: a randomized controlled trial.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Postpartum Period; Venous Thromboembolism | 2023 |
Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial.
Topics: Adolescent; Adult; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; E | 2023 |
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Heparin; Humans; Prospective Studies; Treatment Ou | 2023 |
Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular- | 2023 |
Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Enoxaparin; Gastrointestinal Neoplasms; Humans; Postoper | 2023 |
Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Blood Coagulation; | 2019 |
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Respo | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention.
Topics: Aged; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Postoperative Comp | 2020 |
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hu | 2020 |
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Venous Thromboembolism | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial.
Topics: Aged; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Hemorrhage; Humans; Intermittent Pne | 2020 |
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
Topics: Adult; Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Fractures, Bone; Hemo | 2020 |
Efficacy and Safety of Low-Molecular-Weight Heparin on Prevention of Venous Thromboembolism after Laparoscopic Operation for Gastrointestinal Malignancy in Japanese Patients: A Multicenter, Open-Label, Prospective, Randomized Controlled Trial.
Topics: Adult; Aged; Contrast Media; Drug Administration Schedule; Enoxaparin; Female; Gastrointestinal Neop | 2020 |
Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Decision Support Techniques; Enoxaparin; Fema | 2020 |
Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Infusions, Intr | 2021 |
Adding a Preoperative Dose of LMWH may Decrease VTE Following Bariatric Surgery.
Topics: Adolescent; Adult; Anticoagulants; Bariatric Surgery; Chemoprevention; Enoxaparin; Female; Heparin, | 2021 |
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Topics: Anticoagulants; Atorvastatin; COVID-19; COVID-19 Drug Treatment; Critical Illness; Double-Blind Meth | 2020 |
PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Hemorrhagic Stroke; Humans; Middle Aged; Venous Thr | 2020 |
Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Disease Progression; Double-Blind Meth | 2021 |
Optimal Dosing of Prophylactic Enoxaparin after Surgical Procedures: Results of the Double-Blind, Randomized, Controlled FIxed or Variable Enoxaparin (FIVE) Trial.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Humans; Male; Middle Aged; Postopera | 2021 |
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Enoxaparin; | 2021 |
Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Gastrectomy; Humans; Incidence; Japan; Male; Middle Aged; P | 2021 |
Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial.
Topics: Adult; Anticoagulants; Antithrombin III; Enoxaparin; Humans; Pilot Projects; Prospective Studies; Ve | 2021 |
Acquired antithrombin deficiency is a risk factor for venous thromboembolism after major trauma.
Topics: Antithrombins; Blood Coagulation Disorders; Enoxaparin; Humans; Risk Factors; Venous Thromboembolism | 2021 |
Apixaban or enoxaparin: Which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; | 2022 |
Abelacimab for Prevention of Venous Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Rep | 2021 |
A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
Topics: Aged; Aged, 80 and over; China; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sche | 2017 |
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method | 2017 |
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Topics: Aged; Anticoagulants; Benzamides; Delayed-Action Preparations; Double-Blind Method; Enoxaparin; Fact | 2017 |
Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Body Weight; Dose-Response Relationship, Drug; Drug | 2017 |
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Enoxaparin; Female; Hemorrhage | 2018 |
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
Topics: Adult; Aged; Benzamides; Enoxaparin; Female; Humans; Male; Middle Aged; Pyridines; Recurrence; Secon | 2018 |
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Du
Topics: Anticoagulants; Benzamides; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa | 2018 |
Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Fem | 2018 |
The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; | 2018 |
The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; | 2018 |
The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; | 2018 |
The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; | 2018 |
Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety.
Topics: Aged; Anticoagulants; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Hu | 2018 |
Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Biosimilar Pharmaceuticals; Enoxaparin; Female; Humans; Mal | 2018 |
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asymptomatic Diseases; Benzamides; Enoxaparin; Female; Huma | 2018 |
Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; D | 2018 |
Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial.
Topics: Academic Medical Centers; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Obesity, Mo | 2019 |
Placental Pathological Findings following Adjusting Enoxaparin Dosage in Thrombophilic Women: Secondary Analysis of a Randomized Controlled Trial.
Topics: Adolescent; Adult; Anticoagulants; Data Interpretation, Statistical; Drug Administration Schedule; E | 2019 |
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Critical Illness; Enoxaparin; Factor Xa | 2019 |
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study.
Topics: Aged; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Hemorrhage; Heparin, Low-Molecular-We | 2019 |
Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Colorectal Surgery; Dose-Res | 2019 |
A Prospective, Multi-Center Phase I Study of Postoperative Enoxaparin Treatment in Patients Undergoing Curative Hepatobiliary-Pancreatic Surgery for Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biliary Tract Neoplasms; Chemoprevention; Digestive | 2020 |
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Human | 2019 |
Efficacy and safety of enoxaparin for preventing venous thromboembolic events after laparoscopic colorectal cancer surgery: a randomized-controlled trial (YCOG 1404).
Topics: Adult; Aged; Anticoagulants; Colorectal Neoplasms; Digestive System Surgical Procedures; Enoxaparin; | 2020 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cos | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
Topics: Age Factors; Aged; Anticoagulants; Canada; Enoxaparin; Europe; Female; Follow-Up Studies; Hemorrhage | 2013 |
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Australia; Azepines; Benzamides; Brazil; Canad | 2014 |
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2014 |
The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; | 2013 |
Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
Topics: Aged; Anticoagulants; Body Weight; Cross-Sectional Studies; Enoxaparin; Factor Xa; Female; Hospitali | 2013 |
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Double-Blind Method; Enox | 2014 |
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male; | 2014 |
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Anticoagulants; Critical Illness; Double-Blind Met | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Thromboprophylaxis and Incidence of Venous Thromboembolism in Patients With Hemophilia A or B Who Underwent High-Risk Orthopedic Surgeries.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Compression Bandages; Enoxaparin; Fa | 2016 |
Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Gastrectomy; Humans; Incidence; | 2014 |
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhi | 2014 |
Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Cohort Studies; Enoxaparin; Fema | 2014 |
Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Weight; Dose-Response Relationship, Drug; Enoxaparin; | 2015 |
Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.
Topics: Aged; Aged, 80 and over; Enoxaparin; Factor Xa; Female; Glucuronidase; Humans; Male; Middle Aged; Ne | 2015 |
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Mor | 2015 |
Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.
Topics: Adolescent; Anticoagulants; Bariatric Surgery; Chemoprevention; Drug Administration Schedule; Enoxap | 2015 |
Identifying the Bariatric Patient at Risk for Pulmonary Embolism: Prospective Clinical Trial Using Duplex Sonography and Blood Screening.
Topics: Adult; Bariatric Surgery; Blood Chemical Analysis; Blood Coagulation Tests; Enoxaparin; Female; Huma | 2015 |
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Enoxaparin; Female; Heparin, Low-Molecular-We | 2015 |
Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, Female; Gynecologic Surgical Procedures | 2015 |
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fe | 2015 |
Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Intensive Care Units; Male; Middle Aged; | 2015 |
Standard Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis Is Not Sufficient for Most Patients Within a Trauma Intensive Care Unit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Dose-Response Relations | 2015 |
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors | 2015 |
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Black or Africa | 2016 |
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibito | 2015 |
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
Topics: Adult; Aged; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles | 2016 |
Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism: Initial Experience in a Single Center.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Humans; Lower Extremity; Male; Mi | 2016 |
Prevention of Postoperative Venous Thromboembolism in Thoracic Surgical Patients: Implementation and Evaluation of a Caprini Risk Assessment Protocol.
Topics: Adult; Aged; Anticoagulants; Clinical Audit; Clinical Protocols; Drug Administration Schedule; Enoxa | 2016 |
Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Factor Xa Inhibitors; Female; Hemo | 2016 |
Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Confidence Intervals; Dabigatran; Double | 2017 |
Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial.
Topics: Adult; Anticoagulants; Birth Weight; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Infant, Newbo | 2016 |
Thrombelastography-Based Dosing of Enoxaparin for Thromboprophylaxis in Trauma and Surgical Patients: A Randomized Clinical Trial.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; Middle Aged; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Venous Thromboembolism; Warfar | 2016 |
A Phase II Clinical Trial of the Efficacy and Safety of Short-term (3 days) Enoxaparin for the Prevention of Venous Thromboembolism after Gastric Cancer Surgery.
Topics: Anticoagulants; Clinical Protocols; Drug Administration Schedule; Enoxaparin; Humans; Middle Aged; P | 2016 |
Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2017 |
[Betrixaban reduces tromboembolic events].
Topics: Administration, Oral; Benzamides; Causality; Comorbidity; Enoxaparin; Fibrinolytic Agents; Humans; M | 2016 |
Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma.
Topics: Adult; Aged; Anticoagulants; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Egypt; Enoxa | 2017 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamides; Double-Blind Method; Enoxaparin; Factor Xa Inhi | 2017 |
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigat | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Drug Administra | 2008 |
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind | 2008 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2008 |
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Repl | 2009 |
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Dose-Response | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial.
Topics: Aged; Blood Coagulation; Drug Dosage Calculations; Enoxaparin; Female; Fibrin Fibrinogen Degradation | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enox | 2010 |
Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Guidel | 2010 |
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Kne | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population?
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Combined Modality Therapy; Compression Bandage | 2011 |
Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage.
Topics: Adult; Age Factors; Anticoagulants; Enoxaparin; Female; Humans; Injury Severity Score; Intracranial | 2011 |
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Topics: Adult; Aged; Blood Coagulation Factor Inhibitors; Enoxaparin; Evaluation Studies as Topic; Factor Xa | 2011 |
[Venous thromboembolism prophylaxis after total hip arthroplasty].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Orthopedic Procedures; P | 2012 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazol | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa | 2012 |
Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
Topics: Adult; Anticoagulants; Bed Rest; Blood Coagulation Tests; Body Mass Index; Cohort Studies; Dose-Resp | 2012 |
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Topics: Adult; Blood Coagulation Tests; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination | 2012 |
A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study.
Topics: Adult; Anticoagulants; Brain Injuries; Double-Blind Method; Enoxaparin; Female; Humans; Intracranial | 2012 |
Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies.
Topics: Adult; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asian People; Azepines; Benz | 2014 |
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Topics: Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administr | 2012 |
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Topics: Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administr | 2012 |
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Topics: Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administr | 2012 |
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Topics: Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administr | 2012 |
Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.
Topics: Aged; Brain Ischemia; Delayed-Action Preparations; Double-Blind Method; Enoxaparin; Female; Humans; | 2013 |
Bioactivity of enoxaparin in critically ill patients with normal renal function.
Topics: Adult; Aged; Anticoagulants; Case-Control Studies; Critical Illness; Enoxaparin; Factor Xa Inhibitor | 2012 |
Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparagin | 2008 |
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Argentina; Arthroplasty, Replacement, Knee; Do | 2007 |
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2008 |
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Arthroplasty, Replacement, Hip | 2009 |
Sustained release of tissue factor following thrombosis of lower limb trauma.
Topics: Achilles Tendon; Anticoagulants; Double-Blind Method; Female; Fractures, Bone; Heparin, Low-Molecula | 2014 |
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hemorrhage; Hepar | 2010 |
Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.
Topics: Aged; Anticoagulants; Double-Blind Method; Female; Heart Failure; Heparin; Heparin, Low-Molecular-We | 2011 |
CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Female; Germany; Hemorrhage; Heparin; | 2011 |
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembol | 2022 |
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Topics: Aged; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pulm | 2022 |
A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer.
Topics: Adolescent; Anticoagulants; Child; Dalteparin; Hemorrhage; Humans; Neoplasms; Prospective Studies; V | 2022 |
Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dalt | 2023 |
Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Heparin; Humans; Male; Pulmonary Embolism; Sex | 2023 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Clinical implications of incidental venous thromboembolism in cancer patients.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Venous Thromb | 2020 |
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injec | 2020 |
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Topics: Aged; Dalteparin; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Gast | 2021 |
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
Topics: Aged; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Humans; Male; Neoplasms; Netherland | 2020 |
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Drug Therapy, Comb | 2021 |
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasm Recurrence, Local; Neoplasms; Venous Thromb | 2021 |
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Kidney; Neoplasms; Pyrazoles; Pyridones; Venous Thro | 2022 |
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasm | 2017 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Fibrinolyt | 2018 |
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage | 2018 |
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
Topics: Acute Disease; Administration, Oral; Adult; Anticoagulants; Dalteparin; Europe; Follow-Up Studies; H | 2018 |
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N | 2019 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem | 2019 |
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Drug Administration Sche | 2013 |
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pregnancy; Pregnancy Complicatio | 2014 |
Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
Topics: Acute Disease; Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Drug Ad | 2014 |
Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Drug Administration Schedule; Feasibility St | 2015 |
Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Topics: Anticoagulants; Australia; Brazil; Clinical Protocols; Cost Savings; Cost-Benefit Analysis; Critical | 2014 |
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Topics: Aged; Anticoagulants; Canada; Dalteparin; Drug Administration Schedule; Europe; Female; Hemorrhage; | 2015 |
A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.
Topics: Adult; Aged; Ankle Fractures; Anticoagulants; Dalteparin; Double-Blind Method; Female; Fibula; Fract | 2015 |
A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.
Topics: Adult; Aged; Ankle Fractures; Anticoagulants; Dalteparin; Double-Blind Method; Female; Fibula; Fract | 2015 |
A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.
Topics: Adult; Aged; Ankle Fractures; Anticoagulants; Dalteparin; Double-Blind Method; Female; Fibula; Fract | 2015 |
A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.
Topics: Adult; Aged; Ankle Fractures; Anticoagulants; Dalteparin; Double-Blind Method; Female; Fibula; Fract | 2015 |
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Heparin; Humans; Intensive Care | 2015 |
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Fem | 2016 |
Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Heparin, | 2016 |
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
Topics: Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Treatmen | 2017 |
FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.
Topics: Adult; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Clinical P | 2009 |
Prospective observational cohort study of bioaccumulation of dalteparin at a prophylactic dose in patients with peritoneal dialysis.
Topics: Aged; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; | 2010 |
Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.
Topics: Aged; Dalteparin; Disease Progression; Female; Humans; Male; Middle Aged; Molecular Weight; Neoplasm | 2010 |
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Doub | 2010 |
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2010 |
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Dalteparin; Deoxycy | 2012 |
A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dalte | 2012 |
Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Topics: Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2007 |
Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
Topics: Aged; Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective | 2022 |
Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial.
Topics: Adolescent; Adult; Anticoagulants; Colorectal Neoplasms; Disease-Free Survival; Heparin, Low-Molecul | 2022 |
TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol.
Topics: Anticoagulants; Humans; Pilot Projects; Postthrombotic Syndrome; Quality of Life; Randomized Control | 2023 |
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
Topics: Aged; Anticoagulants; Drug Monitoring; Female; Hemorrhage; Humans; Incidence; International Normaliz | 2018 |
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fibrinolytic Agent | 2018 |
CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Heparin, Low- | 2013 |
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma | 2015 |
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinoly | 2017 |
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
Topics: Adult; Aged; Brain Neoplasms; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2009 |
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.
Topics: Administration, Oral; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Home Care Services | 2009 |
Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Fibrinolytic Agents; Heparin, | 2010 |
The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial.
Topics: Adenocarcinoma; Aged; Canada; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule | 2011 |
Thrombin generation post elective caesarean section: effect of low molecular weight heparin.
Topics: Adult; Anticoagulants; Cesarean Section; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; | 2012 |
Weight-adjusted dosing of tinzaparin in pregnancy.
Topics: Adult; Body Weight; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heparin, Low-Mole | 2013 |
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fibrinolytic Agents; Hepari | 2013 |
[Low molecular weight heparin decreases thrombosis risk in patients receiving chemotherapy for cancer].
Topics: Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weig | 2013 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
587 other studies available for dalteparin and Thromboembolism, Venous
| Article | Year |
|---|---|
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.
Topics: Administration, Intravenous; Anticoagulants; Factor Xa Inhibitors; Humans; Nadroparin; Renal Dialysi | 2022 |
Low-Molecular-Weight Heparins (LMWH) and Synthetic Factor X Inhibitors Can Impair the Osseointegration Process of a Titanium Implant in an Interventional Animal Study.
Topics: Animals; Anticoagulants; Enoxaparin; Factor X; Female; Fondaparinux; Nadroparin; Osseointegration; R | 2022 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
Topics: Adult; Anticoagulants; Critical Illness; Humans; Nadroparin; Venous Thromboembolism | 2023 |
Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; Cerebellar Neoplasms; Cerebellopontine Angle; Female; | 2020 |
Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Cohort Studies; Drug Administration Schedule; Female; He | 2017 |
The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
Topics: Adult; Aged; Algorithms; Anticoagulants; Body Weight; Factor Xa Inhibitors; Female; Gastric Bypass; | 2018 |
A New Protocol for Venous Thromboembolism Prophylaxis in Bariatric Surgery.
Topics: Adolescent; Adult; Anticoagulants; Bariatric Surgery; Blood Transfusion; Clinical Protocols; Female; | 2019 |
Outcomes following pancreatic surgery using three different thromboprophylaxis regimens.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Elective Surgi | 2019 |
Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Causality; Dose-Response Relationsh | 2015 |
No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Injections, Subcutaneous; Male; Nadropar | 2015 |
Differences in the safety profiles of two low-molecular-weight heparins.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Nadroparin; Orthopedic | 2008 |
Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Middle Aged; Nadropari | 2008 |
Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Heparin; Humans; Nadroparin; Pregnancy; Pregnancy Compl | 2010 |
Thromboprophylaxis during chemotherapy in patients with advanced cancer.
Topics: Anticoagulants; Antineoplastic Agents; Humans; Nadroparin; Neoplasms; Pulmonary Embolism; Randomized | 2010 |
[Position of Experts Panel of the Polish Gynecological Society in the application of low molecular weight heparin - nadroparin calcium (Fraxiparine) in obstetrics and gynecology].
Topics: Anticoagulants; Female; Fibrinolytic Agents; Gynecology; Humans; Nadroparin; National Health Program | 2011 |
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
Topics: Antineoplastic Agents; Confidence Intervals; Fibrinolytic Agents; Health Status Indicators; Humans; | 2012 |
Targeted prophylaxis in cancer: the evidence accumulates.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Nadroparin; Neoplasms; Risk Assessment; Venous T | 2013 |
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Antibodies; Anticoagulants; Antiphospholipid Syndrome; Diagnosis, Diffe | 2008 |
Thromboprophylaxis during chemotherapy after advanced cancer.
Topics: Anticoagulants; Antineoplastic Agents; Humans; Nadroparin; Neoplasms; Randomized Controlled Trials a | 2007 |
[The use of parnaparin sodium (Fluxum) in the prevention of thromboembolic complications after surgical treatment of fractures associated with high risks of thrombosis].
Topics: Anticoagulants; Enoxaparin; Fracture Fixation; Fractures, Bone; Heparin, Low-Molecular-Weight; Human | 2020 |
[Parnaparin sodium - modern therapy options and prevention of venous thromboembolic complications].
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Venous Thromboembolism | 2020 |
Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Post | 2022 |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Human | 2020 |
Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study.
Topics: Aged; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; P | 2020 |
Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Female; Heparin, Low-Molecular-Weight; | 2014 |
Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Fibrinolytic Agents; Health Services for the Aged; | 2010 |
A decade of contribution to therapeutic progress: bemiparin in the management of venous thromboembolism. Foreword.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Venous Thromboembolism | 2010 |
Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemorrhage; | 2008 |
A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).
Topics: Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Humans; Prospective Studies; Stoma | 2021 |
Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal mass.
Topics: Anticoagulants; Child; Enoxaparin; Humans; Neoplasms; Thrombosis; Vena Cava, Superior; Venous Thromb | 2021 |
Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
Topics: Blood Coagulation Tests; Chemoprevention; Dose-Response Relationship, Drug; Drug Dosage Calculations | 2022 |
Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
Topics: Adult; Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; | 2022 |
Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection.
Topics: Adult; Aged; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Incidence; Male; Middle Aged; Pul | 2022 |
Time is of the Essence: Impact of a More Aggressive Chemical Venous Thromboembolism Prophylaxis Regimen on Trauma Patients.
Topics: Adult; Aged; Algorithms; Anticoagulants; Blood Transfusion; Colorado; Enoxaparin; Female; Humans; In | 2022 |
Comment on: Risk factors for postdischarge venous thromboembolism among bariatric surgery patients and the evolving approach to extended thromboprophylaxis with enoxaparin.
Topics: Aftercare; Anticoagulants; Bariatric Surgery; Enoxaparin; Humans; Patient Discharge; Risk Factors; V | 2022 |
Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Huma | 2021 |
Thrombotic and hemorrhagic risk in bariatric surgery with multimodal rehabilitation programs comparing 2 reduced guidelines for pharmacological prophylaxis.
Topics: Anticoagulants; Bariatric Surgery; Enoxaparin; Humans; Retrospective Studies; Venous Thromboembolism | 2022 |
Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2022 |
Reply to: Risk factors for postdischarge venous thromboembolism among bariatric surgery patients and the evolving approach to extended thromboprophylaxis with enoxaparin.
Topics: Aftercare; Anticoagulants; Bariatric Surgery; Enoxaparin; Humans; Patient Discharge; Risk Factors; V | 2022 |
Anti-Xa based dosing of enoxaparin in hematopoietic stem cell transplant and adoptive cell therapy patients: A single center experience.
Topics: Anticoagulants; Cell- and Tissue-Based Therapy; Enoxaparin; Factor Xa Inhibitors; Hematopoietic Stem | 2022 |
Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients.
Topics: Adult; Anticoagulants; Body Mass Index; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Male; Ret | 2022 |
Venous thromboembolism risk assessment and prophylaxis in hospitalised medical patients in the Cape Town metropole, South Africa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cross-Sectional Studies; Enoxaparin; Fem | 2022 |
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
Topics: Anticoagulants; Cytochrome P-450 CYP3A; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor | 2022 |
Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease.
Topics: Aftercare; Anticoagulants; Aspirin; Cost-Benefit Analysis; Enoxaparin; Humans; Inflammatory Bowel Di | 2022 |
Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system.
Topics: Adult; Anticoagulants; Cohort Studies; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-M | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
[Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis].
Topics: Anticoagulants; COVID-19; Cross-Sectional Studies; Enoxaparin; Humans; Incidence; Respiratory Distre | 2022 |
Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.
Topics: Adult; Anticoagulants; Child; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Obesity; Venous Thr | 2022 |
Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children.
Topics: Adolescent; Anticoagulants; Child; Child, Hospitalized; Enoxaparin; Factor Xa Inhibitors; Hemorrhage | 2022 |
Prophylactic Enoxaparin Against Catheter-Associated Thrombosis in Postoperative Cardiac Children: An Interrupted Time Series Analysis.
Topics: Anticoagulants; Central Venous Catheters; Child; Enoxaparin; Humans; Infant; Interrupted Time Series | 2022 |
Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients.
Topics: Anticoagulants; Body Weight; Enoxaparin; Free Tissue Flaps; Humans; Venous Thromboembolism | 2022 |
Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism.
Topics: Adult; Anticoagulants; Antithrombins; Cohort Studies; Enoxaparin; Female; Humans; Male; Prospective | 2022 |
One size does not fit all: Sex bias in pharmacologic venous thromboembolism prophylaxis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle | 2023 |
Assessing the use of Extended Venous Thromboembolism Prophylaxis on the Rates of Venous Thromboembolism and Postpancreatectomy Hemorrhage Following Pancreatectomy for Malignancy.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pancreatectomy; Patient Discha | 2023 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Venous Thromboembolism | 2022 |
Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty.
Topics: Ankle; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Che | 2022 |
Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019.
Topics: Aftercare; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dalteparin; Enoxaparin; Hep | 2022 |
You're never too old for optimal venous thromboembolism prophylaxis: Re-thinking current trauma guidelines.
Topics: Anticoagulants; Enoxaparin; Humans; Venous Thromboembolism; Wounds and Injuries | 2022 |
Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study.
Topics: Aftercare; Anticoagulants; Enoxaparin; Humans; Patient Discharge; Prospective Studies; Pyrazoles; Py | 2022 |
Is Rivaroxaban Superior to Enoxaparin for Thromboprophylaxis in Hospitalized Patients of COVID-19?`.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Improving compliance with venous thromboembolism prophylaxis guidelines in obese inpatients.
Topics: Anticoagulants; Enoxaparin; Humans; Inpatients; Obesity; Venous Thromboembolism | 2022 |
Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Neoplasms; Venou | 2023 |
Evaluation of venous thromboembolism (VTE) risk assessment and thrombo-prophylaxis practices in hospitalized medical and surgical patients at Aga Khan Hospital Dar es Salaam: single-centre retrospective study.
Topics: Anticoagulants; Enoxaparin; Hospitals; Humans; Middle Aged; Retrospective Studies; Risk Assessment; | 2022 |
Assessment of BMI and Venous Thromboembolism Rates in Patients on Standard Chemoprophylaxis Regimens After Undergoing Free Tissue Transfer to the Head and Neck.
Topics: Anticoagulants; Body Mass Index; Chemoprevention; Cohort Studies; Enoxaparin; Female; Humans; Male; | 2022 |
Venous thromboembolism risk after spinal cord injury: A secondary analysis of the CLOTT study.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Prospective Studies; Pulmonary Embolism; | 2023 |
Low-molecular-weight Heparin (enoxaparin) versus unfractionated heparin for venous thromboembolism prophylaxis in patients undergoing craniotomy.
Topics: Anticoagulants; Craniotomy; Enoxaparin; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Male; Venou | 2023 |
VTE prophylaxis and anti-factor Xa measurement in major burns: A survey of UK practice.
Topics: Anticoagulants; Burns; Enoxaparin; Humans; United Kingdom; Venous Thromboembolism | 2023 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
Administration of Prophylactic Enoxaparin on the Morning of Surgery Does Not Increase Risk of Blood Transfusion or Wound Drainage Following Internal Fixation of Geriatric Femur Fractures.
Topics: Aged; Blood Transfusion; Drainage; Enoxaparin; Femoral Fractures; Femur; Humans; Retrospective Studi | 2023 |
Administration of Prophylactic Enoxaparin on the Morning of Surgery Does Not Increase Risk of Blood Transfusion or Wound Drainage Following Internal Fixation of Geriatric Femur Fractures.
Topics: Aged; Blood Transfusion; Drainage; Enoxaparin; Femoral Fractures; Femur; Humans; Retrospective Studi | 2023 |
Administration of Prophylactic Enoxaparin on the Morning of Surgery Does Not Increase Risk of Blood Transfusion or Wound Drainage Following Internal Fixation of Geriatric Femur Fractures.
Topics: Aged; Blood Transfusion; Drainage; Enoxaparin; Femoral Fractures; Femur; Humans; Retrospective Studi | 2023 |
Administration of Prophylactic Enoxaparin on the Morning of Surgery Does Not Increase Risk of Blood Transfusion or Wound Drainage Following Internal Fixation of Geriatric Femur Fractures.
Topics: Aged; Blood Transfusion; Drainage; Enoxaparin; Femoral Fractures; Femur; Humans; Retrospective Studi | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
Topics: Anticoagulants; COVID-19; Cross-Sectional Studies; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Hepa | 2023 |
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Risk Assessment; Risk Factors; Venous Thromboembolism; | 2023 |
Enoxaparin adherence for venous thromboembolism prophylaxis in hospitalized patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Enoxaparin; Humans; Retrospective Studies; Venous Thromb | 2023 |
Timing of venous thromboembolism chemoprophylaxis using objective hemoglobin criteria in blunt solid organ injury.
Topics: Anticoagulants; Chemoprevention; Enoxaparin; Humans; Retrospective Studies; Venous Thromboembolism; | 2023 |
Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Topics: Anticoagulants; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Retr | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty-Reply.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; | 2023 |
Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study.
Topics: Anticoagulants; Enoxaparin; Hip Fractures; Humans; Venous Thromboembolism; Warfarin | 2022 |
Time to rethink extended thromboprophylaxis after cancer surgery?
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Postoperative Complica | 2023 |
Enoxaparin Is Better Than Aspirin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Postoperative Complica | 2023 |
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2023 |
Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
Topics: Anticoagulants; Canada; Enoxaparin; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Laparotom | 2023 |
Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin, | 2023 |
Creatinine Clearance May Predict Goal Enoxaparin Dose in Trauma.
Topics: Anticoagulants; Creatinine; Enoxaparin; Female; Goals; Heparin, Low-Molecular-Weight; Humans; Male; | 2023 |
Evaluating Adequacy of VTE Prophylaxis Dosing with Enoxaparin for Overweight and Obese Patients on an Orthopedic-Medical Trauma Comanagement Service.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity, Morbid; Overweight; Pilot Projects; Prospective Studies | 2023 |
Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis.
Topics: Anticoagulants; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Pr | 2023 |
Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients.
Topics: Adult; Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Prospective Studies; Venou | 2023 |
Invited Commentary: A Step in the Right Direction: Anti-Factor Xa Monitoring of Enoxaparin in Emergency General Surgery.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Venous Thromboembolism | 2023 |
In limb or pelvic fracture, aspirin was noninferior to enoxaparin for reducing all-cause death.
Topics: Anticoagulants; Aspirin; Enoxaparin; Extremities; Fractures, Bone; Humans; Venous Thromboembolism | 2023 |
Closer to FREEDOM From Uncertainty.
Topics: Anticoagulants; Enoxaparin; Freedom; Humans; Pyridones; Uncertainty; Venous Thromboembolism | 2023 |
Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy.
Topics: Anticoagulants; Cystectomy; Enoxaparin; Humans; Robotics; Venous Thromboembolism | 2023 |
Evaluation of a novel blood volume-based enoxaparin dosing guideline for venous thromboembolism prophylaxis in trauma patients.
Topics: Adult; Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Retrospective Studies; Ven | 2023 |
Early venous thromboembolism prophylaxis in patients with trauma intracranial hemorrhage: Analysis of the prospective multicenter Consortium of Leaders in Traumatic Thromboembolism study.
Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Intracranial Hemorrhage, Traumatic; Intracranial Hemorr | 2023 |
Twice-Daily Low-Dose Aspirin Is Similar to Enoxaparin for Thromboprophylaxis After Inpatient Treatment for Fracture.
Topics: Anticoagulants; Aspirin; Enoxaparin; Fractures, Bone; Humans; Inpatients; Venous Thromboembolism | 2023 |
Inadequate Venous Thromboembolism Chemoprophylaxis Is Associated With Higher Venous Thromboembolism Rates Among Trauma Patients With Epidurals.
Topics: Anticoagulants; Chemoprevention; Enoxaparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; | 2023 |
Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Heparin, Low-M | 2023 |
Increased bleeding risk with enoxaparin venothromboembolism prophylaxis compared with heparin in patients undergoing bariatric surgery.
Topics: Adult; Bariatric Surgery; Enoxaparin; Female; Fibrinolytic Agents; Gastrectomy; Gastric Bypass; Hepa | 2023 |
Early administration of high dose enoxaparin after traumatic brain injury.
Topics: Anticoagulants; Brain Injuries, Traumatic; Enoxaparin; Humans; Retrospective Studies; Risk Factors; | 2023 |
Clinical Impact of a Standardized Risk-Stratified Thromboprophylaxis Protocol for Multisystem Inflammatory Syndrome in Children.
Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Venous Thromboembolism | 2023 |
Effects of anti-Xa activity monitoring on the outcome of high-risk pregnancies treated with a prophylactic dose of low-molecular-weight heparin.
Topics: Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Pregnanc | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
Thromboprophylaxis in pediatric patients with earthquake-related crush syndrome: a single centre experience.
Topics: Adolescent; Anticoagulants; Child; Crush Syndrome; Earthquakes; Enoxaparin; Female; Humans; Male; Th | 2023 |
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; Biomarkers; Enoxaparin; Gastrointestinal Neoplasms; Hemorrhage; Humans; | 2023 |
Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Topics: Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Humans; Postoperative Complications; Retr | 2023 |
Limited Effect of Prevention Strategies on Incidence of Clinically Detectable Venous Thromboembolism After Lung Transplantation.
Topics: Anticoagulants; Enoxaparin; Humans; Incidence; Lung Transplantation; Prospective Studies; Venous Thr | 2023 |
Prophylactic anticoagulation after minimally invasive hysterectomy for endometrial cancer: a cost-effectiveness analysis.
Topics: Anticoagulants; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Endometrial Neoplasms; Enoxapari | 2023 |
Is low-molecular-weight heparin superior to aspirin for VTE prophylaxis?
Topics: Anticoagulants; Aspirin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Venous Thromboe | 2023 |
The Treatment of Venous Thromboembolism in the Emergency Department in the DOACs Era.
Topics: Anticoagulants; Emergency Service, Hospital; Enoxaparin; Humans; Retrospective Studies; Venous Throm | 2023 |
Neutrophil-Lymphocyte Ratio as a Predictor of Venous Thromboembolism after Total Knee Replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Biomarkers; Chemoprevention; Enoxaparin; Fema | 2021 |
Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Body Weight; Drug Administration Schedule; Enoxapari | 2021 |
Factors associated with women's adherence to postpartum thromboprophylaxis.
Topics: Adult; Anticoagulants; Cohort Studies; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Me | 2020 |
Utilization of the Caprini score in conjunction with thrombodynamic testing reduces the number of unpredicted postoperative venous thromboembolism events in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Colorectal Neop | 2020 |
Aspirin as venous thromboembolic event prophylaxis post total hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2019 |
Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Cohort Studies; Dose-Response Relationship, D | 2019 |
Postoperative Venous Thromboembolism Prophylaxis Utilizing Enoxaparin Does Not Increase Bleeding Complications After Abdominal Body Contouring Surgery.
Topics: Aftercare; Anticoagulants; Body Contouring; Enoxaparin; Humans; Patient Discharge; Postoperative Com | 2020 |
Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit.
Topics: Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Infant, Newborn; Intensive Care U | 2021 |
Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Ther | 2019 |
Venous Thromboembolism Prophylaxis: Safe, but Still Provocative?
Topics: Anticoagulants; Brain Neoplasms; Craniotomy; Enoxaparin; Humans; Postoperative Complications; Precis | 2019 |
The ATLANTIC study: Anti-Xa level assessment in trauma intensive care.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Injections, Subcutaneous; Intensive Care Un | 2020 |
Defects in Processes of Care for Pharmacologic Prophylaxis Are Common Among Neurosurgery Patients Who Develop In-Hospital Postoperative Venous Thromboembolism.
Topics: Aged; Algorithms; Anticoagulants; Chemoprevention; Enoxaparin; Female; Guideline Adherence; Heparin; | 2020 |
Topics: Administration, Oral; Anticoagulants; Contraceptives, Oral; Diagnosis, Differential; Enoxaparin; Fac | 2019 |
A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Female; Humans; Postoperative Complications; Qual | 2020 |
Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Repl | 2020 |
Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients.
Topics: Abdominal Neoplasms; Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Incidence; Male; Mid | 2020 |
Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Hepar | 2020 |
Successful Long-term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve.
Topics: Aged; Anticoagulants; Aortic Valve Stenosis; Coronary Artery Bypass; Enoxaparin; Heart Valve Prosthe | 2020 |
Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients.
Topics: Anticoagulants; Antithrombin III; Dietary Supplements; Enoxaparin; Humans; Retrospective Studies; Ve | 2020 |
Retrospective Evaluation of Venous Thromboembolism Prophylaxis in Elderly, High-Risk Trauma Patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticoagulants; Enoxaparin; Female; Humans; Incidence; | 2020 |
Prophylaxis for Pediatric Venous Thromboembolism: Current Status and Changes Across Pediatric Orthopaedic Society of North America From 2011.
Topics: Aspirin; Enoxaparin; Guideline Adherence; Humans; North America; Orthopedic Procedures; Pediatrics; | 2020 |
Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".
Topics: Body Mass Index; Enoxaparin; Humans; Obesity, Morbid; Retrospective Studies; Venous Thromboembolism | 2020 |
Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".
Topics: Body Mass Index; Enoxaparin; Humans; Obesity, Morbid; Retrospective Studies; Venous Thromboembolism | 2020 |
Changes in serum D-dimer level and effect of enoxaparin sodium after a cesarean section: a retrospective study.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; | 2022 |
Venous thromboembolism prophylaxis in patients hospitalized in medical wards: A real life experience.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; | 2020 |
Venous thromboembolism rates after hip and knee arthroplasty and hip fractures.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2020 |
Commentary on: Postoperative Venous Thromboembolism Prophylaxis Utilizing Enoxaparin Does Not Increase Bleeding Complications After Abdominal Body Contouring Surgery.
Topics: Anticoagulants; Body Contouring; Enoxaparin; Humans; Postoperative Period; Venous Thromboembolism | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Perioperative symptomatic venous thromboembolism after immediate chemoprophylaxis in patients with pelvic and lower-extremity fractures.
Topics: Adult; Aged; Anticoagulants; Bones of Lower Extremity; Chemoprevention; Dabigatran; Enoxaparin; Fema | 2020 |
Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Cisplatin; Enoxaparin; Hemorrhage; Humans; Male; Med | 2020 |
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.
Topics: Adult; Anticoagulants; Biomarkers; Body Mass Index; Cohort Studies; Drug Monitoring; Enoxaparin; Fac | 2020 |
Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2020 |
Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Bariatric Surgery; Comorbidity; Enoxaparin; Female; Humans; | 2020 |
Early Anti-Xa Assay-Guided Low Molecular Weight Heparin Chemoprophylaxis Is Safe in Adult Patients with Acute Traumatic Brain Injury.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Brain Injuries, Traumatic; Chemoprevention; Enoxaparin; | 2020 |
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
Topics: Aged; Anticoagulants; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fibrin Fibrinogen Degrad | 2020 |
Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.
Topics: Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Hemostasis; Humans; I | 2020 |
Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
Topics: Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Humans; Pandemics; Pn | 2020 |
Fondaparinux for treatment of venous thromboembolism: Will it survive a test of time?
Topics: Child; Enoxaparin; Fondaparinux; Humans; Retrospective Studies; Venous Thromboembolism | 2020 |
Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous Thromboembolism.
Topics: Enoxaparin; Female; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembolism | 2020 |
Incidence of venous thromboembolism after robotic-assisted hysterectomy in obese patients with endometrial cancer: do we need extended prophylaxis?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Heparin; | 2021 |
Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy.
Topics: Aftercare; Anticoagulants; Chemoprevention; Cystectomy; Enoxaparin; Humans; Postoperative Complicati | 2020 |
Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy.
Topics: Aged; Anticoagulants; Biological Variation, Population; Body Mass Index; Chemotherapy, Adjuvant; Cys | 2020 |
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis.
Topics: Aged; Aged, 80 and over; COVID-19; Enoxaparin; Female; Fondaparinux; Guidelines as Topic; Hospitaliz | 2020 |
Venous thromboembolism in non-critically ill patients with COVID-19 infection.
Topics: Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fondapa | 2020 |
VTE in ICU Patients With COVID-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; C-Reactive Protein; Computed Tomography Angiography; C | 2020 |
Unawareness of thromboprophylaxis is associated with low venous thromboembolism occurrence in hospitalized patients with acute inflammatory bowel disease flare.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Awareness; Colitis | 2020 |
Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China.
Topics: Anticoagulants; China; Cost-Benefit Analysis; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolis | 2020 |
Medicine wastage in a thromboprophylaxis protocol for ambulatory trauma patients.
Topics: Anticoagulants; Casts, Surgical; Cost Savings; Emergency Service, Hospital; England; Enoxaparin; Fra | 2020 |
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Factor Xa In | 2020 |
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Topics: Aged; Anticoagulants; Antithrombins; Coronavirus Infections; COVID-19; Enoxaparin; Factor Xa Inhibit | 2020 |
Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Female; Humans; Male; Middle Aged; P | 2021 |
The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Protocols; COVID-19; Critical Care; Critica | 2021 |
Is guideline-driven prophylaxis for venous thromboembolism common practice in the South African private hospital setting?
Topics: Anticoagulants; Enoxaparin; Hospitals, Private; Humans; Retrospective Studies; Venous Thromboembolis | 2020 |
Venous thromboembolism and COVID-19: a case report and review of the literature.
Topics: Aged; Anticoagulants; Betacoronavirus; Computed Tomography Angiography; Coronavirus Infections; COVI | 2020 |
Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.
Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Nephrotic Syndrome; Thrombosis; Venous Thromb | 2021 |
Safety and effectiveness of biosimilar enoxaparin (Inhixa) for the prevention of thromboembolism in medical and surgical inpatients.
Topics: Aged; Anticoagulants; Biosimilar Pharmaceuticals; Enoxaparin; Female; Humans; Inpatients; Italy; Mal | 2021 |
Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Cattle; Collagen; Dermatan Sulfate; Disease Models, A | 2021 |
Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit.
Topics: Aged; Aged, 80 and over; Antibodies, Antiphospholipid; Anticoagulants; COVID-19; COVID-19 Drug Treat | 2021 |
Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Enoxaparin; Fe | 2021 |
Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery.
Topics: Aged; Anticoagulants; Asian People; Colorectal Neoplasms; Enoxaparin; Female; Fibrin Fibrinogen Degr | 2021 |
Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19.
Topics: Aged; Body Mass Index; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Hepari | 2021 |
Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients.
Topics: Anticoagulants; Enoxaparin; Humans; Obesity; Prospective Studies; Venous Thromboembolism | 2021 |
More on enoxaparin thromboprophylaxis in pregnancy: A review of 10 years' experience from King's College Hospital.
Topics: Anticoagulants; Enoxaparin; Female; Hospitals; Humans; Pregnancy; Universities; Venous Thromboemboli | 2021 |
Venous thromboembolism in burns patients: Are we underestimating the risk and underdosing our prophylaxis?
Topics: Adult; Aged; Anticoagulants; Australia; Burns; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Inc | 2021 |
Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Neoplasms; | 2021 |
Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Neoplasms; Recurrence | 2021 |
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.
Topics: Anticoagulants; COVID-19; Enoxaparin; Evidence-Based Medicine; Guidelines as Topic; Humans; SARS-CoV | 2021 |
Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Intensive Care Units; Renal Insufficiency; | 2021 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Revision Hip and Knee Arthroplasty as Reported by American Board of Orthopaedic Surgery Part II Candidates.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; | 2021 |
Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients.
Topics: Adult; Aged; Anticoagulants; Burns; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; | 2021 |
Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Pulmonary Embolism; Retrospective Studies; SARS-CoV-2; | 2021 |
Letter to the Editor Regarding Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-analysis. Are All the Underlying Data True?
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Venous Thromboembolism | 2021 |
Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy.
Topics: Anticoagulants; Bariatric Surgery; Enoxaparin; Female; Heparin; Heparin, Low-Molecular-Weight; Human | 2022 |
Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Topics: Adult; Age Factors; Aged; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; E | 2021 |
Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Goals; Hemorrhage; Heparin, Low-Molecular-W | 2021 |
Use of Pre-operative Pharmacologic Venous Thromboembolism Prophylaxis for Robotic Partial Nephrectomy.
Topics: Adult; Aged; Anticoagulants; Blood Transfusion; Enoxaparin; Female; Follow-Up Studies; Humans; Kidne | 2021 |
Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Enoxaparin; Heparin, Low-Molecular-Weight | 2021 |
Anti-Xa levels in critically ill children receiving enoxaparin for venothromboembolism prophylaxis.
Topics: Anticoagulants; Child; Critical Illness; Drug Administration Schedule; Enoxaparin; Humans; Venous Th | 2021 |
Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Intensive Care | 2022 |
A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2021 |
Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Py | 2021 |
Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis Following Robot-assisted Radical Cystectomy: A Retrospective Feasibility Study at a Single Academic Medical Center.
Topics: Anticoagulants; Antithrombins; Chemoprevention; Cystectomy; Enoxaparin; Female; Hemorrhage; Humans; | 2021 |
Commentary on: Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study [Int J Surg 021 Epub ahead of Print].
Topics: Enoxaparin; Humans; Prospective Studies; Stomach Neoplasms; Venous Thromboembolism | 2021 |
A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).
Topics: Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Humans; Prospective Studies; Stoma | 2021 |
Inadequate Enoxaparin Dosing Predicts 90-Day Venous Thromboembolism Risk among Plastic Surgery Inpatients: An Examination of Enoxaparin Pharmacodynamics.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Humans; Male; Middle Aged; Plastic Surgery Proce | 2017 |
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Neoplasms; Cohort Studies; Enoxaparin; Female; | 2017 |
The Perioperative Management of Antithrombotic Therapies Using Enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heparin, Lo | 2017 |
Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism.
Topics: Adolescent; Anticoagulants; Biomarkers; Child; Child, Preschool; Enoxaparin; Factor Xa Inhibitors; F | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
Re: Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin: J. J. Pariser, S. M. Pearce, B. B. Anderson, V. T. Packiam, V. N. Prachand, N. D. Smith and G. D.
Topics: Cystectomy; Enoxaparin; Heparin; Humans; Inpatients; Venous Thromboembolism | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
CORR Insights
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Factor Xa Inhibitors; Humans; | 2017 |
Implementation of a Risk-Based Heparin Protocol for Postpartum Venous Thromboembolism Prevention.
Topics: Adolescent; Adult; Anticoagulants; Cohort Studies; Enoxaparin; Female; Humans; Puerperal Disorders; | 2017 |
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Hepar | 2018 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study.
Topics: Adult; Aged; Analysis of Variance; Anticoagulants; Cohort Studies; Databases, Factual; Enoxaparin; G | 2017 |
Enoxaparin Dosing and the Prevention of Venous Thromboembolism in Plastic Surgery Patients.
Topics: Anticoagulants; Enoxaparin; Humans; Plastic Surgery Procedures; Surgery, Plastic; Thromboembolism; V | 2017 |
Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Comparative Effectiveness Research; Dalteparin; Drug | 2018 |
Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective.
Topics: Aged; Anticoagulants; Blood Coagulation; Databases, Factual; Drug Administration Schedule; Drug Subs | 2017 |
Six Weeks Versus 3 Months of Anticoagulant Treatment for Pediatric Central Venous Catheter-related Venous Thromboembolism.
Topics: Adolescent; Anticoagulants; Central Venous Catheters; Child; Child, Preschool; Cohort Studies; Enoxa | 2017 |
Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin.
Topics: Adult; Bariatric Surgery; Biomarkers; Case-Control Studies; Drug Administration Schedule; Enoxaparin | 2017 |
Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; H | 2018 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle | 2018 |
Pregnancy-related osteoporotic vertebral compression fractures in two patients treated with low-molecular-weight heparin during pregnancy: case reports.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2018 |
Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Topics: Adult; Aged; Anticoagulants; Computed Tomography Angiography; Enoxaparin; Factor Xa Inhibitors; Fema | 2018 |
Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy.
Topics: Aged; Anticoagulants; Chemoprevention; Cystectomy; Enoxaparin; Female; Humans; Injections, Subcutane | 2018 |
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Substitution; Enoxaparin; Factor Xa Inhi | 2019 |
Relation of antifactor-Xa peak levels and venous thromboembolism after trauma.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Embolic Protection Devices; Enoxaparin; Factor | 2017 |
Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery.
Topics: Abdomen; Anticoagulants; Chemoprevention; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Mi | 2018 |
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Age | 2018 |
Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose?
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Enoxaparin; Factor Xa Inhibitors; Female; Fractures, | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; | 2018 |
Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2018 |
Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Drug Administration Sched | 2018 |
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee | 2018 |
Clinical effect of enoxaparin on international normalized ratio following hepato-pancreatico-biliary and gastroesophageal resection.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Digestive System Neoplasms; Digestive System Surgica | 2018 |
Discussion: The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
Topics: Anticoagulants; Enoxaparin; Fibrinolytic Agents; Humans; Risk; Venous Thromboembolism; Venous Thromb | 2018 |
Improving Pharmacologic Prevention of VTE in Trauma: IMPACT-IT QI Project.
Topics: Adult; Aged; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa; Female; Humans; Male; Middle Age | 2018 |
Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Information Storage and Re | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf | 2018 |
Thromboprophylaxis in gynecologic cancer surgery: Is extended prophylaxis with low molecular weight heparin justified?
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Genital Neoplasms, Female; Gynecol | 2018 |
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Benzamides; C-Reactive Protein; Double-Blind | 2019 |
Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment.
Topics: Adolescent; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Administration Schedule; Enoxa | 2019 |
The impact of enoxaparin administration in relationship to hemorrhage in mild traumatic brain injury.
Topics: Animals; Anticoagulants; Brain Concussion; Disease Models, Animal; Enoxaparin; Intracranial Hemorrha | 2018 |
ASO Author Reflections: Venous Thromboembolism After Esophagectomy-The Importance of an Optimal Strategy for Thromboprophylaxis.
Topics: Anticoagulants; Enoxaparin; Esophagectomy; Humans; Prospective Studies; Venous Thromboembolism | 2018 |
Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Hospitalization; Humans; Longitudinal Studies | 2018 |
Enoxaparin: A cause of postoperative fever?
Topics: Aged; Animals; Anticoagulants; Arthroplasty, Replacement, Knee; Cattle; Diabetes Complications; Enox | 2018 |
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States.
Topics: Adolescent; Adult; Aged; Costs and Cost Analysis; Enoxaparin; Female; Humans; Length of Stay; Male; | 2018 |
The Timing of Chemoprophylaxis in Autologous Microsurgical Breast Reconstruction.
Topics: Anticoagulants; Blood Transfusion; Breast Neoplasms; Chemoprevention; Enoxaparin; Female; Free Tissu | 2018 |
Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
Topics: Acute Disease; Adult; Aged; Benzamides; Cost-Benefit Analysis; Decision Support Techniques; Decision | 2019 |
Enoxaparin administration within 24 hours of caesarean section: a 6-year single-centre experience and patient outcomes.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complicati | 2019 |
Safety and efficacy of adjusted-dose enoxaparin in pregnant patients with increased risk for venous thromboembolic disease.
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Postpartum Hemo | 2019 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data | 2019 |
Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Gastrectomy; Humans; Male; Middle Aged; Obesity, Morbid; | 2019 |
Thromboprophylaxis for varicose vein procedures - A national survey.
Topics: Enoxaparin; Female; Humans; Ireland; Male; Middle Aged; Postoperative Complications; Surveys and Que | 2019 |
Routine monitoring for heparin-induced thrombocytopenia following lower limb arthroplasty: Is it necessary? A prospective study in a UK district general hospital.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2019 |
Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?
Topics: Anticoagulants; Benzamides; Critical Illness; Enoxaparin; Humans; Pyridines; Venous Thromboembolism | 2019 |
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; | 2020 |
Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism.
Topics: Adult; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; | 2019 |
Comparison of two pharmacological prophylaxis strategies for venous thromboembolism in spinal cord injury patients: a retrospective study.
Topics: Adult; Anticoagulants; Brazil; Enoxaparin; Female; Humans; Incidence; Male; Retrospective Studies; R | 2019 |
Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients.
Topics: Anticoagulants; Blood Coagulation Tests; Body Mass Index; Dose-Response Relationship, Drug; Drug Adm | 2019 |
Prevention of Venous Thromboembolism in Colorectal Surgery With Enoxaparin: Are We Using the Right Dose?
Topics: Anticoagulants; Colorectal Surgery; Digestive System Surgical Procedures; Enoxaparin; Humans; Venous | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabig | 2019 |
Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery.
Topics: Aged; Anticoagulants; Coronary Artery Bypass; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Lengt | 2019 |
Case report - Gluteal hematoma in two spinal cord patients on enoxaparin for venous thromboembolism prophylaxis: evidence needed for a wiser choice.
Topics: Adult; Anticoagulants; Buttocks; Enoxaparin; Hematoma; Humans; Male; Spinal Cord Injuries; Venous Th | 2019 |
Extended Thromboprophylaxis for Medical Patients.
Topics: Aftercare; Anticoagulants; Benzamides; Duration of Therapy; Enoxaparin; Heparin, Low-Molecular-Weigh | 2020 |
The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery.
Topics: Aged; Anticoagulants; Colorectal Neoplasms; Disease Progression; Elective Surgical Procedures; Enoxa | 2019 |
The Role of Chemoprophylactic Agents in Modulating Platelet Aggregability After Traumatic Brain Injury.
Topics: Amitriptyline; Animals; Aspirin; Blood Coagulation; Brain Injuries, Traumatic; Disease Models, Anima | 2019 |
A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism.
Topics: Anticoagulants; Attitude of Health Personnel; Contraindications, Drug; Enoxaparin; Health Care Surve | 2020 |
Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective.
Topics: Anticoagulants; Chemoprevention; Colectomy; Colonic Neoplasms; Cost-Benefit Analysis; Decision Suppo | 2019 |
The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
Topics: Adult; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Length of Stay; Male; Middle Aged; Retrospe | 2019 |
The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran.
Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Female; Heparin; Humans; Inpatients; Iran; Models | 2019 |
Thromboprophylaxis in pregnant women: For whom and which LMWH dosage?
Topics: Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2019 |
[Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female; | 2013 |
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemopreventi | 2013 |
Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study.
Topics: Aged; Asian People; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Fibrinoly | 2013 |
Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events.
Topics: Adult; Age Factors; Aged; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Hepar | 2013 |
Venous thromboprophylaxis duration and adherence to international guidelines in patients undergoing major orthopaedic surgery: results of the international, longitudinal, observational DEIMOS registry.
Topics: Aged; Aged, 80 and over; Enoxaparin; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Longi | 2013 |
Safety of fondaparinux versus enoxaparin after TKA in Japanese patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Fondap | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Endpoint Determination; E | 2013 |
Is extended thromboprophylaxis necessary in elective colorectal cancer surgery?
Topics: Aged; Anticoagulants; Australia; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; El | 2013 |
The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction.
Topics: Adult; Aged; Anticoagulants; Breast Neoplasms; Chemoprevention; Cohort Studies; Drug Administration | 2013 |
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost- | 2013 |
Population pharmacokinetics of enoxaparin during the antenatal period.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Pregnancy; Prenatal Ca | 2013 |
Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
Topics: Adult; Anticoagulants; Body Mass Index; Cesarean Section; Cohort Studies; Enoxaparin; Factor Xa Inhi | 2013 |
Use of enoxaparin in end-stage renal disease.
Topics: Enoxaparin; Female; Hemorrhage; Heparin; Humans; Kidney Failure, Chronic; Male; Venous Thromboemboli | 2013 |
NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Coronary Artery Bypass; Enoxaparin; Humans; Middle | 2013 |
Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; False Positive Reactions; Female; Hematologic Test | 2014 |
Venous thromboembolism: Edoxaban: as effective and safer than warfarin in VTE.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
Topics: Anticoagulants; Body Mass Index; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up Stu | 2013 |
[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?].
Topics: Adenocarcinoma; Ambulatory Care; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Enoxa | 2013 |
Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; | 2014 |
Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
Topics: Aged; Anticoagulants; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle | 2014 |
Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Factor Xa Inhibitors | 2013 |
The necessity of pharmacological prophylaxis against venous thromboembolism in major joint arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; H | 2014 |
Variability is the standard: the management of venous thromboembolic disease following trauma.
Topics: Anticoagulants; Data Collection; Enoxaparin; Humans; Practice Patterns, Physicians'; United States; | 2014 |
Edoxaban versus warfarin for venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Edoxaban versus warfarin for venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
ACP Journal Club. Edoxaban was noninferior to warfarin for preventing recurrent venous thromboembolism, with less bleeding.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Huma | 2014 |
In intracranial artery stenosis, adding angioplasty and stenting to medical therapy increased stroke or death.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
Topics: Anticoagulants; Cohort Studies; Enoxaparin; Female; Health Care Costs; Heparin; Humans; Injections; | 2014 |
Safety of postoperative thromboprophylaxis after major hepatobiliary-pancreatic surgery in Japanese patients.
Topics: Aged; Anticoagulants; Asian People; Enoxaparin; Female; Fondaparinux; Hemorrhage; Hepatectomy; Human | 2014 |
Managing missed doses could improve VTE prevention.
Topics: Anticoagulants; Enoxaparin; Hospitalization; Humans; Venous Thromboembolism | 2014 |
Maximizing chemoprophylaxis against venous thromboembolism in abdominoplasty patients with the use of preoperative heparin administration.
Topics: Abdominoplasty; Adult; Anticoagulants; Enoxaparin; Humans; Middle Aged; Postoperative Complications; | 2014 |
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrh | 2014 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combina | 2014 |
Prophylaxis against venous thromboembolism in hospitalized medically ill patients: Update and practical approach.
Topics: Adult; Aged; End Stage Liver Disease; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Hospitaliza | 2014 |
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analys | 2014 |
Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Critical Care; Dose-Response Relationship, Drug; E | 2014 |
Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe?
Topics: Abdominal Injuries; Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; H | 2015 |
The Parkland Protocol's modified Berne-Norwood criteria predict two tiers of risk for traumatic brain injury progression.
Topics: Adult; Aged; Brain Injuries; Clinical Protocols; Disease Progression; Enoxaparin; Female; Fibrinolyt | 2014 |
Thrombotic complications in heart failure: an underappreciated challenge.
Topics: Enoxaparin; Female; Heart Failure; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromb | 2014 |
Epidural placement does not result in an increased incidence of venous thromboembolism in combat-wounded patients.
Topics: Adult; Analgesia, Patient-Controlled; Anesthesia, Epidural; Anticoagulants; Enoxaparin; Hematoma, Ep | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; | 2014 |
[The impact of thromboprophylaxis with enoxaparin on bleeding rate in rejuvenating facelift procedures].
Topics: Anticoagulants; Blood Loss, Surgical; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; | 2014 |
Low-molecular-weight heparin and anti-Xa targets in critically ill children: are we on target with our target?*.
Topics: Critical Care; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Venous T | 2014 |
Electronic risk assessment for venous thromboembolism: investigating physicians' rationale for bypassing clinical decision support recommendations.
Topics: Anticoagulants; Decision Support Systems, Clinical; Enoxaparin; Guideline Adherence; Humans; Medical | 2014 |
Chemoprophylaxis for venous thromboembolism in otolaryngology.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Free Tissue Flaps; Hemorrhage; Heparin; Humans; Incidence; | 2014 |
Achievement of therapeutic anti-Xa levels in a proven heparin-resistant patient through the use of nontraditional high-dose enoxaparin.
Topics: Drug Resistance, Neoplasm; Enoxaparin; Factor Xa Inhibitors; Heparin; Humans; Lung Neoplasms; Male; | 2015 |
Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
Topics: Aged; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cohort Studies; Enoxaparin; Factor | 2015 |
Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium.
Topics: Adolescent; Adult; Anticoagulants; Black People; Caribbean Region; Enoxaparin; Female; Fibrin Fibrin | 2014 |
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.
Topics: Anticoagulants; Benzamides; Enoxaparin; Factor Xa Inhibitors; Humans; Pyridines; Venous Thromboembol | 2015 |
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Topics: Anticoagulants; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; H | 2015 |
Late venous thromboembolism prophylaxis after craniotomy in acute traumatic brain injury.
Topics: Adult; Anticoagulants; Brain Injuries; Craniotomy; Enoxaparin; Female; Hospital Mortality; Humans; M | 2015 |
Screening for and prophylaxis of venous thromboembolism in severe carbon monoxide poisoning?
Topics: Anticoagulants; Carbon Monoxide Poisoning; Enoxaparin; Humans; Male; Ultrasonography; Venous Thrombo | 2015 |
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2015 |
The use of optional inferior vena cava filters of type Optease in trauma patients--a single type of filter in a single Medical Center.
Topics: Adolescent; Adult; Anticoagulants; Contraindications; Device Removal; Embolism; Enoxaparin; Equipmen | 2015 |
Venous Thromboembolism after Allogeneic Pediatric Hematopoietic Stem Cell Transplantation: A Single-Center Study.
Topics: Activated Protein C Resistance; Adolescent; Allografts; Catheterization, Central Venous; Child; Chil | 2015 |
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Boston; Brain Neoplasms; Case-Control Studies; Enoxa | 2015 |
Should patients with chronic liver disease receive venous thromboembolism prophylaxis?
Topics: Anticoagulants; Blood Coagulation Disorders; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Human | 2015 |
Enoxaparin dosing after cesarean delivery in morbidly obese women.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cesarean Section; Drug Dosage Calculations; Dru | 2015 |
Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
Topics: Adult; Aged; Anticoagulants; Body Weight; Critical Care; Critical Illness; Drug Administration Sched | 2015 |
The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Topics: Adolescent; Anticoagulants; Cerebral Hemorrhage; Child; Child, Preschool; Drug Administration Schedu | 2015 |
Enoxaparin and Warfarin for Venous Thromboembolism Prophylaxis in Total Hip Arthroplasty: To Bridge or Not to Bridge?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Humans; Male; Middle Aged; Venou | 2015 |
Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan.
Topics: Adult; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Asymptomatic Diseases; Bod | 2015 |
Reduction in Venous Thromboembolism Events: Trauma Performance Improvement and Loop Closure Through Participation in a State-Wide Quality Collaborative.
Topics: Anticoagulants; Clinical Protocols; Enoxaparin; Heparin; Humans; Injury Severity Score; Michigan; Qu | 2015 |
Balancing bleeding in brain metastases.
Topics: Anticoagulants; Brain Neoplasms; Enoxaparin; Female; Humans; Intracranial Hemorrhages; Male; Neoplas | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinic | 2015 |
Underutilization of anticoagulant for venous thromboembolism prophylaxis in three hospitals in Jakarta.
Topics: Acute Disease; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Fondaparinux; He | 2015 |
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Fondaparinux; Heparin; | 2015 |
Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Coagulation; Enoxaparin; Female; Hep | 2015 |
Death Associated with Inadequate Reassessment of Venous Thromboembolism Prophylaxis at and after Hospital Discharge.
Topics: Aged; Anticoagulants; Canada; Enoxaparin; Fatal Outcome; Female; Humans; Middle Aged; Nursing Care; | 2015 |
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Hormonal; Drug Synergism; Enoxaparin; Estrogen Replacem | 2016 |
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Topics: Anticoagulants; Canada; Cost-Benefit Analysis; Enoxaparin; Female; Hemorrhage; Humans; International | 2016 |
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2016 |
Non-weight-based enoxaparin dosing subtherapeutic in trauma patients.
Topics: Adult; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa; Female; Humans; Male; Middle Aged; Re | 2016 |
Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematologic Neoplasms; Hemorrhage; Heparin, Low-Molecular- | 2017 |
Less menorrhagia for women with VTE.
Topics: Anticoagulants; Enoxaparin; Estrogens; Female; Humans; Progestins; Rivaroxaban; Uterine Hemorrhage; | 2016 |
Letter to the Editor on "Rate of Transfusions Following Total Knee Arthroplasty in Patients Receiving Lovenox or High Dose Aspirin".
Topics: Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Venous | 2016 |
Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital.
Topics: Adolescent; Adult; Anticoagulants; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; Fe | 2016 |
Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors | 2016 |
If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2016 |
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
Topics: Aged; Arthroplasty, Replacement, Knee; Australia; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrha | 2016 |
Does sex matter? Effects on venous thromboembolism risk in screened trauma patients.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hospitalization; Humans; Male; Middle Aged; Registries; R | 2016 |
Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency - The PACER pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; | 2016 |
Anti-Factor Xa Assay-A Changing Standard for Venous Thromboprophylaxis?
Topics: Anticoagulants; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Humans; Venous Thromboembolism | 2016 |
Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Erythrocyte Transfusion; Factor Xa Inhibitors; Female; Hematocrit | 2016 |
Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
Topics: Abbreviated Injury Scale; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Male; | 2016 |
Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion | 2016 |
Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin.
Topics: Aged; Anticoagulants; Blood Transfusion; Cystectomy; Enoxaparin; Female; Heparin; Humans; Inpatients | 2017 |
Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; China; Cost-Benefit Analysis; Decision Trees; Enoxa | 2016 |
Response to Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Female; Humans; Male; Middle | 2016 |
A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; | 2017 |
Capillary blood samples for anti-Xa monitoring of heparin in paediatric patients.
Topics: Age Factors; Blood Coagulation; Blood Coagulation Tests; Blood Specimen Collection; Capillaries; Chi | 2017 |
Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Enoxaparin; Female; Hemor | 2017 |
Editorial Comment.
Topics: Cystectomy; Enoxaparin; Humans; Inpatients; Urinary Bladder; Venous Thromboembolism | 2017 |
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Topics: Aged; Anticoagulants; Benzamides; Enoxaparin; Female; Humans; Male; Pyridines; Stroke; Venous Thromb | 2017 |
Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Heparin; Hospitalization; Humans; Incide | 2017 |
Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; China; Cost-Benefit Analysis; Decision Trees; Enoxap | 2017 |
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Age | 2017 |
Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin; Facto | 2017 |
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombo | 2016 |
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Europe; Female; Hemor | 2017 |
Venous thromboembolic events: How low can you go?
Topics: Anticoagulants; Case-Control Studies; Enoxaparin; Female; Guideline Adherence; Humans; Male; Middle | 2017 |
Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery.
Topics: Adult; Aged; Aged, 80 and over; Digestive System Surgical Procedures; Enoxaparin; Female; Fibrinolyt | 2017 |
Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Anticoagulants; Case-Control Studies; Enoxapa | 2016 |
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.
Topics: Administration, Oral; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Kidney | 2017 |
Venous thromboembolic disease reduction with a portable pneumatic compression device.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Combined Moda | 2009 |
New anticoagulants--the path from discovery to clinical practice.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Veno | 2008 |
Selective factor Xa inhibition for thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pos | 2008 |
Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.
Topics: Adult; Bariatric Surgery; Chi-Square Distribution; Enoxaparin; Female; Fibrinolytic Agents; Heparin, | 2008 |
Prostasol and venous thromboembolism.
Topics: Aged; Aged, 80 and over; Complementary Therapies; Dietary Supplements; Drugs, Chinese Herbal; Enoxap | 2008 |
The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial.
Topics: Adolescent; Adult; Aged; Bariatric Surgery; Enoxaparin; Female; Fibrinolytic Agents; Humans; Inciden | 2008 |
VTE prevention in major orthopedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Fondaparinux; Humans; Orthopedi | 2008 |
Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population.
Topics: Adult; Anticoagulants; Clinical Protocols; Enoxaparin; Female; Humans; Incidence; Intermittent Pneum | 2008 |
Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Topics: Adult; Anticoagulants; Antithrombin III; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Femal | 2008 |
Thromboembolic prophylaxis in blunt traumatic intracranial hemorrhage: a retrospective review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; H | 2008 |
Venous thromboembolism clinically detected after hip fracture surgery with prophylaxis in a clinical practice setting.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Cohort Studies; Dalteparin; Enoxapari | 2008 |
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Direct Service Costs; Drug Costs; Enoxaparin; Health Care Cos | 2008 |
Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Head Injuries, Close | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Body Weight; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thi | 2008 |
Improving inpatient venous thromboembolism prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administratio | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Veno | 2008 |
Prevention of venous thromboembolism: improving practice in surgical patients.
Topics: Adult; Clinical Protocols; Decision Support Techniques; Enoxaparin; Fibrinolytic Agents; Guideline A | 2009 |
[Thromboembolic disease in orthopedic surgery].
Topics: Anesthesia, Conduction; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Early Ambul | 2008 |
[Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass].
Topics: Aged; Body Mass Index; Enoxaparin; Factor Xa; Female; Fibrinolytic Agents; Hospitalization; Humans; | 2008 |
Reminders: a simple measure to ensure the mandatory venous thromboembolism risk assessment of hospitalised patients.
Topics: Anticoagulants; Enoxaparin; Hospitalization; Humans; Risk Assessment; Venous Thromboembolism | 2009 |
Successful protein C concentrate administration during initiation of oral anticoagulation in adult patients with severe congenital protein C deficiency: report of two cases.
Topics: Adult; Anticoagulants; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; E | 2008 |
Dabigatran etexilate for prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2009 |
Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Case-Control Studies; Enoxaparin; Female; Follow-Up Stud | 2010 |
[Thrombin inhibitor shows stable safety profile in the practice].
Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replaceme | 2008 |
Symptomatic venous thromboembolism: incidence and risk factors in patients with spontaneous or traumatic intracranial hemorrhage.
Topics: Adult; Aged; Anticoagulants; Critical Care; Enoxaparin; Female; Humans; Incidence; Length of Stay; M | 2009 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2009 |
Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hip; Humans; Male; | 2009 |
High incidence of venous thrombosis after surgery for abdominal aortic aneurysm.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Aneurysm, Abdominal; Drug Administration Schedule; E | 2009 |
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; Body Weight; Drug Administration Schedule; Enoxaparin; | 2010 |
Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Cohort Studies; En | 2009 |
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Fondaparinu | 2009 |
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; F | 2010 |
[New agents for the prevention of venous thromboembolism].
Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomi | 2009 |
The importance of VTE prevention after orthopaedic surgery.
Topics: Anticoagulants; Cost of Illness; Enoxaparin; Evidence-Based Medicine; Humans; Length of Stay; Morpho | 2009 |
Fondaparinux: an overview.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Interactions; Enoxapar | 2009 |
Thromboprophylaxis in radical retropubic prostatectomy: efficacy and patient compliance of a dual modality.
Topics: Aged; Anticoagulants; Enoxaparin; Humans; Intermittent Pneumatic Compression Devices; Male; Patient | 2009 |
Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heparin; Hospital Costs; Humans; | 2009 |
Systemic bleeding in a patient with enoxaparin-induced thrombocytopenia.
Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Thrombocytop | 2009 |
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cos | 2009 |
Hospital-based costs associated with venous thromboembolism prophylaxis regimens.
Topics: Adult; Aged; Anticoagulants; Costs and Cost Analysis; Databases, Factual; Enoxaparin; Female; Humans | 2010 |
Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.
Topics: Anticoagulants; Arizona; Drug Overdose; Enoxaparin; Factor V; Humans; Male; Medical Records; Middle | 2009 |
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Topics: Chemoprevention; Cost-Benefit Analysis; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agent | 2010 |
Apixaban or enoxaparin for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Pu | 2009 |
Clinical and economic outcomes with appropriate or partial prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Data Collection; Enoxaparin | 2010 |
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.
Topics: Adenocarcinoma; Adult; Aged; Anticoagulants; Biomarkers; Carcinoma, Squamous Cell; Combined Modality | 2010 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2010 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; | 2009 |
[Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Audit; Drug Utilization; Enoxaparin; Female | 2010 |
Apixaban to prevent venous thromboembolism after knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Fibrinolytic Agents; Humans; Postoperat | 2010 |
Current primary care practice in the diagnosis and management of patients with suspected venous thromboembolism and prescription of initiation dose of enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Belgium; Chi-Square Distribution; Cross-Sectional Studies; | 2010 |
Adequate thromboprophylaxis in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Humans; V | 2010 |
Health trends.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Bone Density Conservation Ag | 2010 |
Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2010 |
Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; | 2011 |
Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Drug Adm | 2010 |
Aggregating and disaggregating patients in clinical trials and their subgroup analyses.
Topics: Acute Disease; Anticoagulants; Data Interpretation, Statistical; Delayed-Action Preparations; Enoxap | 2010 |
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.
Topics: Aged; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Com | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benz | 2010 |
Incidence of venous thromboembolic disease following hip arthroscopy.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Contraceptives, Oral, Hormonal; Enoxaparin; F | 2010 |
[Therapy of venous thromboembolisms].
Topics: Anticoagulants; Conflict of Interest; Drug Industry; Enoxaparin; Germany; Humans; Venous Thromboembo | 2010 |
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase II as | 2010 |
Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Injuries; Chi-Square Distribution; | 2010 |
Venous thromboembolism: appropriate risk assessment and treatment can save lives.
Topics: Anticoagulants; Enoxaparin; Fatal Outcome; Female; Humans; Obesity; Ovarian Neoplasms; Pneumonia; Ri | 2010 |
Extended-duration venous thromboembolism prophylaxis for medical patients.
Topics: Adult; Aged; Anticoagulants; Body Weight; Drug Administration Schedule; Enoxaparin; Female; Humans; | 2010 |
Extended-duration venous thromboembolism prophylaxis for medical patients.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Immobilization; Risk F | 2010 |
Extended-duration venous thromboembolism prophylaxis for medical patients.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Immobilization; Risk F | 2010 |
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Ar | 2011 |
Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL.
Topics: Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Child; Costs and Cost Analysis; Decision Ma | 2011 |
Therapeutic potential of oral factor Xa inhibitors.
Topics: Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Interrupted pharmocologic thromboprophylaxis increases venous thromboembolism in traumatic brain injury.
Topics: Anticoagulants; Brain Injuries; Chi-Square Distribution; Enoxaparin; Female; Glasgow Coma Scale; Hep | 2011 |
Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relationship, | 2011 |
Increased enoxaparin dosing is required for obese children.
Topics: Adolescent; Anticoagulants; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; E | 2011 |
Optimal duration of anticoagulation after venous thromboembolism.
Topics: Aged; Altitude Sickness; Anticoagulants; Cholesterol, HDL; Clinical Trials as Topic; Enoxaparin; Fem | 2011 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigat | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2011 |
Apixaban vs. enoxaparin after hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hemorrhage; Humans; Outcome Assessment, | 2011 |
Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Health | 2011 |
Outpatient management of pulmonary embolism.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Hospitalization; H | 2011 |
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle | 2012 |
Changing practice: implementation of a venous thromboembolism prophylaxis protocol at an academic medical center.
Topics: Academic Medical Centers; Adult; Enoxaparin; Female; Follow-Up Studies; Guideline Adherence; Humans; | 2011 |
Pharmaco-economics and decision making in health care. The case of "Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis".
Topics: Enoxaparin; Fibrinolytic Agents; Humans; Orthopedic Procedures; Polysaccharides; Postoperative Compl | 2011 |
A survey of current practice patterns in prophylaxis against venous thromboembolism (VTE) and gastrointestinal (GI) ulceration among Canadian burn centers.
Topics: Anti-Ulcer Agents; Anticoagulants; Burn Units; Canada; Enoxaparin; Heparin; Humans; Practice Pattern | 2011 |
[Improving recanalization of deep veins and the "outcomes" of venous thromboembolic complications in prolonged therapy with enoxaparin].
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle | 2010 |
Delayed subdural hematoma after receiving enoxaparin for prevention of thromboembolic events from high-risk surgery.
Topics: Aged; Emergency Service, Hospital; Enoxaparin; Fibrinolytic Agents; Hematoma, Subdural, Acute; Hip F | 2012 |
Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
Topics: Aged; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Emergency Medical Services; Enox | 2011 |
The effect of postoperative enoxaparin on risk for reoperative hematoma.
Topics: Anticoagulants; Bariatric Surgery; Benchmarking; Clinical Protocols; Enoxaparin; Hematoma; Humans; M | 2012 |
Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.
Topics: Academic Medical Centers; Adult; Anticoagulants; Body Weight; Cohort Studies; Dalteparin; Dose-Respo | 2011 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Dose of enoxaparin in review of rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; M | 2013 |
Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dalteparin; Data Interpretation, Statistica | 2012 |
Nurse practitioners can improve VTE prophylaxis prescribing in plastic surgery.
Topics: Anticoagulants; Compression Bandages; Enoxaparin; Humans; Nurse Practitioners; Nursing Assessment; P | 2012 |
Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin; | 2011 |
Transfusions, major bleeding, and prevention of venous thromboembolism with enoxaparin or fondaparinux in thoracic surgery.
Topics: Anticoagulants; Antithrombins; Blood Transfusion; Drug Substitution; Enoxaparin; Female; Fondaparinu | 2011 |
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Ph | 2011 |
Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Burn Units; Burns; Cohort | 2011 |
Postoperative enoxaparin prevents symptomatic venous thromboembolism in high-risk plastic surgery patients.
Topics: Adult; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2011 |
Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
Topics: Acute Disease; Anticoagulants; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Decision Sup | 2012 |
Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
Topics: Aged; Anticoagulants; Case-Control Studies; Confidence Intervals; Endpoint Determination; Enoxaparin | 2011 |
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Repla | 2012 |
Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female; Fibrinoly | 2012 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis | 2012 |
Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Cohort Studies; Creatinine; | 2012 |
Enoxaparin dosing after discharge from US hospitals in patients with total knee replacement.
Topics: Adolescent; Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Databases, Factual; Enoxap | 2012 |
Apixaban versus enoxaparin in medically ill patients.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism | 2012 |
Eligibility for medical thromboprophylaxis based on risk-factor weights, and clinical thrombotic event rates.
Topics: Anticoagulants; Enoxaparin; Humans; Inpatients; Patient Selection; Practice Guidelines as Topic; Ris | 2012 |
Treatment, survival, and thromboembolic outcomes of thrombotic storm in children.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Child; Child, Preschool; Cytokines; Enoxapari | 2012 |
Increased use of enoxaparin in pediatric trauma patients.
Topics: Adolescent; Child; Child, Preschool; Databases, Factual; Drug Utilization; Enoxaparin; Fibrinolytic | 2012 |
Postoperative stress-related stomach bleeding in a flap surgery patient.
Topics: Enoxaparin; Female; Humans; Male; Postoperative Complications; Surgery, Plastic; Venous Thromboembol | 2012 |
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; D | 2012 |
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analys | 2012 |
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio | 2012 |
Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Female; Genital N | 2012 |
Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Cohort Studies; Creatinine; Diet; Enoxaparin; | 2012 |
Practice patterns in high-risk bariatric venous thromboembolism prophylaxis.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Health Care Surveys; Heparin; Humans | 2013 |
Benefits and risks of preventing thromboembolism with enoxaparin in patients with general surgery in real world--the CLEVER study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Venous Thromboembolism; | 2013 |
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, | 2012 |
Intentional low-molecular-weight heparin overdose: a case report and review.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Overdose; Enoxaparin; Factor VIIa; Factor Xa; F | 2012 |
Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2012 |
Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Topics: Aged; Chemoprevention; Cohort Studies; Dalteparin; Data Collection; Enoxaparin; Female; Fondaparinux | 2007 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Pha | 2007 |
Extended travel after hip arthroplasty surgery. Is it safe?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Enoxaparin; Fondaparinux; Hip Joint; Hum | 2007 |
Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chemoprevention; Cost-Benefit Analysis; Dalteparin; Enoxapa | 2007 |
Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
Topics: Aged; Anticoagulants; Cohort Studies; Dalteparin; Enoxaparin; Female; Fondaparinux; Health Care Cost | 2008 |
Dabigatran versus enoxaparin after total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; E | 2007 |
Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin.
Topics: Adult; Anticoagulants; Bariatric Surgery; Enoxaparin; Factor Xa; Female; Humans; Male; Middle Aged; | 2008 |
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Topics: Adult; Disease Progression; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Heparin, Low-Molecu | 2008 |
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cohort Studies; Enoxaparin; Female | 2008 |
Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Drug Administration Schedule; Enoxapar | 2008 |
The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation In | 2008 |
The Effect of Prophylactic Doses of Reviparin on the Postoperative Value of Platelets.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cholecystectomy; Female; Heparin, Low-Molecular-Weig | 2019 |
Topics: Aftercare; Aged; Ambulatory Care; Female; Heparin, Low-Molecular-Weight; Humans; Length of Stay; Mal | 2018 |
Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Knee; Dabigatr | 2021 |
Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women.
Topics: Anticoagulants; Dalteparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Postpartum Hemor | 2022 |
Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.
Topics: Anticoagulants; COVID-19 Drug Treatment; Critical Illness; Dalteparin; Factor Xa Inhibitors; Heparin | 2022 |
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Neoplasms, Second Primary; Venous Thrombo | 2022 |
[Modern anticoagulation with factor Xa inhibitors in oncology: is the gastrointestinal bleeding rate (also) decisive?]
Topics: Anticoagulants; Dalteparin; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Neoplasms; Pr | 2023 |
Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data.
Topics: Anticoagulants; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pr | 2023 |
New Pediatric Indication for Dalteparin Sodium.
Topics: Anticoagulants; Child; Child, Preschool; Dalteparin; Humans; Infant; Venous Thromboembolism | 2019 |
Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers.
Topics: Aged; Dalteparin; Factor Xa Inhibitors; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Middl | 2020 |
The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer.
Topics: Anticoagulants; Dalteparin; Female; Humans; Neoplasm Recurrence, Local; Rivaroxaban; Venous Thromboe | 2020 |
Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring.
Topics: Academic Medical Centers; Adult; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Heparin, | 2019 |
No effect of norepinephrine dose on anti-Xa activity in critically ill patients
.
Topics: Adult; Anticoagulants; Critical Illness; Dalteparin; Factor Xa Inhibitors; Humans; Intensive Care Un | 2020 |
[Toward the use of direct oral anticoagulants as a first line therapy in cancer-associated venous thromboembolism].
Topics: 4-Hydroxycoumarins; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Hemo | 2020 |
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous | 2020 |
Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.
Topics: Adolescent; Age Factors; Anticoagulants; Biomarkers; Body Weight; Child; Child, Preschool; Daltepari | 2021 |
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.
Topics: Adolescent; Adult; Anticoagulants; Child; Child, Preschool; Dalteparin; Drug Approval; Female; Follo | 2020 |
Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; COVID-19 Drug Treatment; Crit | 2020 |
Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin.
Topics: Anticoagulants; Dalteparin; Humans; Renal Insufficiency; Retrospective Studies; Venous Thromboemboli | 2022 |
Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock.
Topics: Anticoagulants; Child; Dalteparin; Humans; Pediatrics; Ships; Venous Thromboembolism | 2020 |
Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism.
Topics: Anticoagulants; Dalteparin; Female; Humans; Neoplasms; Retrospective Studies; Rivaroxaban; Venous Th | 2021 |
Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H | 2018 |
[Treatment of cancer-associated venous thromboembolism].
Topics: Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Practice G | 2018 |
VTE and anti-coagulation therapy in cancer patients.
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dalteparin; Factor Xa Inhibitors; Human | 2019 |
The cost of outpatient venous thromboembolism prophylaxis following lower limb injuries.
Topics: Ambulatory Care; Anticoagulants; Dalteparin; Fracture Fixation; Health Care Costs; Humans; Leg Injur | 2013 |
Aspirin after dalteparin was noninferior to continued dalteparin for preventing VTE after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
Aspirin versus low-molecular-weight heparin after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
Aspirin versus low-molecular-weight heparin after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
[Thrombosis prophylaxis after hip surgery- aspirin is not inferior to heparin].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Topics: Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Dose-Response Relationship, Drug; Drug Admi | 2014 |
Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Topics: Adult; Anticoagulants; Dalteparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Injections, | 2014 |
The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment.
Topics: Adult; Anticoagulants; Biomarkers; Dalteparin; Drug Administration Schedule; Female; Fibrin Fibrinog | 2014 |
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Topics: Anticoagulants; Cost-Benefit Analysis; Critical Illness; Dalteparin; Female; Health Expenditures; He | 2014 |
ACP journal club. Dalteparin was at least as effective as UFH for VTE prevention in critically ill patients, with similar costs.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Health Expenditures; Heparin; Humans; Male; Ve | 2015 |
Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients.
Topics: Adult; Aged; Dalteparin; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Risk Factor | 2015 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog | 2016 |
Femoral nerve palsy associated with bilateral spontaneous iliopsoas haematomas: a complication of venous thromboembolism therapy.
Topics: Aged, 80 and over; Anticoagulants; Dalteparin; Female; Femoral Neuropathy; Hematoma; Humans; Magneti | 2016 |
Low-Molecular-Weight Heparin Did Not Differ from Placebo in Preventing Clinically Important Deep Venous Thrombosis After Surgical Repair of Leg Fracture.
Topics: Anticoagulants; Dalteparin; Female; Fractures, Bone; Humans; Leg Injuries; Male; Venous Thromboembol | 2016 |
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Topics: Anticoagulants; Austria; Cost-Benefit Analysis; Dalteparin; Female; France; Humans; Male; Middle Age | 2017 |
Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Dalteparin; Electiv | 2017 |
Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery.
Topics: Adult; Anticoagulants; Biliopancreatic Diversion; Chemoprevention; Dalteparin; Factor Xa; Female; Hu | 2010 |
Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Female; Heparin; Humans; Inc | 2008 |
Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Topics: Anticoagulants; Canada; Cost-Benefit Analysis; Dalteparin; Drug Administration Schedule; Humans; Met | 2009 |
Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin.
Topics: Adult; Anticoagulants; Cesarean Section; Dalteparin; Female; Fetal Growth Retardation; Fibrinolytic | 2010 |
Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Bariatric Surgery; Colonic Neoplasms; Daltepar | 2010 |
[Prolonged prophylaxis of thromboembolic disease in patients with colorectal surgical resections for malignancy].
Topics: Anticoagulants; Colorectal Neoplasms; Dalteparin; Female; Humans; Male; Middle Aged; Postoperative C | 2009 |
The management of recurrent VTE in cancer patients receiving therapeutic anticoagulation: the use of dual anticoagulant therapy combined with an IVC filter.
Topics: Adult; Anticoagulants; Combined Modality Therapy; Dalteparin; Female; Humans; Middle Aged; Vena Cava | 2010 |
Safety of a regimen for thromboprophylaxis in head and neck cancer microvascular reconstructive surgery: non-concurrent cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Cohort Studies; Dalteparin; Fe | 2012 |
The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy.
Topics: Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2007 |
Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.
Topics: Aged; Anticoagulants; COVID-19 Drug Treatment; Female; Hospital Mortality; Humans; Male; Middle Aged | 2022 |
Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study.
Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective Studies; Thrombosis; Tinzaparin; Venou | 2022 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study.
Topics: Aged; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pilot Projects; Prospective Studies; Re | 2023 |
Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more.
Topics: Anticoagulants; Bariatric Surgery; Heparin; Heparin, Low-Molecular-Weight; Humans; Retrospective Stu | 2021 |
Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study.
Topics: Adult; Aged; Anticoagulants; Cohort Studies; Female; Follow-Up Studies; France; Humans; Male; Middle | 2022 |
Impact of Weight-Band Dosing of Tinzaparin for Venous Thromboembolism Prophylaxis on Persistent Wound Drainage in Adult Patients Undergoing Hip and Knee Arthroplasty.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drainage; Hu | 2022 |
Tinzaparin thromboprophylaxis prescribing practice after caesarean delivery 2009-2014.
Topics: Cesarean Section; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; History, 21st Century; | 2018 |
Compliance with current VTE prophylaxis guidelines and risk factors linked to complications of VTE prophylaxis in medical inpatients: a prospective cohort study in a Spanish internal medicine department.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Guideline Adherence; Hemorrhage; Heparin, Lo | 2018 |
Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery.
Topics: Adult; Anticoagulants; Body Weight; Drug Administration Schedule; Drug Dosage Calculations; Female; | 2018 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol | 2013 |
Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women.
Topics: Adult; Body Weight; Cohort Studies; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2014 |
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-W | 2015 |
Safety of therapeutic doses of tinzaparin during pregnancy.
Topics: Adult; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2015 |
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
Topics: Animals; Blood Vessels; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Factor Xa Inhibitors; | 2016 |
Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibri | 2008 |
Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile.
Topics: Adolescent; Adult; Canada; Cohort Studies; Europe; Female; Fibrinolytic Agents; Heparin, Low-Molecul | 2011 |
Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; | 2007 |
The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Agents; Control Groups; Controlled Clinical Trials as To | 2017 |
Routine heparin for patients with cancer? One answer, more questions.
Topics: Fibrinolytic Agents; Fibrinopeptide A; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Venous Thro | 2012 |
Semuloparin helps prevent thromboembolic events in patients receiving chemotherapy.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Venous | 2012 |